Plaintiff PEC Cross-Notice of Remote Deposition and Non-Retained Expert Witness Disclosure of Dr. Rahul Gupta

Exhibit 2

Gupta Deposition September 11, 2020

```
Page 1
            IN THE UNITED STATES DISTRICT COURT
1
         FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
 2
 3
 4
     THE CITY OF HUNTINGTON,
 5
               Plaintiff,
 6
                                         CIVIL ACTION
     vs.
 7
                                       NO. 3:17-01362
     AMERISOURCEBERGEN DRUG
     CORPORATION, et al.,
8
9
               Defendants.
10
     CABELL COUNTY COMMISSION,
11
                Plaintiff,
12
13
     vs.
                                              CIVIL ACTION
                                            NO. 3:17-01665
14
     AMERISOURCEBERGEN DRUG
     CORPORATION, et al.,
15
                Defendants.
16
17
18
              Videotaped and videoconference deposition
19
     of RAHUL GUPTA, M.D., taken by the Defendants under
     the Federal Rules of Civil Procedure in the above-
20
     entitled action, pursuant to notice, before Teresa
     S. Evans, a Registered Merit Reporter, all parties
21
     located remotely, on the 11th day of September,
2.2
     2020.
23
2.4
```

```
Page 2
1
                             APPEARANCES:
2.
    APPEARING FOR THE PLAINTIFFS:
3
             Anne McGinness Kearse, Esquire
             Monique Christenson, Esquire
4
             MOTLEY RICE
             28 Bridgeside Boulevard
5
             Mt. Pleasant, SC 29464
6
             Paul T. Farrell, Jr., Esquire
7
             FARRELL LAW
             422 Ninth Street
8
             3rd Floor
             Huntington, WV 25714-1180
9
    APPEARING FOR THE DEFENDANT CARDINAL HEALTH:
10
              Jyoti Jindal, Esquire
11
             WILLIAMS & CONNOLLY
             725 Twelfth Street, N.W.
12
             Washington, DC 20005
13
             Steven R. Ruby, Esquire
              David R. Pogue, Esquire
14
              CAREY, DOUGLAS, KESSLER & RUBY
15
              901 Chase Tower
              707 Virginia Street, East
16
              Charleston, WV 25323
17
    APPEARING FOR THE DEFENDANT McKESSON CORPORATION:
18
             James A. Goold, Esquire
19
             Nicole Antione, Esquire
             COVINGTON & BURLING
20
             One City Center
             850 Tenth Street NW
             Washington, DC 20001
21
22
23
2.4
```

```
Page 3
                     APPEARANCES (Contd.)
1
2
    APPEARING FOR THE DEPONENT:
3
             Mark Colantonio, Esquire
             Robert Fitzsimmons, Esquire
4
             FITZSIMMONS LAW FIRM
             1609 Warwood Avenue
5
             Wheeling, WV 26003
6
7
    ALSO PRESENT:
              Adam Hager, Videographer
8
              Hunter Shkolnik, Esquire
              Lauren Mahaney, Esquire
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
```

| | | | Page 4 |
|----|--------|-------------------|--------|
| 1 | | EXAMINATION INDEX | |
| 2 | | | |
| 3 | BY MS. | JINDAL | 9 |
| | BY MR. | COLANTONIO | 115 |
| 4 | BY MS. | KEARSE | 181 |
| | BY MS. | JINDAL | 188 |
| 5 | BY MR. | GOOLD | 328 |
| | BY MS. | JINDAL | 338 |
| 6 | | | |
| 7 | | | |
| 8 | | | |
| 9 | | | |
| 10 | | | |
| 11 | | | |
| 12 | | | |
| 13 | | | |
| 14 | | | |
| 15 | | | |
| 16 | | | |
| 17 | | | |
| 18 | | | |
| 19 | | | |
| 20 | | | |
| 21 | | | |
| 22 | | | |
| 23 | | | |
| 24 | | | |
| | | | |

| | | | | Page 5 |
|--------|----------|----------|---|--------|
| 1 2 | | | EXHIBIT INDEX | |
| 3 | Exhibit | 1 | Deposition transcript of Dr. Gupta dated 8-16-16, State of WV | 12 |
| 4 | | | ex rel v. AmerisourceBergen, et al., Circuit Court of Boone | |
| 5 | | | County, WV, Civil Action No, 12-C-141 | |
| 6 | Evhihit | 4 | E-mail from Haddy to Haddy and | 299 |
| 7 | EXIIIDIC | T | others Re: WV HAN #128 Novel Opiates dated 12-13-16 with | 233 |
| 8 | | | "Health Advisory #128 Novel Opiates" attached | |
| 9 | Evhihit | 5 | E-mail from Massey to Kilkenney | 295 |
| 10 | ПХПТОТС | J | Re: MMWR dated 5-27-17 with "Public Health Investigation of | 233 |
| 11 | | | an Opioid Overdose Outbreak - West Virginia, August 2016" | |
| 12 | | | attached | |
| 13 | Exhibit | 14 | E-mail from Gupta to Mock and Taylor Re: Presentation dated | 308 |
| 14 | | | 4-4-17 and E-mail from Richman to Boggs Re: April 4th - MCMS | |
| 15 | | | dated 3-29-17 (DHHR FEDWV 0038760) | |
| 16 | Exhibit | 15 | "2017 Legislation and Substance | 308 |
| 17 | | | Use Disorder Epidemic: West Virginia's Call to Action" by | |
| 18 | | | Gupta dated 4-4-17 (DHHR FEDWV 0038761) | |
| 19 | | | (2120000701) | |
| | Exhibit | 16 | E-mail from Christy to Wagoner | 303 |
| 20 | | | and others Re: GUPTA DATA NEEDS UPDATED - Social Worker | |
| 21 | | | Conference (next week) dated 4-21-17 (DHHR_FEDWV_0047102) | |
| 22 | | | | |
| 23 | Exhibit | 17 | "West Virginia's Contemporary Public Health Challenge: Drug | 303 |
| | | | Overdose Deaths" by Gupta dated | |
| 24 | | | 4-29-17 | |

| | | | Page 6 |
|-----|---------------------------|---|--------|
| 1 2 | | EXHIBIT INDEX (Contd.) | |
| 3 | Exhibit 20 | E-mail chain between Gupta and others Re: MEDIA REQUEST = Fatal | 339 |
| 4 | | overdose victims by county and where they were from dated | |
| - | | 9-27-17 to 9-29-17 | |
| 5 | Exhibit 37 | E-mail chain between Melton, | 246 |
| 6 | | Gupta and others Re: Overdose Death Investigations dated | |
| 7 | | 3-26&27-18 with 2016 West Virginia Overdose Fatality | |
| 8 | | Analysis attached (DHHR_FEDWV_0317258-322) | |
| 9 | Exhibit 38 | Gupta testimony before the House | 254 |
| 10 | | Oversight and Government Reform Committee entitled "A | |
| 11 | | Sustainable Solution to the Evolving Opioid Crisis: | |
| 12 | | Revitalizing the Office of National Drug Control Policy" | |
| 13 | | dated 5-17-18 (DHHR FEDWV 0391628-651) | |
| 14 | Exhibit 45 | E-mail from Dora to Gupta and | 313 |
| 15 | HAIIIDIC 13 | others Re: 2018.07.05 Final packet mailed to Judges re MAT | 313 |
| 16 | | dated 7-5-18 (DHHR FEDWV 1148108-126) | |
| 17 | Evhihi+ 51 | Resume of Rahul Gupta, MD, MPH, | 60 |
| 18 | EXHIDIC SI | MBA, FACP | 00 |
| 19 | - 1 · 1 · · · · · · · · · | (WVSMA_FEDWV_00039036-091) | 2.2 |
| 20 | EXNIDIT 54 | "State of Health" presentation by Rahul Gupta, MD, MPH, MBA, | 99 |
| 21 | | FACP dated 10-26-18 (CT2 RGupta000919-966) | |
| 22 | Exhibit 56 | "Notice of Plaintiffs' Preliminary Witness List," U.S. | 23 |
| 23 | | Dist. Ct. Case No. 3:17-01362 filed 6-3-20 | |
| 24 | | | |
| | | | |

PROCEEDINGS

VIDEO OPERATOR: Good morning. We are going on the record at 9:04 a.m. on September the 11th, 2020. Please note that microphones are sensitive and may pick up whispering, private conversations and cellular interference. Please turn off all cell phones or place them away from the microphones as they can interfere with the deposition audio.

Audio and video recording will continue to take place unless all parties agree to go off the record.

This is Media Unit 1 of the video recorded deposition of Rahul Gupta, M.D., taken by counsel for the Defendants in the matter of City of Huntington and Cabell County Commission versus AmerisourceBergen Drug Corporation, et al, filed in the United States District Court for the Southern District of West Virginia, being Civil Action Nos. 3:17-01362 and 3:17-01665.

This deposition is being conducted remotely via Zoom conferencing. My name is Adam Hager from the firm Veritext and I'm the videographer. The court reporter is Teresa Evans

Page 8 from the firm Veritext. 1 2 I am not authorized to administer an 3 oath; I'm not related to any party in this action; nor am I financially interested in the outcome. 5 Counsel and all present in the room and everyone attending remotely will now state their 6 7 appearances and affiliations for the record. If there are any objections to 8 9 proceeding, please state them at the time of your appearance, beginning with the noticing attorney. 10 11 MS. JINDAL: Jyoti Jindal with 12 Williams & Connolly on behalf of Cardinal Health. 13 MR. RUBY: And Steve Ruby and David Poque also for Cardinal Health. 14 15 MR. GOOLD: James Goold, Covington & Burling and Nicole Antonine from Covington 16 17 & Burling for McKesson Corp. 18 MR. FARRELL: Paul Farrell, Jr. and 19 Anne Kearse for Plaintiffs. 20 MR. COLANTONIO: Mark Colantonio, Bob 21 Fitzsimmons representing Doctor Gupta for purposes of this deposition. 22 VIDEO OPERATOR: If there are no 23 further appearances to be noted, would the court 24

Page 9 reporter please swear the witness? 1 2 (The witness was sworn.) 3 VIDEO OPERATOR: Please begin. GUPTA, M.D. 4 RAHUL 5 was called as a witness by the Defendant, and having been first duly sworn, testified as follows: 6 7 EXAMINATION BY MS. JINDAL: 8 9 Good morning, Doctor Gupta. We met just a little bit ago, but I'm going to introduce myself 10 again right now. I am Jyoti Jindal and I am the 11 12 attorney for Cardinal Health, one of the defendants in this lawsuit. 13 14 I understand that you are former State 15 Health Officer and Commissioner of the Bureau of Public Health in West Virginia. 16 17 Before we get into your work for those 18 roles, I have a few preliminary questions. 19 you ever testified under oath before? 20 Α. Yes. 21 How many times? I would say one time that I can recollect 22 23 in the last three years or so. Prior to that, I may have two to four times or two or three times. 24

Page 10 I do not have specific recollection. 1 And in the last -- before we get into the 3 most recent time you testified, those previous times, was that at trial? 5 Previous was a deposition. Uh-huh. The two to four times that you 6 Ο. 7 mentioned before the most recent time, were those at trial? 8 9 They were depositions, and there was one trial also. 10 11 Okay. And was -- do you recall the nature of those cases? 12 13 The ones that I can recall right now Α. included my deposition in the Attorney General of 14 15 West Virginia versus AmerisourceBergen. There was 16 one of plaintiffs against West Virginia-American 17 Water. 18 There was one that I was deposed for --I believe it was related to Bayer a while back, 19 it's difficult to recognize -- remember. 20 21 And then there was maybe one or two that would have related more of -- one, of a 22

Q. I see. Of the ones that you mentioned

personal nature, related to my spouse.

23

24

- regarding Bayer, what was the nature of your testimony in that case, if you recall? Just at a high level.
 - A. Public health.

- Q. Okay. And was that also the case with the water case that you mentioned?
- A. It was related to the 2014 West Virginia water crisis.
- Q. Okay. And were -- in both of those cases, were you testifying on behalf of the plaintiffs or defendants or neither party?
 - A. Plaintiffs.
 - Q. Were you an expert in those cases?
- A. I believe not. Although in the West
 Virginia water crisis, I was the local health
 officer in charge of that, so I would not be clear
 -- I would not be sure at this point whether I was
 testifying on behalf of the plaintiffs or actually
 I believe to be that my testimony was based on my
 knowledge and dealings during the crisis more so
 than being on behalf of one side or the other.
- Q. Uh-huh. And you say you also testified in the West Virginia case against AmerisourceBergen.

 Was that in 2016, sir?

Page 12 I believe so. Α. 1 2 Ο. Okay. Could you please open Exhibit 1? 3 GUPTA DEPOSITION EXHIBIT NO. 1 (Deposition transcript of Dr. Gupta 4 5 dated 8-16-16, State of WV ex rel v. AmerisourceBergen, et al., Circuit 6 7 Court of Boone County, WV, Civil Action No, 12-C-141 was marked for 8 9 identification purposes as Gupta 10 Deposition Exhibit No. 1. 11 MR. COLANTONIO: Okay, go ahead. 12 Q. Doctor Gupta, is this a transcript of your 2016 testimony in the West Virginia versus 13 AmerisourceBergen case? 14 I can go through it. 15 MR. COLANTONIO: While the doctor is 16 17 going through that, I just want to note for the 18 record that this copy of the deposition does not have a signed errata sheet, so I'm not sure if that 19 was ever done, but this one that's being offered is 20 not signed. 21 So this seems in testimony familiar to --22 23 and the time frame is familiar to my deposition. 24 However, I have not read through this deposition so

I cannot ascertain to the validity of my responses as of right now.

- Q. Sure. I'm not asking you to determine the validity of your responses, but do you have any reason to doubt that it is not a true and accurate copy of your testimony in that case?
- A. I do not believe I have had a chance to review and correct any errors, so I would not be able to provide that opinion at this time.
- Q. Okay. All right. You can go ahead and set Exhibit 1 aside for now.

Do you -- so because you've testified under oath before, I under -- I would expect that you understand what that means. Correct?

A. Yes.

- Q. And so you know that it's the same oath that you'd give if we were in a courtroom in front of a judge?
 - A. Yes.
- Q. And my questions today are about what you know to the best of your ability, not about what your lawyers know. So -- or what they've told you. And is there any reason why you may not be able to testify accurately and fully today?

- A. Not to my knowledge.
- Q. I'm going to do my best to make my questions clear and presentable -- I'm sorry, understandable. Off to a great start here.

So if you ever need clarification or you want me to rephrase my question, just let me know. Okay?

A. Yes.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Q. And as your lawyers may have already told you, it's important that only one of us speak at a time so that the court reporter can keep track of everything. I'll do my best not to start my next question until you finish your answer, and please just -- I ask that you wait until I finish my question before you begin your answer.

Can we agree to do that?

- A. Yes.
- Q. And if I make a mistake in that regard and cut you off, just let me know and we'll fix that.
 - A. Understand.
- Q. You received a sealed box prior to the start of this deposition. Correct?
- MR. COLANTONIO: Well, the -- this is

2.4 --

Q. Your lawyer --

MR. COLANTONIO: The attorneys received -- his attorneys received a sealed box, and we delivered them to the doctor here today.

MS. JINDAL: Okay.

- Q. And that box, as you've already become aware, contains documents that we're going to review today. Pursuant to the deposition protocol in this case, you and your lawyer may not review any of those documents until I ask you to do so.

 Do you understand?
 - A. Understood.
- Q. Doctor Gupta, what did you do to prepare for this deposition?
- A. I had spoken to my attorneys to understand what the deposition would be about.

I was also able to - on the request - provide documentations that were requested in the subpoena, so in that process, I was able to seek, find, review and provide, including providing the technological - including scanning, and copying and other measures - to be able to provide that to you and to my attorneys.

Q. Thank you, Doctor. You said you've met

- with your attorneys -- I'm sorry, you said you spoke to your attorneys. How many times did you speak to them?
- A. I spoke to my attorneys yesterday, and there may have been a few other times for very brief chats, for questions I may have had in the past as well.
 - Q. And who were those attorneys?
- A. That's Mark Colantonio, and yesterday I was able to also speak with Bob Fitzsimmons.
 - Q. Anyone else?
- 12 A. No.

1

2

3

4

5

6

7

8

9

10

11

13

14

15

16

17

18

19

20

21

22

23

24

- Q. You said you met with them for a few short times previously. How long did you meet with them yesterday?
- A. So I met with them yesterday for, I would say, about approximately five to six hours, and prior to that, I did not meet with them. I had brief phone calls. And that was with Mark.
- Q. And approximately how long did those phone calls last?
- A. They could last anywhere between five seconds to 15 minutes, and that's a range.
 - Q. And other than Mr. Colantonio and

Mr. Fitzsimmons, did you have any conversations with the lawyers for either Cabell County or the City of Huntington in this case?

- A. I did not. However, I would like to qualify that with the fact that I do recollect receiving e-mails for contact -- this was a while back, so I do not exactly know the time/dates.
- Q. Do you recall what those e-mails were about?
- A. Some would be about establishing or attempting to establish contact.
 - Q. Did you respond to those e-mails?
- A. I may have on an occasion provided a courteous response, but there was no that I can remember conversations that continued beyond that.
- Q. Okay. And in your meeting yesterday with Mr. Colantonio and Mr. Fitzsimmons, what did you do to prepare?

MR. COLANTONIO: Let me just object.

I think that that goes beyond the scope of what's permissible and gets into attorney/client privileged information, so unless you would give me a good reason why he should answer, I'm going to

Page 18 instruct him not to answer. 1 2 MS. JINDAL: Let me rephrase my 3 question. During your preparation yesterday -- or 4 your meeting yesterday, did you review any 5 documents? 6 Α. No. Have you read the Complaint in this case? Ο. 8 9 Α. I have not. Do you know what the Complaint is? I just 10 0. want to make sure you understand that question 11 fully. 12 13 I understand broadly based on my prior experience with depositions and being the 14 15 Commissioner as well as public reports what that 16 would be. However, I've had not had an opportunity 17 to specifically read this particular Complaint. Aside from your time with your attorney 18 yesterday, did you review any documents on your own 19 20 in preparing for this deposition? 21 MR. COLANTONIO: Just to be clear, I think he's already testified when the assimilated 22 documents, he had a chance to review the things 23 24 that we sent you all. So I just wanted to make

Page 19 sure that -- he's already said that. 1 2 MS. JINDAL: Right. And I'm sorry, I 3 understood that as to be a review for responsiveness and to satisfy -- you know, in 4 5 response to a subpoena. I'm asking whether he reviewed any 6 7 documents specifically in preparation for this deposition today. 8 9 I will answer it as this: I reviewed the documents, including conducting the search for and 10 11 ensuring that those documents pertained to the 12 request that was made, and that included not just 13 review, but also making copies or scanning them in, providing them to you. 14 And did any of those documents refresh your 15 recollection about the work you did as 16 Commissioner? 17 18 Α. Yes. 19 Which documents were those? Ο. 20 The last time I reviewed those documents Α. 21 was several weeks ago, so I would be happy to go through them if I would be allowed to remember that 22 23 again. Okay. So you don't recall right now the 2.4 Q.

documents -- is it fair to say that the documents you produced in response to the subpoena refreshed your recollection about your work as Commissioner?

- A. They may have. I cannot say that at this point without having to take another look at those documents.
 - Q. Did you review any deposition transcripts?
- A. I did not.
 - Q. And outside of your meetings with your attorneys, did you talk to anyone about the substance of this deposition?
 - A. No.

1

2

3

4

5

6

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

22

23

24

- Q. And in searching for documents in response to the subpoena, what did you do?
 - A. I'm sorry, could you repeat that, please?
- Q. Sure. You testified that you were made aware of the subpoena, that you collected documents, you scanned and sent them to your attorneys. Is that right?
 - A. Yes.
- Q. In terms of searching for the documents, what did you do?
- A. I to the best of my ability searched my personal files, my home in Virginia, my home in

Page 21 West Virginia, any of the aspects of files that may 1 2 be electronically stored, and did the best of my 3 ability to recollect and remember for any files or documents as well as there were a number of documents that I had to -- I did recollect, but I 5 did not have immediately with me, and there may 6 7 have been some that I had to search online to be able to get in response to that and provide those. 8 The ones that you --9 Ο. MS. JINDAL: Strike that. 10 You understand, Doctor Gupta, that you're 11 Ο. 12 being deposed in connection with an ongoing 13 litigation, right? Α. Yes. 14 15 And who do you understand to be the plaintiff in this case? 16 17 My understanding is the plaintiffs is Α. 18 Cabell County and the City of Huntington. 19 And who do you understand to be the 20 defendants? 21 I understand the defendants represented here today include Cardinal Health, McKesson, as 22 23 well as AmerisourceBergen.

And in your own words, what is the case

24

Q.

about?

- A. I'm sorry, can you repeat that, please?
- Q. Sure. What is your understanding of this case? What is it about?
- A. My understanding is that this case is related to the number of overdose deaths and generally the suffering and the carnage that has occurred broadly in the state of West Virginia, but narrowly in Cabell County and the City of Huntington as a result of oversupply as well as the over-availability of prescription opioids and the consequences resulting from that.
- Q. And what is the basis of your understanding? How did you come to have that understanding?
- A. As I had mentioned before, that including my work as the Commissioner for the Bureau of Public Health as well as the State's chief health officer, having worked in this area, having read the reports as well as public records and accounts and have been deposed and involved in the workings of the Department of Health and Human Resources of West Virginia, is how I come about to have that understanding.

Page 23 Okay. And are you aware that your name was 1 2 disclosed in plaintiffs' preliminary witness list that they filed on June 3rd, 2020? 3 Α. I am not aware. 4 Doctor Gupta, could you please open Exhibit 5 Ο. 56? 6 7 MR. COLANTONIO: I'm sorry, did you say "56?" 8 9 MS. JINDAL: 56, yes. I apologize. 10 We're going to be jumping around a bit today. 11 MR. COLANTONIO: Let me just find it 12 here. Hold on. Okay. 56. 13 GUPTA DEPOSITION EXHIBIT NO. 56 14 ("Notice of Plaintiffs' Preliminary 15 Witness List, " U.S. Dist. Ct. Case No. 3:17-01362 filed 6-3-20 was marked for 16 17 identification purposes as Gupta 18 Deposition Exhibit No. 56.) 19 MR. COLANTONIO: Like some kind of a game show. 20 21 THE DEPONENT: Thank you. I have this in front of me. 22 Α. 23 Okay. Doctor Gupta, this is --Ο. 24 MR. COLANTONIO: Could you just hold

Page 24 for a second until I get my copy, please? 1 2 Thanks. Okay, go ahead. I'm sorry. 3 Go ahead. 4 MS. JINDAL: I'm sorry. Are you 5 ready? MR. COLANTONIO: Yes. Go ahead, 6 7 Thank you. please. MS. JINDAL: Okay. 8 9 Q. Doctor, this is a filing filed by plaintiffs in this action. It is dated, as you can 10 11 see, at the very top in blue in the center, dated 12 June 3rd, '20, and it states here that "Plaintiffs 13 have identified the following individuals likely to be called as witnesses at trial." 14 15 And if you turn to the second page, you 16 will see your name as No. 22. Is that correct? 17 That is correct. Α. 18 And your testimony is you were not aware that your name was going to be included on such a 19 20 list. 21 This is -- my testimony is this is the first time I'm actually seeing this. 22 23 Okay. Setting aside the document, were you 24 aware that plaintiffs intended to call you as a

Page 25 witness at trial? 1 2 MR. COLANTONIO: Objection, asked and 3 answered. As of this date that you mentioned, I was 5 not formally aware of that. Q. Did you become aware after that date? 6 7 MR. COLANTONIO: He's aware now. Α. I am aware. 8 9 Q. When did you become aware, besides -outside of today's conversation? 10 Today is when I've been made aware that --11 12 of the document that officially lists me as plaintiff witness. 13 I'm not doing a good job of making my 14 question clear; I apologize. Doctor Gupta, when --15 did plaintiffs ever contact you about testifying on 16 their behalf at trial in this case? 17 18 Α. Yes. When was that? 19 Q. 20 I would have to go back for that. 21 Approximately about eight to twelve months. And with that, I want to say, Ms. Jindal, I'm not an 22 attorney, so I am -- I'm a physician, so I am not 23 24 often aware of that just a contact means I'm on a

Page 26 list somewhere. 1 2 So I just want to make sure that you 3 understand that my understanding of legal proceedings is very minuscule as opposed to the 5 court and the system. MR. COLANTONIO: And --6 7 Sure, absolutely. 0. MR. COLANTONIO: I don't mean to 8 9 interrupt, but just so you're clear, he may be 10 confusing his involvement in the state case with 11 this case. I'm not -- so I just want to be -- you may want to question about that, because that may 12 explain his answers better. 1.3 14 But it's your deposition. 15 MS. JINDAL: Thank you, I appreciate 16 that. And I will get to that other case. 17 MR. RUBY: Just -- Jyoti, just a 18 Mark, when you say "the state case," you 19 mean the old AG case or the current --20 MR. COLANTONIO: No, I'm sorry, what I 21 meant was the MLP case. 22 MR. RUBY: Okay. I thought that's 23 what you meant. I just wanted to make sure it was 24 clear.

Page 27 MR. COLANTONIO: Yes. 1 2 BY MS. JINDAL: 3 Q. And Doctor Gupta, have plaintiffs contacted you -- attorneys for Cabell County and City of 4 5 Huntington, have any attorneys for those two entities, contacted you about testifying in this 6 7 case, which is set to begin trial on October 19th, 2020? 8 9 As I mentioned, that there may have been e-mails in that time frame, as I mentioned, the 10 past eight to twelve months, that I may have 11 12 received and provided a courtesy response to that 13 -- that e-mail. But beyond that, I have -- I do not 14 15 recollect having any phone conversations, 16 agreements with others with -- you know, with any particular attorney, but I can -- I can provide you 17 18 the information that I do have on that -- on this 19 case. 20 I'm happy to do that. 21 Q. Okay. I just need to know what you know I will follow up as needed, Doctor. 22 today. Thank 23 you. 24 Did you agree in response to those

e-mail inquiries to testify for plaintiffs in this trial?

- A. I did not respond, as I mentioned, beyond courtesy responses. I can tell you that the -meet -- at the time that all of this communication
 was occurring, I did not also have the time to be
 able to make decisions on that and so -- and I
 would really like to know which attorneys we're
 talking about, because once again, I don't want to
 conflate with the -- you know, people who have been
 -- who attempt to contact me, so I would love to
 know the names who might be that we're talking
 about here.
- Q. Sure. Has Paul Farrell, Jr. contacted you about testifying in the case brought on behalf of Cabell County?
- A. Yes, and that may be the e-mail that I have provided -- had provided a courtesy response to.
- Q. And do you currently intend to testify at trial in this case?

MR. COLANTONIO: Well, if he's subpoenaed to testify at trial, then depending on what the subpoena is -- I mean, he'll -- he'll, you know, respond to that appropriately.

Page 29 But are you asking him if a lawyer for 1 2 the plaintiffs has asked him to appear voluntarily 3 or -- I'm --I just want to make sure we're being 4 clear. 5 MS. JINDAL: I am asking him: 6 7 Do you plan to testify at trial currently? 0. I have not been asked to testify beyond my 8 Α. 9 appearance today for trial. MS. KEARSE: This is Anne Kearse. 10 11 me just -- you know, Doctor Gupta is represented by 12 counsel, so our communications upon finding that 13 Doctor Gupta is represented by counsel have been through counsel, so I just want to make that record 14 15 there too as well. And there has not been some direct 16 17 contact once we realized he was represented by 18 counsel. 19 MR. FARRELL: And this is Paul 20 Farrell. Hey, Doctor Gupta, will you come testify 21 at our trial? THE DEPONENT: If I am available and 22 23 if I can, I would be able to do that. 24 MS. KEARSE: Thank you, Doctor.

Page 30 BY MS. JINDAL: 1 2 Ο. All right, Doctor. If you are called at 3 trial, what do you expect to testify about? MR. COLANTONIO: Object to the form. 4 5 I would provide my expertise, my experience and the knowledge that I have with respect to both 6 7 being a local health officer for Kanawha County, Putnam County as well as the State's Health 8 9 Commissioner for Bureau of Public Health and the state health officer. 10 11 And we did hear -- we did talk briefly 12 about another opioid litigation that's currently 13 going on, the state MLP case. Do you have any intend to testify currently -- do you have any 14 15 intention to testify in that case? MR. COLANTONIO: He -- he'll testify 16 17 in that case. 18 My response would be very similar, because if I am asked to, I would consider, subject to the 19 availability to do that. 20 21 Q. And will the subject of your testimony be the same, or different? 22 MR. COLANTONIO: That hasn't been 23 24 determined yet.

- A. As I am asked, I will be able to provide that.
- Q. And Doctor Gupta, other than your expertise, experience and knowledge in the -- in -- through your work at the local -- as a local health officer for Putnam and Kanawha County Health Departments as well as your work as State Health Officer and Commissioner for Bureau of Public Health, is there anything else that you expect to testify about in this case?

MR. COLANTONIO: Object to the form.

- A. I have certainly provided national expertise and would be able in a limited amount of circumstances, subject to my expertise to provide national trend information.
 - Q. When you say "national" --

MS. KEARSE: This is Anne Kearse. Let me just say it again: Doctor Gupta obviously has extensive history in the state of West Virginia on the opioid epidemic, and so he's being deposed today for you to inquire about what he knows about the public health hazards associated with opioids and what it's done to the state.

So the fact that he may not know

Veritext Legal Solutions 888-391-3376

Page 32 specifically what question we're going to ask him 1 2 at trial, to the extent he comes to trial, I think 3 that is an unfair question to ask him what he's going to be asked. He's got extensive knowledge about the 5 public health crisis in the state of West Virginia 6 7 that includes the City of Huntington and Cabell County, so I would suggest you move on and just ask 8 9 him the questions about what he knows and what he 10 knows about the health epidemic. 11 MR. RUBY: Anne, it's a fair question 12 -- let's not -- let's not have this speech making. 13 If he intends to testify, it's perfectly fair game, and let's not have -- let's not have the speaking 14 15 objections, please. 16 MS. JINDAL: Thank you, Steve. BY MS. JINDAL: 17 18 Doctor Gupta, when you say "national expertise, " what do you mean? 19 20 With regards to the opioid crisis and the Α. 21 public health crisis resulting from the opioid 22 crisis. 23

Q. Thank you, Doctor. And any other subject matter with regard to your testimony?

24

Page 33 MR. COLANTONIO: He'll respond to 1 2 questions as asked. I think that's -- go ahead, 3 Doctor, if you can have a magic ball and figure out what they're going to ask you, go for it. 5 I will be happy to respond to the questions and know that my portfolio and I will keep 6 7 reiterating that was not exclusively limited to opioids during my tenure, so I'm unable to answer 8 9 what I would testify to not knowing what the questions will be. 10 11 I understand that, Doctor. Have you been 12 retained as an expert - if you are familiar with 13 that specific term in the context of a legal case by plaintiffs in the -- in this case? 14 15 MR. COLANTONIO: No. 16 Ο. Have you been retained -- I'm sorry. 17 Doctor Gupta, you can respond. 18 Α. No. 19 MR. COLANTONIO: No, to the extent 20 that that involves a legal --21 Ο. Thank you. Have you --My response is "No," but with a caveat that 22 23 I am not really aware of what the legal meaning of 24 -- of this -- he says, what this question is.

Page 34

Q. Sure. I guess have you been asked to -MR. COLANTONIO: I'm sorry, I don't
mean to interrupt, but just so we're clear, he's
not been retained as an expert, but he has a volume
and wealth of factual information about these
issues, and he also is prepared to render opinions
if asked about these issues.

So while he's not retained as an expert, he's both a person who has facts and is prepared to render opinions.

- Q. Doctor Gupta, are you -- have you been asked to draft -- write any expert reports about your work or experience or knowledge relating to the opioid crisis in West Virginia?
- A. I have been asked to provide my opinion, my -- using my knowledge, asked to -- what would it take to solve the problem that we're facing.

MR. COLANTONIO: And just so we're clear, again, the doctor is not used to the process, so just -- I'm going to put this on the record. He's been retained as a consultant in the MLP case on the issue of maintenance at this point, so I think he's speaking with that.

But just to be clear, he has

information and opinions about other issues, so if he's asked the questions, he'll respond.

- A. I think one of the challenges for me is to be able to differentiate between what case and what specific legalities, so do let me know on that aspect as you ask those questions.
- Q. I will, Doctor. Your answer is perfectly fine. I understood what you meant. Thank you. I just want to have one little clarifying question.

 When you said, "solve the problem we're facing," do you mean the opioid abuse problem in West Virginia?
 - A. Yes. And the public health ensuing crisis.
- Q. Thank you. Doctor, do you have a general understanding of the system of distribution for prescription opioids?
- A. My role as the State Health Commissioner and public health officer, I have a broad bird's eye view of the understanding of the system of distribution.
 - Q. What is that understanding, sir?
- A. My understanding is that based on the quota that's determined by the DEA, manufacturers are able to produce the volume of those pills and then the distributors are able to as registrants of

Page 36

the DEA - able to provide that volume of pills to other registrants in terms of pharmacies which then fill the prescriptions that have been written by licensed providers.

- Q. You mentioned DEA registrants. Are you familiar with that registration process?
- A. To the extent that I am a -- one of the registrants of the DEA to prescribe scheduled substances, I am familiar.
- Q. Doctor Gupta, what -- please describe your experience registering as a DEA -- as a DEA registrant authorized to prescribe Schedule II controlled substances.
- A. So my initial registration was many moons ago, so I can probably recollect that most of the experience will be renewing my DEA registration, which has to occur every two years.

That involves going through a process at the very beginning, we go on the website, the DEA; we enter our DEA number and a few specifics like Social Security number and date of birth; and it opens up a form.

You provide your specific information; you acknowledge to being able to prescribe; and

then there are a few other questions that you have to answer, you know, and then you pay the appropriate fees unless you're waived, you work in government, and that makes your registration.

1.3

I know this so well because as my registration was expiring this month, I've just done that last week.

- Q. You said that you have to provide specific information on a form. What kind of information do you have to provide?
- A. It's all electronic. You have to provide your practice location, your mailing address, if you are going to be prescribing or anticipate/plan to prescribe Schedule II, III, IV substances.

You also have to attest that, obviously, you have not have had a felony and other offenses, asks you to testify to that.

So it's mostly details: Street address of your work, your mailing address, things of that nature.

- Q. And when asked to describe your current prescribing or plans to prescribe controlled substances, how did you respond this month?
 - A. There isn't a lot. I just -- I believe --

my recollection is that there is a box that you have to check or at least somewhere that you are going to prescribe those substances, that you are eligible to prescribe those substances.

There is also a place where you have to provide your medical license information, including the state, so those are some of the areas.

- Q. And that's all part of the renewal process, correct?
 - A. Yes.

- Q. As best as you can recall, what was the initial registration process like?
- A. What I can recall, it was more extensive than the renewal process, but that's the extent that I can recall at this point.
- Q. And this is the process that all physicians who want to or need to prescribe controlled substances need to go through to be able to do so.

 Is that correct?
- A. I would say all prescribers, because prescribers may include physicians, but they may not be exclusively physicians.
- Q. You're right, Doctor. This is a process that all prescribers need to go through to be able

to prescribe controlled substances in the United States, correct?

A. To my knowledge, yes.

- Q. And as you said earlier, this is also a process that all pharmacies who dispense prescription opioids also need to go through.

 Correct?
 - A. To my understanding, yes.
- Q. Right. I understand you're not familiar with the details of the process on -- from the perspective of a pharmacy, but you do understand that pharmacies also need to be registered with the DEA to receive and dispense controlled substances?
- A. My understanding is that -- that all those who are involved in the -- from a manufacturing, to distribution, dispensing and writing prescriptions have to be registrants of the DEA.
- Q. You said you learned about this process through your work as a Commissioner for the Bureau of Public Health. Do you recall approximately when you came to learn about this process?
- A. The process of being registered is something that occurred way back when I was -- I was going through finishing up my residency and

getting into clinical practice. I could not tell you exactly, but approximately -- I finished my residency was in 1999, so that would have been around the years based on my license, permitted license, that I would have filled out that process.

So I would be aware of the DEA registration process since that time.

- Q. I see. Thank you. I -- my question was confusing. We started by talking about the system of distribution for controlled substances. When did you become generally aware of that system of distribution?
- A. So it was -- it was more during my term as the health commissioner and the state health officer because I was engaged in addressing the opioid crisis and the public health consequences that I became more aware and became more in contact with the Board of Medicine, the Board of Pharmacy and the controlled substances monitoring program and that was the time during which I came to know much more about the process than I had previously.
- Q. And beyond the requirements for all of the actors in the supply chain to be DEA registrants, what else have you learned about the -- that

Page 41 process? 1 2 Α. I'm sorry, if you can ask me a more 3 specific question? I'm not sure I can answer it and address my four years of experience in one question. 5 No, so I'm asking specifically with respect 6 Ο. 7 to the system of distribution. For example, are you aware also that distributors are -- as you 8 said, through your work with the Board of Pharmacy, 9 that they're regulated by the West Virginia Board 10 11 of Pharmacy in West Virginia? Is that correct? 12 Α. I'm sorry, can you repeat that, please? 13 Sure. You said you learned more about the Ο. system of distribution during your term as 14 15 Commissioner, correct? 16 Α. Yes. 17 And you said part of that learning came 18 from your work with the Board of Pharmacy. 19 Correct? 20 Α. Correct. 21 Ο. Could you describe in detail --22 MS. JINDAL: Strike that. 2.3 What did you learn from your work with the Ο. Board of Pharmacy with respect to the system of 24

distribution for controlled opioids?

2.4

A. I do think, Ms. Jindal, you know, that this is an area of process that you're meeting with the Board, you're attending their meetings, providing perspective and you're learning over time.

So it's very difficult for me to outline that as one, two, three, four, five things. But broadly speaking, I developed a better understanding and a more improved understanding of the process of distribution from the volume to the prescribing and dispensing.

We worked closely both to understand what was going well, what was not going well, what were the components of the controlled substances monitoring program; what were the obligations.

Also -- within the Bureau of Public

Health. But also, what can we do more? I mean,

part of my work was not just learning, but also

trying to and attempting to - oftentimes struggling

to - find solutions to a crisis that we did not

create.

Q. You said one of the things that you learned more about was the volume. What do you mean by that?

A. What I mean by "the volume" aspect is, clearly by the time I became Commissioner, it was becoming more relevant and more clear that there was a volume issue when it came to the deaths and the suffering on the streets.

What that meant was, the overwhelming volume that was reaching the people of West Virginia was plainly involved in the killing of West Virginians almost every 12 hours around the clock, and that became important to us, as well as other sufferings that were occurring.

Q. Volume of what?

- A. The volume of prescription opioid pills.
- O. And what was the source of that volume?
- A. So the source of that volume clearly was coming from -- through the manufacturers and distributors into the state of West Virginia and then through the pharmacies, being dispensed into the hands of innocent public.
- Q. You said you also looked at what was going well and what was not going well. What did you think was going well?
- A. Well, by the time I came into the office, clearly we had passed some policies -- please mind

you, that these are downstream efforts. We were drowning, and we were trying - struggling - to do what we could do at a city, county and a state level to help people survive.

So what we did was, we had passed several pieces of legislation and policy that had made its way into commonplace, which means that we had by the time figuring out how to get physicians trained into understanding how diversion occurs, how they could prescribe more responsibly to prevent that diversion. Although they're trying to help the people that they're working with, meaning their patients.

We were looking at figuring out how to provide the antidote called naloxone into the hands of the public so they can actually get an opportunity to live.

We were trying to figure out how to control -- you know, provide limitations to the -- some of the bad docs, and how do we go after those bad docs?

So there was a whole host of initial work that was happening in terms of downstream attempts to control what we could control, what was

within our hands, our power, to be able to do, at a cost that was overwhelming.

Because at the same time, we were having more and more children going to foster care. Our child welfare cost was rising at an enormous rate that we were having difficulty to control, controlling the budget for the state.

So we were at the edges of going bankrupt as a state, and primarily the crisis was being driven but through the volume that was coming up upstream to us.

So those were some of the things that we were attempting to do. We were also trying to do justice reform, criminal justice reform, reininvestments into -- because what we found was a significant proportion of people that were ending up incarcerated had substance abuse problems, and that was primarily the reason, and they were not being helped by being incarcerated and being in prison.

We were losing -- as I mentioned, every 12 hours, we were losing a working West Virginian, never to come back again, so this was a transgenerational crisis.

Page 46

Q. Doctor, did your -- you said that you focused on educating physicians about diversion and how to prescribe more responsibly. Did that help address the volume issue you were talking about?

A. So yes, in an incremental way. We were taking baby steps to a problem. I would hasten back to the dam was broke, our cities were being flooded and now we were trying to put sandbags to form some type of levy while people are dying because of the flood.

That's literally what was happening in West Virginia.

- Q. I see. And then when you said that you limited or tried to go after bad doctors, did that also help with the volume issue?
- A. Again, in incremental ways, but right now, having the hindsight, I don't know if it helped or hurt more.
 - Q. Why do you say that?
- A. I say that because every time we went after bad doctors, we shut the operations down. There were some really legitimate and credible patients that need -- also needed pain medications. They could not find other physicians and prescribers in

Page 47 the community. 1 2 There were some people who had 3 addiction to these things that could not find addiction treatment facilities. So what would 5 these people do? That we learned again in hindsight. 6 7 They would go and try to seek these pills on the street. And as we were attempting, in 8 9 our way, incrementally to reduce the supply on the street through these actions, they were starting to 10 11 transition into the more readily available cheaper and affordable street alternative, which was at the 12 13 time heroin, and other -- some of the other injection drugs. 14 15 There's a lot there, Doctor, so I'm just 16 going to try and take it one at a time. 17 Let's go back to the -- you said that 18 these actions only helped curb the volume of prescription opioids in an incremental way. Did 19 you do anything --20 21 MS. JINDAL: Strike that. Let me 22 rephrase my question. Did you take any actions to regulate the 23 2.4 conduct of distributors?

Page 48 I'm sorry, object to MR. COLANTONIO: 1 2 the form of the question. Are you asking him as a 3 State Health Officer if he somehow can regulate through the Controlled Substances Act the distributors? 5 I'm not sure I understand your 6 7 question. MS. JINDAL: Sure. Let me rephrase. 8 9 Q. Doctor, as State Health Officer and as Commissioner for the Bureau of Public Health, you 10 were in a position to propose legislation, correct? 11 Yes. 12 Α. 13 And you were also on the Governor's Council -- Advisory Council on Substance Abuse, correct? 14 15 Α. That's correct. And these positions put you in a position 16 Ο. 17 to offer suggestions for what could be done to 18 abate the opioid problem in West Virginia, correct? 19 Α. Yes. 20 And you also testified that you learned 21 about the system of distribution through your work on these -- on these committees and in your 22 position as Commissioner for the Bureau of Public 23 24 Health, correct?

A. Yes.

- Q. At the end of all that, did you propose any solution or regulation or law that was directed at the conduct of wholesale distributors?
- A. As a result of all of the aspect of questions that you've asked me, we did put a task force together and did everything possible under the sun under my authority in the state of West Virginia that we could do to address this terrible killer of a crisis that was happening.

And I'd be happy to talk to you about that.

- Q. Okay. Doctor, that was not my question. Did you ever propose a course of action with respect to the conduct of wholesale distributors and geared at abating the opioid problem in West Virginia?
- MR. COLANTONIO: Objection to the form.
 - Go ahead, Doctor, if you can answer that.
 - A. I did not have -- as State Health Officer, did not have the authority to propose and control the Controlled Substance Act, a federal law, and as

Page 50

part of the authority of state health commissioners all across the country, we have the ability to do what we can within our states and our communities, and that's exactly what I was attempting to do:

MR. RUBY: I'm going to call a time-out here and just note for the record that the witness' answer is parroting the improper speaking objection in which his counsel coached him to give testimony as to the Controlled Substances Act, and I'm going to ask counsel to refrain from speaking objections to coach the witness as to how you'd like him to answer.

MR. COLANTONIO: Well, that wasn't intended as a speaking objection, Steve. It was an objection intended to be a proper objection, so we'll move on and I'll object as I see fit, and you can --

MR. RUBY: Well, no, no, the -- we make objections to form. We don't make an objection and ask if the question is asking the witness whether he had the authority do thus and such under the Controlled Substances Act and then invite him to testify - as he just did - that he didn't have the authority to do thus and such under

Page 51 the Controlled Substances Act. 1 2 That's exactly what happened there, 3 and we're not going to -- we're not going to put up with that as the day goes on. MR. COLANTONIO: Yeah. Whatever. 5 MR. FITZSIMMON: Steve, the witness 6 7 wants a break also. MR. COLANTONIO: Oh, okay. Can we 8 9 take a break now for a few minutes? MS. JINDAL: I just have a couple more 10 11 questions, and then I think we can take a break if 12 that's okay. 13 MR. COLANTONIO: Go ahead. BY MS. JINDAL: 14 Doctor Gupta, through your work with the 15 16 Board of Pharmacy, are you aware that the Board of 17 Pharmacy licenses and regulates distributors in the 18 state of West Virginia? What I'm aware of is that the Board of 19 Pharmacy does have the ability and the authority to 20 21 provide the licensing and -- for the distributors, 22 yes. 23 And members of the Board of Pharmacy were 24 on the Governor's Advisory Council for Substance

Abuse, correct?

1

3

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- A. I do not recall that at the time. I mean, I think we can check the record on that.
- Q. Okay. But you were able to call someone up at the Board of Pharmacy if you wanted to while you were Commissioner, correct?
 - A. That would be reasonable.
- Q. Okay. Did you ever call someone at the Board of Pharmacy and ask them to look into the conduct of wholesale distributors?
- A. I would have conversations all the time to be asking the Board of Pharmacy to make sure that they do everything they can under their authority to help us reduce this crisis.

So the answer is yes.

- Q. And do you think the Board of Pharmacy has done all it could to help abate the opioid problem in West Virginia?
 - MR. COLANTONIO: Object to the form.
- A. My knowledge and my interactions lead me to believe with the small, minuscule sometimes staff that they had that they did everything that they potentially could to respond to the crisis.
 - Q. And if they continued to license and renew

Page 53 the licenses of wholesale distributors --1 2 MS. JINDAL: Strike that. 3 Q. Are you aware that the Board of Pharmacy, like the DEA, requires renewal of licenses? I would assume so at this time to the best 5 of my knowledge that that would be the case, just 6 7 because I am a registrant of the DEA and I am required to make sure that I renew my registration. 8 9 That would be the same mechanism for any of those. 10 And if you had a particular concern with the conduct of wholesale distributors, you would 11 12 expect that Board of Pharmacy -- you would have shared that concern with someone at the Board of 13 Pharmacy, correct? 14 15 MR. COLANTONIO: Object to the form. 16 Α. Can you repeat that question? 17 Sure. You said you asked the Board of Ο. 18 Pharmacy to do anything and everything within its power to help abate the opioid problem in West 19 Virginia, correct? 20 21 Α. Yes. And if you had any particular concern about 22 conduct of wholesale distributors, you would have 23 24 communicated that in those discussions, correct?

A. Just so you know, my previous statement still holds, because I specifically requested to the Board of Pharmacy and its leaders to do everything in their power to help us stop the killing of West Virginians by the hour, and that in -- that wasn't exclusive of anyone.

That was inclusive of every aspect that they can do and turn over every case that they can.

- Q. Did you ever have any specific conversations regarding the conduct of wholesale distributors?
- A. I did not have specific conversations that I can recollect at this time. I can't recall specific conversation, and please note this has been several years ago.
 - O. Understood.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

MS. JINDAL: I think we can go ahead and take a break now. Maybe about ten minutes, Doctor?

THE DEPONENT: Sure. Thank you.

VIDEO OPERATOR: Going off the record.

The time is 10:11 a.m.

(A recess was taken after which the proceedings continued as follows:)

VIDEO OPERATOR: This begins Media
Unit 2 in the deposition of Rahul Gupta, M.D. We
are back on the record. The time is 10:26 a.m.
BY MS. JINDAL:

- Q. Doctor Gupta, you had -- had you heard of Cardinal Health before you became Commissioner?
 - A. I had not.

- Q. When did you first hear of Cardinal Health?
- A. I do not recall a specific date and time.
- I would say somewhere in 2015, I would have heard it, after joining in January my position.
- Q. In what context did you hear about Cardinal Health? How did you first learn of them?
- A. It's very difficult to recall for me at this point in what context. At this point, I think it would have been around the opioid crisis as well as, you know, what can we do to solve the crisis and, you know, what's the mechanism --

It's my sort of practice to under -when I -- when I go into a position, to understand
the -- both the entire history as well as where we
are we going with it and that sort of thing. So it
would have been my attempt to better get a
comprehensive view of the crisis.

Page 56 Within my purview, I had about 130 1 2 different program lines with -- you know, sort of 3 mandate, statutory mandate to monitor the public health and its consequences across the state of 5 West Virginia, and so this would have been my attempt during that time to better get to 6 understand the most current and devastating public 7 health crisis that was eating up the state, and 8 9 that's what --You know, in the process of 10 11 understanding and learning more -- more comprehensively the crisis, I would have -- it 12 would have come to understand that -- I would have 13 come to understand that. 14 15 Have you ever had any professional interactions with an employee of Cardinal Health? 16 17 Α. Not that I'm aware of. 18 And is the -- had you heard of McKesson Ο. before you became -- McKesson Corporation before 19 you became Commissioner? 20 21 Α. No. And when did you learn about McKesson 22 23 Corporation? 24 I would say it would have been very similar Α.

to the details I provided about Cardinal Health.

- Q. And have you ever had any professional interactions with an employee of McKesson?
 - A. Not to my knowledge.
- Q. And is your answer equally applicable to AmerisourceBergen Drug Corporation?
 - A. I would say yes.

1

2

3

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. And just to be clear, that -- you mean that you had not heard of AmerisourceBergen before you came Commissioner?
- A. That's correct, to my ability to recall at that time.
- Q. And as best as you can recall, you learned about ABDC, AmerisourceBergen Drug Corporation, after you became Commissioner while you were learning more about the opioid problem in West Virginia?
- A. That's to the extent that I can recall at this time.
- Q. And as far as learning more about the opioid problem after you became Commissioner, do you -- just at a high level, what sort of sources did you rely on?
 - A. I relied on a number of nationally-known

1 sources, state level sources, regulatory sources.

2 So that would be the reports that may be coming out

from the CDC, from other federal agencies. It

4 | would be media reports as well, both national,

5 state and local.

3

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

It would be talking to families individually and -- because I was on the ground dealing with the deaths literally every single day.

It would also be the state reports as well as the data that we would be collecting as well as monitoring and providing reports.

It would also be the chief medical examiner's office that was under my purview, that -- the challenge that we were going through to deal with the death and destruction on a daily basis and the challenges that we were having with resources.

It would be the legislature, West

Virginia legislature. That would be -- you know,

some other -- other sources as well that I cannot

recall at this time.

- Q. And do you recall West Virginia's lawsuit against wholesale distributors?
- A. I do not recall a lot of -- any significant great detail at this time.

Q. But do you recall the fact that West Virginia filed suit against Cardinal Health, AmerisourceBergen and McKesson Corporation?

A. At some point in my thinking back in my time at -- as a Commissioner, I would have been contacted by the general counsel of the -- my parent agency - Department of Health and Human Services - to both brief me as well as ask for work in understanding better the opioid crisis and the devastation it was causing in terms of these programs we had, as well as then to -- to be deposed subsequently.

That would be the context, now looking back, that I would learn about that.

- Q. Did you ever have an opportunity to read the Complaint in those cases?
 - A. I do not recall.
- Q. Did you agree with West Virginia's decision to file suit?
 - MR. COLANTONIO: Object to form.
 - A. I don't think I could provide you an opinion there, because that was something that was existing before my time. I had no input into that decision-making process.

Page 60 I'm going to go ahead and switch gears now 1 2 and talk to you a bit about your background. 3 you have an undergraduate degree? I have a one-year bachelor of science. So 4 5 I do not have a full undergraduate degree. And where is that from? 6 Q. That's from University of Delhi. Α. And when was that? Ο. 8 9 Α. That was 1987 to 1988. 10 Ο. And what did it focus on? 11 Α. It focused on biology. So bachelor's of science in biology? 12 Q. 13 Correct. Α. And you -- do you have any advanced 14 Ο. 15 degrees? 16 Α. I do have a doctor of medicine degree. Ι 17 have an additional master's of public health. And a master's of business administration. 18 19 Doctor Gupta, if I could ask you to open Ο. 20 Exhibit 51. 21 GUPTA DEPOSITION EXHIBIT NO. 51 22 (Resume of Rahul Gupta, MD, MPH, MBA, 2.3 FACP (WVSMA FEDWV 00039036-091) was 24 marked for identification purposes as

Page 61 Gupta Deposition Exhibit No. 51.) 1 2 MS. KEARSE: I'm sorry, what exhibit? 3 MS. JINDAL: 51. 5-1. Α. I have it. Doctor Gupta, are you familiar with this 5 document? And I'll specify. Are you familiar with 6 7 the attachment to this e-mail that was sent to you? Yes, it seems like it's my resume. Α. 8 9 Q. And was this your resume as of March 23rd, 2017? 10 11 I'm going to check. I'm just using the date of the e-mail, 12 Q. 13 Doctor. Yes, I see the date on the e-mail, and that 14 15 is the appropriate attachment that it should be. And did you draft this resume? 16 Ο. 17 I would -- I would think so. 18 Doctor, if you turn to -- do you see in the Ο. lower right-hand corner of each document, there are 19 two Bates stamp numbers? They start with some 20 21 letters WVSMA here and then they end with a serial 22 number? 23 Α. Yes. 24 Q. I'm going to ask you to focus on the top

Page 62 document when we review the documents. And the top 1 2 number -- could you please turn to the page that 3 ends with 9042? MR. COLANTONIO: 9042. 4 5 THE DEPONENT: Yeah, I've got it. I believe it's page 6 of your resume, if 6 7 that makes things easier. Α. I see it. 8 9 Q. Okay. And you see the heading "Education"? 10 Α. Yes. 11 And does that accurately reflect the dates Ο. 12 and universities from which you have received those advanced degrees that we just discussed? 1.3 Α. Yes. 14 15 And did you complete your residency training at St. Joseph Hospital in Northwestern --16 of Northwestern University in Chicago, Illinois? 17 18 Α. Yes. And what did you complete your residency 19 Ο. in, Doctor? 20 21 Α. Internal medicine. And do you have any special trainings or 22 certificates? 23 24 Α. I trained prior to my residency in

Page 63 pulmonary medicine. That's listed as "Chest 1 2 Diseases and Tuberculosis" with a two-year diploma, 3 and then I have had since then the special training in public health as reflected here with an M.P.H. 5 degree from the University of Alabama-Birmingham, and it was followed by a specialization in business 6 7 administration that is listed as the M.B.A. in Information and Technology Management. 8 9 Q. Aside from the subspecialty training of chest disease and tuberculosis and your training in 10 11 internal medicine, have you had any other specialized medical training? 12 13 Α. No. And have you -- have you had any -- aside 14 15 from these trainings, do you participate in any ongoing physician education? 16 17 Α. Yes. And is that pursuant to any active licenses 18 that you currently have? 19 20 Α. Yes. 21 Ο. What are those currently active licenses? License to practice in the state of West 22 Α. Virginia. 23 24 Q. And have you principally practiced as -- in

- internal medicine since you completed your
 residency?
- A. I have practiced in the areas of internal medicine, primary care, family medicine, as well as I had to also cover the emergency room on occasions in the past.
- Q. And I'm going to try and save us some time.

 Rather than -- does -- if we can, could you please
 go through the various hospitals and clinics that
 you've worked at over the years since you completed
 your residency?
- A. I certainly can. Would it be okay if I use my listed Exhibit 51 as a reference?
 - Q. Absolutely.

1

2

3

5

6

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

22

23

24

- A. Thank you. Can you please clarify exactly what aspects you want to cover -- want me to cover?
- Q. Sure. Let me clarify the question. On page Bates stamped at the end, last four digits are 9039, page 3 of your resume --
 - A. Yes.
- Q. -- after you completed your residency, did you practice as a physician, as a primary care physician, as Florala Medical Clinic in Alabama?
 - A. Yes.

- Q. And after -- and you were there for four years?
 - A. Yes.

- Q. And after you completed that, you became a physician at the University of Alabama-Birmingham?
 - A. Yes, in Huntsville, Alabama.
 - Q. And what was your practice there?
- A. I was a primary hospitalist, academic physician. My position was assistant professor of medicine for the school, and also did primary care. So I was an internal medicine hospitalist and then saw patients outpatient care as well and did teaching of the residency program and the medical school at UAB.
 - Q. What courses did you teach there?
- A. I taught internal medicine, public health, various aspects of internal medicine, as well as preventive medicine and public health.
- Q. Did any of your courses focus on treatment of pain?
- A. There was a broad focus on pharmacology of compounds. There was a daily focus in the hospital rounds on treatment, including treatment for pain, because we saw a range of patients admitted from

cancer and the end-of-life to all the way to, you know, broken bones, head trauma, accidents, neurosurgery, those type of patients.

1.3

So there was a various range of patients that we would typically see for a hospitalist, and so our education that I provided to -- in realtime, along with the School of Pharmacy, Auburn School of Pharmacy, was on a daily basis that we discussed management of conditions, including management of pain.

- Q. And in discussing the management of pain, did you teach with respect to the prescribing of prescription opioids?
- A. It's difficult for me to recall at this time specifically what was taught, but I could say that amongst the pharmacology and teaching would have included the appropriate prescribing of opioids and appropriate prescribing for antibiotics and a number of other groups of medications.
- Q. And when you say "appropriate prescribing," what would you consider to be the appropriate prescribing that you would have taught them?
- A. The appropriate prescribing would be one in which we utilized opioids not as first line and not

something for that is for everyone. But we actually made sure that these are treated as serious medications, prescription medications, potentially deadly medications, and they are provided to patients when the -- there is an appropriate indication for these medications.

- Q. And is that also what you taught with respect to antibiotics use?
- A. Yes. And in the antibiotic use, it would be a little bit different. We would focus on the development of resistance to antibiotics, which was also a major issue, and you would want to make sure -- as an example, just like that, you know, a very simple skin lesion with a little bit of inflammation, you would not be automatically jumping to prescribe opioids.

Same way if you had a cold, you would not be jumping to prescribe an antibiotics. Both of the results are not good for medicine and they're not good for certainly public health, and they have both of these examples have deadly consequences.

Q. So your approach to prescribing of opioids was similar -- was your general approach to

prescription -- to prescribing any medicine. Is that fair to say?

MR. COLANTONIO: Object to the form.

- A. My approach to prescriptions and care of the patient was primarily not only driven by data and science, but the oath we take to first do no harm, and I happen to take that very seriously, and I made sure that my residents and my medical students and my pharmacy students and nursing students were taught the same approach.
- Q. And after you left the Florala Medical
 Clinic -- I'm sorry, after you left the University
 of Alabama-Birmingham, you then taught at
 Vanderbilt University; is that right?
- A. I was the primary faculty at Meharry
 Medical College which is also at Nashville, with a
 secondary appointment at Vanderbilt Medical Center.
- Q. And you were both practicing and teaching in those places as well?
- A. Yes, I was practicing primarily at

 Nashville General Hospital, downtown Nashville. I

 was both a hospitalist, very similarly placed, but

 also a primary care and an outpatient physician in

 a very inner city environment where we had a lot of

African-American urban population with a little bit of different set of challenges that was to consult.

We -- this was the only public hospital in Nashville, surrounded by several private hospitals, so the population was a little different. But I was still also teaching medical students of the Meharry Medical College as well as the internal medicine program residents and typically involved in helping the residency program become successful.

- Q. And did any of the courses there involve or relate to management and treatment of pain and the use of prescription opioids?
- A. So my teaching is very similar to what I was doing in Huntsville. It involved daily rounds and hospitals when I was posted to the wards, so to speak, and understanding and teaching students how to properly manage various medical conditions, including pain.

We also had an incarceration, like a jail ward, on the top floor, which was very similar, but it was important to have the students and residents understand that the concepts of both pain management as well as good medical management

are not contradictory to each other.

- Q. So you didn't teach any specialized courses concerning the management or treatment of pain?
- A. I don't -- I did not -- I did not teach any specialized courses.
- Q. And then after your time in Tennessee, is that when you moved to West Virginia in 2009?
 - A. Yes.

- Q. And when you moved to West Virginia, what were you doing?
- A. So when I moved to West Virginia, I became the health officer for Kanawha/Charleston Health Department. That was a combined city/county health department, the largest in the state, local health department.

I was the local health officer, physician director. So my responsibility and jurisdiction was Kanawha County. And the responsibility was amongst various aspects that included everything from monitoring safe water to air to making sure that there were clean indoor air regulations, that people -- various programs of health and prevention, while making sure that restaurants were properly monitored for the food

code, the sewage, the licensing of making sure that, you know, there were proper sewage and air conditioning and other things -- aspects.

Hotels, licensing, making sure that they were properly done from a health aspect.

So I was responsible for all of those public health aspects of the county.

I was also teaching at the same time.

I obtained as a -- I don't exactly remember -- I'd have to go back to my resume and look at it as to when, but a faculty appointment at West Virginia University as well as University of Charleston.

I became a clinical teaching faculty at the largest hospital in the state of West Virginia, which is CAMC, and I was also volunteering at the local charitable clinic called Health Right, West Virginia Health Right.

- Q. What prompted you to pursue a career in public health at that point?
- A. The primary driving force for me was as a primary care physician in a town of about 850, Florala, I was seeing a lot of challenges that were primarily public health in nature.

I was also seeing at the same time that

Page 72

whereas I had a more traditional evidence-based approach, I did have colleagues that were much more liberal - who we know now as bad doctors, by the way - in opioid prescribing.

But that wasn't the only piece. It was part of the conversation that prompted me to seek a better understanding of our systems, our health policy and our health care systems, and that's the reason I got my master's in public health after which --

Because during the same time, I would consult with UAB, and I recognized that, you know, a confirmation health approach as pretty decently good as I was in clinical medicine, to understand and just had mostly clinical teaching in the wards and on the campus --

-- that I could have a larger impact in addressing the more population aspect of crises and challenges that we face, whether it's obesity, the consequences of which, or other aspects.

And that was the primary driver for me to be able to do good at a much larger upstream level, just to be more impactful in addition to individual level of care which I still felt was

important to be grounded.

That was the reason that I continued to donate my personal time to the charity clinic in addition to understanding and working on policy and other problematic aspects of public health.

- Q. I want to go to the beginning of your answer there, Doctor. You said you had some colleagues at Florala Medical -- I don't recall the name.
- -- Florala Medical Clinic in Alabama who you characterize as "bad doctors."

Could you describe more about what your concern was there?

MR. COLANTONIO: Object to the form.

A. So you know, we're going to go back and I'm going to talk about this, having the benefit of doubt that we have today in 2020. But when I was there at the time in the year 2000, this was a time when I -- this is the Town of Florala, as well as my colleagues, were getting regular visits - if not daily, certainly weekly, multiple visits - from pharmaceutical representatives who were telling us that, yeah, we should prescribe and adequately treat pain.

Veritext Legal Solutions 888-391-3376

I was a front-line physician that was managing not only a full-time clinic, but also the emergency room of the local hospital every third day by rotation, every third weekend by rotation. So that was a lot of coverage.

And we were being bombarded at the time with these messages that were coming to us.

Samples were being dropped. And some of us took the approach of being driven still by data and evidence, whereas there were a few that did not.

And so those are the colleagues I talk about, which we now know as bad doctors, that perhaps at the time we hadn't recognized that they had incentives to be able to writing prescriptions -- did have patients come from far off, sometimes hundreds of miles away, line up in the parking lot, and having cash-only clinics.

These are not bad people; they were just what we know now as bad doctors. Not bad human beings, but just bad prescribers. And the ones at least I know, I know they were trying to help do the best they could for the training they received and they were sold a bill of goods that they felt that they were trying to help the

Page 75 patients. 1 2 Q. Do you recall ever expressing any concern 3 about the lack of data and evidence-driven prescribing? It's hard to go back 20 years or 15 years. 5 But yes, I generally -- and I say that because I 6 7 generally have a view of utilizing data and evidence to drive -- drive my decisions, whether 8 9 it's in policy making or clinical care. So I do remember being concerned about 10 11 this issue. As I was concerned, to be honest, at 12 the time -- as an example, we were using -- this is -- doesn't relate to opioids, but we were using a 1.3 lot of Celebrex and Vioxx. 14 15 These are jus -- you may or may not remember these medications, but they were also 16 17 being consumed and used. And I had done the review

These are jus -- you may or may not remember these medications, but they were also being consumed and used. And I had done the review of their initial studies, and that did show casualties. And I was skeptical about that too. That some of the patients I was seeing were having DVTs and they were having consequences.

So that's the level of detail that I

had happened to focus on. Many of my colleagues -

and most of my colleagues - did, but some did not.

18

19

20

21

22

23

24

1.3

Page 76

And so that's an example of where when all the prescribers were being sold the bill of goods, most decided to do the right thing and follow what they were taught to follow in medical school, but just follow the science.

And some fell victim to the message.

And as a result, now what we know became bad docs.

- Q. And when you say they "fell victim to the message," are you referring to the messaging from manufacturers about prescription opioids?
- A. I would overall generally say yes, and the reason for that is that the representatives that were coming to our offices did represent manufacturers, and they had a product to sell, bottom line.

But it was also other things which -you know, physicians were asked to go on trips, to
take weekends to other type of lavish and
extravagant type of investments that were being
made. I could not tell you who was making those
because I wasn't part of that.

But there were other aspects of this too.

Q. Do you recall ever a wholesale distributor

approaching you about prescription opioids?

- A. As I testified earlier, I was -- I do not recall any -- any wholesale distributors approaching me.
- Q. Have you ever heard any of your colleagues say they were approached by a wholesale distributor?
- A. At this time, it would be hard for me to recall that.
- Q. So you don't recall whether your colleagues have ever said that they have been approached by a wholesale distributor with respect to their prescription opioids?
- A. I don't recall that. I also don't recall them telling me that they were approached by manufacturers. So that's the rationale, that I just -- that is -- we talk more about patient care as -- and as the standards began to change for pain, we began to discuss and sort of in a scientific way, discussed the basis of the standards that were changing, not really how that was being caused --

At the time. I go back to this thing
-- it's very easy now in hindsight to look at this.

Page 78

But at the time that we were in, we were prescribers and primary care physicians who's first duty was actually to help our patients, because that's where we were engaged mostly. We were not in policy making.

And we would discuss the standards and how they're changing literally in realtime during the 2000s. That's what I do recall about that.

- Q. What do you recall about the change in standards with respect to treatment of pain? Or the use of prescription opioids?
- A. I recall that the American Pain Society promoted pain as being the fifth vital sign. At the time, I wasn't acutely aware that they were being supported with financing by a pain manufacturer or others.

I recall that at the time both the -what we know as Joint Commission now - but JCAHO
then - came out with recommendations for utilizing
pain as a vital sign, pushed by the American Pain
Society.

As I would be in the hospital in subsequent years, as a hospitalist, we would be subject to the ten-point pain scale with the happy

faces. That was a consequence of that.

And that all sort of played into changing the standard of pain as a fifth vital sign when we did not go to that extent to change other four vital signs at that time.

That's why it stood out, because we took a subjective symptom and we turned it into a vital sign without any of the data or research or work that had gone into the other four vital signs.

So in that sense, for many of us - for most of us, I would say - the standard of -- for pain were changing and evolving around the 2000s when I was practicing in Florala.

- Q. Doctor, going back to your resume, I want to draw your attention to the -- page 4 of your resume. It ends with Bates Stamp No. 9040.
 - A. I have it.
- Q. And I want you to focus on the bottom of this resume, it says you were an associate professor at the University of Charleston School of Pharmacy starting in 2011. How long did you teach there?
- A. I believe I should be still faculty there, but the last time would have been sometime before I

Page 80 left West Virginia. That would be in 2018 that I 1 2 actually taught a class. I could not recall an 3 exact month and time. But that -- you know, I taught there. 4 5 I teach at -- I was a professor at Harvard as well, as well as Johns Hopkins and West Virginia 6 7 University and Georgetown, so --And just continue to focus at the 8 Ο. 9 University of Charleston School of Pharmacy, I'm going to just talk to you about that first bullet 10 point there. You "Teach class on the role of 11 community pharmacist in addressing public health 12 13 challenges." Did I read that correctly? 14 15 Α. Yes. 16 Ο. What do you mean by "community pharmacists?" 17 18 So community pharmacists have oaths to pure -- and I'm not very well versed in the science of 19 this from a pharmacy standpoint but as opposed to a 20 21 retail pharmacy -- pharmacist or a wholesale 22 pharmacist. 23 Really relates back to the mom and pops 24 across the country, the pharmacists that are

Page 81

embedded in the community, that the role that they have in ensuring that they're addressing whatever the contemporary public health crisis or challenges may be ongoing in their own communities.

- Q. And when you talk about the public health challenges that could be going on in the community, do you have any specifics in mind?
- A. Yes. So I'll give you a couple examples.

 One, the class really came across because when I

 was in Florala, I would have oftentimes the person

 who owned the Florala pharmacy call me and say,

 "Hey, Doc, I've got two cases of diarrhea. You

 sure there's nothing going around, like a bug?"

So this was -- this was our community way of being the sentinel providers and working with each other to figure out challenges when the robust system -- to become those sentinel providers and detectors -- or these detectives. That was one example.

The other can clearly be -- at least part of what I taught, the second example was:

Okay, if you're starting to see a lot of prescriptions come in for opioids, that you really have to question that as well. And you could be

that sentinel provider that could raise that concern.

- Q. And do you talk about the role, I quess, as a sentinel in -- for prescription opioids in the class?
 - Α. Yes.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Ο. And what kinds of --MS. JINDAL: Strike that.
- Q. Let me put it this way. You said there were -- you know, you had a pharmacist who called you about two cases of diarrhea. In terms of educating your students, what did you tell them should generate or lead to a call to a physician about prescription opioids?
- An example would be if they start -- you're seeing a volume of prescriptions come from the same place or same prescriber or a prescription that doesn't look like -- it could have been fabricated, then you make sure you conduct your due diligence, your responsibility as a pharmacist - to these students - that you ensure that you're not dispensing any of these drugs that could potentially harm your community members.

Veritext Legal Solutions 888-391-3376

And remember -- I just want to add here

that these -- this is an example of the kind of things we were doing that would potentially help with downstream have some even a minute amount of incremental impact to help the crisis that we had not generated or we had not caused.

1.3

- Q. And do you believe there are pharmacists who failed to fulfill the community pharmacist role in West Virginia?
- A. I can only base my opinions on reports that I would read like the public or anyone else. I do not have any data or knowledge beyond that.
- Q. Based on those reports, what is your opinion?
- A. My opinion is that there was plenty of blame to go around, and there was definitely, you know, some pharmacies in West Virginia that could have done a better job at conducting their own due diligence.
- Q. Do you have any particular pharmacies in mind?
- A. Not at this time. I -- you know, I haven't reviewed the data and everything. This has been a while back.
 - Q. At one time, did you have any particular

pharmacies in mind?

- A. I'm sure I did. I do not recall at this point.
- Q. Do you recall what you did once you learned that there might be some specific pharmacies who are failing to fulfill their community caretaking role or maybe not conducting their due diligence?
- A. I am not sure if I was a physician -- if I was in Florala and I was reading about a pharmacy and kind of see -- I don't think I had the role or the ability to influence that, unfortunately.

And that goes back to my answer about why I decided to go to public health.

- Q. Sure. I'm actually focused on pharmacies in West Virginia. So let's just stick to your time in West Virginia from 2009 on. Did you ever come to believe that pharmacies in West Virginia were not fulfilling their community caretaking role?
- A. So the time that I was the local health officer from 2009 to the end of 2014 -- I'm trying to recall if there were any times and I can't within my jurisdiction that we had a problem and I did not recognize those.

I don't remember that -- being aware at

the time of that.

2.3

Q. Okay. And then while you were a Commissioner or -- and on the Governor's Advisory Council on Substance Abuse, were there any particular pharmacies that were brought to your attention as ones that were problematic or had failed to fulfill their role as community care -- community pharmacists?

And again, focusing on West Virginia pharmacies.

A. So that wouldn't be brought to my attention because that would be brought to the attention of the Board of Pharmacy and I would not be made aware of that, because those investigations would be confidential in nature.

So that would be the reason that I wouldn't be made aware of that. My knowledge comes still from the published reports at the time, as I've stated earlier.

- Q. And did you refer any West Virginia pharmacies to the Board of Pharmacy for investigation?
- A. I would have no cause to investigate or find any cause to report those pharmacies. Back to

my earlier assertion that, you know, in my contact with the Board of Pharmacy, and being secretary of the Board of Medicine as well as the State Health Commissioner of Public Health and State Public Health Officer, my singular message was - for the Board of Pharmacy - do everything they can within their power and within their jurisdiction to ensure that they curb the supply that's coming out in the state of West Virginia.

- Q. And if you ever heard a patient describe a interaction with a pharmacist that you believed to be problematic or not fulfilling his role of a community pharmacist, would you have referred that pharmacist or pharmacy to the Board of Pharmacy for investigation?
- A. I would. I just don't recall that -- you know, specific instances. But my --
 - Q. Okay. Thank you.

- A. -- practice is if I had, I would.
- Q. Okay, thank you. I think we talked a little bit about this already, but you agree that there's a role for prescription opioids in the treatment of pain. Correct?
 - A. I would agree with that.

- Q. And including chronic pain?
- A. I would agree with that.

- Q. Is it fair to say then that a prescription for opioids is not, in and of itself, illegitimate or illegal?
 - A. I'm not sure if I would agree with that.
- Q. You believe that there are some instances in which -- let me clarify my question, and maybe this will help. A prescription for opioids written by a DEA-registered and state-licensed medical professional is not, in of itself, illegitimate, correct?

MR. COLANTONIO: Object to the form.

- A. The way I would respond to that question would be that no prescription that becomes illegitimate just because it's a prescription; in fact, just the opposite is true. However, it's the intent with which the prescription is written as well as the whom to which the prescription is written and what purpose that is the essence of a prescription writing process.
- Q. Okay. So when a pharmacist receives a prescription or --

MS. JINDAL: Sorry, strike that.

Page 88

Q. When a pharmacist has a patient come in with a prescription for opioids, is it fair to say that a pharmacist needs more information to make a judgment about whether or not that prescription is one that should be dispensed or filled?

MR. COLANTONIO: Object to the form.

- A. They could. I mean, if you could repeat that question -- I'm trying my best to answer.
- Q. Sure. I guess what I'm trying to say is: We talked a little bit about it already. You said that when a pharmacist, for example, generally might be concerned when he starts seeing too many prescriptions from a prescriber or a facility for prescription opioids or he might be concerned when the patient who comes in through the door is someone who is from far away.

What I'm trying to get at is: That all
-- that information -- that kind of information is
not ascertainable from the prescription itself.
Correct?

A. Just the face of the prescription, it depends. If it's an electronic prescription, that can be ascertained through the required interrogation of the prescription monitoring

Page 89 1 program. 2 So it just depends. It doesn't have to 3 be a black or white answer. It just depends. Okay. And are pharmacists in West Virginia 5 required to check the prescription monitoring program before they fill a prescription for 6 7 opioids? Α. Yes. Now. 8 9 Q. When did that become law? I believe the -- what West Virginia called 10 11 its Controlled Substance Monitoring Program - it's the PDMP version - it's called the CSMP. It was 12 13 established in 1995, and there were changes that 14 have been made over time. 15 The last one, I would say, approximately around 2012 when they were -- when 16 17 they were able to do that, and I think during 2015. 18 I don't -- I can't exact -- I can't exactly tell you when. But we did work on that over my tenure 19 to require that. 20 21 And when you refer to that requirement, are you referring to the requirement that pharmacists 22 are required to enter any information about 23 24 prescriptions that are dispensed within 24 hours of

having dispensed them?

2.3

- A. Broadly, I believe so. Again, I'm not a pharmacist, and I do not own any pharmacies, so I -- it's very hard for me to speak about the regulations within the pharmacy world. At least I'm going to try to answer the best I can.
- Q. Sure. So you could be mistaken that -- about whether pharmacists are required to check that database before deciding whether to fill a prescription for opioids?
- A. I have a reasonable degree of certainty that they are required to do that. Now, there could be some that do not do that, and I cannot vouch for those people.
- Q. Turning back to Exhibit 51, and staying on that same page and focusing on the University of -your work with the University of Charleston School of Pharmacy. The second bullet describes your class on "expansion of the role of pharmacy under the Patient Protection and Affordable Care Act."

Did that class involve any discussion of prescription opioids?

- A. That one did not. To my recollection.
- Q. So we've discussed your work with the

Page 91 Kanawha/Charleston Health Department from 2009 to 1 2 the end of 2014. And then you became a 3 Commissioner starting in January 2015, correct? Α. Yes. Turning to the first page of your resume, 5 that describes - at a high level - some of the work 6 you did as the Commissioner and State Health 7 Officer for the Bureau of Public Health, correct? 8 9 Α. Yes. 10 Ο. Okay. Turning to that second page, I just want to focus on the last bullet of -- under that 11 12 heading of Commissioner and State Health Officer. 13 This states, "Serve as Secretary and Ex Officio member of the West Virginia Board of Medicine where 14 15 along with the President, I am responsible as signatory authority for all medical licensing, 16 17 disciplinary, and other actions of the Board." 18 Did I read that correctly? 19 Α. Yes. 20 How long did you serve as secretary of the Ο. 21 West Virginia Board of Medicine? So the service of this position is inherent 22 Α. with the job of the Commissioner of the State 23

Public Officer through statute in West Virginia.

So this is a position that comes along with being the Commissioner and the State Health Officer.

1

2

3

5

6

7

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

22

23

24

So my tenure was the same. The day I joined as the Commissioner/State Health Officer, I became the secretary and ex officio member. The day I left the prior position is the day I tendered my resignation for this position as well.

- Q. Did you have any involvement with the Board of Medicine before you became Commissioner?
- A. I was a licensee of the Board of Medicine in West Virginia since 2009.
- Q. And do you recall the process for becoming a licensee of the Board of Medicine?
- A. I can vaguely do my best to -- to tell you that.
 - Q. As best as you recall, please.
- A. So generally licensing requirements for states require that you demonstrate a proficiency in the practice of medicine, that you agree to the medical practice act of that state, understand the policy and procedures and read those.

You also have to demonstrate your passing of whatever qualifications of the states are for the minimum licensing requirements, which

includes medical school, residency of some sort, several years. And then providing documents to authenticate that, and as well as references.

Certain states, I believe, like West Virginia have questionnaires around, you know, child support, alimony and others. There's questionnaires around previous criminal acts demonstrating that you must be in good standing.

Previous acts by other boards of medicine that could be against your license or --

So there's a whole course of questions including, as I mention, your acts and actions against your DEA certificate or your state certificates.

So it's a whole entire process that takes anywhere from an average of two to twelve months in any particular state given -- to be able to obtain your license. It's a long a tenuous process.

- Q. And you said there are specific questions directed at your DEA registration as part of that process?
- A. I would like -- I recall that. Please don't hold me to it, but I believe that there are.

- Q. And any other questions about prescriptions -- prescribing of controlled substances?
- A. I don't recall that point. But most of the questions come -- emanate with the application process tend to pretty much be in the statute of rules of West Virginia Medical Practice Act for licensing aspects.
- Q. Doctor, you said that you are currently teaching at West Virginia University and Harvard Schools of Public Health; is that correct?
 - A. That's correct.
 - Q. And what do you teach at those schools?
- A. So -- I'll start with Harvard because that one particular class next week. I'm a visiting faculty and I teach risk communications, primarily using the West Virginia water crisis as example, but walk through the class.

We have anywhere between 60 or so participants from all over the world. It's an executive education class that are mid to high level, to be taken by experts from nuclear propulsion labs to the eco labs of China to Singapore, FDA, CDC, all of them. And we basically -- I'm part of the faculty that teaches them how to

communicate risk in a time of crisis.

- Q. And do any of those classes involve discussions of prescription opioids?
- A. My teaching part does not. I cannot recall if any of the -- because it's an interactive class and the participants may have asked in the last several years that I've been teaching the class that could have been related to opioids, but I do not specifically recall any of that.

In West Virginia University, I do teach at the School of Public Health, grand rounds generally, focused on public health issues. That does involve detailing the opioid crisis.

I'm someone who helped the process of founding of the School of Public Health in West Virginia University, so I feel vested in ensuring that the school's graduates have a comprehensive education, and it's the only School of Public Health in the state in both public health, but also specifically whatever the crises are ongoing in the state, which has tended to be opioids for several years now.

Q. And does your focus in that class on -- I'll start again.

Page 96

You said you focus on the opioid -detailing the opioid crisis in that class. Does
your investigation include the causes of the opioid
epidemic?

A. We have a discussion on the description of charts and historical perspective. We created -- I ordered - as one of the first acts of being a

Commissioner - a historical perspective report that - it's online available - of West Virginia's opioid crisis from 2000 to 2015 data.

I take several pieces of information from that report, that's a public report, done under -- I believe, it was Governor Justice. And I use that as an example to talk about historical. We talk about, obviously, all aspects/facets -- it's a pandemic -- it's an epidemic of epidemics.

We talk about all the consequences that are happening. And then we talk about things that we're doing to solve. The bottom line is, we do talk about, you know, how we got here; but our focus often is: How do we fix this?

And we want, you know, in West Virginia our students to understand that while we didn't break it, we'll have to fix it. And we're going to

have to get together.

So whether it's the HIV outbreaks that happened in Cabell County recently -- which is the second-largest HIV outbreak in the nation's history recently, in Vienna, or the Hepatitis A outbreak that I personally dealt with during my tenure; or the highest levels of Hepatitis C.

We have a record in our country being first or second - compete with Kentucky oftentimes - and the highest levels of -- historic high levels of Hep B, which both transmitted through IV drug use and other aspects. 15 -- 13 to 15 times the national average.

We talk about those things. We talk about: How do you solve these problems? We talk about how do we prevent, you know, 5 percent of the babies that are born with neonatal abstinence syndrome in this state, and that costs a million dollars a baby. And that's a billion dollars - if you add the numbers - of an ongoing liability to the state every single year.

I produced a white paper to -- to the Senate finance chairman about that years ago.

So we talk about actual real issues,

fighting this crisis on the ground, trying to stop people from dying, trying to get people to enter into treatment.

So you know, frankly enough, we have a job to do when I teach, and I'm not -- I don't -- my job is really to figure out how to solve this crisis with the tools we have. Not the tools we wanted or we could have.

But what we've got, we have to work with to solve a really deadly problem. And that's where a lot of my focus and effort is, not really on a daily basis playing the blame game. That's not what I focus on, frankly and honestly.

I could talk about it, but that's -really honestly, that's not -- my focus has been to
solve the problem.

Q. I appreciate that, Doctor. And I'm going to just ask you to focus on my questions and limiting your answers to what I specifically ask.

It just will help us get through this a lot faster.

And so I'm going to repeat my question, and I think I heard the answer, but is it accurate to say that you do discuss the causes of -- or the factors that led to the opioid problem in West

Page 99 Virginia or the extent of the opioid problem in 1 2 West Virginia? 3 Α. We do discuss and have a discussion around the factors that mainly lead -- have led to the 5 opioid crisis and its consequences in West Virginia. 6 7 And could you please turn to Exhibit 54? Ο. GUPTA DEPOSITION EXHIBIT NO. 54 8 9 ("State of Health" presentation by 10 Rahul Gupta, MD, MPH, MBA, FACP dated 11 10-26-18 (CT2 RGupta000919-966) was 12 marked for identification purposes as 13 Gupta Deposition Exhibit No. 54.) 14 MR. COLANTONIO: Is this a new one? 15 MS. JINDAL: And I recognize I'm 16 introducing a topic that, you know, will go on for 17 a while. I suggest we take a break at 12:00 -- I 18 recognize -- I think opposing counsel also want to ask some questions, so why don't we continue until 19 20 12:00 o'clock, we can take a short break for lunch, 21 and then opposing counsel can ask their questions. 22 Does that sound fair? 23 MR. COLANTONIO: That sounds fine.

That's fine. Let me just --

- Q. Doctor Gupta, are you okay with that?

 MR. COLANTONIO: She wants to know if you're okay with that.
 - A. I'm okay with that.

MR. COLANTONIO: I'm sorry. Let me try to get this envelope open here. I'm trying -- I don't want to mess this up, because I lose things very easily, that what my wife says anyway --

Exhibit 54. This is an opportunity to -- okay. Got it.

- A. Okay, we're there.
- Q. I apologize. My computer's taking a little

Doctor Gupta, are you familiar with this document?

- A. These slides do look familiar, yes.
- Q. And I'm going to direct your attention to the -- it's hard to see on the first page, but it's a bit easier to see on the second page. Do you see how in the left -- bottom left corner, there's an -- and it's vertical. There's a similar sort of serial number?
 - A. Yes.
 - Q. And I'll represent to you, these documents

- were -- or this is one of the documents that your counsel produced to us. Is this something that you collected and gave to your counsel?
- A. I would say so. This looks very familiar to some of the documents I had provided.
- Q. Okay. And this is a presentation titled "State of Health"?
 - A. Yes.
 - Q. And it's dated October 26, 2018?
- 10 A. Yes.

1

2

3

4

5

6

7

8

9

15

16

18

19

20

21

- 11 Q. And is this something you created?
- 12 A. Yes, I would have created. I may have used
 13 the assistance of my employees at the Bureau to
 14 create this.
 - Q. Okay. But they would have done so at your direction, correct?
- 17 A. Yes.
 - Q. I would like you to turn to that first slide of the presentation, and I'll tell you it's the Bates stamp number that ends in 0920.
 - A. Yes.
- Q. The second bullet on here discusses "the worst public health crisis in recent American history the opioid epidemic as a supply/demand

Page 102 issue." 1 2 Did I read that correctly? 3 Α. Yes. And what do you mean by "supply/demand 4 Ο. issue?" 5 So over the time -- as you see, the date is 6 Α. 7 2018, and I was in the office January of 2015, and I'm, of course, living in West Virginia. You could 8 9 not escape this crisis even in 2009. There have been various ways to discuss 10 11 the most impactful crisis in a generation in the 12 state, and I was always figuring out how can I talk 13 about this topic and issue -- everybody's passionate about it. 14 15 But how can I explain and talk about it 16 in a way that I can get the most of the time --17 make most of the time that I have the time, and 18 often -- often it's easier to talk about -- it's 19 very easy -- let me rephrase that. 20 It's very easy to become a passionate 21 supporter of one side or another side or one aspect 22 or blame folks. What is important - and was 23 important for me; and still remains so - is to be 24 able to communicate in evidence-based,

science-driven manner the complexities of the challenges that we were dealing with in a simple way.

So the challenge for the Commissioner is to distill down extremely complex issues that are killing Americans in general and West Virginians every 12 hours in a way that you can make people understand - all audiences of all types - in a matter of, you know, 30 minutes, 40 minutes, the big points.

And this was my way of explaining in a way as a demand/supply that people get it.

- Q. And did that discussion include a explanation of essentially how the crisis came to be, or the factors that led to the development of the opioid epidemic?
- A. Not necessarily always. Oftentimes, the factors discussed was oftentimes the volume of pain pills. It wasn't as I mentioned before necessarily a blame game that we did in public. It was more about, "Listen, we had this volume; here's how much it evolved over time; here's how it correlates with death and destruction; and then here's what we're doing about it," which is the

Page 104 third bullet. 1 2 Ο. And if you could turn to Slide 30, which is 3 ending in Bates stamp number 0949. Α. I'm here. 4 Does that reflect your discussion of a 5 supply-side driver? 6 7 It's a blank slide. It does say "Supplyside drivers." 8 9 Ο. It does or it does not? 10 It does. It just says "Supply-side 11 drivers." It's not a slide. 12 Q. Right, I apologize. But going from there 13 to Slide 35 which ends in Bates stamp number 0954, does that reflect your completion discussion of the 14 15 supply-side drivers? MR. COLANTONIO: Object to form. 16 17 I -- no, it doesn't. That's a really easy Α. 18 to answer, which is it does not. 19 Why not? Q. 20 Because this discussion doesn't talk about 21

A. Because this discussion doesn't talk about all of the factors. It uses the opioids, both in West Virginia, changes that has happened to opioids in West Virginia, as opposed to the country, as well as one of the factors, and it --

22

23

24

But it doesn't talk about the entire demand/supply chain; it doesn't talk about manufacturing; it doesn't talk about production; it doesn't talk about quotas; it doesn't talk about distribution; it doesn't talk about pharmacies; it doesn't talk about dispensing; it doesn't talk about the transition to heroin and fentanyl.

It doesn't talk about how the transition has happened from prescription to actively illegal and illegitimate drugs; it doesn't talk about how the deaths transitioned to meth and other stimulants in addition to depressants.

So there's a lot of facets to this. As I mentioned before, my job was to get people in a simplified way to understand in a matter of 30 to 40 minutes. So I could spend all day talking about it but I wouldn't have anybody listening to me, because they would all be gone.

Q. Sure. And I understand that this doesn't reflect the full description of the opioid problem in West Virginia or nationally. What I'm asking is: Does this reflect your discussion of the supply-side drivers, as you've written here, of the opioid epidemic?

MR. COLANTONIO: Object as asked and answered.

A. So that isn't -- I only answered the supply-side. You know, all my previous answer includes that. I did not talk about the consequences of HIV, Hep C.

I only talked about the supply-side, so the entire -- the entirety of my answer includes the supply-side dynamics which I do not include in the slide -- in the slides that I have here.

Q. Okay. So does this rep -- I think you used the term "the big points." Does this reflect your understanding of "the big points" as far as supplyside drivers go?

MR. COLANTONIO: I'm sorry, object to the form. I'm sorry, I didn't hear what you said. You said "big point" --

MS. JINDAL: I'm sorry. He testified just a bit ago that his presentation here was the

Q. So you said, Doctor: "So the challenge for the Commissioner is to distill down extremely complex issues that are killing Americans in general and West Virginians every 12 hours in a way

Page 107 that you can make people understand - all audiences 1 2 of all types - in a matter of, you know, 30 3 minutes, 40 minutes, the big points." Does this reflect your understanding of 4 5 what the big points are when it comes to supplyside drivers? 6 7 No, I think my big points are the three bullets that you see on page 2 of that 8 9 presentation. Those are the big points. So if you see, I don't have a list of 10 -- under Objectives, ten things. It's like three 11 12 big points. Update on state of health; discuss the 13 demand/supply issue. But that -- the big points doesn't relate to every slide or every aspect. 14 15 big --So I could have objectives -- 20 16 objectives, but at the end of the day, I have to 17 18 have three big points. Like here's what I'm gonna talk about. I'm going to talk about the demand 19 side here. That doesn't mean that the supply issue 20 21 is also a big point that I have in slides or the demand side. 22

I can tell you the same thing in demand side, it doesn't include the big points. There's a

23

number of points, but that's not it.

So I refer to the big points as the objectives of my talk.

- Q. I see. So when you put this presentation together, focusing again just on your -- the supply-side drivers, you recognize that you couldn't talk about everything under the sun, correct?
 - MR. COLANTONIO: Object to the form.
 - A. Could you please repeat that, please?
- Q. Sure. When you wanted to put together some slides that explain the supply-side drivers of the opioid epidemic, you knew that you couldn't spend your entire 40-minute presentation on just that.
 - A. That would be reasonable.
- Q. And you wanted to focus on the most significant take-away for your audience, correct?
- A. That's correct. But I will ask if you look at the top of Slide No. 30, the title is "Opioid Epidemic An Evolving Crisis."
- So if you listen to me speak at the time, I would caveat this particular slide with a lot of things. So I can say, you know, "This is an

evolution and I don't want you to take away from this that this is exclusively what I focused on here. There are other aspects."

So I can get a discussion out of the public or whoever I'm presenting so we can have a discussion. So I wouldn't take what's on the slides as the -- the entirety or as the most important pieces.

They are very important parts of a discussion. I just want to make that clear.

- Q. When you were determining what to include in this discussion of supply-side drivers, what were the other things that you could have included in this discussion but did not?
- A. So as I mentioned, I would -- I would include -- "Let me explain to you how it works.

 Let me explain to you where the quotas come from.

 Let me explain to you the goal of everyone on the supply chain side." To the extent that I'm aware of that.

But you know, I would also say, "This is something that you should go look into, you should learn more about, because these things all relate back, you need to have a level of

understanding about these things, because they do impact whether " --

So I'm speaking to an audience of physicians or residents, I will say, "This impacts your prescribing." If I was speaking to a lay audience, I would say, "This impacts, you know, your son who has died or your uncle who has died and this is the reason this is the case."

So based on the audiences, I would be able to relate this back to those audiences. But this would be part of that discussion, but it would include a number of other factors, but those factors would also be guided by the audience I was speaking to.

So it's not a monogamous kind of discussion each time.

- Q. And if you could just go through Slide 31 really quickly. Slide 31 and 32 show the rate of all the prescriptions in West Virginia compared to the rest of the country, correct?
 - A. Yes.

- Q. And this is not focused on opioid prescriptions specifically, but all prescriptions?
 - A. Yes.

- Q. Okay. And you've highlighted West Virginia here on Slide 32 and Bates 0951, where West Virginia ranks number one in its rate of prescriptions.
- 5 A. Yes.

1

2

3

4

18

19

20

21

- Q. Okay. And that is the statistic as of 2016?
- 8 A. The source for that is the QuintilesIMS
 9 Xponent data of 2017. That's actually referenced
 10 at the bottom.
- 11 Q. Okay. I think I'm focusing on the title at 12 the top. It says --
- 13 A. Yes, that's 2016 data.
- 14 Q. I'm sorry?
- 15 A. Yes. 2016.
- 16 Q. 2016. So West Virginia ranked number one 17 in the annual prescriptions per capita in 2016?
 - A. According to this data, yes.
 - Q. Okay. And the next slide reflects the decrease in opioid prescription rates specifically from 2015 to 2016 in West Virginia, correct?
- 22 A. Yes.
- Q. And West Virginia had the greatest decrease at 15.6 percent, correct?

- A. According to this data, yes.
- Q. Okay. And this is, again, the
 QuintilesIMS Xponent 2017 data for that report?
- 4 A. Yes.

1

2

3

5

6

8

9

10

11

13

14

15

16

17

- Q. Do you have any reason to doubt the accuracy of this data?
- A. I would not.
 - Q. And Slide 34 and 35 these end in Bates
 Nos. 0953 and 0954 these reflect the number of
 opioid prescriptions that were filled per capita in
 2017 -- in 2016, correct?
- 12 A. Yes.
 - Q. And meaning the number of prescriptions that were written by DEA-registered and state-licensed doctors and that were presented to a DEA-registered and state-licensed pharmacy by a patient, right?
- 18 A. "Prescribers" is the correction I would
 19 make.
- 20 Q. I --
- 21 A. But generally, yes.
- Q. Thank you. I appreciate that. And is it fair to say that just looking at these slides, your assessment of the supply-side factors that led to

2.3

Page 113

the epidemic - at least the ones that you have the most information on - is that prescribers wrote too many prescriptions for opioids?

- A. Could you please restate that question?
- Q. Yes. Let me put it this way: Why do you discuss the volume of prescriptions in West

 Virginia and in the rest of the nation as part of this presentation focusing on supply-side factors?
- A. Because the total volume that was available had a direct relationship and a correlation with the death and destruction that was happening related to overall overdoses in the state of West Virginia.
- Q. And when you say that the "total volume that was available," do you mean the total volume of prescriptions?
- A. "Prescription" is a surrogate for the amount of pills that were flowing through in communities across towns of West Virginia.
- Q. And the number of prescriptions are a surrogate for the number of pills why, in your opinion?
- A. Because that is probably the closest way for a public health commissioner like me to be able

Page 114 to correlate. I would not have access to the 1 2 actual data other than published reports, you know, 3 to the tune of what we found later to be 780 million or what have you pills. We at the time - as I recollect -5 weren't really aware of actual numbers, or we were 6 7 close to aware of that -- being aware of that, but at the same time, prescriptions is the way to have 8 9 the pills out there. I mean, there is appropriate 10 prescribing and there is inappropriate prescribing. 11 But at the end of the day, it is 12 through prescriptions that the flow of the pills are gonna end up there and be diverted. 13 Okay, Doctor, I think we're almost at noon 14 15 now. Why don't we go ahead and take that lunch break for about, say, until 12:30 and then we can 16 17 come back and opposing counsel can take their -- do 18 their questioning? 19 Α. Okay. 20 MR. COLANTONIO: Okay, thank you. 21 THE DEPONENT: Thank you. Going off the record. 22 VIDEO OPERATOR: The time is 11:53 a.m. 23 24 (A recess was taken for lunch after

Page 115 which the proceedings continued as 1 2 follows:) 3 VIDEO OPERATOR: Now begins Media Unit 3 in the deposition of Rahul Gupta, M.D. We are 4 5 back on the record. The time is 12:34 p.m. MS. JINDAL: And I'll just explain --6 7 we are going to pass the witness to counsel for Cabell County and City of Huntington for an 8 9 opportunity for them to ask their questions, and then they will pass the witness back. 10 11 Go ahead. MR. COLANTONIO: Okay. This is Mark 12 13 Colantonio, and I'm counsel for Doctor Gupta. Ι was actually going to ask Doctor Gupta questions 14 15 now if that's okay with everybody. 16 MS. JINDAL: Sure. I'm sorry. I -that's fine. 17 18 MR. COLANTONIO: That's okay. 19 THE DEPONENT: Do you want me to move 20 the camera --21 MR. COLANTONIO: No. You know what. This is a little bit awkward because we're doing 22 23 this Zoom, and I'm actually sitting beside Doctor 24 Gupta. So --

EXAMINATION

BY MR. COLANTONIO:

2.3

- Q. Doctor, just because of the extraordinary circumstances of this case in terms of the COVID and everything, what I would suggest is just look at the camera and what I will do is ask questions from the side, and then if you don't understand or need me to, you know, rephrase the question, just tell me and I'll do that. Okay?
 - A. Okay.
- Q. All right. So Doctor, what I'd like to do in the next hour or so is kind of go through first your background, training and experience a little bit, and then go through -- you answered questions, bits and pieces, of your knowledge of this problem.

And I want to go through it basically from start to finish and what your views are and what conclusions you have been able to reach concerning what you've done in West Virginia and hopefully to give us some ideas about or opinions about how we might be able to potentially fix this problem. Okay?

A. Yes.

MR. GOOLD: Counsel, before you start,

this is Jim Goold. I represent -- Covington 1 2 Burling. I represent McKesson. I just want to 3 interpose a -- I'll call it a standing objection, that as far as I know, the doctor -- the good doctor is not a party, so he's not entitled to be 5 run through a direct examination by his personal 6 7 counsel. I won't object to every question as we 8 9 go along, but I do want the record to have my 10 objection on it. Thank you. 11 MR. COLANTONIO: I understand, and you 12 can have that standing objection. Okay? MR. RUBY: And Mark, this is Steve --13 in a maybe related vein, just to make sure we are 14 15 clear on the record, you are also - in addition to 16 being counsel for Doctor Gupta here today - you are 17 counsel for Cabell County and the City of 18 Huntington in the cases before Judge Faber. 19 MR. COLANTONIO: That's correct, we are, and we have appeared as such. That's right. 20 21 MR. RUBY: But your position is that 22 you are questioning Doctor Gupta today as his

counsel and not -- not on behalf of the plaintiffs

in the case?

23

24

Page 118 MR. COLANTONIO: Well, I would take 1 2 the position that we're questioning at this time on 3 behalf of both. MS. KEARSE: And this is Anne Kearse. 4 5 I'm appearing on behalf of the City of Huntington, so -- if there's any issue with that. 6 7 MR. RUBY: So you're -- Mark, you are -- you're questioning as counsel for plaintiffs. 8 9 MR. COLANTONIO: That is correct. MR. GOOLD: Well, but I believe you 10 11 introduced yourself as appearing as personal counsel for the witness. 12 13 MR. COLANTONIO: I have. That's right, I have. I represent two -- at this point in 14 15 time, I represent the witness and I represent 16 Cabell County. That's correct. 17 MR. GOOLD: Well, we'll have to sort 18 this out later. Okay. 19 MR. COLANTONIO: But no, I do. 20 There's no question that in this particular 21 instance, myself and Mr. Fitzsimmons represent both Doctor Gupta as a witness in this case, and we have 22 23 - and still do - represent Huntington and Cabell 24 County in connection with the litigation. That's

```
Page 119
1
     correct.
 2
                  MR. GOOLD: But he's not as -- has not
 3
     been designated an expert witness in Cabell/
     Huntington.
4
                  MR. COLANTONIO: I don't -- I think
 5
     he's been designated as a nonretained expert, but I
 6
7
     haven't reviewed the pleadings.
                 He's not a party; you're right about
8
9
            But he's not a -- I don't believe he's a
     retained expert. I believe he's a nonretained
10
11
     person who may render opinions as a nonretained
     expert.
12
13
                  MR. GOOLD: Okay, well, my objection
     stands, but I don't like to get into a long
14
15
     colloquial --
16
                  (Phone ringing)
17
                  MR. GOOLD: It's noted.
18
                  MR. COLANTONIO: Understood.
19
     BY MR. COLANTONIO:
20
              All right, Doctor. So quickly just going
         Ο.
21
     through your educational background, you did retain
     -- you did obtain your doctor's degree from the
22
     University of Delhi. Is that correct?
23
24
         Α.
              Yes.
```

Page 120 And that's 1993? Ο. 1 2 Α. Yes. 3 Q. And then you obtained a master's in public health from the University of Alabama-Birmingham. 4 You testified to that, correct? 5 Α. Yes. 6 7 And you also obtained a master's in business administration from the London School of 8 9 Business and Finance, true? 10 Α. Yes. 11 And then you have some teaching positions Ο. that you've held through the years and even now; is 12 that correct? 13 14 Α. Yes. 15 You described some of these. Let's go through them briefly. So you were an assistant 16 professor of medicine at the University of Alabama; 17 is that correct? 18 19 Α. Yes. 20 And also a clinical assistant professor of medicine at Vanderbilt -- from 2007 to 2009? 21 22 that true? 2.3 Α. Yes. 24 Q. You also were assistant professor of

Page 121 medicine at Meharry Medical College in Nashville; 1 2 is that true, from 2007 to 2009? 3 Α. Yes. You've held clinical teaching faculty 4 5 position at the West Virginia School of Osteopathic Medicine in Charleston from 2010 to '14; is that 6 7 correct? Α. Yes. 8 9 You are a -- were a clinical assistant 10 professor at the WVU School of Medicine in the 11 Charleston campus from 2010 to 2015; is that true? 12 Α. Yes. 13 You are an associate professor at the University of Charleston School of Pharmacy from 14 15 2011 to now; is that correct? 16 Α. Yes. 17 And you are a visiting professor at the 18 Chan School of Public Health, Harvard University, 19 from 2015 to now. Is that correct? 20 Α. Yes. 21 An adjunct professor of the Department of Health Policy, Management and Leadership at the 22 public -- School of Public Health in West Virginia; 23

24

is that correct?

A. Yes.

2.4

- Q. And did I understand you to say that you helped form that school or helped form that program?
- A. Yes. I helped both speak to the legislature to find the funding as well as instill the idea of the School of Public Health, the first school in the state of West Virginia.
- Q. And you are board certified in internal medicine; is that true?
- A. I am board certified as of 2019. I have passed the first part of the board exam in 2020. I let that certification lapse, again, because I was busy with other things, but I intend to regain that certification. The second examination is in October of this year.
- Q. And I've looked at your resume. It appears that you have approximately 123 or so peer-reviewed articles you've published; is that correct?
 - A. Yes.
- Q. And you've also appeared nationally on various national television programs and different programs related to opioids. Is that true?
 - A. Yes.

- Q. Can you give us some examples of that?
- A. Yes, so the PBS Nova did a documentary called "Addiction" and I was one of the four -three or four people that was featured, and the work of West Virginia was featured in that documentary. That's an example.

Politico did a feature on the work that was happening as well. And we've had over the time several number of both people recording, visiting and sort of following the work that has been happening in West Virginia.

- Q. All right. And you've also served on editorial boards of different entities; is that correct?
 - A. Yes.

- Q. You served as a peer review on several entities; is that correct?
- A. Several medical journals and public health articles, yes.
 - Q. Have you also done some work for the CDC in connection with opioids?
 - A. Yes, I've worked very closely with CDC and their physician and have had the director of the CDC visit and he really made comments that he'd

like to see the work that we had done replicated across the country and other areas as well.

We've had also -- hosted the then-secretary of HHS, Tom Price, as well as the counsel to the president, you know, to demonstrate and showcase what was happening in West Virginia with Kellyanne Conway.

- Q. And I've heard this term before of social autopsy. Have you heard that term often?
- A. Yes. We -- so we seeing the declines in death about 10 to 15 to 20 percent each year during my tenure from 2016 and prior to that to -- finally in 2017, I asked -- one of the responsibility of the Commissioner is to be able to produce reports. So I asked my department to work at cross structures in West Virginia for example, the Medicaid program, the EMS program, the Office of Medical Examiner, the Board of Pharmacy, the Board of Medicine payors, to create a social autopsy.

What that meant was: We went back to all of the thousand or so deaths in 2016 from overdose and we basically conducted - a simplistic way to say it - a CSI-type of investigation.

So we up and did, we wanted to learn

from the dead to help inform those who are living.

And one of the ways we did that is: We looked at every single death and we investigated their past one year prior to death and understand what happened, what led to them dying, and then we cataloged that and published that report.

That report helped form -- helped us form an opioid task force where we brought in experts from Johns Hopkins, Marshall University, West Virginia University, as I had helped create the Office of Drug Control Policy under the supervision of the State Health Office and Commissioner at the time.

The drug czar that I hired who was the former police chief of Huntington, West Virginia, he led this task force that came up with recommendations that then subsequently resulted in two pieces of legislation - the Senate Bill 273 and Senate Bill 272 in 2018 - one of which was called the Opioid Reduction Act.

Now, back to the social autopsy, why we ended up with the Senate -- two Senate bills essentially passing unanimously for both parties and being signed by the Governor is because of the

findings, the evidence-based findings that we had from the social autopsy.

We found that even then - in 2016 - a significant amount of people who were dying had filled their prescription within 30 days of their death. We also found a significant type of people that were incarcerated and then released and then died, overdosed and died.

We found that three out of those four people that died tried to seek help before their time of death within the last year. We also found that there wasn't sufficient amount of naloxone that was being given to people to help them survive.

There weren't enough facilities that were available. So those are the kind of things that became important, and that was something that was not only done in West Virginia, but subsequent to that, we started receiving requests from states and large cities all over the country, because they wanted to repeat what we had done.

So we started providing temporary assistance to, you know, a handful of states at the time, but many more afterwards, and therefore the

- CDC director obviously made that point to me personally that he wants to see this happen for other diseases as a way -- a new way to learn in order to inform how to address the problems.
- Q. And when you mention you did this -- you did this study about deaths and you said within 30 days of their death, they had a prescription, a prescription for what?
 - A. Prescription for a controlled substance.
- Q. And did those controlled substances include opioids?
 - A. Yes.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- Q. So you also obviously served as the chief health officer in Kanawha County, State Health Officer, correct?
- A. I was the local health officer for Kanawha County prior to becoming the State Health Officer.
- Q. And Kanawha County is from '09 until what year?
 - A. December of '14.
- Q. In December of '14, you took the role as the state chief officer and you kept that role until 2018?
 - A. January of 2015 to November of 2018.

- Q. And in your positions in West Virginia, did you deal with the issues related to the opioid problem on essentially a daily basis?
 - A. Yes.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

- Q. You've also served on some advisory councils listed in your CV, and do any of those specifically deal with as you recall opioids?
- A. The Governor's advisory council, as was mentioned earlier, is one of the most prominent ones that my position allowed me to sit on and this had mostly the heads of the agencies within the state of West Virginia that were working to attempt to help create solutions to this crisis.
- Q. You now work for March of Dimes; is that true?
 - A. Yes.
 - Q. What's your position?
- A. I'm the senior vice president and the chief medical and health officer and interim chief science officer of March of Dimes.
- Q. And what's the mission of the March of dimes?
- A. It's to have healthy moms and strong babies, so it's basically maternal and infant

health.

- Q. And you mentioned your background and experience in terms of primary care physician, you did have some experience in Alabama and Tennessee; is that correct?
 - A. Yes.
- Q. And you were able to see firsthand from that experience the -- as you describe, the change in how opioids were being prescribed?
- A. Yes, I saw it -- I actually wanted to mention it -- and I'll mention now -- the fact that today is September 11th, and I could tell you, on September 11th, 2001, I was in Florala, and I believe on September 12th, 2001, as I came to my office around 8:00 o'clock in the morning, my secretary said, "Hey, there's two FBI agents waiting for you in the waiting room."

And you can imagine. I mean, it was a very fearful time for everybody across the country. And as they came into my office and started talking, it became very clear -- this is, again, a very rural town in the middle of nowhere literally.

And basically they brought with them a fake prescription of someone that had managed to

provide my signatures and they basically were doing the due diligence investigation and it was for opioids. Basically asking --

So this is something that I dealt with firsthand, both from a suffering patient standpoint to both, you know, having law enforcement agencies, and work with them in a local capacity, to see the carnage that was happening at the time.

- Q. All right. So in your roles that you served in West Virginia in dealing with this problem, the opioid problem, did you -- did it cause you to learn over the years, working there, the number of prescriptions or pills delivered to the state of West Virginia during the time you were there?
 - A. Yes.

- Q. How about the number of overdoses in West Virginia during the time that you were there?
- A. Yes. I was -- remained over the chief medical examiner, I oversaw -- you know, I was monitoring that.
- Q. How about the number of deaths that was occurring in West Virginia and the addiction rates in West Virginia?

Page 131

A. So the deaths were so bad, now they hear on the news, you know, that New York City has air-conditioned trailers out there for pandemic. I can tell you we had those back in 2015. We had dead bodies that were accumulating at a rate that we could not keep up at the medical examiner's office.

So we had to get trailers that were air conditioned, and when we sort of figure out what -- how do we say that, so we can keep the gracefulness of dead bodies. So we -- you know, we developed names, mobile units, blank lines so that when we explained to the public how we are doing it, we are speaking in a graceful way so it doesn't look like we are disrespecting the dead.

But the fact of the matter was, we were putting bodies in trailers outside because we were so overwhelmed with the number of bodies that were coming in every single day.

Now, on one hand, that was happening. That's carnal.

The second side of this was, you know, our medical examiner offices inside Charleston had bullet holes in it. So that was the other

Page 132

consequence -- law enforcement consequence. That this was leading to drug wars and other aspects within the town and our building was physically being destroyed. That was the safety.

And the third half aspect was that we were not only having autopsies conducted as accordance with law, but we were also monitoring the number of drugs in decedents.

So we would send it off and we have sophisticated labs -- better laboratories than the office of the chief medical examiner, and we were finding that there was an incline in the number of drugs that were being found in the body of the decedents, legal and illegal. So they would have between three and five substances being found.

That often included opioids; it could include street drugs; it could include the benzodiazepine group of drugs as well.

- Q. And so did you also learn from these experiences the type of drugs that were being used and abused and by people that were addicted to these drugs?
- A. Yes, we had some of the best data in the country because we were being very meticulous in

the way we were doing things though we were lacking a lot of resources.

- Q. And in your role -- roles you served in West Virginia, did you become -- did you deal with families yourself on a daily basis?
- A. Yes. So I had a open door sort of method to my office, so I would often get calls from individual families. I would go to funerals when I could. I would go to town halls, work off of members of the legislature to hold town halls.

I would hear mothers talking about that they'd rather their child stays in the jail just so that they wouldn't die because they know that they're gonna die if they get on the street.

So we heard a lot of heartbreaking stories, first person, of families that were suffering. Oftentimes -- I mean I vividly remember going to speak at the County Board of Education -- we had about 400 school teachers, at least, and I asked the question when I'm speaking, I said, "How many of you -- raise your hand if you've been affected by the opioid crisis."

And not a single hand that did not go up. So this was a routine -- that was a rule, not

Page 134

an exception. That any meeting I'd go to - whether there was 100 people, 10 people, 1,000 people in West Virginia - I would have -- see literally every hand go up when you asked people, and they would all have their own stories to tell.

- Q. And in your experience in West Virginia, your roles as you've described, did you also have occasion then to deal with -- identifying, as you've described, and deal with this problem of volume?
- A. We did. We actually worked with the Board of Pharmacy, so we got funded by the CDC.

 Somewhere in 2015-16, it was the PDO grant, I remember, prescription drug monitoring grant, that we were then able to embed a person from the Board of Pharmacy and pay for them, basically, to be able to --

One of my initial problems was, other than law enforcement, we didn't have access to the data.

So it was very easy to say, how do we fix it -- but the problem was that the law enforcement and other people, I mean, the law did not allow us free access to the data, and then it

should not either allow anybody free access to very sensitive data.

So one of the ways we were working with it -- we were trying to work within the confines of the law to make things happen to find solutions.

So we were able to embed an individual -- an employee of the Board of Pharmacy, so that's when we started to understand better the characteristics of the dead.

That's when we did the social autopsy and that's when we were getting a better idea of what was happening.

- Q. And you also, is it true, firsthand dealt with West Virginia's response to this epidemic and problems and things were responsive to; is that true?
- A. Yes, so we saw -- oversaw a HIV outbreak.

 We saw a -- not only in Huntington subsequently,
 but prior to that, we saw a outbreak of HIV in the

 LGBT community in southern West Virginia. And I

 can tell you that was one of the most sensitive and
 and difficult outbreaks to manage without having to
 raise flags.

Because we knew -- I had seen in my

Page 136

experience in local hospitals where in our state in West Virginia, just being outed as a gay person could get you killed, to be honest.

So we had an outbreak that came -- had to deal with, a very -- so we have to work with dark web and other aspects. We saw Hepatitis A outbreak that was directly related to the opioid crisis and the IV drug use that was happening, which was large and started -- part of a multi-state outbreak, but it got really ingrained.

But we had -- we continued to have the highest levels of Hepatitis B and C also in addition to other challenges. We had from 83 to 85 percent of the foster care cases that were happening - which is one of the largest budgets of DHHR - was actually being attributed to, in one way or the other, opioids, whether through the family or otherwise.

But we were dealing with that, in addition to the neonatal abstinence syndrome tsunami that was coming in.

Q. All right. So do you believe from your background trending experience - especially in West Virginia - that you had a firsthand seat viewing

the causes and effects of this opioid problem in West Virginia?

- A. Unfortunately, I did. And I had to see firsthand what was happening on a daily basis, going to the practitioner, as somebody who lived in the community, had children going to school in the community and seeing those consequences as part of being in the community, as well as being one that was trusted to find solutions to this.
 - Q. And that would include Cabell County, true?
- 11 A. Yes.

- Q. And now, you mentioned the term in some questioning before "upstream/downstream." What do you mean by that?
- A. So there are limitations to what states can do, and that has to be recognized, and I certainly did.

The upstream relates to things that are not directly under our control. That means it's everywhere from having the quotas, enough to manufacture, to be able to have the manufacturing to be -- and to distribution.

Most people have something that -- if we compare it to, it's like the dam. There are

Page 138

aspects of that dam that are in place, and there's rules and systems in place that generally are governed by federal law in order to prevent downstream effects.

But when that dam breaks, the problem is the flooding of towns and cities and death and destruction. So the downstream effects that happen because that is all of the things that we were trying to do: Incrementally address problems through legislation, policy changes, you know, doing everything we could in our power to bring from social autopsy to finding ways to start Harm Reduction clinics.

I was the first Commissioner to -- in the first few months of my coming in, I helped fund the first program in Cabell County, Harm Reduction Program, that still exists today from state dollars because we knew that was important. So those are the downstream pieces.

And a lot of times the downstream pieces are just being reactive. You're trying to fix the problems because if not, people die or suffer. But the opportunities really to do something, I believe, are much more being proactive

Page 139 at the upstream. 1 2 Ο. So based upon your experience you 3 described, your background, training and experience, you believe that you possess a high 4 degree of understanding about addiction? 5 6 I believe I possess a -- a pretty good 7 degree of understanding addiction. Ο. And how it happens? 8 Α. 9 Yes. About what it does to the body? 10 Q. 11 Α. Yes. About its consequences? 12 Q. 13 Α. Yes. 14 And about potential treatment of that? Ο. 15 Α. Yes. Do you also believe that you possess a high 16 Ο. 17 degree of understanding as to the opioid crisis/ 18 epidemic in West Virginia? 19 Α. Yes. 20 As to its timeline? Ο. 21 Α. Yes. 22 As to its causes? Ο. 23 Α. Yes. As to its consequences to the state of West 24 Q.

Virginia, including Cabell County?

- A. Yes, having lived and seen it, yes.
- Q. And hopefully this is maybe the most important question potentially how to fix it or abate it?
- A. Yes.

- Q. All right. So let's talk a little bit about history and -- so go back to the 1990s, that time frame. You've described this before. There are legitimate reasons to prescribe opioids. Is that correct?
 - A. I believe so.
- Q. And what is -- in your view, what are the legitimate reasons to prescribe opioids?
- A. So I believe the legitimate reasons that opiates have not really changed a lot since the 1990s. And they can be chronic disabling pain towards the end of life, especially unrelenting -- the pain that happens as a consequence of cancer, some of those areas.

There are sometimes disabling arthritic disease -- a number of arthritis processes through which they are progressive, chronic and difficult to deal with, those situations.

So there are a number of chronic conditions in which -- these are two examples where opioids should be the last resort, but they do often become the last resort and it's very important that we continue to have the ability and availability to provide that.

- Q. All right. And that --
- A. And --

- Q. I'm sorry. Go ahead.
- A. Of course, I was going to say, acute pain, oftentimes same way. When fractures happen, injuries happen, post-operative, other aspects.

 There are places for opioids to be appropriate to supply.
- Q. All right. And post-operatively, acute pain, would that be what you would consider short-term, long-term or how would you --
- A. That would be short-term, and that may not be a first choice. Opiates may not be a first choice to prescribe that, but they would be in the process somewhere in there.
- Q. And is it true -- were you involved with an act in West Virginia that talks about prescribing opioids and the appropriate circumstances? Are you

Page 142 familiar with that? 1 2 If you are referring to the Opioid 3 Reduction Act --Ο. Yes. -- which is Senate Bill 273 in 2018 -- and 5 I know that because I helped draft that. 6 7 All right. And would that bill contain Ο. your views about opioids? 8 9 So we drafted it. We could get legislation 10 successfully passed with overwhelming support, and it applied -- you really need, you know, all sides 11 12 to come together. 13 So one of the things that happened was that it went through the process of negotiation and 14 15 agreeing. So I met with the chairman of both the House and -- House Health Committee and other 16 17 leaders, to make sure that it got to a place where 18 everybody was satisfied and agreed and did not compromise the essence of both CDC quidelines as 19 20 well as good clinical practice. 21 So we ended up in passing that Act, was a -- a reasonable effort to address the 22 23 contemporary crisis that we were facing.

Veritext Legal Solutions
www.veritext.com
888-391-3376

24

Q.

Have you had a chance to examine statistics

concerning - as you described - the legitimate uses for opioids? Have you had a chance to examine statistics that showed the need in the West Virginia population for those legitimate needs, as it existed back, let's say, in the 1990s?

A. So part of the Commissioner's job is to be a -- not only Commissioner with force, but be monitoring those reports -- so yes, as time went on in my tenure at the office, it was very important for me to monitor: What are the rates of obesity? What are the rates of arthritis overall going on? What's the rate of poor health condition? What's the rate of dental health? What's the rate of, you know, injuries that are happening overall?

So some of the reasons for which you would provide opioids are the rates that we monitor year after year.

- Q. All right. And so you've heard the term "baseline" before?
 - A. Yes.

Q. What -- in your view, would those statistics, in your view, form sort of a baseline for -- you could consider as a physician, as a public health person experienced as a baseline for

need of opioids back in the 1990s for West Virginia?

A. Yeah, I think that would be as a fair assumption, not having absolute numbers and absolute science behind it. I think you could say that whatever the prescriptions were happening before the standards of care for pain changed could be taken and construed fairly as a baseline, but also understanding at the same time that some of those dynamics also may involve a change.

For example, you know, cancer rates or the mining jobs that may have required opioids before, the changes in job -- actually should change -- also parallel the need for opioids over time.

- Q. Yeah. So that gets to my next question, which is: Have you had a chance to look at whether there were changes in those -- the rates or the number of those categories of people that might lead you to believe there was a need -- increased need for opioids?
- A. So when I commissioned the report to look at analytically the opioid crisis from a historical context from 2000-2015 again, that was the first

Page 145

report of its kind during this crisis - I don't recollect at this point whether it made it in there or not, but we did look at those numbers.

And, you know, we had found that, hey, the cancer rates are actually going down over time. We found that, for example, mining jobs went down. I mean, that's kind of public knowledge. So you know, industry jobs that require hard labor and other aspects, that was part of the job loss that we were having.

We know that the mining injuries were going down. That was the -- you know, the mining work. We know that the -- you know, there was a little rise in arthritis because there was a rise in obesity, so to counter that.

There was some -- you know, one point rise in arthritis. There was additional people that came into by the expansion of ACA that I was a proponent of in 2010 to Governor Tomblin, and there were some more people that were sick and needed medication.

But that was a miniscule amount as opposed to the people that had cancer or mining injuries or other things, other prescriptions going

down.

But as a minimum, it was a fair -- no change. But it could be that the need went a little bit down actually over time.

- Q. So from that analysis, were you able to form any conclusions about whether or not these legitimate needs for opioids had changed from the 1990s to, let's say, 2016/2017 in West Virginia?
- A. Yes. So the population loss happened overall in West Virginia over that time, and as I mentioned, the legitimate need at best was the same, and most likely actually went down a little bit.
- Q. And during that same time period, were you able to discern from your -- the statistic you had available and the work you did whether the volume of opioid pills from the 1990s to 2000 to '16/'17 actually decreased?
- A. The volume clearly increased several fold, several loss --
- Q. And do you have any statistics you can you tell us -- you mentioned prescriptions and some questioning for in terms of number of prescriptions, the number of pills, give us an idea

Veritext Legal Solutions
www.veritext.com
888-391-3376

of the increase in volume that you found.

A. You know, I think the most compelling is the review of the work that I -- you know, I read, which is -- it comes from Eric Eyre's work which is about 780 million pills between the span of between 2006/'07 and 2012. That would be in terms of volume.

That would be the most emphatic to me to look at.

- Q. And do you have anything for us to compare that to to give us an idea of what would be -- how big that measure is, that 700 and some million pills, compared to something -- something else?
- A. So for a population of 2 million people, approximately 1.8 million people, clearly that would be significant. In my presentation, I also talk about, you know, overall the total volume in the country was the total volume prescription per person in 2006.

That was about 130 prescriptions per 100 people - men, women and child - in West Virginia, and clearly the numbers -- I don't remember right now, but the numbers are significantly lower in the '90s.

Q. Now, you mention in some questions and answers about change in the standard of care and attitudes about opioids. What I'd like you to do now is, if you can -- do you first have an opinion as to what you believe was the cause of the dramatic increase in opioid pills delivered to West Virginia within Cabell County from the late 1990s through the mid two thousand teens?

A. So as I stated, the first inciting event was the effort to change the standards of pain and care for pain. As we changed the standard of care for pain in somewhere around late 1990s -- and really, I think it was like Robert Wood Johnson funded the work initially in 1997 that led to the JCAHO having that changed standard and the Pain Society working at the same time, the VA, federal government had changed, and this extraordinary effort was placed.

There was quote, you know, several reasons for it that we were being detailed on. One was the more ethical, we have an obligation to provide patients an absolute zero level of pain, they have to come down from 10 to zero.

The other was, you know, you could be

held liable if you don't do that, so it was the most punitive aspects of it.

And the third was, that there is no addiction, no consequences and this was a really good safe medication to buy and there's no diversion.

What was happening really during this time was the message that was being sent to us - now looking in retrospective back - was that, you know, you have a set population that was going to get the prescriptions in this context of changed standard of care of pain.

They were getting the prescriptions, so you get a tooth pulled - and that numbers hasn't changed over time - you know, and you get 30 days of -- 30 days of liberal prescribing of an opioid.

You may be using two pills or three pills and then they go, you know, in your closet, medicine cabinet.

So what happens is: If you used it for more than three to five days, you have a high risk of becoming addicted -- having addiction. If you used it for fewer days, then there's a high risk of diversion right there.

1.3

Page 150

When that diversion started to happen, and it became a norm in the community - meaning your children or grandchildren or other people; they were there, they got it - friends and families, then that caused those people to become addicted to these medications.

When that happened, then that diversion led for those people to find ways to get those prescriptions. So they would then figure out all of the inappropriate prescribing began or continued and really got voluminous at that point.

So what then happens was: These people were pushing through doctor shopping; they were pushing through -- come out of the woodwork in so many ways. There were lost prescriptions, you know, getting and stealing from anywhere they can steal from, and that just drove the volume -- that continued to drive the volume.

And that volume continued to get diverted. So we got to a point where the significant percentage of that volume that was coming out was inappropriate, and the -- it basically -- you know, the appropriate volume that was appropriate at one point just dwarfed in front

Page 151

of the extremely high amount of inappropriate volume, which is actually going towards diversion in all of these cases literally, and that as a result of that, the only way to get out of that was to die.

So once you have addiction and we -there were no -- an adequate amount of treatment
facilities, because that hasn't been identified as
an issue at the time, and the way you could get out
of addiction is by dying, by overdose and dying.

So that was the -- that was what was happening at the time.

- Q. All right. Let's talk a little bit about addiction. So how do you define "addiction"?
 What's your working definition?
- A. So the way these medications -- I can just broadly first of all say addiction is a process that can be physical or physiological in nature where your body gets used to whatever that substance is and wants to have it -- desires it a lot more.

Now, it can result in both a physical addiction as well as a psychological addiction, either or both.

Veritext Legal Solutions
www.veritext.com
888-391-3376

Page 152

Speaking of the opioids in specific, when we take opioids, we have this very basic foundational understanding of the brain. There's our inner brain or the fundamental places of the brain, you know, there's stimulus that allow us to survive.

What that means -- what I mean by that is it exists in all animals. You -- you feel hungry, there's a reason you eat, because when you eat, you feel good.

The reason you feel good is that there's a release of this chemical called Dopamine. So same way, when you're thirsty, you drink. The result of that drinking water is that your Dopamine gets released and tells you -- that's a positive reinforcement for you.

Same way with sexual activity. So there are a few things that are important to our survival as human beings, or any animal. The way we get rewarded, the reward system, is by this Dopamine release and it makes us feel good.

Now, these medications, seem to work similarly. But what they do is basically they hijack that system. And so in that hijacking, that

Veritext Legal Solutions
www.veritext.com
888-391-3376

Page 153 inner brain that is causing the release of 1 2 Dopamine --3 Initially the morphine - actually, or opioid of any type - makes you release that 5 Dopamine, and you feel good. After a while, it doesn't work as well. 6 7 And then you start to require an escalation of the dose. And so basically that inner brain, if it 8 9 doesn't get that, it asks your outer brain in some 10 way - it's a prefrontal cortex - to do things, to change its behavior in ways in order to seek that 11 12 drug to supply it. 13 So after a while, it's not just about getting high; it's actually about surviving and not 14 15 getting withdrawal symptoms. So typically, if you don't do it, the inner brain is going to punish 16 17 you. 18 And a person is fearful of that punishment, so that inner brain sends messages to 19 20 the outer brain to say, "Hey, I need you to go and 21 engage in activity" - whether that's stealing, prostitution, other aspects - "in order to feed me 22 the habit to continue with the drugs." 23

Veritext Legal Solutions

www.veritext.com

888-391-3376

And that's why when we say it isn't an

24

- addiction, it's a disease, it's not a will -- it's not something that people can will to do. Maybe it was a will the first couple of times; but afterwards, it's not. It truly is a disease, because that inner brain basically hijacks the rest of your brain and the rest of your body.
- Q. All right. So is it fair to say and you tell me if I'm wrong about this that when people become addicted; when they're not able to get what they can to fill the addiction that they -- the brain tells them, "Go out and do anything you can to fill that need."
 - A. Yes.

- Q. And does that, in your opinion -- or do you have an opinion whether that leads to things like diversion and further abuse of drugs and adverse consequences of addiction?
- A. So at that point, that person is not in control of themselves. Their inner brain has hijacked the entire body. At that point, this monster inside is telling them to seek opioids in one form, shape or other.

Whether it's for them to divert the prescription pills; it's for them to fake a

1.3

Page 155

prescription; it's for them to go to the doctor and lie in order to get their prescription; or it's for them to go and harm themselves or their children - which I have also seen - or their pets - which I have also seen - and get those medications by hook or by crook; or go on the street, if it's not available, and get heroin or fentanyl-laced heroin.

It doesn't matter to them, the brain.

What matters to the brain is: It needs that feed.

And that's basically the forces that are in play.

- Q. You mentioned "inappropriate prescriptions" before and used that term. And "inappropriate," do you mean both diverted and unnecessary prescriptions in your view?
- A. Yes. So the one side of supply which is, you know, when you make the standards of care change, what basically happens is, you're logorhythmically increasing the number of people who become addicted, and as they are using more prescriptions, they are also demanding and aquiring more prescriptions.

So that's where the inappropriate prescriptions lead to increased volume, and most of that is diverted volume.

Page 156

So basically that's the inappropriate prescription, and it may have begun with being unnecessary: Like I said, 30 days prescription for a tooth pulled. But it eventually leads to diversion. And that diverted prescription leads to more diverted prescriptions and more diversion of pills.

So over time -- that's the reason you saw progressive increase in deaths. It wasn't in 2000 the system changed and in 2003 we have the peak. We start to increase because more and more population over the time gets more and more addiction and then so therefore they need more and more prescriptions.

- Q. All right. And so do you -- based on this -- your opinions you form in this -- this crisis and your work, if you were to take a hypothetical year sometime in I don't know, 2010, 2008 and look at the total volume of prescriptions or pills in West Virginia, would you be able to have an opinion as to how much of that total volume would be what you call "inappropriate" versus "appropriate?"
 - A. So you would have to -- you could do that.

What you would have to do is you would have to go back to the baseline, and you have to make an assumption here that, let's say, before 2000, the amount of prescriptions --

If you have a relatively stable population and relatively stable conditions for which the opioid prescribing was done, you use that as a baseline prior to the change in the standard of practice -- standard of care for pain.

And then you start comparing it throughout those years. And you see the prescriptions are going up, that means the pills are increasing more in amount as well as in volume as well as in the strength. But the conditions aren't changing and your population necessarily isn't changing.

So that tells you how much of a difference between the two is the diversion of prescriptions -- and so that's how you get there.

If you ask me what that number would be - I think that's what you're trying to ask - I think it -- at best, that would be about 80 percent of those prescriptions are diverted, at best. It could be more than that, clearly based on whatever

the numbers are in 2000. But that's what I would say.

- Q. All right. In terms of addiction -- you talk about how it affects the brain. In your back -- based on your background, training and experience, do you believe that the addiction's effects on the body can be altered or --
 - A. I'm sorry, could you repeat that?
- Q. Sure. So in terms of -- you talk about one of the effects of this crisis is the number of addicted people, to the drugs. Do you believe that that addiction can be -- I don't want to use the word "cured, fixed."

Can it be abated, can it be -- can that problem be solved?

A. So it could be solved basically two ways.

The one is the way we would -- we -- it's being solved before anything, which is by death. So that would be the ultimate liberator.

And unfortunately, that's been happening way too much in West Virginia. In fact, we have 33 percent above the next state year after year.

The second way to do is - which I think

Veritext Legal Solutions

www.veritext.com 888-391-3376

there's a very broad agreement of this - is to actually have evidence-based programs that could provide the FDA -- free medication that are FDA-approved, some version of it -- and engage the person but it's not just medicine. It's actually medicine, it's counseling; it's providing best supportive lifelong care.

Because once a person becomes addicted -- you know, it's like anything else, whether you're addicted to -- in some ways, addicted to food, addicted to tobacco, alcohol, others, you need lifelong support.

So yes, you can. And if you get appropriate lifelong care, you have three out of four people, we will be able to actually help them.

Now, how far do we fix them? We just don't know that. There are some characteristics, some people that might need treatment for a few years and they may be able to get off. Others may need lifelong. We don't know in science very well with high level of confidence what drives some people to get off --

Just like we don't know if you give ten people opioids for four to five days, few -- some

people become addicted and not others. So there is lot we don't know in science.

- Q. These medications, the treatment, how do they work in terms of trying to fix the brain?
- A. So there's three FDA-approved medicines:
 Methadone, Buprenorphine, Naloxone. So the
 methadone is a agonist. So there's immune
 receptors in the brain. That's where the opioid
 acts. And they're acting in a different way.

So the methadone is an agonist, meaning it goes and attaches to the receptor, pretty much, stimulates it a little bit and keeps it occupied.

Buprenorphine is kind of a agonist/antagonist. So in some properties, it is an agonist and does occupy it; in some properties, it doesn't supp -- push a lot of the good feeling. And then you combine with that naloxone, which is an antagonist.

So basically the bottom line is they occupy the same receptors and in occupying the same receptors, the way people who have suffered through addiction - having described it to me personally - is that they say -- when they get into the treatment, after a few days or weeks, we feel like

the monster is off their head.

"Now when I go to my family, I can actually have a conversation and remember it with my family. I can start to feel feelings. I feel I've come back from death. I can watch television, I can remember and I can understand what's happening."

So that piece -- it allows these medications allow you not to worry about just seeking your next fix; it allows you to actually get a job, have a purpose in life, rebuild your community, rebuild your family and actually be able to function.

- Q. All right. So turning back to the evolution of this opioid problem in West Virginia, did you at some point see an evolution, a change, from opioids to heroin?
- A. As I came in as the Commissioner in 2015, I think that evolution was occurring. I think we were starting to see some of the laws that had been taking place in 2012-2013 -- certainly Governor Tomblin had initiated the Governor's Advisory Committee on Substance Abuse and some of the results were happening.

So we had a sliver of hope at the time that, "Listen, I think we're starting to see a light at the end of the tunnel" in the sense that, look, we're seeing slight reductions, and that's in the presentation you saw where I showed from 2015 to 2016, we went down 15 percent.

So we were becoming very hopeful that now perhaps the deaths will follow, meaning reduction in deaths and suffering and other things.

- Q. I'm sorry, you said reduction -- reduction in --
 - A. Reduction in deaths.
- Q. I'm sorry, you said you saw a slight reduction --
- A. Reduction in prescriptions. So we started to see from 2015 to 2016, about a 15 to 20 percent reduction in opioid prescriptions.
 - Q. Okay.

A. And then we were hopeful that we would start to see a reduction in deaths. But we didn't. And then we started to search that why that we're seeing reduction in prescribing but we're not seeing reduction in the deaths from overdose; we're not seeing significant reduction in the substances

Veritext Legal Solutions
www.veritext.com
888-391-3376

of overdose people when they died.

And one of the elements that was happening at the time that, again, now it's easier -- a little bit more easier to recognize, is that every time law enforcement would go and do a drug bust of the bad docs, those people would end up on the street that once were addicted to medication -- prescription medications, now would have to find -- seek and find an alternative, and they would go to the street.

And then they started to use IV drugs, heroin. That was not the only reason it was happening. It was also because the supply of prescription drugs from a diversion standpoint was drying up a little bit.

So as the diverted drugs - opioid prescription drugs - were drying up, then people still needed that fix, as I explained the addiction pathway. That doesn't solve the problem. We were too naive to think just reducing the prescription -- diversions would just cure the problem.

And what actually happened is the opioid crisis began to evolve -- evolve into a second crisis, which would then started to become

this heroin crisis. As we were dealing with that current crisis within the first, a third crisis, which is --

You know, everyone asking -- you know, wanting to make most profit from its product, and we saw the -- this happen, the phenomenon happen, with -- where people were dealing heroin, frankly. So they found -- they realized that they could get a bigger profit if they were -- if they could cut their heroin with another substance that could still give the high or give the need that needs to be fed to the people.

That was called fentanyl. It was a clandestine lab-produced fentanyl that's about 50 to 100 times more potent than morphine. So they would -- they began to cut the heroin with this substance on the street.

The problem that became for people who are addicted is: A, they wouldn't know that; the second, B, every time they inject themselves, not only are they risking HIV or hepatitis or what have you, but they're also basically playing Russian roulette with their life, because they wouldn't know if this is the time they were going to die/

overdose.

This stuff was so potent that some of our law enforcement officials, sometimes they happened to inhale or touch it and they would be overdosed.

So I saw a lot of people who had addiction, they didn't want to die. Neither did the drug dealers want them to die. So what they started to do, as a cry out for help, they would actually go to restaurants, they would go to gas stations, they would go to malls in the bathrooms and inject themselves just so they could be found if they played the Russian roulette and the gun got fired.

So we started to find dead bodies in those places as a result of that. So that's the evolution. That's when I came into the office and I was seeing on literally on a daily basis.

Q. So do you have an opinion based upon everything you've done in your work in West Virginia and your background, training and experience as to whether or not the abuse of heroin, fentanyl, methamphetamines and these cocktail drugs that you saw in the 2014 to 2018

time frame was a -- was caused by the original opioid volume that you saw that resulted in these addicted people.

A. So for a majority of them. There would always be a small portion of people who will have and seek, you know, various forms of addictive substances. That's been true for civilizations over time.

But for the majority of them, there's no doubt in my mind that there's a direct correlation between the diverted prescription pills and its evolution into street drugs in terms of heroin, fentanyl, meth, you name it.

- Q. And when you say "a majority," are you able to quantify that any further in terms of if you take 100 percent as total, were you able to quantify it any more specific than that?
- A. When I say "majority," I'm really talking about 80 to 90 percent of the population that actually suffered through this. Because if you go back and look at the overdose death rate numbers, prior to this epidemic, it would be like that, Counsel, to get that -- that's where I would go back.

Page 167

A small amount of people -- certainly those, the noninvolved people - that would be a general baseline - do not tend to be generally also the population that dies. They tend to be people that would use one form of drug or the others - a tiny population, proportion - that has existed, as I said, through civilization, hundreds of years, thousands of years.

But that is minuscule as compared to what we're dealing with today.

- Q. And in terms of overdose deaths, you do have knowledge from your work as to the number of overdose deaths -- overdose deaths in West Virginia from, let's say, 2004 until 2018 when you left. Is that true?
- A. Yes. I mean, I'm trying to recall the -- I mean, I can recall that in 2017, we finally passed the 1,000 number, which was not only the -- one of the highest rates ever, but it was consistently about 33 percent higher than the second state -- and the second state varied. Sometimes it was New Hampshire, sometimes it was Ohio, sometimes it was Pennsylvania.

But we could -- what didn't change was:

We were high and there's a bunch of lots of states, and then it was the next state in line.

- Q. And do you have an opinion as to whether the increase in overdose deaths West Virginia saw during that time was caused by the large volume of opioid pills that originally was deposited or delivered to West Virginia?
 - A. I think there's no doubt for that.
- Q. Now, are NAS babies a causative issue in terms of the opioid epidemic?
 - A. Yes.

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- Q. So what is an NAS baby?
- A. So NAS stands for neonatal abstinence syndrome, also sometimes called NOWS, or neonatal opioid withdrawal syndrome. We try to differentiate between opioids and other substances.

But in essence, it's a -- it's a syndrome, it's a set of symptoms that could happen in a baby as soon as they're born to a few hours or days afterwards.

Those symptoms could include incessant crying, not being able to be fed, being over irritable. They can have seizures. They can have diarrhea.

And unfortunately, in the early part especially of the crisis, they could die. It is -we saw that it was directly linked, and here's why:
As we saw the total amount of diverted drugs
increase, we also saw a similar increase in the
number of pregnant women that were taking these
diverted drugs.

The pregnant women are still part of the same community, part of the same population.

They're no different. So it would be an extraordinary thing to think that they would behave differently.

As they were also taking -- at one point, one in four pregnant women were taking some of these diverted medications. As they do, they become addicted, and as they develop the addiction, and continue to feed their addiction, so is the baby getting the same medications through the placenta while the baby is in the womb.

So the baby's brain, now imagine, is also being fed through the same mechanism. This developing new life inside the womb is also getting the same line of feeding of opioids through the bloodstream of the mother.

Page 170

So its brain is also -- not only not as -- it's not -- it's supposed to be developing right when it's not only -- we don't know a lot about how it develops in the presence of opioids, but it's developing the same time as being confounded by these opioids.

So as the cord gets cut, meaning the placenta gets cut and the baby gets delivered, that baby goes into withdrawals. It's literally the equivalent of a withdrawal. We know that because we treat the withdrawals by various mechanisms, but one of the mechanisms -- the pharmaceutical mechanism to treat it, is through morphine. Giving the baby morphine.

I mean, it's one of the last resorts, but that's one of the ways we do it. So what we don't know about neonatal abstinence syndrome yet - because there's a lot of work going on - is: These are the immediate side effects.

We have also seen some associations with birth defects, like heart defects, gastric defects. We also have had some literature that shows there's defects in hearing, vision, other aspects.

1.3

Page 171

Now, when I was speaking to schools, officials, teachers, parents, oftentimes they would tell me that in 2015, some of those babies that were born in 2006, '07 would be then eight, nine, ten years old and they're getting to a point and they're --

What is happening to the babies now is:

These teachers would tell me that "We have these
kids," it's called -- you know, opioid babies, they
are now being -- "they are not able to control
their impulse. They're not able to keep attention.
So they're having some version of attention deficit
disorder; they're having impulse control issues."

So because that's a problem and teachers' job is to teach, they were referring to the parents -- if there were parents. Because in often cases, these kids got moved around three, four, five times a year in the school system.

And they were often within foster care or the care of grandparents or great-grandparents at times. But then they ultimately end up in the doctor's office, at a pediatrician, and the pediatrician would diagnose them oftentimes - erroneously or let's just say through symptoms -

with ADD, and guess what happens then?

These kids get prescribed another addictive potential drug called Adderall.

So then we basically -- we already know that kids who are born with NAS have a high predilection to get -- to become addicted in the future. And now through the system, we're actually providing them the same drugs that they actually have a further habit with.

So we're actually setting up these kids to fail in life, and this is a huge problem in West Virginia. We're talking about 5 percent of the entire population. It's a huge number. And then a higher percentage perhaps in Cabell County and Huntington.

So all these kids -- we don't even know what the long-term consequences will be. Will they be able to adjust in society? Will they be able to have sustained social interaction and enjoy life the same way as others? We don't know that.

But we do know that there are some short and long-term consequences of NAS.

Q. Has anybody tried to -- you or anybody you know tried to quantify the cost of the effects of

NAS babies on a single NAS baby?

A. So we were working very hard -- one of the reasons that I am at March of Dimes today is because of my work that I focused a lot of work on this issue, and not only did we expand the drug-free moms and babies program, but one of the things we did was we tried -- again, downstream work, incremental impact, but that's all we could do at the time.

But one of the things that happened was: We figure, how can we prevent this? And one of the ways to prevent this is to offer in a nonthreatening way women who have addiction, the ability to have family planning.

And there is a women's prison, there are jails, and these women are -- you know, are cycling through and we offer it to men and women, by the way, family planning. It's not gender-biased.

So we wanted to have funding beyond

Federal funding, because Federal funding for IUDs

and other things does not go for the prisons. So

we wanted to make a case -- lay out a case to a

Republican legislature in West Virginia why it

makes sense for us to think about family planning.

It's a tough issue. It's a tough issue. So what we did was: We did an analysis and we provided a white paper to the Senate Finance Chairman at the time, Craig Blair, which basically laid out -- and we accounted for all the costs, the ICU costs.

We laid out the costs of child welfare costs, the development costs. But do we know what will happen long-term?

And that cost we calculated was a little over a million dollars per baby.

Q. Per NAS baby?

A. Per NAS baby. And for 5 percent -- we have about 20,000 births in West Virginia approximately, and 5 percent of that is about 1,000 babies, and that would be about a billion dollars if we multiply the math, a billion dollars per year, year after year, that were incurring this future cost to the state of West Virginia.

And when we went into that, I can tell you, the only thing -- this is a very conservative Senator from a very conservative part of West Virginia, and his response was, "Here's the money.

What can I do more for you to make sure that we allow these women who have addiction to enter treatment programs so when they do get pregnant, they have a shot at life and their kids have a shot at life."

And this came -- and we were, you know, pleasantly surprised. He came back to us year after year to give us more money to appropriate because it was a just cause. So these are the type of downstream impact things we were doing.

Q. All right. Now -- so you worked in West Virginia from '09 to '18 and you've talked about different efforts that were made, you've talked about this problem in depth. And I want you to think back and I want you to see if you can answer this question for me.

Do you believe in your heart of hearts that you and everybody in West Virginia that you were associated with - whether it's DHHR, PEIA, other departments, legislature - did what you could do with the resources you had to fight this problem that, as you stated, you didn't create?

A. Yes, I can tell you my entire time in West Virginia, you know, some of the best people on

earth that you will find, warm people wanting to chip in and help give you, you know, a shirt from their back, if they can. If they're wearing a shirt --

And they was -- everybody was in as a team, had the best intentions with limited resources, and we were struggling every day to help do everything within the power of our state as well as individuals, their capacity, to find those solutions.

So we did everything possible. We left no corner unturned in order to find solutions. But once again, this seemed to have fallen short in our expectations each time, because it's very difficult - and very inefficient, to be honest - to provide and spend that amount of money when this can be and could have been prevented upstream.

- Q. Okay. Now, you talk about -- a little bit about this transition from opioids to heroin, and what I'd like to do is ask you some more questions about that. In terms of heroin in connection with the opioids, is there some chemical somewhere -- why would people take heroin as opposed to opioids?
 - A. Well, basically heroin -- when you take

street heroin, it breaks down into two compounds and both are active, and one of those is morphine. So heroin is basically nothing but a form of morphine. It is the same chemical release. They're all related. They work through the same

receptors, and the body cannot tell one from the other.

And so chemically speaking, you know, you could have synthetic opioids; you could have semi-synthetic; you could have natural opioids.

But to the body that needs to feed the need, it's the same compound.

And so chemically speaking, what you write in the prescription pills, again it's the same feed -- the feeding mechanism is the brain. It does not discriminate.

- Q. Right. So it's your opinion that heroin -if someone went to heroin, that would satisfy the
 need created by an opioid addiction?
 - A. Absolutely.

Q. All right. In terms of the number of opioid addicts that transitioned to heroin, is there any way for us to quantify in terms of the total number of people that would be moving to

Veritext Legal Solutions
www.veritext.com
888-391-3376

heroin -- how many of those people started out as opioid-addicted people?

A. I think what we have to do is -- I'll go through the math a little bit here. We know that for every person who overdoses -- we're going to do the math in reverse.

So every person who dies in overdose, there's about 25 to 30 people that have what we call nonfatal overdose. Because we saw that in our social autopsy, that people -- overdose is a cry for help. And we have 25 to 30 people.

For every fatal overdose, there's about 250 to 300 people that actually are suffering from addiction, basically. So if you look at the numbers in West Virginia - there's 1,000 people that have died of overdose, and obviously there's anywhere from 250,000 to 300,000 people that are suffering from addiction - and that addiction could be -- the more you turn the pump off, the tap off, from the diverted prescription pills, they're gonna go to the street drugs available in terms of heroin.

So it's a free-flow basically. I don't see a difference between if it's the diverted

Page 179

prescription opioids or it's the heroin, except that they are able to die very quickly -- with the contaminated heroin, the cut heroin. So that's the only way.

- Q. Is there a way to look at national statistics that might help us glean more information about that transition in terms of heroin or opioids?
- A. Yeah, I think the -- what we have learned over time is the more -- you know, you go -- again -- this is not -- not meant to defend bad docs, but it's meant to say we need to have better systems downstream in order to manage the people who are addicted when we do drug busts.

But, you know, the more we become aggressive in drying up, the more people downstream are going to convert into heroin and fentanyl addiction, basically.

- Q. All right. I'm going to transition a little bit here to a different topic. Can we take a two-minute break?
- MR. RUBY: Hey, Mark, where are you on time overall?
- MR. COLANTONIO: Another -- I can be

```
Page 180
     done in 40 minutes? Is that okay?
1
 2
                  MR. RUBY:
                             40?
 3
                  MR. COLANTONIO: Yeah. 30?
                  MR. RUBY: If you guys -- if you guys
 4
 5
     were taking your own evidentiary depo of Doctor
     Gupta, I wish you'd noticed it.
 6
 7
                  MR. COLANTONIO: Okay, well -- let's
     take a --
8
9
                  MR. ZIMMERMAN: To answer your
10
     question, Steve, 40 minutes. Approximately 30-40,
11
     try to get it done.
12
                  MR. COLANTONIO: What time is it?
13
                  MR. GOOLD: It is --
14
                  MR. ZIMMERMAN: 1:48.
15
                  MS. JINDAL: 1:48.
16
                  MR. COLANTONIO: All right. Let's
     take a two-minute break and then we can talk about
17
18
     it. Is that okay?
19
                  MR. RUBY: That's fine.
20
                  MR. COLANTONIO: All right, thanks.
21
                  VIDEO OPERATOR: Going off the record.
22
     The time is 1:48 p.m.
                   (A recess was taken after which the
2.3
24
                  proceedings continued as follows:)
```

Page 181 VIDEO OPERATOR: This begins Media 1 2 Unit 5 in the deposition of Rahul Gupta, M.D. We 3 are back on the record. The time is 2:00 o'clock p.m. MR. GOOLD: Let me just -- this is Jim 5 Goold for McKesson. Let me just briefly reserve an 6 7 objection on the record for opinion testimony from the witness while we check about the previous 8 9 designations of the witness which we will do off 10 the record at a later point. 11 MR. COLANTONIO: Ready? 12 VIDEO OPERATOR: Yes, please begin. 13 BY MR. COLANTONIO: All right. So Doctor, have all of the 14 15 opinions that you've rendered here in response to my questions here today been rendered by you to a 16 17 reasonable degree of certainty, whether it's public health certainty, medical certainty or certainty 18 within your field? 19 20 Α. Yes. 21 MR. COLANTONIO: I have no further 22 questions. 23 EXAMINATION BY MS. KEARSE: 24

2.4

Page 182

Q. Doctor Gupta, this is Anne Kearse with the City of Huntington and Cabell County as well. I only want to follow up with a couple of things that I believe you testified about today and just make sure I've got the documents or the reports that you issued correct.

MS. KEARSE: Monique, can you pull up the first -- August 17, 2017 document? And I'll mark this as, I guess, Plaintiff's No. 1 for the purposes of this deposition.

PLAINTIFF'S EXHIBIT NO. 1

("West Virginia Drug Overdose Deaths Historical Overview dated August 17, 2017 was marked for identification purposes as Plaintiff's Exhibit No. 1.)

- Q. Doctor Gupta, you testified today about an historical overview since 2001 to 2015 of drug overdose deaths. Is that correct?
- A. It's, I believe, 2000 to -- yeah, yeah, that's -- thank you for that. Yes.
- Q. Okay. And that's -- and that's what -- I just wanted to make sure for the record that this --

Page 183 MS. KEARSE: Monique, wait a second, 1 2 please. 3 O. -- that this document, cover page "West Virginia Drug Overdoes Deaths Historical Overview 4 5 2001-2015" is a report that you were referring to today. Is that correct? 6 7 That's correct. MS. KEARSE: And Monique, if you'll go 8 9 to the second page, just for the record. 10 This is a report that obviously your name is on there, Doctor Gupta, as the Commissioner for 11 12 the Bureau of Public Health, the State Health 13 Officer. Is that correct? That's correct. 14 15 And you were involved not only in working 16 on the analysis and reported here of this, but you 17 were doing this in the capacity of your role as 18 Commissioner of the Bureau for Public Health. Is 19 that correct? 20 Yes, I ordered the commission of this 21 report. 22 PLAINTIFF'S EXHIBIT NO. 2 2.3 ("2016 West Virginia Overdose Fatality Analysis" was marked for 24

Page 184 identification purposes as Plaintiff's 1 2 Exhibit No. 2.) 3 Q. And then Doctor Gupta, I believe also Plaintiff's No. 2, in your capacity as the 4 Commissioner for the Bureau of Public Health, state 5 of West Virginia, I believe you also testified 6 7 about a 2016 overdose fatality analysis? Yes, and I have submitted that, I believe, 8 Α. 9 as part of the documents that I was requested to 10 provide. 11 Ο. Okay. 12 MS. KEARSE: And just for the record, Plaintiff's Exhibit No. 2, is this the report and 13 analysis that you were referring to in your 14 15 testimony earlier today titled "2016 West Virginia Overdose Fatality Analysis"? 16 17 Α. Yes. 18 And Monique, if you'll go MS. KEARSE: 19 to page No. 2 on that. 20 And that's also -- you appear on that as Ο. 21 the Commissioner for the Bureau of Public Health; is that correct? 22 2.3 Α. Yes. 24 Q. And in your -- both of these reports, these

Page 185 were reports either done at your direction and your 1 2 involvement and you're thoroughly familiar with the 3 -- with the conclusions and opinions issued in those reports; is that correct? 5 Α. Yes. And in addition to your testimony today, 6 Ο. 7 you would be prepared to testify - if you do come to trial - in regards to the analysis and results 8 9 contained in those reports. Is that correct? 10 Α. Yes. 11 MS. KEARSE: Thank you, Doctor Gupta. THE DEPONENT: Thank you. 12 13 MR. COLANTONIO: Hey, Steve? MR. RUBY: Sorry, I was muted. 14 15 Mark. 16 MR. COLANTONIO: So I just want --17 think about this, the questions earlier about our 18 roles here and make sure we're clear about that. 19 So just to be clear, we have appeared in this case in specific instances in deposition, 20 21 so our role in this case as counsel has been - at 22 this point, at least - limited to depositions, and 23 today we are appearing as counsel to Doctor Gupta

and -- his personal counsel.

Page 186 So that's our role today, as his 1 2 personal counsel. And we have appeared in other 3 depositions for purposes of those depositions so far. That's been our role. 4 MR. RUBY: Okay. And I don't want to 5 -- I have to -- we may have to think through all 6 7 the implications of it and we would certainly preserve any -- any objection that might relate to 8 9 it. 10 But Mark, just so I'm clear on your 11 position, does that amend your --MR. COLANTONIO: Yes. 12 13 MR. RUBY: -- statement at the outset of the questioning that you were questioning him on 14 behalf of the County --15 16 MR. COLANTONIO: Yes. We're 17 representing him today. That's our role. 18 MR. RUBY: Okay, so the questioning --19 and, again, I have to think through what the 20 significance is, if any. But the evidence today 21 that you've conducted of Doctor Gupta, your behalf is that it's now not on behalf of the County or the 22 23 City; is that right? MR. GOOLD: It is what it is. 2.4

Page 187 MR.COLANTONIO: Yea, we're 1 2 representing him personally. 3 MS. KEARSE: But Steve, to the extent then that any of the testimony that Doctor Gupta 4 5 has given is the testimony on -- that applies also to the City of Huntington and Cabell County, Paul 6 7 Farrell and Anne Kearse are both here in that capacity, as well as Mark Colantonio --8 9 COURT REPORTER: Anne, I'm having a terrible time hearing -- Anne, I can hardly hear 10 you at all. I don't know if the record is picking 11 12 you up but if you have a better way to get to a phone or closer or something. 13 14 MS. KEARSE: Okay. All I was saying to Mr. Ruby's comments that Dr. Gupta's testimony 15 16 today's is also applicable to the City of 17 Huntington and Cabell County, which is what this 18 case is being taken for. 19 MR. RUBY: It's a depo in 1332, in the Cabell and Huntington case. And like I said, Anne, 20 21 I would have to think of what the significance of it is. I just wanted to make sure I understood 22 23 Mark's position clearly on the record. 24 MS. KEARSE: Okay. It's Friday. You

Page 188 hear that? Thank you, Doctor Gupta. 1 2 MS. JINDAL: Okay, Anne, are you done? 3 MS. KEARSE: Yes, I'm done. So you 4 can keep going. 5 EXAMINATION BY MS. JINDAL: 6 Okay great. Doctor Gupta, I'm just -- this 0. is Jyoti Jindal just for the record on behalf of 8 9 Cardinal Health. I'm just going to ask you a quick 10 follow-up question to Ms. Kearse's questioning. Are there any other documents that you 11 relied on in forming your opinions that you can 12 13 name right now? I don't remember if I submitted this to 14 15 you, but there was an order in my role as the secretary of the Board of Medicine that had to do 16 17 with 2017 quidance to the physicians, orders on 18 prescribing or somewhat related to that, like the practicing standards for opioids. 19 20 And that was 2017. Because we 21 attempted to make sure that the 2016 CDC recommendations were actually being followed in the 22 state of West Virginia. 23 24 So that may be another document. I'm

not sure right now that that was one of the ones that was submitted or even I thought about it.

I don't have possession of it, but it would be available somewhere online somewhere.

- Q. And that was an order issued by the Board of Medicine which you signed as secretary for the Board of Medicine?
 - A. Yes.

- Q. And if you recall any other documents upon which you relied or research upon which you relied in the course of forming your opinions, I would appreciate it if you could name those for me on the record so we can follow up after this.
 - A. Of course I will.
- Q. Thank you. All right. I am going to go back a bit. You talked a little bit about the DEA quota. What is that?
- A. It is my understanding that the DEA quota, is the amount up to which manufacturer is able to produce their particular drugs related to controlled substances.
- Q. So it's the amount of controlled substances that a manufacturer can make. Is that right?
 - A. It's the -- it's the amount of what -- it's

the amount -- it's the limit basically -- to up to which it can be.

- Q. I see. And how is that limitation or quota determined?
- A. That quota really goes back to really the sales data. So it's the amount of sales in the previous year has been a -- sort of a guiding principle, one of the guiding principles, for DEA to determine what the quota for next year would be for manufacturers and distributors.
 - Q. And what are other guiding principles?
- A. That's the extent to which I understand.
- I'm sure there are other frame works, but that's my role in understanding this piece.
 - Q. And DEA is the Drug Enforcement Administration?
 - A. Correct.

1

2

3

4

5

6

7

8

9

10

11

12

15

16

17

20

21

- 18 Q. And that's a federal agency?
- 19 A. Correct.
 - Q. And aside from the DEA, who else is involved in setting the quotas?
- A. To my knowledge, in addition to what I've mentioned, I'm not aware of other actors.
 - Q. Thank you. Do you know what the quota was

Page 191 that was set by the DEA for controlled substances 1 in 1980? 3 I could not tell you that. I do not know. Do you know it for prescription opioids in 4 O. particular in 1980? 5 6 Α. No. 7 What about just, let's say, oxycodone in 1980? 8 9 Α. No. Okay. Do you know what the DEA's quota was 10 Ο. 11 for oxycodone in 1990? 12 Α. No. 13 O. What about 2000? 14 Α. No. 15 Ο. 2010? 16 Α. No. 17 Ο. 2020? 18 UNIDENTIFIED MALE: Say that again? 19 Hello, can you hear me --20 MS. JINDAL: Can you hear me? 21 Someone needs to mute themselves, I 22 think. Doctor Gupta, you talked about 1990, the 23 Ο. 24 amount of prescriptions for -- that were sold --

that were written in 1994, prescription opioids, as providing a baseline for the need for prescription opiates. Is that a fair summary of what you testified to?

- A. Your voice was a little muffled. Could you please repeat the question?
 - Q. Sure. Let me see if -- does this help?
 - A. Yes.

1

2

3

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

- Q. Okay. You talked about a baseline for determining legitimate need for prescription opioids, and you set that baseline as 1990, the number of prescriptions in 1990. Is that correct?
- A. I said 1990s, with an "s," so if you could take a particular year prior to 2000.
 - O. So --
 - A. Or the average of multiple years.
- Q. Okay. So your baseline for determining the legitimate need for prescription opioids is rooted to the 19 -- the entire decade of 1990 -- to 1999.
- A. Well, no. What I am saying is that you can determine a -- determine the baseline need of a community or a state for the need for opioids based on a variety of -- you could either do a particular year in the 1990s or you can take statistically an

average of a few years and then look at that.

1

2

3

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

But that would be the closest prior to 2000 when the standards changed.

- And do you know what the number of prescriptions that were written for prescription opioids in 1990 were?
- MR. COLANTONIO: I'm sorry, you said "1990?" 8
 - MS. JINDAL: Yes, 9-0.
 - MR. COLANTONIO: 1990. Okav.
 - I would not know off the top of my head right now.
 - Okay. In the course of determining that -the decade immediately prior to the change in the standard of care was the -- should be the baseline or assumption, why did you come to that conclusion?
 - Α. Because if you take the decade prior to that, that would be too far off of the population demographic changes that would happen.

If you take the decade after that, that would make no sense, because the distribution of prescriptions, the diversion and the amount of pills that flowed, we have enough of evidence that we can all agree upon that that would not be

applicable.

So the only reasonable conclusion would be that you would look at the time prior. This is not something I would -- this is a very routine way to do biostatistics, and you know, you know, in the epidemiological world, this is not abnormal at all.

And then I say a number of years to average, because sometimes there tends to be to these trends and others that could provide you a wrong number. So that's why I would favor potentially looking at an average year. If the numbers were flat for all ten years for the 1990s, then you could take a particular year.

If the numbers went up and down, then you could take an average of few years. So the idea is to get to a baseline within a reasonable degree of certainty that you can make predictions moving forward for.

Q. And in making that baseline assumption, do you -- you mentioned the changes in population. Right?

For example, the migration and immigration into and out of the state of Virginia. Is that one of the things that you would have to

Page 195 control for, to make sure your baseline assumption 1 2 is accurate with, as you said, a reasonable degree 3 of certainty? 4 MR. COLANTONIO: I'm sorry, I think you said "Virginia." 5 MS. JINDAL: West Virginia. 6 7 Sorry. I'm from Virginia, so sometimes Ο. I slip up --8 9 MR. COLANTONIO: We were one state at 10 one sometime. 11 There could be a lot of factors. One of 12 those -- so you have to account for all of the --13 the both directions to being accurate. So you have to account for all of the variables potentially. 14 15 One of those variables would be the demographics. The other variables would be the 16 17 movement in/out, in population loss. Another variable would be the need for legitimate 18 prescription. That would be, for example, okay, in 19 an average -- what was the '90s average for mining 20 21 jobs, for example, or timber jobs as a industry, for example, and then you look at. 22 So for example, if the mining jobs were 23 24 35,000 in, you know, 1996 - making this up - and

they end up becoming 35,000 to 20,000 in 2006, you have to account for that because those -- those are the conditions - the ruggedness, the arthritic condition and others - that actually can explain and justify some of the opioid prescriptions used even in the '90s.

So what I'm saying is that a curve of the '90s, the numbers, you could use that as a baseline, but you may have to say, then moving forward, we'll have to adjust that curve down or up based on consideration of all these factors, including cancer and some of the end-of-life issues.

- Q. And in the change in the standard of care, is it also possible that doctors are now meeting a need that was previously unrecognized in terms of treating pain?
- A. I am sorry, could you repeat -- I think I understand. I'm not sure I understand 100 percent.
- Q. Sure. Before the standard of care changed, as you said, in 2000, the focus on treating pain was I believe you said limited to end-of-life care, acute post-operative pain and injury-based pain. Is that correct?

Page 197

A. No, there was multiple other recommendation for use of opioids and other medications for pain.

It was not exclusively those areas.

When the standard of pain of care -standard of care for pain changed, what we're
talking about is that we almost began to prioritize
the use of opioids over other alternatives, in
addition to expand the vocabulary or the areas in
which opioids could be used.

- Q. Right. And so in terms of expanding or -focusing on that last bit, expanding the areas in
 which prescription opioids could be used, how did
 that translate to the medical conditions for which
 prescription opioids could be used now versus
 before the standard of care changed?
- A. So if you look at various conditions, for example, in West Virginia over time, we have reduction in some of the cancer cases. We have certainly a reduction over time in mining injuries. We have slight increases in arthritis.

We have slight increases in disability or fair poor condition. A lot of that is related to obesity, and diabetes, high blood pressure.

So it's not going to be a clear bag one

Page 198

way or the other. It will be a mixed bag. We will have to do that analysis, what I'm saying. But I would not suggest that for some reasons that the doctors for the last 100 plus years were not doing their job by undertreating pain. I think that would be a false conclusion to arrive at.

- Q. But it is possible that some doctors were undertreating pain before 2000. Is that poss -- is is that fair to say?
- A. Anything is possible. But it is very difficult for me to agree that the state of West Virginia needed 780 million pills coming into West Virginia, a population of 1.8 million, to sufficiently and adequately treat the pain of West Virginians.
- Q. I'm going to refocus you on my question,
 Doctor --
- MS. JINDAL: And move to strike that answer as nonresponsive.
 - Q. -- is it possible that doctors, before 2000 some of them, at least were undertreating pain in West Virginia?
- MR. COLANTONIO: Objection. Asked and answered.

- A. I do not have evidence to suggest that.
- Q. And you said this is an analysis that needs to be done. So it's not something you have done.
 - A. I have not --

MR. COLANTONIO: Object to the form of the question.

But go ahead, Doctor, if you understand it.

- A. No, I did not conduct that specific analysis as I have elicited here today.
- Q. And just to be clear, what you're saying is that you have not done the analysis of determining -- of controlling for all these other factors we discussed demographic, population size change, legitimate need for pain to determine what should be the baseline assumption in determining the legitimate need for pain.

MR. COLANTONIO: Object to form.

- A. I have provided you a very high level of certainty of my opinion without actually conducting that analysis during my tenure as the State Health Commissioner.
- Q. And so how -- I guess my question is: How are you certain in your opinion when you haven't

conducted the analysis that you -- that needs to be conducted to come to that conclusion?

- A. Through my work, my experience, my detailed analyses of each one of these individual factors, and following these trends in my job on a daily level. That's how I accumulated the knowledge and the expertise to be able to provide you an opinion with a high level of certainty.
- Q. So I want to be clear. The first part of your answer seemed to point to anecdotal evidence that you've seen in your field work. Is that correct?

MR. COLANTONIO: Object to the form. Objection.

- A. No, that is not correct.
- Q. Okay. So when you said that -- you said that you have -- my question was: "How are you certain in your opinion about what is the accurate baseline assumption for determining" -- and I'm adding words here. I understand. I just want to be clear.

How are you certain in your opinion that 1990 is the best decade for determining a baseline assumption for the need for prescription

opioids when you haven't conducted the analysis that you say needs to be conducted to come to that conclusion?

1.3

And you answered, "Through my work, my experience, my detailed analyses of each one of these individual factors and following these trends in my job on a daily level."

And my question is: When you said "Through my work and my experience and my detailed analyses," what do you mean?

A. What I mean is, it is a 20 -- 25-plus years of expertise and experience in the field with highest levels of degrees that I have and working within the population, that's where my opinion comes from.

And just as an example, you don't need to conduct a analysis of people on a plane, that you throw some of those people without a parachute and some with a parachute, just to figure out if you need a parachute to come down.

Some of this is very much a common sense analyses which I present to you.

- Q. What part of it is a common sense analyses?
- A. The fact that you look at the decade before

Page 202

in order to figure out what was the baseline of prescriptions that would be legitimate and include the criteria of requirements of pain that I've elicited to you to look at how much of that in the next forward decade that you would need the opioid prescriptions for.

Q. Okay. So if I understand you correctly, your opinion was that 1990s would be the best decade, but you don't actually have a specific baseline in mind. You just think 1990s would be the best decade to study to determine a baseline. Is that correct?

MR. COLANTONIO: Object to the form.

A. No, I do have a specific timeline in mind, and that's the 1990s. There's a reason I didn't compare with 1890s or 1860. But the reason I say "1990s" is because of those specific reasons that conforms to my expertise, which is a very common thing in the medical sphere.

When you don't have abject data, you provide expert opinion. That is not an abnormal thing, and I am here providing you that my expertise with -- both being a former Commissioner of West Virginia as well as experience in this

field through training, education and experience.

- Q. And I just -- maybe I'm -- I don't -- I just want to make sure we're not speaking past each other, Doctor. That's all. I understand that you said 1990s is the best decade to determine a baseline for legitimate need for prescription opioids. Is that correct?
 - A. Yes.

- Q. Okay. Do you have a specific number in mind as to: This is the number that is my baseline for what -- these number of prescriptions represent the legitimate need for prescription opioids in 2019 -- in 1990?
- MR. COLANTONIO: Object to the form of the question.
 - Q. 100 prescriptions or 200 prescriptions? That's what I'm trying to get at.
 - A. I think I've already asserted that we would need to look at that data, so for me to sit here and guess that data would not be appropriate.
 - Q. Okay. And so all you've determined is the decade to review to determine the baseline for legitimate need.
 - MR. COLANTONIO: Object to the form.

Page 204

A. So I -- so I've mentioned the 1990s is the decade, and what -- where you can get a peek of the assessment, is start to look at some of my reports, that you -- and the -- the counsel -- the plaintiff's counsel have highlighted.

If you care to review that report, you can see that I've done the analysis from the year 2001 onwards, and the year 2001 can give you a hint as to what was happening in the late 1990s.

And that's where I formed the opinion that 80 -- perhaps 80 to 90 percent of the volume in the 2000s and onwards was being diverted and was being used inappropriately, whether it was unnecessary prescriptions or diverted prescriptions.

So I keep answering the question. The bottom is, you need to look at the report I've submitted.

- Q. Sure. And if you look at that report, will I find an analysis of the 1990s in there?
- A. How could you when the title says 2001 to 2015?
 - Q. Okay. Thank you.

I want to talk about some of the

Page 205 demographic changes that you mentioned that would 1 2 need to be studied. Is one of them the age of the 3 population? Α. Yes. 4 And has West Virginia's average age of its 5 population grown over the last two decades? 6 Α. Yes. Has it grown since the 1990s? 8 9 Α. Yes. And is -- does West Virginia in fact have 10 Ο. one of the highest -- or I'm sorry, one of the 11 oldest populations in the state -- in the country? 12 13 Α. Yes. And is another factor the number of adverse 14 15 childhood events that an individual is exposed to? 16 Is that something you would need to analyze to determine -- strike that. 17 18 Doctor, we previously looked at Exhibit 19 54. Could you go back to that exhibit? 20 MR. COLANTONIO: You want me to pull 21 it up --22 MS. JINDAL: Yes, please. MR. COLANTONIO: Let me find it for 23 you. I'm sorry, can you identify that for me? 24

Page 206 Because my envelopes -- I didn't put it back in. 1 2 Is that the --3 MS. JINDAL: That's the State of Health presentation that was dated October 26, 4 2018. 5 MR. COLANTONIO: He's got it. 6 7 I have it. Α. And could you please turn to Slide 6 of 8 that presentation? It's Bates stamped 0925, I 9 believe. 10 11 Α. I'm here. And do these reflect some of the 12 Ο. 13 demographics that you would need to study to determine the legitimate -- the legitimate need for 14 15 prescription opioids --16 Α. Yes. 17 -- in a particular state? Ο. 18 Α. Yes. 19 Okay. And the first of these, the one we Q. just discussed, is the median age. Is that right? 20 21 Α. Yes. And does this identify that West Virginia 22 has the fourth-highest in the nation based on the 23 24 2016 U.S. Bureau of the Census America Community

Page 207 Progress? 1 2 Α. I think we just agreed to that. 3 Q. Great, okay. The next one is Medicaid, correct? 4 5 Α. Yes. And does this reflect the fact that 30 6 Ο. 7 percent of West Virginia residents are served by Medicaid? 8 9 Α. As of the date that's down there, yes. 10 Q. And that date is March 2017, right? 11 Α. Yes. 12 0. And further to determine legitimate pain, 13 we'd also have to review the percent of the population that is disabled. Is that the third 14 15 factor that's there? 16 MR. COLANTONIO: Just object to the 17 form of the question. 18 Α. Yeah, so --19 I apologize. I'll withdraw and ask again. I want to be sure that my question is clear. 20 21 third factor -- the third demographic factor that you've identified here is the percent of the 22 23 population that is disabled. Is that right? 24 MR. COLANTONIO: On this page.

- A. On this page, not to determine the need for opioids.
- Q. But would you want to look at the rates of disability to determine the need for prescription opioids?
- A. Yes, but not necessarily the Medicaid population. I just want to be clear about that.
- Q. I see. So you would not consider the percentage of people who are on Medicaid in terms of considering whether or not there's a legitimate need for prescription opiates?
 - A. Not necessarily.

- Q. I appreciate -- okay. When you say "not necessarily," could you explain?
- A. Yes. So it can be in some states the Medicaid population; in other states, it can be the percentage of the Medicaid population. Because Medicaid is insurance status and no way are we trying to say that people on Medicaid are more or less likely to use opioids.

That's a political statement, and I would like to -- I don't think that bears any weightage or evidence behind it.

Q. Okay. Thank you for that clarification.

Going back to the third factor you've identified here, disability, is that one that you would measure to determine the legitimate need for prescription opioids?

A. Yes.

- Q. And does West Virginia have a disability population of 18 percent compared to 12 percent of the U.S. population?
- A. Yes.
- Q. And that's as of the March 2017 date, correct?
 - A. I -- the asterisk is --
- 13 O. Or --
 - A. -- only for Medicaid. So I would say at the time of the presentation, those were probably valid and most current data.
 - Q. Okay, thank you. And then going to the next page, are these factors that you would consider in determining the legitimate need for prescription opioids?
 - A. You know, some might be; some might not be. So I wouldn't say necessarily. There are some that are missing, like you know -- so this -- these slides, these two slides, were not meant to convey

Page 210 the message, I think, what -- what we're trying to 1 2 convey here. 3 Q. Sure. I understand. But when you say some of them would be something you would consider in 4 5 determining legitimate need, which ones would those be? 6 I would use --Just focusing on the slide -- I'm sorry, 8 9 Doctor. Just focusing on the slide, there are three factors, correct --10 11 Α. Yes. -- that are listed on this slide? And one 12 13 of those -- the first is "Bachelor's degree or 14 higher"? 15 MR. COLANTONIO: I'm sorry, I wanted to make sure we're clear. You said there's three 16 17 on the slide. Are you referring to --18 THE DEPONENT: Flip over. 19 MR. COLANTONIO: Well, it says, four, 20 five and six. That's why I'm a little bit confused 21 because it indicates --22 MS. JINDAL: I see. 2.3 MR. COLANTONIO: Not three, but --24 MS. JINDAL: I will ask again.

- Q. I apologize, Doctor, I know we're moving a little fast here. On the Slide 7 which ends in Bates 096, you identify additional demographic factors that you have studied, correct?
 - A. Yes.

- Q. And the fourth of these demographic factors
 or the one that's numbered No. 4 on this slide is the percentage of the population that has a
 bachelor's degree or higher, correct?
 - A. That is it, correct.
- Q. Okay. And is that a factor that you would consider in determining the legitimate need for pain -- or legitimate need for prescription opioids?
 - A. Not necessarily.
 - Q. Could you please explain your answer?
- A. Sure. Because if -- if I was looking at the legitimate needs for opioid prescription, I would focus my attention on -- in addition to the trend data from the 1990s, with actual conditions that actually require people to use opioids as a last resort, not necessarily the determinants of their living meaning, you know, what's their income, what's the degree, are they poor or not.

I think those would be very stigmatizing factors to figure out, and that would not be the way I would recommend necessarily that we go first and foremost. I would be focused more on health conditions at the end of the day, because when we write people opioids -- at least when we're supposed to write prescriptions -- legitimate prescriptions for opioids, they have to be related back to their health and medical conditions, not the other way around.

Q. Okay. So just to be clear, you would -- I think actually, you were clear. I'm going to move on.

The next one, is that the same true for median household income, it's not the first thing you would consider, but it's something you might consider if you needed to?

A. Yeah, again, these are the socially determinant factors that I would generally not prioritize in the consideration for the need for pain medications overall, but also for need for nonpharmaceutical options.

And so when I say -- when we talk about opioids, I like to make sure that we're talking

Page 213 about nonpharmaceutical options, pharmaceutical, 1 2 nonopioid options and opioid options. So there's 3 these three categories, going backwards. So that's -- those are the things that 4 5 I would look at. But these are not the categories I would look at beyond age and disability. 6 7 Okay. So I'm a little confused now, Ο. Doctor, because I thought we were talking about a 8 9 baseline assumption for the need for prescription 10 opioids. 11 Α. Uh-huh. 12 Ο. Were we not? 13 Yes. I can explain that if you would like Α. 14 me to. 15 What I'm trying to understand is, 16 Doctor, your -- when you said that you would look 17 at the 1990s as the decade for determining the 18 baseline for the need for prescription opioids, you were talking -- when you said "Prescription opioids 19 20 there, " you were talking about controlled 21 substances, correct? Yes. 22 Α. Okay. And so when I asked you if you would 23 Ο. 24 consider the demographics listed on page 0926 of

Exhibit 54, you were saying that these are some that you may consider in terms of determining social -- the social environment in the 1990s in ultimately determining a real number for that baseline. Is that correct?

MR. COLANTONIO: Object to the form.

- A. No. And once again, I like to be clear and consistent rather than have twisted way of getting through, so if you don't mind, I'd like to clarify once again, but I'd like to be very clear and consistent about it, if that's okay.
 - Q. Please.

A. So what I basically said both to my counsel, plaintiffs, and to you, is this: That in order to figure out what would be the appropriate prescriptions or the legitimate credible prescriptions for opioids today or in the last few years, what you would have to see is you would have to find a baseline.

The closest you can get to baseline is within the decade, some formula for in the 1990s.

If that's a consistent prescribing, you could take a particular year; if it's a up and down, then you could do an average.

Page 215

Now, with that, when you took -- take a number of other factors to determine that. Those factors include individual health factors of folks. They may or may not include Medicaid status, for the reason we mentioned.

They also include the -- what we know now. So that means that we cannot ignore the CDCs evidence-based recommendations of 2016 that now say that we do not use opioids as first line of treatment. To the point and to the extent that that was being done in the 1990s, we need to correct for that.

And that's where the thought comes in that we have to look at those numbers and that we have to look at, okay, if there was 100 prescriptions, you know, for 1,000 people, how many of those would have been credibly reduced by using nonpharmaceutical options, and then how many of those would have been further reduced by using nonopioid pharmaceutical options, and then we get to the bottom line of, okay, how many would have been okay to use for opioids.

So that's why I'm not -- I'm not coming to you with a "I know the answer." I'm giving you

a range that I believe 80 to 90 percent.

But at the end of the day, if you do the math, then we can know for certain. But those are the factors, the pillars of how -- what it would take to make that determination.

But it may -- it may be 80 percent diverted; it may be 90 percent diverted; it may be 99 percent diverted.

I cannot tell you that right now sitting here. But I can tell you the factor that would take -- and again, I'm -- I'm working very hard to be clear and consistent.

Q. No, that was really helpful. Thank you, Doctor. So again, this is an anal -- what we're outlining here, what we're discussing here, is the analysis and how it should be conducted, not what your old analysis has been, correct?

MR. COLANTONIO: Object to the form.

- A. No, I think I have a right to provide -- look, when the Governor of the State asks me --
 - Q. Doctor --
- MR. COLANTONIO: Hold on. Let him finish his answer, please.
 - A. When the Governor of the State, in my

capacity as the State Health Commissioner, State Health Officer, asks me, I don't go after every question and say, "Governor, I can't answer you.

Let people die until I conduct an analysis."

We provide -- and the way the medicine and public health works is we provide our best estimate based on our experience and based on our knowledge and training in order to move forward and provide solutions. And that's exactly what I'm providing to you here.

Q. Okay. So your analysis that 80 to 90 percent of prescriptions were unnecessary in the -- I'm sorry, Doctor, I actually don't know if you gave a range.

MS. JINDAL: I'll strike all that.

Q. Your analysis that 80 to 90 percent of prescriptions were unnecessary, that is based on your experience and you -- but not any particular scientifically-rigorous analysis that you have conducted. Is that fair to say?

 $$\operatorname{MR}.$ COLANTONIO: Object to the form of the question.

A. I don't think so. Because if you look at my report, you will find the rigorous scientific

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Page 218 analysis that was conducted and that gives you a very good cry tear I can't to build that off of from and to arrive at that estimate that I have provided. So you -- and just to be clear, when you say your report, you're referring to Plaintiff's Exhibit 1? MR. COLANTONIO: Object to the form. Q. Is that the historical overview? MR. COLANTONIO: Object to the form. I -- I'm referring to wherever the analysis resides that I know of exists which is the prescription -- prescription opioids overlaid with the deaths and other substances. That was -wherever the form might be. I'm happy to find it for you and provide it for you, but that's what the analysis was. It might be in the report. I have not had a chance to review that report fully.

MS. JINDAL: Mark, do you have a copy of the report with you by any chance?

MR. COLANTONIO: I'm sorry, I'm a little confused myself. Because I'm not sure what you're referring to. And I just don't -- I don't

Page 219 1 want to --2 Well, I don't want to --MR. FITZSIMMONS: Didn't we make that 3 as an exhibit? 4 MR. COLANTONIO: I don't want to make 5 any speaking objections, but I think maybe there's 6 7 a miscommunication going on. I think what the doctor is trying to tell you is he's done a lot of 8 9 reports and in those reports, he's got a lot of information, some of which may or may not be 10 11 exhibits here, and if you want us to - after this 12 deposition or sometime - give you something that --13 I mean, I don't know what to tell you. It -- anyhow, I don't know what you're referring 14 15 to, so --16 MS. JINDAL: Okay. 17 MR. COLANTONIO: That's as clear as I 18 can be. 19 BY MS. JINDAL: 20 Doctor Gupta, you don't know right now any 21 particular report that contains your opinion that 80 to 90 percent of prescription opioids were 22 23 illegitimate -- a prescription for opioids was 24 illegitimate?

MR. COLANTONIO: Objection to the form of the question.

I'm sorry, I don't think he said that. What he's saying is that the basis for his -- part of the basis for what he's saying is in that report, the data. I think.

He's gonna speak for himself, and I don't mean to interrupt. Just trying to help.

A. It's an opinion -- to answer the question, it's an opinion that I'm providing to you based on the question being asked to me, of me, and based on my extensive work, knowledge, products created over time as well as what exists nationally in terms of the prescription opioids, the trend data as well as the overdose data.

So that would be my answer.

- Q. And just to be clear, you haven't written out this analyses that ultimately led to your conclusion that 80 to 90 percent of prescriptions for opioids were unnecessary anywhere. Anywhere in one place. To be clear.
- A. I personally did not write down what I have expressed to you as my expert opinion today.
 - Q. One of the factors -- or one of the things

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

that?

get this right.

Page 221 you talked about, Doctor, was -- I want to go back to your testimony, because I want to make sure I

You said if you -- and this is in the context of -- this was in response to plaintiff's counsel's questions. Plaintiff's counsel asked you about the cause of the dramatic increase in opioid pill prescriptions in West Virginia from the late 1990s to the mid two thousand teens.

And as part of that answer, you said, "If you use it" - "it" referring to prescription opioids - "for more than three to five days, you're at a high risk of becoming addicted or having an addiction."

And what is your basis for believing

MR. COLANTONIO: I'm just going to maybe ask you to read the whole answer so he can get the context.

MS. JINDAL: Yeah. The whole answer is a very long one, but I can point you to it if -if you can, but --

> MR. COLANTONIO: I don't have the --MS. JINDAL: Sure. I'll read the

whole answer.

Q. "So as I stated, the first inciting event was the effort to change the standards of pain and care for pain. As we changed the standard of care for pain in somewhere around late 1990s -- and really, I think it was like Robert Wood Johnson funded the work initially in 1997 that led to the JCAHO having that changed standard and the Cancer Society work at the same time, the VA, the federal government had changed, and this extraordinary effort was placed.

There was quote 'several reasons for it that we were getting details on.' One was the more ethical, we have an obligation to provide patients an absolute zero level of pain, it had to come down from 10 to zero.

The other was that you could be held liable if you don't do that, so it was about punitive actions.

And the third was, there is no addiction, no consequence and this was a really good safe medication and there was no --

What was happening really during this time - now looking in retrospective in fact - was

that, you know, you have a set population that was going to get the prescriptions in this context of changed standard of care of pain.

1.3

They were getting the prescriptions, so you get a tooth pulled - and that numbers hasn't changed over time - you know, anything you get 30 days of -- 30 days of liberal prescribing of an opioid.

You may be using two pills or three pills and they go, you know, in your closet, medicine cabinet.

So what happens is: If you used it for more than three to five days, you have a high risk of becoming addicted -- having addiction. Use it for a few days, then there's a high risk of diversion right there."

And I'm going to stop reading there because I just want to focus on that first sentence right there, "If you use it for more than three to five days, you have a high risk of becoming addicted."

Now, there, were you referring to someone with a prescription for opioids?

A. So I just want to correct -- if I made the

mistake, the Robert Wood Johnson work was commissioned in 1997, I believe, just for details.

I was -- yes. So to the answer, yes.

I was referring to someone who may have
appropriately or inappropriately been prescribed a
prescription for opioids.

Q. Okay. And you said "If someone is using prescription opioids pursuant to their prescription and they use it for more than three to five days, you have a high risk of becoming addicted."

My question for you is: Where does that -- where does that number come from? Where does that understanding come from?

- A. So the higher risk as opposed to no risk of becoming addicted after using three to five days is well established in literature, and the most -- probably the best reference would be the CDC's opioid guidelines of 2016, the opioid prescribing guidelines.
- Q. And have you reviewed that literature yourself?
- A. Yes. The opioid -- CDC's opioid guidelines, yes, I have. I have not recently, so I'm gonna have a little bit difficult time

recalling every aspect of it right now.

- Q. And you haven't reviewed the underlying study that the CDC cited?
- A. I do not recall right now. I believe I would have. It was one of the basis for me to -for the Opioid Reduction Act, Senate Bill 273,
 where we agreed on limiting the initial
 prescription to four days.

There was a -- a good discussion about this, three to five days, within the physician community, of the legislature and myself and others, and we agreed upon four days.

So yes, I have.

Q. And you said "use it for a few days and then there's a high risk of diversion right there."

So I want to ask you: Your -- when an

individual is prescribed opioids and they use them for, let's say, two to three days and then leave the remainder in their medicine cabinet, do the prescription opioids sitting in the medicine cabinet themselves induce addiction in others?

MR. COLANTONIO: Object to the form.

A. I'm sorry, I don't know -- I didn't understand that question.

Q. Okay. I'm talking about the pills in the medicine cabinet that are, as you said, there's a risk -- high risk of diversion right there. Is that accurate?

MR. COLANTONIO: I'm sorry. I object to the form of the question. I'm not sure of the question.

- A. Could you repeat the question, please?
- Q. Sure. Do prescription pills that are -you said prescription pills in a medicine cabinet
 form a high risk of diversion. Why is that?
 - A. I did not say that.
- Q. Okay. Do prescription pills in a medicine cabinet --

MS. JINDAL: Let me strike that.

Q. You know, it might be that my coff -- my tea was too weak and I need some coffee. So if we can, can we just take a ten-minute break and then I'll gather my notes and we'll come back?

MR. COLANTONIO: Okay.

VIDEO OPERATOR: Going off the record.

The time is 2:55 p.m.

(A recess was taken after which the proceedings continued as follows:)

24

1

2

3

5

6

7

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

22

2.3

Page 227 VIDEO OPERATOR: Now begins Media Unit 1 2 6 in the deposition of Rahul Gupta, M.D. We're 3 back on the record. The time is 3:10 p.m. BY MS. JINDAL: Doctor Gupta, you've been retained as an 5 expert consultant for opioid litigation in West 6 7 Virginia, correct? I'm looking at -- because I've been asked 8 9 for this deposition and --(A discussion was had off the record 10 11 regarding the court reporter having 12 been disconnected.) 13 Could you -- could you repeat the question Α. please. 14 15 Dr. Gupta, not focusing on today's 16 deposition, you have been retained as an expert 17 consultant for opioid litigation in West Virginia, 18 correct? 19 MR. COLANTONIO: In the MLP, yes. 20 Dr. Gupta, if you can answer? Q. 21 VIDEO OPERATOR: Now begins Media Unit 6 in the deposition of Rahul Gupta, M.D. We're 22 23 back on the record. The time is 3:10 p.m. 24 BY MS. JINDAL:

Q. Doctor Gupta, you've been retained as an expert consultant for opioid litigation in West Virginia, correct?

A. I'm looking at -- because I've been asked for this deposition and --

(A discussion was had off the record regarding the court reporter having been disconnected.)

- A. Could you -- could you repeat the question please.
- Q. Dr. Gupta, not focusing on today's deposition, you have been retained as an expert consultant for opioid litigation in West Virginia, correct?

MR. COLANTONIO: In the MLP, yes.

Q. Dr. Gupta, if you can answer?

THE COURT REPORTER: Are we back on the record and I missed that piece. Did Adam put us back on the record.

VIDEO OPERATOR: We never went off the record but we heard you when your phone audio cut and so we just paused and we've been waiting.

THE COURT REPORTER: Okay. I'm sorry.

A. So, yes for MLP and, yes.

- Q. By Mr. Colantonio's firm?
- 2 MR. COLANTONIO: Yes. And Napoli
- 3 | Shkolnik as well.
- 4 A. Napoli Shkolnik.
 - O. In addition to Mr. Colantonio's firm?
- 6 A. Yes.

1

5

9

21

22

23

24

- Q. And are you being paid for that work?
- 8 A. I have received -- yes.
 - Q. By the hour?
- 10 A. Yes.
- Q. How much per hour?
- 12 A. I believe it's \$500.
- Q. And the opinions that you've expressed in your testimony today, are those opinions that you provided in the course of your expert consulting for Mr. Colantonio's firm?
- MR. COLANTONIO: No, he has not.
- A. No. It's -- I'm providing because I was asked to be -- I was asked -- I was provided a subpoena and I was asked to be deposed today.
 - Q. Well, I'm not asking why you're testifying today, sir. I'm asking whether the opinions that you have expressed today in your deposition testimony are also ones that you've provided in the

course of your consulting, expert consulting, for Mr. Colantonio's firm.

MR. COLANTONIO: So let me just place an objection. So this -- we are in state court in West Virginia. The state court in West Virginia, as a consultant, I don't believe you're entitled to obtain information about his opinions as a consultant.

We've not yet identified trial experts. And so if he does become a trial expert, at that point you will be able to find that out. But at this point, he's a consultant, and so I want to have a continuing objection about that, and I'm not sure - given the overlay of this deposition in federal court - how that would play out procedurally, but I don't believe you're entitled to inquire in state court in the litigation at this point because he's a consultant, not identified as a trial expert, testifying expert, yet so you can't inquire into those areas.

MR. SHKOLNIK: This is Hunter
Shkolnik. I'm also on this deposition. I'm
objecting because under the Federal Rules, 26, you
are not entitled to any information about a

Page 231 retained consultant until they're a designated 1 2 expert, and I'm directing him not to answer, and 3 I'll make the motion in federal -- I'll go to federal court and argue that. MR. RUBY: He is a -- he has - and I 5 did confirm this over the break - been designated 6 7 as an expert in this case. He's been evidently retained as a paid 8 9 expert by counsel for the plaintiffs in this case, 10 and --11 MR. COLANTONIO: No, no. Hey, Steve, that's not correct. Let me make sure -- let me 12 13 tell you exactly what the -- what this is, okay, just so we're clear. 14 15 He has not -- he has been retained as a 16 paid expert consultant in the MLP case, okay? 17 He has not been retained as an expert, 18 paid expert, or a retained expert in the federal case. As I understand it, he is a nonretained 19 expert in the federal case. 20 21 He is a retained consultant in the 22 state MLP case, which I think Hunter is correct, 23 does not entitle you to get into what we're talking 24 about in the state case because he's a consultant

Page 232 at this point, not identified as trial testifying 1 2 expert. But he's not -- he's not been retained 3 as a -- as a retained expert in the federal case. 4 MR. RUBY: No, I understand the 5 distinction that's being attempted, but --6 7 MR. COLANTONIO: No, it's a fact. That's a fact. That's not being attempted. That's 8 9 what it is. 10 MR. FITZSIMMONS: Let me just put it 11 on the record, let's move on. Come on. Let's move 12 on, let's go. 13 MR. RUBY: Well, I -- there's a -there's a question -- the problem, Bob, is that 14 15 there's a question pending and Mr. Shkolnik has instructed him not to answer. 16 17 MR. FITZSIMMONS: Okay. So that -- so 18 we can move on from there. MR. RUBY: No, I think we -- I'm 19 trying to work this out before we have to call 20 21 Judge Wilkes --22 MR. COLANTONIO: Let me make sure I'm 23 clear. So it's a timing issue. He was retained as a consultant in the MLP case before you guys issued 24

a subpoena, all right? So, I mean, your subpoena is with -- what brought him here, not nothing else but your subpoena.

So I mean, it is what it is. He responded to subpoena, and so that's what brought him here, nothing else. And if you hadn't issued a subpoena, we wouldn't be here and this wouldn't be an issue.

MR. FITZSIMMONS: Right.

MR. RUBY: No, no, no, we're here and we issued a subpoena because he -- because he was on plaintiffs' initial list of witnesses, and as has already been pointed out, he's disclosed as --

MR. FITZSIMMONS: Whatever.

MR. RUBY: -- he's disclosed as an expert in this case, as a nonretained expert in this case, and yet he's being paid under a retainer agreement by counsel for the plaintiffs in this case, and so --

MR. COLANTONIO: He's not being paid by -- in this case. He's not being paid in this case. You can ask him that.

MS. KEARSE: Just to be clear, it's clear in our disclosure that he's an unretained

Page 234 expert. While his testimony will be very factual 1 2 in nature, there could be information that may be 3 considered expert testimony based on his experiences and his work, so that's why it's under Rule 26(a)(2)(C) that we have disclosed him as an 5 unretained expert in addition to a witness with 6 7 knowledge in regards to the issues in the federal 8 case. 9 MR. RUBY: And he's being paid in a different case where he's a consultant for counsel 10 who are also counsel for plaintiffs in this case. 11 12 Is that correct? Is that the position? 13 MR. COLANTONIO: That's true. But it's 14 a different case. 15 MR. RUBY: And the question --16 MS. KEARSE: I want to clarify it to 17 the -- I'm not -- I do not know in the MLP case on 18 behalf of my Motley Rice clients on what that 19 relationship is. There may be some other cases 20 that have formerly retained him. 21 We are all in the MLP, but I, as counsel for the City of Huntington, I just don't 22 think it would be correct to say that plaintiffs' 23

counsel, that is, the City of Huntington and Cabell

24

Page 235 County in this case, have retained him in the other 1 2 case. 3 That may be a down-the-road case and I would have to talk with Mr. Colantonio about that 4 5 as well, just for clarity's sake on that. MR. RUBY: And I think the -- just so 6 7 we're all clear, I think the question that is pending, the question that's on the floor, is 8 9 whether the opinions to which he's testified today 10 are opinions that he has provided in his retained 11 engagement in other West Virginia opioid 12 litigation. 13 MR. COLANTONIO: Are we on the record or off the record, by the way? 14 15 MR. RUBY: We're on. 16 MR. COLANTONIO: I'm sorry, on or off? 17 MR. RUBY: I don't think anybody's 18 taken us off. And we'd like to stay on for this 19 discussion. 20 MR. COLANTONIO: Okay, that's fine. 21 Well, whatever, Bob. Is there a question pending? 22 Yes. MR. RUBY: 2.3 MR. FITZSIMMONS: What's the question? 24 MR. RUBY: Teresa, are you able to go

Page 236 that far back? 1 2 THE COURT REPORTER: Sure. Yes. 3 "And the opinions that you have expressed in your testimony today are those 4 5 opinions that you provided in the course of your expert consulting for Mr. Colantonio's firm?" 6 7 MR. COLANTONIO: And I think at that point -- Hunter, are you instructing him not to 8 9 answer? 10 MR. FITZSIMMONS: He is. MR. SHKOLNIK: Yes, because first of 11 all he's not retained by any firms other than ours, 12 13 not Motley Rice or anybody else, and under the federal rules, he does not have to be giving 14 15 answers as a retained consulting expert as to what 16 he's considered, done, his opinions or anything 17 along those lines. 18 MR. RUBY: And the problem --19 MR. SHKOLNIK: And just so -- wait. 20 The problem is, the question specifically asks, 21 what did you do in the MLP case for my firm and the 22 Colantonio firm, and that's the inappropriate 23 question. 24 If you rephrase the question, it may be

Page 237 appropriate. 1 2 MR. RUBY: The question doesn't say 3 anything about the MLP; the question is about Mr. Colantonio's firm, which is counsel for the 4 5 plaintiffs in the case in which this deposition is being taken. 6 7 MR. SHKOLNIK: No, that's not the question. Read it back again. 8 MS. KEARSE: We clarified that. 9 10 MR. COLANTONIO: The question was: 11 Did you provide these opinions in the other case in which we retained him, and that's -- that's what 12 13 Hunter's saying. That's the question. You're asking for whether or not --14 15 MR. SHKOLNIK: It's under the federal 16 rules of civil procedure. 17 MR. COLANTONIO: -- in the other case. 18 That gets into the other case. 19 MR. RUBY: And so -- well, if -- just 20 let me make sure I understand. If your -- if your 21 position is that we can't ask whether he's provided these opinions as part of his retained 22 23 engagement --MR. COLANTONIO: -- in the MLP --24

Page 238 MR. FITZSIMMONS: Why don't you just 1 2 have, Steve -- have Jyoti answer the question 3 aqain. Let's go from there. MR. RUBY: Jyoti, go ahead. 4 5 MS. JINDAL: Sure. BY MS. JINDAL: 6 7 The opinions that you expressed in your Ο. testimony today, are those opinions that you 8 9 provided in the course of your expert consulting for Mr. Colantonio's firm? 10 11 MR. FITZSIMMONS: Mark. 12 MR. COLANTONIO: Hunter, are you instructing him not to answer? Is Hunter on 13 14 there? MR. SHKOLNIK: Yeah, I'm here. 15 That 16 question, is it something they gave to 17 Mr. Colantonio's firm, I think that's privileged. 18 We're his counsel for this deposition. 19 MR. RUBY: Oh, come on. He's your 20 expert and your client so everything you discuss 21 with him as an expert is privileged? 22 MR. SHKOLNIK: Until he's a designated 23 expert in litigation, yes. 24 In our litigation.

MR. RUBY: His relationship with your firm, Hunter, I think is different from your relationship with Mark's because you haven't appeared as counsel for the plaintiffs in this case, but the Fitzsimmons firm has, and he is a disclosed expert in this case, in which Mark and Bob are counsel for plaintiffs. MS. KEARSE: And I think I clarified earlier, Mr. Colantonio has appeared, I believe, his firm, on some depositions on there, but Mr. Colantonio's firm does not represent the City of Huntington. No, they --MR. RUBY: They've noticed an appearance for the City of Huntington. I mean, you can't notice an appearance for a specific deposition and say "We're only representing you in this deposition." MS. KEARSE: Well, there are certain depositions in the ML -- in the MDL versus the MLP that they've appeared, some third-party depositions, and I understand on behalf of the Prosecutor's Office in Cabell County. MR. RUBY: That was -- that's different. My understanding is they were

1

2

3

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

Page 240 representing the Prosecutor's Office there. 1 2 they filed -- they have appeared as counsel for 3 plaintiffs, Cabell County Commission and City of Huntington, in this case. 4 5 MR. FITZSIMMONS: Hey, Steve, this is Bob. Do you mind if we just take a moment -- we'll 6 7 step out. Do you mind if we actually talk to our client at this point? Because we're talking about 8 9 privilege here and it gets a little -- the designation with Hunter --10 11 MR. RUBY: Sure, that's fine. 12 MR. FITZSIMMONS: -- resolve this for 13 a second. MR. RUBY: Yeah, let's go off the 14 15 record. 16 MR. FITZSIMMONS: Okay. 17 VIDEO OPERATOR: Going off the record. 18 The time is 3:25 p.m. (A recess was taken after which the 19 20 proceedings continued as follows:) 21 VIDEO OPERATOR: Now begins Media Unit 7 in the deposition of Rahul Gupta, M.D. We are 22 23 back on the record. The time is 3:29 p.m. 24 BY MS. JINDAL:

- Q. Doctor Gupta, the opinions that you expressed in your testimony today, are those opinions that you've provided in the course of your expert consulting for Mr. Colantonio's firm?
 - A. No.

- Q. And did Mr. Colantonio approach you to serve as an expert consultant for opioid litigation in West Virginia?
 - A. No.
- Q. Apologies. Did someone from

 Mr. Colantonio's firm approach you to serve as an

 expert consultant for opioid litigation in West

 Virginia?
 - A. No.
- Q. Who approached you to serve as an expert consultant for opioid litigation in West Virginia?
- A. I am not sure that I -- I've been approached to serve as expert consultant in West Virginia. I mean, I am sorry, I'm not a legal person, as I said at the very beginning, so various cases, I don't --
- Q. Let me try to make myself more clear. Who did you -- who first contacted you about serving as an expert consultant for opioid litigation

regarding the opioid crisis in West Virginia?

A. I think I spoke with Hunter a bit back and we had talked about, and I really -- you know, it's been a long time, but I did not really have the time for quite a bit to be able to do any work beyond --

So we had a good discussion. I listened to him and said I will just, you know, make a decision based on being available and time and other things.

So that's basically where I think, you know, my work or my agreements or talks have been, with mostly Hunter.

- Q. And that's Mr. Hunter, the Hunter you're referring to, that's of Hunter Shkolnik, the firm?
 - A. Yes, Hunter Shkolnik.
- Q. The firm Hunter & Napolini, I believe -- or I'm sorry, Shkolnik Napolini.

MR. GOOLD: I believe it's Napoli.

MS. JINDAL: Sorry, Napoli. I apologize. You see it so many times on e-mails that you don't actually read it after a while so -- BY MS. JINDAL:

Q. Doctor, you were asked about a social

Page 243 autopsy; is that right? 1 2 Α. Yes. 3 Q. And that refers to the 2016 fatality overdose analysis that your team at the West 4 5 Virginia Bureau for Public Health conducted, correct? 6 Α. Yes. And the purpose of that study was to 8 9 identify causes of overdose deaths. Correct? The purpose of the work was to understand 10 11 better the factors associated with people that 12 result in death, but the entire consequence of a 13 period of time by one year prior to their death, to 14 better understand their characteristics. 15 And was it all deaths or just opioid 16 deaths? This was all deaths from overdose in 2016 17 Α. 18 in the state of West Virginia. 19 So that includes prescription opioids, for Q. 20 example? 21 Α. Yes. It also includes heroin, for example? 22 Ο. It could. 2.3 Α. Does it also include overdose deaths where 24 Q.

Page 244 methamphetamines was used? 1 2 Α. It could. 3 Q. Almost every overdose death involves multiple substances, correct? 5 Not necessarily. Α. Q. You're right. I used the word -- sorry. 6 7 Doctor, if you could turn back to that Exhibit 54. 8 9 Α. That's the presentation? Yes. State of Health on October 26, 2018. 10 Ο. 11 I have it. Α. Okay. Could you please turn to Slide 17? 12 Q. And that ends with Bates No. 0936. 13 14 Α. Yes. 15 Okay. And does this slide reflect the fact 16 that most overdoses include multiple drugs? 17 Α. I'm reviewing it. 18 So the slide we're looking at really 19 involves the average number of drugs per fatal 20 overdose. That is very different than the 21 statement that you provided me. What this means is that it could be out of 100, that one person could 22 have 100 substances and we could call it -- there's 23 24 -- and the other 99 would have a total of 100

substances, and we could say, "Well, it's two substances per person" because we added up and divided by 100.

Or it could be that the other 100 could have two each rather than having 100 substances in one person. So I don't think this slide provides adequate evidence to make the claim as has been stated.

Q. Focusing just on the time period from 2001 to 2013 there, is there a general trend --

I'm sorry. Focusing on the dark blue box that's on that slide - it's written "2001" to "2017 Percentage Difference:" Plus "16.9%" - does that reflect an average trend upward in the number of average drugs -- in the average number of drugs involved per fatal overdose over that time period?

A. Yes, from 2001 to 2017, if you look at the numbers above the blue bar, you will see in 2001, it says, "2.32." And in 2017, you see it says "2.79." If you subtract the two and you get a number and you divide it by 2.32 and multiply that by 100, I believe you will arrive at the number of 16.9 percent.

Now, simplistically looking at that,

Page 246 we'll ignore the fact that these values peaked in 1 2 2012 and '13 and '14, and there have been a 3 crescendo effect. And the average increase per year is 4 5 identified as 1 percent. Am I reading that correctly? 6 You're reading that correctly. Once again, that's 17 years and 17 8 9 percent, so the average becomes 1 percent per year. 10 Going back to the 2016 autopsy report that you were discussing, did that report say anything 11 about wholesale distributors? 12 13 I don't have the report in front of me. Ι did submit that, so I am not able to collect --14 15 recollect that information right off -- right now, without reviewing the report. 16 17 Ο. I think it's Exhibit 37. Sure. 18 GUPTA DEPOSITION EXHIBIT NO. 37 19 (E-mail chain between Melton, Gupta 20 and others Re: Overdose Death 21 Investigations dated 3-26&27-18 with 22 2016 West Virginia Overdose Fatality 2.3 Analysis attached

(DHHR FEDWV 0317258-322) was marked

2.4

Page 247 for identification purposes as Gupta 1 2 Deposition Exhibit No. 37.) It will take me a little bit of time to 3 Α. review this. 4 And Doctor, you're welcome to review it at 5 your pace. But I will represent to you that it 6 does not include the word "wholesale distributors" 7 in there. 8 9 I will -- I will believe you at this point and concede at that point without having to fully 10 11 review the report. Sure. You said that many people who died 12 Q. 13 of drug overdoses had filled prescriptions for controlled substances in the 30 days before they 14 15 died? 16 Α. Yes. 17 And were those prescriptions written by a 18 physician? 19 I would make an assumption that those 20 prescriptions were provided by prescribers. 21 Ο. I apologize. You've always got me on that. 22 I appreciate it. Were those prescriptions written by 23 24 prescribers?

Page 248

- A. I cannot be as certain of that I can make an assumption but if there were any fraudulent prescriptions, I could not -- I could not tell you in a verified way.
- Q. So as far as assuming that the prescriptions were written by prescribers and did not include fraudulent prescribe -- prescriptions, were the prescribers -- they would have been licensed by the state of Virginia, correct?

 $$\operatorname{MR}.$ COLANTONIO: Object to the form of the question.

A. It is possible, plausible, but not for sure. And the reason I say that is because what I -- we found was that those decedents who went to three or more pharmacies -- four or more pharmacies, were 70 times -- I'm sorry, were 70 times more likely to have died.

What that means is -- so let me repeat that. So it says here, the decedents that were more -- 70 more times likely to have a prescription as four more pharmacies that died.

What that means is because we were sharing data with CSMP with cross border states, some could have obtained it in doctor shopping,

diverted prescriptions from elsewhere, but the data did come from CSMP.

I cannot validate whether they were exclusively West Virginia prescriptions.

- Q. I see. Would the prescribers have been licensed by a state, if not West Virginia?
 - A. I would hope so.

- Q. And they would have also have had to have been registered with the DEA, correct?
 - A. Similarly, I would hope so.
- Q. Okay. And did you do any -- did you identify any physicians who wrote those prescriptions -- I'm sorry, any prescribers who wrote those prescriptions without being licensed?
- A. Our study was -- and work was not intended to study and look at the licensure aspects of prescribers.
- Q. So the answer is no, you didn't review the -- because you did not review the licensure of the physicians in the database, you don't -- you did not identify any who were not licensed.

MR. COLANTONIO: Object to the form.

A. It was not the purpose of the study that -- I already testified to the purpose of the study, so

- it does not -- the answer does not conform -- the question does not conform to what I have already stated.
- Q. You testified that you started to develop an understanding of the overdose problem when you got better access to the controlled substances program -- monitoring program data. Is that correct?
 - A. That would be accurate.
- Q. Wholesale distributors don't have access to the data in the CSMP, correct?
 - A. I have no knowledge to verify that.
- Q. You did testify that access to the CSMP is regulated, correct?
 - A. Correct.

1

2

3

5

6

7

8

9

12

15

24

- Q. And it's not something that anyone has access to, right?
- MR. COLANTONIO: Object to the form.
- A. It is not something that's open as a public database. That's the way to answer it.
- Q. And in fact, you, as a Commissioner for the
 Bureau of Public Health, did not have access to the
 CSMP, correct?
 - A. The Bureau of Public Health did

subsequently have access to it.

- Q. At the time you started, you did not have access, correct?
- A. I don't know that for sure. The work -when we did this work, we did have access to the
 CSMP. I cannot tell -- say for certainty that in
 2015 I personally, as Commissioner, did or did not
 have access to the CSMP for the purposes of what we
 call fishing.

I am reasonably certain in my statement that I did not have authority to go fishing inside the database of the West Virginia's Controlled Substances Monitoring Program.

- Q. And I suppose I'm referring to your testimony earlier today, that you had to embed somebody within the Board of Pharmacy to gain access to the CSMP data, correct?
- A. We embedded Board of Pharmacy employee into the Bureau for Public Health that was in accordance with the law at the time to be able to conduct public health surveillance activities, in the due process of which we're able to access some of the queries that we had.
 - Q. So again, it was only a Board of Pharmacy

employee who was able to access the CSMP data in that?

- A. That would be accurate.
- Q. You testified also that the medical examiner's office had bullet holes in it, correct?
 - A. Correct.

Q. Is it your testimony that those bullet holes had something to do with opioids?

MR. COLANTONIO: Object to the form.

A. I wanted to -- before I answer that question, I also want to say: So in my capacity as a licensed physician and a registered prescriber, I did have access to CSMP to interrogate the CSMP if I were to for a patient.

I did not have the authority to fish or interrogate CSMP for those who are not my personal patients. I just wanted to add that.

The bullet holes were a result of violence; oftentimes the violence was a result of individuals who were under the influence of various drugs; and oftentimes those drugs included opioids.

Q. Do you know whether the individual who put bullet holes in the medical examiner's office was under the influence of opioids at the time?

- A. I do not know who the individual was who put the bullet holes in the Office of the Chief Medical Examiner's office.
- Q. But do you know whether that individual -without knowing their name, do you know whether
 that individual was under the influence of opioids
 at the time?
- A. If I do not know the identity of that individual who shot through whether it was a cop, it was a criminal or somebody under the influence there's no way for me to make a judgment as to what they were under the influence of.
- Q. The IV drug use problem that you mentioned, that's related to the use of nonprescription drugs, correct?
 - A. Could you repeat that question, please?
 - O. Uh-huh. You --

- MS. JINDAL: Ms. Evans, if you could read it back.
 - THE COURT REPORTER: "The IV drug use problem that you mentioned, that's related to the use of nonprescription drugs, correct?"
 - A. The IV drug use problem was an evolution of the prescription drug problem.

- Q. And users -- individuals who inject these drugs, they are -- IV use is primarily associated with heroin. Is that right?
- A. It could be used with heroin, although we have seen that evolve into being cut with fentanyl and other substances as well.
- Q. Someone who's just using prescription drugs is unlikely to be using -- is unlikely to be injecting that; is that right?

MS. KEARSE: Object to form.

A. Not necessarily.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

Q. Doctor, if you could turn to Exhibit 38.

GUPTA DEPOSITION EXHIBIT NO. 38

(Gupta testimony before the House
Oversight and Government Reform
Committee entitled "A Sustainable
Solution to the Evolving Opioid
Crisis: Revitalizing the Office of
National Drug Control Policy" dated

5-17-18 (DHHR_FEDWV_0391628-651) was

marked for identification purposes as

Gupta Deposition Exhibit No. 38.)

- A. I have it.
- Q. And I know, Doctor, you're not on that

Page 255 cover e-mail. I'd like you to focus on the 1 2 attachment that begins on page 1630 -- or the Bates 3 -- I'm sorry, the Bates, the last four numbers are 1630. 4 I have it. 5 Α. Okay. And I point that out just to reflect 6 7 that this document that begins on Bates stamp DHHR FEDWV 0391630 is an attachment to the cover 8 9 e-mail dated December 20th, 2019 from Carolyn Mullen to Christina Mullins. 10 11 Do you see that, Doctor? 12 Α. Yes. No relation between the two Mullins. 13 Right. And the document that ends with the Q. Bates stamp 1630, are you familiar with this? 14 15 Α. Yes. 16 Ο. What is it? 17 It's my testimony to the House Oversight Α. 18 and Government Reform Committee in Congress on May 17, 2018. 19 And did you give this testimony as a part 20 21 of a hearing titled "A Sustainable Solution to the 22 Evolving Opioid Crisis: Revitalizing the Office of National Drug Control Policy?" 23

24

Α.

Yes.

- Q. Could you turn to page 3 of this testimony, the Bates stamp that ends in 1632?
 - A. Okay.

2.3

- Q. And I'm going to read from the penultimate paragraph on this page. It begins, "The opioid crisis is evolving." Do you see that?
 - A. I see it.
- Q. Okay. You write, "The opiate crisis is evolving -- illicit fentanyl and other synthetic opioids are the major driver of overdose deaths in many parts of the country now. While the opioid crisis is not just a criminal justice issue, we must support and strengthen the role of law enforcement to address the supply of illicit fentanyl, as well as other emerging illicit drugs. Overdose deaths are increasingly being associated with methamphetamine, indicating that a comprehensive approach to all illicit substances, that include law enforcement and health agencies, is needed."

Did I read that correctly?

- A. Yes.
- Q. Do you still agree with the statement?
- A. I think in the context of my testimony,

including the first two and a half pages, I do agree with the statement. At the time.

- Q. And the defendants in this case don't distribute heroin, do they?
 - A. Not to my knowledge.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2.4

- Q. And they don't distribute illicitly manufactured fentanyl, do they?
 - A. I have never received any reports of such.
- Q. And they don't distribute methamphetamine, correct?
 - A. I'm not sure about that one.
- Q. They don't distribute illicit methamphetamine, correct?
- A. Excuse me. Illicit methamphetamine could be produced through some other pharmaceutical products that are available over the counter, which the distributors may be distributing that I'm not aware of.
- Q. Okay. But in this -- in the context of your testimony here, were you referring to over-the -- not over-the-counter, but were you referring to controlled substances that are also stimulants? Or were you referring to illicit methamphetamine?
 - A. I was referring to methamphetamine which

tends to be illicit, but it can be developed from licit drugs, as well as in factories in Mexico.

So it could be developed -- illicit methamphetamine could be developed through licit or illicit routes.

- Q. Are you aware of defendants in this case developing licit methamphetamine?
- A. I'm aware of over-the-counter products, pharmaceutical products, that can lead individuals to generate methamphetamine -- methamphetamine, and my depth of knowledge does not lead for me to know one way or the other if the defendants were distributors for those products.
- Q. You're referring to codeine, for example, like Sudafed.
 - A. Yes.

2.3

- Q. Okay. So setting aside precursor chemicals for methamphetamine, are you aware of wholesale distributors distributing methamphetamine, the drug itself, in the form to be used by someone for the purposes of obtaining a high?
 - A. Not that I'm aware of.
- Q. Thank you. You testified that the change in the standard of care for opioids started with a

change in the standard of care for treatment of pain, and you also mentioned that, for example, the Joint Commission and the American Pain Society promoted that change.

Is that correct?

A. Yes.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

- Q. What prompted that change?
- A. Are you asking me to hypothesize?
- Q. No. As far as you know, what prompted the change in the standard of care for treatment of pain and prescription of opioids? Prescribing of opioids, excuse me.
- A. I think in the medical community, there's a general consensus that the approval of OxyContin in the few years prior to that was an -- a factor in prompting that change. But I'm not aware of any specific indications for what prompted the change.
- Q. And are you aware of any evidence that distributors played any role in that?
 - A. No.
- Q. You testified that a significant part of the volume that was coming in was inappropriate.

 Correct?
 - A. Could you please repeat? I missed one

word.

- Q. Uh-huh. You testified earlier today that a significant part of the volume that was coming in was inappropriate. Correct?
- A. I testified that the significant amount of prescriptions that were being provided for opioids were inappropriate.
 - Q. In what way were they inappropriate?
- A. They were inappropriate because they were either unnecessary or they were being diverted. Or they were unnecessary that led to diversion.
- Q. In taking the first set you said the ones that were unnecessary did the prescribers who wrote them know that those prescriptions were unnecessary?
- A. It's hard for me to state that if every one of those prescribers, whether they knew or did not know. That's where the context of change in standards of care for pain come into play.

So if a dentist wrote someone a 30 days of opioid prescription, that's clearly unnecessary.

If a 17-year-old kid got a football ankle sprain and got three months of Lortabs, that's clearly unnecessary.

1

2

3

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

www.veritext.com

Page 261

Whether the writer of that prescription knew about that or not, I do not know for each one of those prescribers across the United States or for West Virginia or for Huntington, West Virginia.

- Q. So your categorization of them as unnecessary is based on your retrospective review?
- A. Both retrospective and prospective, because I was not one of those physicians when I was practicing that was writing that volume of prescriptions for those particular indications.
- Q. And did the physicians who wrote -- or the prescribers who wrote these prescriptions that you categorize as unnecessary, did they know that the standard of care was wrong?

 $$\operatorname{MR}.$ COLANTONIO: Object to the form of the question.

- A. It's hard for me to say what they were thinking and what they felt, how they felt about this changing standard of care for pain.
- Q. Is that also your answer for the categories that you said were unnecessary but led to diversion?

MR. COLANTONIO: Object to the form.

A. Could you restate the question?

Veritext Legal Solutions

Q. Sure. You identified three categories of ways that you can identify prescriptions that were inappropriate. You said some were unnecessary; some were diverted; and some were unnecessary that led to diversion.

Correct?

A. Yes.

Q. So your perspective that you don't know whether the prescribers who wrote the unnecessary prescriptions, whether they knew that the prescriptions were unnecessary or that they knew that the standard of care was wrong, does that equally apply to the ones that wrote unnecessary prescriptions that led to diversion?

Let me -- let me maybe rephrase that a little bit. The prescribers who wrote prescriptions that were unnecessary that led to diversion, did they know that those prescriptions were gonna be diverted at the time they wrote them?

A. So I think they -- it's impossible to categorize the entire prescribers in the United States - or for that matter, West Virginia - in one box. I think the fact of the matter is, to be frank and honest, that we had some bad docs and bad

prescribers. They clearly knew what they were doing.

And we have others that were of the category that they were taking a reasonable, prudent approach as from evidence-based care.

And the third category that felt that what they were doing what they could to help the patients.

And in a change of standard of care scenario, they felt that they could give more prescriptions and they were being told these prescriptions were safe and they are helpful and they could get sued if they didn't do that, and they were just trying to help people at the end --bottom -- end of the day.

So I think we do have to start to look at prescribers differently based on those intentions. So that was my answer.

- Q. And the prescribers who are just trying to do the best by their patients, would you say that they were prescribing those opioids in good faith?
- A. I would say in the environment of changed standards of care for pain, they were prescribing -- for some, it was in good faith and helping. For

others, it was making sure not getting sued or being -- being regulated for the Board of Medicine for the full management of pain.

And still others, they were ensuring that - for example, in hospitals, when I was a hospitalist - that you're making sure that if people are -- you know, to the extent possible, having adequate controlling of pain, but also then there were colleagues of mine that were looking at the pain scales, the happy faces, and ensuring that everybody had a little nice sticker with a happy face on them.

- Q. And is it your testimony that 80 percent or more of the prescriptions that physicians wrote in West Virginia were inappropriate?
 - A. Over a period of time, yes.
 - Q. What period of time is that?
- A. I would say you start to look at that from 2001, and clearly it starts to rise slowly. In about 2006, I think it was about 130 prescriptions per 100 people man, woman, child, infant and then, you know, peaking perhaps around 2012 and then starting to decline.

So if you look at it over the period of

time -- that period of time, that would be my estimate.

O. So 2001 to 2012?

1

2

3

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

- A. I think it was with a -- with a gradual rise. Between 2006 and 2012, clearly. That would be my testimony.
- Q. I'm sorry, so I just want to be clear. Is it your testimony that 80 percent or more of the prescriptions that physicians wrote during 2006 to 2012 were inappropriate?
 - A. That would be my testimony.
- Q. Okay. 2006 to 2012. Should pharmacies have refused to fill those prescriptions?
- A. So the pharmacies, the distributors, physicians, prescribers, everyone had a duty for due diligence at the end of the day.

So everybody has a responsibility.

That's how our system is set up. There's a upstream responsibility which can actually prevent and avoid a lot of the carnage downstream, and then pharmacies are clearly part of the downstream impact. They also have a responsibility. They

Q. So your answer is yes, pharmacies should

also have a level of impact. So the answer is yes.

have refused to fill those prescriptions.

MR. COLANTONIO: Object to form.

- A. The pharmacies should have conducted a due diligence in filling any and all prescriptions, just like the distributors should have as well.
- Q. All right. And so is it your testimony that distributors are presented with prescriptions?
- A. It's my testimony that the distributors are part of the supply chain through which those prescriptions are filled.
- Q. Is it -- are you saying the distributors know what prescriptions are going to be filled when they fill an order for prescription opioids placed by a pharmacy?
- A. No. What I'm saying is: When hundreds of millions of pills are being distributed across a state with 1.8 million population, we should be able to recognize that pattern clearly.
- MS. JINDAL: I'm going to move to strike everything after "No" as nonresponsive. Thank you.
 - MR. COLANTONIO: Well --
- Q. Did you ever propose any action to reduce the number of prescription opioids that a pharmacy

Page 267 could order? 1 2 MR. COLANTONIO: Hold on a minute. 3 That -- I just want to make a comment. He responded to your question. You may not like the answer, but you asked a question and he responded 5 to it. 6 7 Go ahead. MS. JINDAL: Well, I'll leave that on 8 9 the record and we can fight about it another day. 10 Did you ever propose any action to reduce the number of prescription opioids that a pharmacy 11 could order? 12 13 MR. COLANTONIO: Object to the form. I'm sorry, pharmacies are not ordering 14 15 prescriptions, so I don't understand the context of 16 the question --17 I'm sorry, I may have missed a word in my 18 question. Did you ever propose any action to reduce the number of prescription opioids that a 19 pharmacy could order? 20 21 MR. COLANTONIO: Object to the form of 22 the question. I once again do not understand the question 23 real well, so if you could rephrase it for me, 24

please.

- Q. When a pharmacy -- how does a pharmacy get prescription opioids?
- MR. COLANTONIO: Object to the form of the question.
- A. My understanding is that the pharmacy would make the request to the distributor to provide the supplies.
- Q. And did you ever consider legislation or action that would reduce the number of -- the quantity of prescription opioids that a pharmacy could request from a wholesale distributor at any one time?
- MR. COLANTONIO: Object to the form of the question.
- A. We did promulgate legislation that reduces the amount of prescriptions including the initial prescribing, which would lead to reduction in pharmacies requesting supplies of opioids from distributors.
- Q. I understand. Separate and aside from what you did with respect to what prescribers could prescribe, did you ever propose any regulations that would directly impact the number of

Page 269 prescriptions that a pharmacy could order --1 2 prescription opioids that a pharmacy could order at 3 any one time? Our role to impact the amount of 4 5 prescriptions was by doing everything we could to reduce the amount of prescriptions, and that's what 6 we did. I still do not understand the question 7 that you're asking, so if you can restate that in 8 9 some other form, I'm happy to answer it. 10 I just don't --11 Ο. Sure. 12 Α. I'm not sure --13 We agreed that a pharmacy has to place an O. order or request prescription opioids from a 14 15 wholesale distributor before it obtains them. Correct? 16 17 Α. Yes. 18 And let's say a pharmacy places an order for 10,000 prescription opioids for the month of 19 July 2007. 20 21 Α. Yes. Okay. Did you ever consider telling all 22 23 pharmacies in West Virginia -- regulating all pharmacies in West Virginia and saying, "You cannot 24

Page 270 order more than 5,000 prescription opioids for any 1 2 month in any year"? 3 MR. COLANTONIO: Object to the form of the question. Is that -- does that make the question 5 clearer? 6 There is something called the Α. Controlled Substances Act that already requires the 8 9 distributors and pharmacists to ensure that their suspicious orders that are monitored, raised, 10 11 investigated, quarantined. Why would we do that when there was 12 13 already existing federal law to prevent that? 14 There is also existing federal law about --Ο. 15 MS. JINDAL: Strike that. 16 Q. Prescribers are also regulated by federal 17 law with respect to their prescribing of controlled 18 substances, correct? 19 Α. Yes. 20 They also have to be regulated by DEA, 21 correct? 22 Α. Yes. 23 And yet you still passed law that regulated 24 their conduct within the state of West Virginia,

Page 271 correct? 1 2 MR. COLANTONIO: Object to the form of 3 the question. Α. 4 Yes. So why does the fact that there is federal 5 law that also regulates the conduct of pharmacies 6 7 impact your decision whether or not to propose any legislation with -- that would amount -- that would 8 9 regulate pharmacies under West Virginia law? MR. COLANTONIO: Object to the form of 10 11 the question. 12 Α. The law that we passed with respect to what you're stating had to do with standards of care. 13 This was -- it was to align ourselves with CDC 14 15 recommendations, following CDC recommendations and 16 quidelines that came out. 17 We wanted to make sure we were aligned 18 with that, and it's about people of West Virginia. 19 It's about making sure that the people and the 20 residents of West Virginia are getting the highest 21 standard of care, and that's what that related -the law was related to. 22 We expect that -- to do that. That's 2.3 24 our responsibility. Now, let's be clear. It is

not our responsibility to ensure that there's enforcement of the federal law. That's not our job. That's your job. That's your client's job.

And we did everything we could to make sure that the standards of care for health, for medicine, were being held to the highest standards possible, and that includes the CDC guidelines.

Now, when it comes to maintaining suspicious orders - and I'll call them suspicious orders - and adhering to rules and laws that already exist, we depend on this relationship for the system to function that we are all doing our own respective jobs. And that clearly wasn't the case here.

Q. If you had limited the number of prescription opioids that a pharmacy could order, then there's a certain percentage of prescriptions that they would not have been able to fill.

Correct?

MR. COLANTONIO: Object to form.

A. That would be inherently unfair to the citizens of West Virginia, because if you understand a rural state like West Virginia, you would understand that oftentimes -- and you

yourself mentioned that we have an aging population. You mentioned yourself that we have a disabled population. 50 percent higher than the rest of the country.

2.4

And the last thing we want them to be doing is driving 80 miles because the quota for some pharmacy has been filled. So this is a balancing act, and we -- we really need all actors to be working in good faith, to be doing their part of the work.

If we have -- if we had one fix to all solutions, believe me, we would have done it.

Everything that we could have done was on the table.

But what happens -- or maybe -- what states in policy, we have to make sure that at the end of the day, we're not hurting the people of West Virginia more than what they're already being hurt.

So this is the reason why it was important for all of us to do it our own respectives -- to take on our own due diligence and do our jobs.

That's my response.

- Q. And you're not aware of the Board of Pharmacy taking any action against wholesale distributors for not doing their jobs, correct?
 - A. I'm not aware, right.

- Q. You testified that the majority of heroin use in West Virginia was caused by prescription opioid use. Correct?
 - A. I testified that -- yes.
- Q. Is your evidence for that -- let me rephrase. What is your evidence for that?
- A. So if you see the pattern over the years in my report, you will see that as prescription drugs and prescriptions for that have fallen over the years because of the incremental actions that have been taken at state level, we did not see a proportionate fall in overdose deaths.

We certainly did not see a fall in the number of people who were having nonfatal overdoses, as well as those who were having addiction.

And at the same time, you'll see the chart, the graph that demonstrates an increasing utilization of heroin as well as synthetic opioids. That's indisputable.

Q. And that -- does that "use of prescription opioids" refer to use pursuant to a doctor or another prescriber's prescription, or does that refer to nonmedical use as well?

A. It refers to the amount of volume of pills that were there. As they begin to dry up because of all the incremental steps and mechanisms that were put into place - so at the end of the day, it's all about volume - as the volume starts to decrease, the tap starts to turn off, we should see a proportional declines in addiction and overdose if it was a simple chart like that.

And that's why I mentioned evolving crisis, because this crisis may have begun with the prescription opioids, but it certainly has continued to evolve.

- Q. And that evolution includes nonopioid such as methamphetamine, correct?
- A. It has been a recent phenomena, and it is a part of the evolution, and it is not only in Cabell County, Huntington or West Virginia. This is a national trend that we're seeing, yes.
- Q. Is it your testimony that the -- that users who use prescription opioids also transition to

methamphetamines because they used prescription opioids?

A. They can transition to methamphetamine.

They can transition to heroin. They can transition to a lot of things. If you allow me, I would like to provide you a real life example.

I mentioned prior that I volunteer at a charity clinic. One of the patients that I saw was a 72-year-old grandmother, and this woman was on opioids, prescriptions, for her shingles for a long time.

And as we turned the policy and turned the corner, her physician refused to give her any further prescriptions for opioids. So as a result, she began to take heroin.

Now, when I talked to her - she's my patient - and I said, "Hey, can I help you? How can I help you?" Her response was, "Listen, I completely trust my drug dealer." This is what she said, she said, "I completely trust my drug dealer. Yet when I -- I don't do my drugs every day. But when I do, I do -- I take three syringes. I take the first, a small trial dose, to make sure I don't die.

I take a little bit of higher dose, inject, and if I'm still alive, then I take the full bolus." She's afraid because of the contamination with fentanyl, illicit fentanyl. She's taking heroin. And she has addiction, and she has other problems.

But when I offer her to get treatment, she doesn't want to go because she says, "I have my son that lives with me. He drops me here at the free clinic, but if I go to a mental health clinic, he's gonna wonder what's wrong with me."

So unfortunately, this is not a theoretical issue for me. This is a reality. I've seen these patients firsthand when they have transitioned from prescription opioids and the stigma and the suffering and the addiction that goes.

And it is not limited to this one group of people; it's an entire community that's being destroyed as a result of this in West Virginia.

Q. Right. And I'm just trying to understand the -- the transition that happened there, is that due to the desire to -- what you -- the phrase you used earlier, I believe, was "to get the monster

off your back." Is that -- the transition to another -- let me rephrase.

The transition to another drug, is that fueled by the disease of addiction, or is that fueled by the nature of the previous drug that was used?

A. It's primarily fueled by addiction. The person is now in the grips of a disease, which is substance use disorder, and they've got this disease because of diverted opioids, prescription medications, and now this addiction has gotten ahold of them and they need to find somewhat to continue to fuel the habit.

And it's really not a habit; it's a disease. And that's what drives them going on to a cheaper affordable street alternative, which causes - as I mentioned before - a whole set of different problems for us.

- Q. And as far as what drug they transition to, it -- heroin is a cheap readily-available drug in West Virginia. Correct?
- A. Yes. And to answer the question about transition, you know, we initially saw the people either would take suppressants like heroin or

opioids, or stimulants. But as this crisis has evolved, the distinction has become without a difference.

So we now see combinations on the street that has combined stimulants and depressants. So there -- the fine line that existed between people who took meth as opposed to heroin has also been done away with.

- Q. So the fact that someone used prescription drugs and they needed to find another drug to fuel that addiction doesn't mean that they're more likely to use heroin over methamphetamine over a combination of the two or anything. Correct? Is that what -- is that the trend you're describing?
- A. That's the trend. That's the evolution, and unfortunately for a brain that has -- is suffering from addiction and has been hijacked, something is better than nothing. And nothing could spell lots of pain and eventually could be potentially fatal.

MR. COLANTONIO: You okay?
THE DEPONENT: I'm okay.

Q. Sorry. I'm just reviewing a document. Have you ever looked at research that has

demonstrated a link between prescription opioids and illicit drugs like heroin?

A. Not recently.

Q. When -- the research that you have reviewed, do you know whether that research looked at users who had taken prescription opioids pursuant to a prescription?

MR. COLANTONIO: Object to the form.

A. So there's two -- the 2017 survey by SAMHSA, it surveyed about 1.1 million people in the country, and what they found was of the -- the inappropriate diverted opioids, about a third of those were actually prescribed by a physician; a little over half of the people got it from friends or family, which is all diversion; and the rest of it was anywhere between stealing, buying, you know, all of those aspects.

So that's at least what actual data shows.

Q. I guess what I'm asking, Doctor, is a little bit different. Focusing on the population of people who have used prescription drugs pursuant to a medically-necessary prescription that you would qualify -- that you would qualify as a

medically-necessary prescription, what percentage of those people end up being addicted? Do you know?

1.3

A. So if -- if somebody has cancer - I'm going to put that in real terms - at the end-of-life cancer and they're being given opioids for their long-term pain control and they have, let's say, six months to live because of terminal cancer, if you're asking what percentage of those people end up becoming addicted, I would answer first of all for that person, who cares?

It's the quality of life at the end of life that's important.

Second, I would say that there's -- you can -- if you are -- you can and you could have some addiction in a certain number of people, but that's the precise reason why you have to make sure the people who are legitimately receiving long-term opioids for pain control is the right group of people.

Because there could be people who might need opioids for 10, 15 or 20 years. But you want to keep them functional. If they end up developing addiction, then you have to deal with that.

1.3

Page 282

So you know, I would say a certain percentage can happen, but I think we significantly lower that percentage if we actually follow appropriate prescribing for legitimate pain.

- Q. And assuming appropriate prescribing, for someone that's been -- for the population that has been appropriately prescribed opioids for long-term pain, do you know what percentage of that population ends up being addicted to prescription opioids?
- A. So first I'll say this: No certain way to know that what exact percentage will be. But it is possible for those people at certain percentage to be, but at this point right now off the top of my head, I couldn't tell you exactly what that percentage would be.
- Q. Is it correct that the vast majority of people who take prescription opioids do not become addicted to them?
- A. Not necessarily. And I like to say that because there's a lot of underdiagnosis oftentimes of addiction.

So you know, it goes back to my previous answer. We just don't know that exactly.

Page 283 But I think it would be -- it would not be accurate 1 2 to say that the vast majority of people that are 3 appropriately prescribed would never become addicted to those medications. 4 That's the --5 Are you aware --6 Q. 7 Α. Go ahead. No, I'm sorry, I didn't mean to cut you 8 off. 9 I'm saying that's the previous position and 10 presumption under which the bill of goods was sold 11 in the early 2000s based on a, you know, two-or-12 13 three-sentence letter to the Editor, New England Journal of Medicine by Jane Porter, and that just 14 15 has not panned out to be true. 16 Q. Are you aware, though, that research actually demonstrates that? 17 18 I'm not aware of that. 19 Have you ever looked for research on this Ο. 20 connection? 21 Α. Yes. And what -- what research specifically have 22 23 you reviewed?

Veritext Legal Solutions
www.veritext.com
888-391-3376

Recently, I have not reviewed any

24

Α.

Page 284 particular research. At the time, we did look at 1 2 some of these, but I would not be able to tell you 3 right now specifically which research I looked at. Ο. You testified about the chemical similarity 4 5 between prescription opioids and heroin, correct? Α. Yes. 6 7 And there's no chemical similarity between opioids and methamphetamine, correct? 8 9 Α. There is no chemical similarity, that's 10 correct. 11 Earlier today, you testified that for every 0. 12 fatal overdose, there are 25 to 30 people who are 13 using but are not overdosing. Correct? 14 I testified that for every fatal overdose, 15 there's 25 to 30 nonfatal overdoses. I apologize. And where did you get that 16 Ο. 17 number? 18 From literature. I could not tell you 19 exactly right now which particular study. 20 You also said that for every fatal Ο. 21 overdose, there are 200 to 300 people who are addicted. Correct? 22 (Nodded affirmatively). 2.3 Α.

Veritext Legal Solutions

www.veritext.com 888-391-3376

Where did you get that number?

24

Q.

A. From literature.

2.3

- Q. Do you know what analyses that literature conducted to determine from fatal overdoses the numbers that were nonfatal overdoses?
 - A. I'm sorry, could you restate that, please?
- Q. Sure. I know that you can't recall the exact name of the literature you reviewed or a particular study. Do you recall what methodology was used to determine that for every fatal overdose, there are 200 to 300 people who are addicted?
- A. I don't recall. I'll be very happy to provide you the references for each of these statements. I will add in addition to that that this is no different than what we have seen in West Virginia.

So if you look at the visitation rates and one of the things that did happen as a consequence of some of the legislation is there's a dashboard that has been developed that actually keeps tab in West Virginia of the overdoses coming to the emergency room.

What we're seeing in real life experience is very consistent with what we're

seeing in literature and my research. But we're happy to provide you both of those as needed and when needed.

Q. I would appreciate that.

UNIDENTIFIED MALE: Hello.

MS. JINDAL: Yes? I'm sorry, I thought someone was trying to say something.

Q. Doctor, why don't we take a ten-minute break and then we'll reconvene. Thank you.

MR. RUBY: Hey, Adam, real quick before we get off the record and before we break, just in the interest of not spending another hour pulling teeth on this: Mark, I just wanted to make sure we've got clarity on the nature of Doctor Gupta's engagement with your firm.

Can we just stipulate among counsel that the subject matter of Doctor Gupta's paid expert work for your firm is the opioid problem in West Virginia and move on from that?

MR. COLANTONIO: Well, it's more compli -- I don't think that says it. But -- that's not -- that's not what happened. We talked about this. You and I talked about this before the deposition.

```
Page 287
                 I mean, I -- we retained him in the MLP
1
 2
     and --
                  MR. FITZSIMMONS: We're still on the
 3
     record.
 4
                  MR. COLANTONIO: Are we on the record?
 5
                  MR. RUBY: Yeah.
 6
 7
                  MR. COLANTONIO: We'll go off the
     record and talk about it.
8
9
                  MR. RUBY: No, no, I want to -- it's
10
     fine. We're going to have to keep going at this on
11
     the record.
12
                  MR. COLANTONIO: We can't agree to
13
     that stipulation. I don't think we can agree to
     that stipulation. The way you said it, Steve, I
14
15
     don't think we can agree to it.
16
                  MR. RUBY: I just -- I would like to
17
     get on the record and we can either stipulate it --
18
                  MR. COLANTONIO: Okay. So what do you
19
     want put on the record? You want something -- us
20
     to again tell you what his retaining arrangement
21
     is with us?
22
                  MR. RUBY: What's the subject matter
23
     of his engagement?
24
                  MR. COLANTONIO: Which engagement?
```

Page 288 MR. RUBY: His engagement with your 1 2 firm. 3 MR. COLANTONIO: Okay. So we have -we have engaged him as a consulting expert in the 4 5 MLP litigation. Now, as far as the subject matter, I'm not sure that's something -- I mean, he was 6 7 retained initially to talk about abatement. MR. RUBY: Uh-huh. 8 9 MR. COLANTONIO: That's it. That's it. We've not discussed with him in that case 10 11 anything else but abatement. 12 And then this subpoena came up, and --13 MR. FITZSIMMONS: Those subpoenas aren't designated. 14 15 MR. COLANTONIO: No, they're not 16 designated. They're not. That was the scope of 17 his retention at that time, and eventually, when 18 you get into the deposition in that case, you'll 19 find that out. 20 The scope of his retention was just to 21 talk about abatement, and then the subpoena came up. He retained us as counsel, and we're here. 22 That's the truth. 23 24 MR. RUBY: And has the scope of his --

Page 289 his work in the -- in the other case expanded 1 2 beyond abatement? 3 MR. COLANTONIO: I can tell you that -- here's -- I think I told you this before the 5 deposition. I know we had this conversation a while back. 6 7 But what I told you, I think, was that since he retained us as counsel in this -- with 8 9 respect to this deposition, we have not had any discussions about the MLP case. All our 10 11 discussions have been about this retention, this 12 deposition. 13 And at that time, it was only 14 abatement. That's all it was. And he --15 MS. KEARSE: And Steve, on behalf of 16 -- you know, we also have clients in the MLP, and 17 we have not disclosed expert witnesses, obviously, 18 and are just working through that, and I can represent we have not had any discussions at all 19 with Doctor Gupta about retaining him as --20 21 MR. COLANTONIO: It was only because we had a mediation, so we -- that's -- that's where 22 that came about. 23 24 MR. RUBY: And I hope, at least, that

Page 290 you all can understand why we want to understand --1 2 MR. COLANTONIO: I get it. Ι 3 understand. I'm trying to explain it. But that's -- what happened is: We retained him sometime ago - and I forget when it was; I don't remember -- it 5 was a while ago - in the MLP to talk about 6 7 abatement. That was what we talked about, was abatement. 8 9 And in that -- in that retention -- and 10 we never had -- I mean, I'm not gonna get into --11 MR. FITZSIMMONS: Quit talking about 12 it. 13 MR. COLANTONIO: It was about abatement and that's it, and we haven't talked 14 15 about it since -- and that -- we haven't talked 16 about that case since he retained us in this case 17 about this deposition. That's it. 18 MR. RUBY: Okay. I mean, look, it's an unusual arrangement to have counsel for a party 19 paying an expert in one of a set of parallel cases 20 21 and taking the position that he is a lay expert in 22 another closely-related parallel case. That's why I wanted to make sure --23 MR. COLANTONIO: Yeah, and I --24

Page 291 MS. KEARSE: This is Anne. I'm not 1 2 going to agree with your characterization about 3 that, but we can talk about it later. MR. COLANTONIO: Yeah. I don't know 4 how unusual it is. I'm -- it is what it is. 5 -- so there you have it. 6 7 MR. RUBY: Okay. 8 MR. COLANTONIO: Okay. 9 VIDEO OPERATOR: We can go off the 10 record? Okay. Going off the record. The time is 4:45 p.m. 11 (A recess was taken after which the 12 13 proceedings continued as follows:) VIDEO OPERATOR: Now begins Media Unit 14 15 8 in the deposition of Rahul Gupta, M.D. We are 16 back on the record. The time is 5:02 p.m. BY MS. JINDAL: 17 18 We've talked today about diversion of prescription opioids. What do you qualify as 19 20 diversion? 21 So diversion would be any medications that 22 are being used without being properly prescribed 23 and properly indicated. So that would be -- and 24 they are unintended for the user.

So any medications that are not being used by the prescribe -- the patient who has been prescribed those medications.

- Q. And if someone were --
- A. Go ahead.
- Q. I'm sorry. Did I cut you off?
- A. No.

- Q. Someone who obtains and uses prescription opioids that weren't prescribed to them, is that an illegal act?
- A. Illegal act in the sense that do people get jail for that? I'm not sure I know a lot of people that have been jailed in West Virginia because they took their grandma's pain pill.
- Q. Right. But the purpose of the -- the purpose of state laws and federal laws regulating the supply of distribution is to ensure that people who are not prescribed prescription opioids do not obtain them. Correct?
- A. I think the purpose of -- for myself being a licensed DEA to be able to prescribe, the distributors being registrants, the pharmacy being registrants, is for the primary purpose of ensuring that we are all of us are responsible and

accountable for our actions.

I think by calling it -- laying the blame and the responsibility on the public is the upside down way of looking at things.

- Q. If someone is in possession of prescription opioids that were not prescribed to them, can they be arrested for that?
- A. Sure. People can be arrested for jaywalking. I mean, I -- I go back and I will reassert that I think that is the upside down way of looking at it, that let's go start arresting people.

I'm not aware of in Kanawha County or Cabell County or any other county that a single elected prosecutor went ahead and arrested people for using -- including children, for using somebody else's prescription drugs. But I'm not a lawyer.

- Q. Okay. So setting aside whether they should or should not be arrested, is it against the law to possess prescription opioids that were not prescribed to you?
- A. I would guess so. I'm -- again, I'm not a prosecutor or a lawyer; I'm a physician.
 - Q. Someone who takes a prescription opioid

from a family member's medicine cabinet, is that diversion?

- A. Yes, someone who is not prescribed the -that particular prescription or that particular
 medication and then accesses -- someone accesses
 that, of course, that would be part of that
 diversion.
 - Q. And can someone be arrested for doing that?
- A. Again, I couldn't tell you that, because again, I'm not -- neither a prosecutor nor a lawyer.

I tell my patients, when I would write for them -- I would make sure my prescriptions are prescribing appropriate, for legitimate pain, and I would tell them to store it and just sufficient quantities to relieve them.

Now, what happens after that or who's legally responsible, that's something after -- that's up to law enforcement and prosecutors.

- Q. Do wholesale distributors have control over an individual's medicine cabinet?
 - MR. COLANTONIO: Object to the form.
- A. Wholesale distributors do not have the physical control over people's medicine cabinets,

Page 295 1 no. Doctor Gupta, could you turn to Exhibit 5? Q. 3 GUPTA DEPOSITION EXHIBIT NO. 5 (E-mail from Massey to Kilkenney Re: 4 MMWR dated 5-27-17 with "Public Health 5 Investigation of an Opioid Overdose 6 7 Outbreak - West Virginia, August 2016" attached was marked for identification 8 9 purposes as Gupta Deposition Exhibit No. 5.) 10 11 I have it. Α. 12 Ο. The first page is a cover e-mail from 13 Doctor Kilkenny, correct? It's from Doctor Massey to Doctor Kilkenny. 14 15 I'm sorry. You're right. I'll like you to 16 turn to the next page. 17 Α. Okay. 18 Are you familiar with this document? Ο. 19 It's been a while, so it seems like one of the manuscripts that would have been submitted as a 20 21 result of the outbreak in Cabell County, yes. And the first page, that e-mail that you 22 23 were just looking at, does that refresh your memory 24 at all about what the attachment is?

A. Yes.

- Q. And are you one of the authors of the attachment?
- A. Yes. My memory is to the point that I could see this to the extent that I see myself as author at the time.
- Q. And does this report gather various data and -- together to study the 20 opioid overdoses in Huntington in August 2016?
- A. It's more than three years old. I'd really have to go through it to understand it and review it.
- Q. Sure. Just looking at that first page -and I'll just help direct you for your review to
 Bates stamp 8533. That first paragraph reads, "On"
 August 20 -- "August 15, 2016, the Mayor's Office
 of Drug Control Policy in Huntington, West Virginia
 notified the Cabell-Huntington Health Department
 (CHHD), that several calls regarding opioid
 overdose had been received by the Emergency Medical
 System (EMS) during 3:00 p.m." to "8:00 p.m. that
 day. A public health investigation and response
 conducted by the West Virginia Bureau of Public
 Health (BPH) and CHHD identified 20 opiate overdose

cases within a 53 hour period in Cabell County,
West Virginia; all cases included emergency
department (ED) encounters."

Did I read that correctly?

A. Yes.

Q. And it goes on. "Concurrent" -- sorry. In the next paragraph, does this essentially describe -- does this refresh your recollection that this document describes the public health investigation that occurred with respect to this opioid overdose outbreak in Cabell County in 2016?

MS. KEARSE: Counsel, this is Anne
Kearse, and I just -- this appears to be a draft.
I just wanted to put that on the record there. I
don't think it's a final document that you're using
or going to show, but it's a just a draft of a
report. So I just wanted to say that for the
record.

A. Yeah, I am unable to at this point recollect the accuracy of the report, and when I look at this Page No. 1, it talks about several of the medical reviewers have made revisions and comments.

I do not see comments here attached.

Page 298 So -- I also do not see a final MMWR publication 1 2 that would have probably alluded to the actual 3 report rather than just a, you know, undone preliminary manuscript that I have in front of me. 4 I don't know for what reason that would 5 not be available, but without -- without any 6 7 certainty, I'm -- unless I read the whole, it would be difficult for me to talk about one of the 8 9 versions of the manuscript. Because sometimes manuscripts do go 10 11 through several versions and final version is very different than the initial version. So I don't --12 13 I don't want to misstate any -- any statements 14 here. 15 I appreciate that, Doctor. I will represent for the record that this is how it was 16 17 produced to us, so whether or not it's written 18 comments, that's how it was produced. 19 And I will also note that the cover e-mail says it's a clean copy that is attached. 20 21 MS. KEARSE: This didn't come from Doctor Gupta's files. I'm just noting that. 22 23 MR. FITZSIMMONS: There's no question 24 pending.

Page 299 MR. COLANTONIO: Do you have a 1 2 question? 3 Q. Setting aside the report, do you recall the 2016 outbreak in Cabell County? 4 5 Only remotely at this point. Do you recall commissioning an analysis of 6 Ο. 7 the -- of that outbreak? Α. Yes. 8 9 Q. Could you please turn to Exhibit 4? GUPTA DEPOSITION EXHIBIT NO. 4 10 11 (E-mail from Haddy to Haddy and others 12 Re: WV HAN #128 Novel Opiates dated 13 12-13-16 with "Health Advisory #128 14 Novel Opiates" attached was marked for identification purposes as Gupta 15 Deposition Exhibit No. 4.) 16 17 I have it. Α. 18 All right. I apologize. My computer's Q. taking a second here. Is this -- I'm not sure if 19 the cover e-mail is familiar to you, but the 20 21 attachment, the second page, is titled a health -public "Health Advisory Number 128." Do you see 22 that? 23 24 Α. Yes.

- Q. And this advisory is dated from October of 2016, correct?
 - A. It's dated December of -- 13, 2016.
- Q. I apologize. I'm still waiting for it to load. December 13, 2016. I'm going to read from -- is this -- are you listed as an author of that health advisory?
 - A. Yes, the health advisories would normally go out from the Commissioner, State Health Officer, as a -- that the standard.
 - Q. And this health advisory is titled "Novel Opiates"?
- 13 A. I see that.
- Q. And this is something that you would have distributed "TO COMMUNITY HEALTH PROVIDERS,
- 16 HOSPITAL-BASED PHYSICIANS, INFECTION CONTROL
- 17 PREVENTIONISTS, LABORATORY DIRECTORS, AND OTHER
- 18 | APPLICABLE PARTNERS"?
- 19 A. Yes.
- Q. And you also directed that it be distributed "TO ASSOCIATION MEMBERS, STAFF, ETC."?
- 22 A. Yes.
- Q. Which association members and staff did you

24 mean?

1

2

3

8

9

10

11

12

- A. Local health department associations and staff.
- Q. That first sentence says, "The West Virginia DHHR/"Bureau of Public Health "Office of the Chief Medical Examiner (OCME) has detected analog fentanyls that are contributing to overdose deaths in West Virginia."

Did I read that correctly?

A. Yes.

- Q. Any reason to dispute the accuracy of that statement?
 - A. Not that I know, at that time.
- Q. The next is "Multiple derivatives of fentanyl are being detected in toxicology results in West Virginia, as well as other states." Did I read that correctly?
- A. Yes.
- Q. And is there any reason to dispute that statement?
 - A. At the time, there would not be to my understanding.
 - Q. I'm sorry. Do you mean that you don't have a reason to dispute it now, or you don't have a -- you didn't have a reason to dispute it then when it

was written?

1.3

- A. I would not have a reason to dispute it now as of the events that were happening then.
- Q. Describe -- it goes on to describe a prior health advisory that you issued, Health Advisory #126, titled "Carfentanil responsible for West Virginia overdose deaths."

Correct?

- A. I see that written here.
- Q. The next paragraph says that "The presence of novel opioids in the illicit drug market cause concern for increasing overdose death, even among opioid-toleranced users. Now, seven other analogs, such as U-47700 (Pink or Pinky), Acetyl fentanyl, Furanyl fentanyl, para-Fluoro(iso)butyrnl fentanyl, Acryl fentanyl, and 3-Methyl fentanyl, in addition to Carfentanil, are being detected in toxicology results and linked to overdose deaths. Emergency departments visits for heroin overdoes with suspect fentanyl laced analogs are an alarming new trend."

Is that correct?

- A. That's appropriate statement.
- Q. And you have no reason to dispute that statement today?

- A. I have no reason to dispute it today for what it said at the time.
- Q. The next statement says "The preliminary number of drug overdose" "in West Virginia reported as of December 8th, 2016 totaled 624." Correct?
- A. You missed the "deaths" part in there, but
- Q. I'm sorry. Overdose deaths. Did you ever quantify the number of those deaths that were attributed to fentanyl or a fentanyl analog?
- A. I cannot recollect at this time with this information that I have in my hands.
 - Q. Could you please turn to Exhibit 17?
 - A. Okay.

1

2

3

4

5

6

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

2.4

GUPTA DEPOSITION EXHIBIT NOS. 16 and 17

(E-mail from Christy to Wagoner and others Re: GUPTA DATA NEEDS UPDATED - Social Worker Conference (next week) dated 4-21-17 (DHHR_FEDWV_0047102) and "West Virginia's Contemporary Public Health Challenge: Drug Overdose Deaths" by Gupta dated 4-29-17 were marked for identification purposes as Gupta Deposition Exhibit Nos. 16 and

Page 304 17.) 1 2 And if you'd also look at Exhibit 16. Ο. 3 And I'll represent, Doctor, that Exhibit 16 -- I'm sorry, 15, was produced as -- no, 4 5 I apologize. I got that backwards. Exhibit 14 is the cover e-mail to 6 Exhibit 15. 7 MR. COLANTONIO: Would you like him to 8 9 10 MS. JINDAL: So we're looking at 11 Exhibit 17 and Exhibit 16, sorry. Yes, Exhibit 16 is a cover e-mail to 12 Ο. 13 Exhibit 17. I apologize. It gets a little bit more confusing with the native PowerPoints. 14 15 MR. COLANTONIO: Okay. So he's 16 looking at 16 and 17, is what you want him to do 17 now, right? 18 MS. JINDAL: Yes. And 16 is the cover e-mail for Exhibit 17. 19 20 MR. COLANTONIO: Okay, he's got those. 21 Α. I have it. And Doctor Gupta, is Exhibit 16, does that 22 23 reflect a conversation among your staff concerning 24 your request for a presentation?

- A. Yes, Exhibit 16 reflects that my staff were providing me with slides and PowerPointing those slides for me to present at a presentation, at a conference.
 - Q. And if you could turn to Slide 35.
 - A. I have it.

- Q. And Slide 35, is that -- is that a graph document the presence of various drugs in overdose deaths from 2001 to 2016 in West Virginia?
- A. Slide 35 is a trend analysis looking at five prescription drugs of which most of the fifth ones is fentanyl that is illicit and nonprescriptions and it's comparing a trend of very select group of opioids from 2001 to 2016.
- Q. Okay. And with respect to that fentanyl line, do you see that the increase for fentanyl has gone up from just over 50 in 2014 to somewhere between 150 and 200 in 2015 and well over 350 in 2016?
- A. Yes, that's consistent with my testimony that in 2015, 2014, is the time I was starting to see a transition happen from exclusively opioid -- or majority opioid prescriptions to street drugs.
 - Q. And it's written here that the vast

Page 306 majority -- on the slide, that the "Vast majority 1 2 of fentanyl deaths are believed to be illicit." 3 Did I read that correctly? Α. Yes. And these graphs reflect the number of 5 deaths involving this particular drug, correct? 6 Α. Correct. So just to be clear, there could be overlap 8 9 in these deaths in the sense that some of these deaths could have involved both fentanyl and 10 11 oxycodone, for example? 12 Α. Correct. And this is 2016 preliminary 13 data, just to make a point. 14 The previous slide, Slide 34, looks 15 at major selected drugs, correct? It does look for overdose deaths in West 16 Α. 17 Virginia for the same period of time for certain 18 selected group of drugs. 19 And the title supplied is "Trend Analysis -20 Major Selected Drugs, " correct? 21 Α. Correct. And this one also documents the right --22 this one also documents heroin, correct? 23 24 Α. Yes.

- Q. And is there a general trend in the increase in heroin?
- A. Yes, the general trend and declines in oxycodone and hydrocodone with a heroin increase trends in heroin exists.
- Q. And it may be a little hard to see, but do you also see the line for cocaine?
 - A. I'm --
 - O. A --

1

2

3

5

6

7

8

9

- 10 A. I think I found it.
- Q. And does it also show that cocaine -- there have been deaths involving cocaine as going as far back as 2001?
- 14 A. I can try to follow the line of cocaine to 2001. Yes.
- Q. And does that line show a general increase in about 2014?
- 18 A. I believe it does.
- Q. So since 2014, the incidence of heroin -I'm sorry, cocaine in overdose deaths has grown in
 West Virginia, correct?
- A. I would say along with other substances in this chart, cocaine use also went up. Deaths from cocaine.

Page 308 Does the -- could you please turn to 1 2 Exhibit 15? And then also Exhibit 14? 3 MR. COLANTONIO: 14 and -- I'm sorry, 14 and 15? 4 5 MS. JINDAL: Yes, please. GUPTA DEPOSITION EXHIBIT NOS. 14 and 15 6 7 (E-mail from Gupta to Mock and Taylor Re: Presentation dated 4-4-17 and 8 9 E-mail from Richman to Boggs Re: April 10 4th - MCMS dated 3-29-17 11 (DHHR FEDWV 0038760) and "2017 Legislation and Substance Use Disorder 12 13 Epidemic: West Virginia's Call to Action" by Gupta dated 4-4-17 14 15 (DHHR FEDWV 0038761) was marked for 16 identification purposes as Gupta 17 Deposition Exhibit Nos. 14 and 15.) 18 MR. GOOLD: What's the time with the 19 court reporter on the deposition and what time did 20 Mark take? 21 This is Jim Goold. I'm going to have about ten or fifteen minutes that I'm going to be 22 23 happy to start when I can. What's the time with the court 24

Page 309 reporter on the time because --1 2 VIDEO OPERATOR: This is the 3 videographer. Give me one moment and I can give you a total time. 4 MR. GOOLD: Okay, good. Thank you. 5 Doctor, I would like you to look at Exhibit 6 14, which is the cover e-mail to which Exhibit 15 7 is attached. Is Exhibit 14 a cover e-mail to you 8 9 from Allen Mock? 10 Α. Yes. 11 And Mr. Mock is the -- the chief medical Ο. examiner for West Virginia, correct? 12 Doctor Mock is the Chief Medical Examiner 13 Α. of West Virginia, yes. 14 Doctor Mock, I apologize. The PowerPoint 15 that you've attached is titled "2017 Legislation 16 17 and Substance Use Disorder Epidemic: West 18 Virginia's Call to Action." Correct? 19 Α. Yes. 20 And you authored this presentation? Ο. 21 As you've seen in the previous exhibits, I 22 often do not personally author presentations as the Commissioner. I had staff that does that. 23 Did you commission this presentation? 24 Q.

A. I do not recollect at this time. However, I was requested -- the request was made for the Commissioner to provide a presentation and generally I would commission the development of such a presentation and then appropriate -- myself, with the appropriate staff availability to do the presentation.

VIDEO OPERATOR: This is the videographer. We've been on the record for about 6 hours, 45 minutes total.

MR. COLANTONIO: Okay.

MR. GOOLD: Did you take out

Mr. Colantonio's examination in that?

VIDEO OPERATOR: I did not. That's just the total time.

- Q. And Doctor, if you could turn to Slide 26 of this presentation. I'm sorry, Slide 27.
 - A. Okay. I have it.

Q. And I apologize. It's the nature of working on a computer. I was looking at my PDF number versus the number in the lower right-hand corner. I do mean Slide 26 as indicated by the number in the lower right-hand corner of the presentation, so the slide that is titled, in

Page 311 quotes, "The Heroin Landscape." 1 2 Do you see that? 3 Α. Yes. And it's written here, "Heroin use is part of a larger substance abuse problem." Correct? 5 Α. Yes. 6 Do you still agree with that statement? I would agree with that statement as it's 8 9 stated here. And you've written here that nearly all 10 people who use heroin also use at least 1 other 11 drug. Most use at least 3 other drugs." Correct? 12 13 Α. That would be correct at the time this was done. 14 15 Do you have any reason to believe it's not correct now? 16 I don't have the most current statistics to 17 18 be able to say whether this is or this is not correct at this time. 19 20 And you've also written here that "People who are addicted to ... Alcohol are 2" times "... 21 more likely to be addicted to heroin." Correct? 22 23 Α. Yes. 24 Q. And "People who are addicted to...

Page 312 Marijuana are 3" times "...more likely to be 1 addicted to heroin." 2 3 Α. Correct. And "People who are addicted to...Cocaine are 15" times "...more likely to be addicted to 5 heroin." 6 Α. That's what it says. And "People who are addicted to... Ο. 8 9 Prescription opioid painkillers are 40" times "...more likely to be addicted to heroin." 10 11 Correct? That's what it says. 12 Α. And this doesn't define a causal 13 Ο. relationship between one drug and another drug, 14 15 correct? This is a very strong correlation, not 16 Α. 17 causal. 18 MR. COLANTONIO: Let me just object to the form of the question, as it's calling for a 19 20 legal --21 Doctor, could you please turn to Exhibit 22 45? GUPTA DEPOSITION EXHIBIT NO. 45 23 (E-mail from Dora to Gupta and others 24

Page 313 Re: 2018.07.05 Final packet mailed to 1 2 Judges re MAT dated 7-5-18 3 (DHHR FEDWV 1148108-126) was marked for identification purposes as Gupta 4 5 Deposition Exhibit No. 45.) I have it. 6 Α. 7 And this first page reflects an e-mail to Ο. you from -- from a Dora; is that right? 8 9 I can't see on the top who the e-mail is 10 I can only see one single name, Dora. I do 11 not recognize that name right away. 12 Q. This e-mail's addressed to you as well as 13 secretary Bill Crouch of the DHHR, correct? That's what it seems like. 14 15 Do you have any reason to doubt that this e-mail is not what it is? 16 17 I just don't know Dora. I mean, I don't Α. 18 know who Dora is. 19 Sure. Do you have any reason to doubt that 20 this was not an e-mail sent to you on Thursday, 21 July 5th, 2018? I'll take it as it is. 22 Α. 2.3 If you could turn to the second page, this Ο. 24 is ending -- this is Bates stamped

DHHR_FEDWV_1148109. Does this reflect a letter from the West Virginia Department of Health and Human Resources to the Honorable Anita Ashley, a judge in West Virginia?

- A. It does seem to reflect as you stated.
- Q. And does this reflect -- this attachment in total reflect a packet of information that was sent to a judge regarding medication-assisted treatment?
- A. I would have to review the attachments to the packet or to review -- just a second.

Upon a cursory review, it looks to me like there's a letter to one judge in the front.

There seems to be an anonymous kind of "Your Honor" letter from Secretary Crouch, and then I see a letter to another judge from a different county.

So I'm not sure if this is all part of the same packet. It does seem to be going to different places, the packet, including anonymous people.

- Q. Okay. Just focusing on that first letter, the one that's ending in Bates stamp 8109, do you see the part where it says, "Enclosed with this communication are the following documents"?
 - A. I see that here.

Q. Okay. And the first describes -- that first bullet describes "A letter from Bill J. Crouch, DHHR Cabinet Secretary, directed to Attendees of the Spring Circuit Judges Training conducted May 2nd, 2018 in Morgantown, West Virginia."

Did I read that correctly?

- A. I believe you did.
- Q. And the second bullet reflects "A letter from Dr. Rahul Gupta, State Health Officer from West Virginia DHHR Bureau of Public Health; and, co-written with Doctor James Becker, DHHR Bureau of Medical Services." Did I read that correctly?
 - A. Yes.

- Q. Does that refresh your recollection about what the second document is, the second letter?
- A. My recollection is that that letter is not to Judge Ashley; that's to Judge Tatterson here that I see here, so I cannot verify the accuracy of this packet.
- Q. You're saying that you doubt that the -- I guess what I'm saying is: The letter to Judge
 Ashley describes communications that are being sent to her, correct?

A. The first bullet looks to me a letter from Bill J. Crouch, Cabinet Secretary, presented to the Spring Circuit Judges Training conducted May 2nd, 2018 in Morgantown, West Virginia.

I do not see that. All I see is a letter -- the next document is a letter dated May 1st, not May 2nd. So I'm confused as to where that letter to the packet is.

Q. Okay. Well, I'll represent that this is how the attachment was produced as part of this e-mail and there have been no alterations made to this attachment by us. So if there were any typos in this document, you know, I can't be -- I'm just trying to tell you that I didn't create the typos in this document.

I didn't create this document period.

This is how it was produced to us, and this is how

I'm presenting it to you.

- A. I'll take your word for it.
- Q. Okay, thank you. I just want you to see that -- the final bullet here is a white paper entitled "Medication-assisted treatment-An Evidence-based Pathway to Recovery in West Virginia."

Veritext Legal Solutions 888-391-3376

Page 317 Do you see that? 1 2 Α. Yes. 3 Q. Okay. Could you please turn to the --I've got to find the page myself. It ends 4 with Bates stamp 8119? 5 Α. Yes. 6 7 Okay. It's about halfway in the presentation. And do you see that it's titled 8 "Medication Assisted Treatment"? 9 T do. 10 Α. And the subtitle is "An evidence-based 11 Ο. 12 pathway to recovery in West Virginia." 13 Α. I do see that. And it's published on the West Virginia 14 15 Department of Health and Human Resources -- it's letterhead -- it's got the stamp right there in the 16 17 upper left-hand corner, correct? 18 I see that is submitted by a Rebecca Roth, 19 the Office Director of Policy, Research, Planning 20 and Compliance at the Bureau of --21 Ο. And the date of ---- Behavioral Health and Health Facilities. 22 23 And the date of this document is May 20, Ο. 24 '18, correct?

- A. That's what it seems like.
- Q. Could you please turn to the -- I believe it's the fourth page of this document, is Bates stamped 8123.
 - A. Yes.

1

2

3

5

6

7

8

9

10

11

12

1.3

14

15

16

17

18

19

20

21

22

23

24

- Q. I'm going to read from the third paragraph down under the heading "POLYSUBSTANCE USE AND MAT."
 "In 2016" -- do you see where it says that?
 - A. I see that.
- Q. It says, "In 2016, preliminary data indicated that heroin-related and fentanyl-related overdose deaths increased dramatically since 2014." And it's cited as West Virginia Health Statistics Center, Vital Statistics System.

It goes on to say, "Stimulant overdoses are also on the rise; amphetamine or methamphetamine-related, as well as cocaine-related overdoes deaths increased significantly between 2004 and 2016."

Did I read that correctly?

- A. Yes.
- Q. Do you have any reason to dispute the accuracy of those statements?
 - A. I wouldn't, but I would want to review the

- full report before I would make a statement, because I don't know what the rest of the report is about since I can't remember/recall that and it was not authored by myself.
- Do these statistics reflect the ones we just looked at in the graph from your presentation?
 - That would be accurate.
- I'm going to turn to the next paragraph, the one beginning "The focus on opioids." Do you see that?
- 11 Α. Yes.

1

2

3

5

6

8

9

10

- 12 Ο. "The focus on opioids does not in any way diminish the need to address other substance use 13 14 disorders or mental health disorders nationally or in West Virginia. Prevalence of alcohol use 15 disorders (AUDs) has increased dramatically over 16 17 the last decade in multiple populations subgroups: 18 Women (83.7% increase); African-Americans (92.8%); 19 age 45-64 (81.5% increase); and age 65" plus 20 (106.7% increase); only high school education 21 (57.8% increase); individuals with incomes less than \$20,000 (65.9% increase)." 22 Did I read that correctly? 2.3
- I think so. 24 Α.

- Q. Do you have any reason to doubt the accuracy of those statistics?
- A. It's been quite awhile, so I -- I would have to believe these statistics. I have not myself verified any of these statistics, at least recently.
- Q. It goes on to say that "More than 1 in 4 (26.3%) of WV women reported smoking during pregnancy, double the national rate of 13%, and 60% of births in WV are to mothers with Medicaid. More than 4,000 births in WV are to mothers with substance use disorders. Cannabis is the most commonly used drug among pregnant women, at 11.63% of pregnant mothers, and leads to 2.3 times greater risk of still birth as well as poor cognitive functioning."

Did I read that correctly?

A. Yes.

2.4

- Q. And do you have any reason to doubt the accuracy of this -- these statistics?
- A. At the time that was written, I -- I just
 -- I have not done the verification of research
 around this, but I would take it as for what it
 states here at the time.

- Q. Could you turn back to Exhibit 38?

 And again, this is your testimony in front of the House Committee, correct?
 - A. I have it, yes.
 - Q. And this testimony is dated May 2018?
 - A. It's actually May 17th, 2018.
- Q. Thank you. Could you please turn to page 5 of this testimony? The last four numbers of the Bates stamp are 1634.
 - A. Okay.

- Q. I'm going to read from the second full paragraph down. It says, "As the committee" -- do you see that?
 - A. I see that.
- Q. "As the Committee considers evidence-based approaches to the opioid crisis specifically, I strongly urge you to refrain from a narrow focus on," in quotes, "'opioids.' While the opioid epidemic is a crisis of the moment, in many states other drugs such as methamphetamine, cocaine, and benzodiazepines, often in combination with opioids, are the emerging predominant causes of substance abuse and misuse among some populations. This is in addition to the long-standing challenge of

Page 322 alcohol misuse and addiction." 1 2 Did I read that correctly? 3 Α. Yes. And is your testimony today consistent with the statistics that we saw in the white paper that 5 we just reviewed? 6 7 MR. COLANTONIO: Object to form. Α. I think without any context whatsoever, I 8 9 cannot agree to it being consistent. What greater context do you need, Doctor? 10 Ο. I think you read me out of a paragraph from 11 12 one document and another paragraph of another document and you're piecing together a theory 13 without providing any additional content or having 14 15 me the opportunity to actually address the context of the previous document or this document. 16 17 Doctor, if you would like to go through the Ο. 18 white paper in greater detail, you're welcome to. I -- there are sources listed at the back of that 19 document. And I just -- you know, this is your 20 21 testimony. I'm just trying to make sure -- make

MR. COLANTONIO: Okay. Let him go

sense of what you testified and why you might have

22

23

24

testified that way.

Page 323 through the report then, Doctor. Take your time 1 2 and go through the report. 3 Which report --THE DEPONENT: The previous one. 4 I feel like this is unfair to me as a 5 witness by having me read pieces and moving because 6 7 I feel I'm not getting adequate opportunity to be able to provide context to the data without 8 9 reading. 10 Ο. Let me make this a little bit easier then, 11 The paragraph I just read from your 12 testimony --13 MR. COLANTONIO: Hold on. You wanted -- I thought we were going to read the report. 14 15 want to read --16 THE DEPONENT: The previous one. 17 MS. JINDAL: Let me just see if I can 18 try to ease the doctor's concerns, please. 19 The paragraph we just read from your testimony, what was your basis for making those 20 21 statements? 22 So the paragraph you just read and the 23 paragraph in the previous letters to the judges 24 that you took out, by itself, does not have a leg

Page 324

to stand on. It's in the context of an opioid crisis that has transitioned now killing West Virginians from opioid prescription drugs to heroin to cocaine, and we've established that as we went through.

And now to take that out of context and to act like opioid prescriptions have nothing to do with it is unfair and not really in context, so I take offense to that fact that we're taking pieces and trying to cobble those together instead of actually allowing a fair opportunity to be explaining what actually happened in West Virginia.

So I -- that's the piece that I think that is unfair.

- Q. Has alcohol use disorder been a long-term -- long-standing challenge in West Virginia?
- A. Yes, an alcohol disorder within -- which I will discuss as a very different challenge in many of the states, and we've already talked about today earlier how there will be always a level of population where there will be addictive behaviors.

So now to take that out wouldn't be fair because alcohol -- alcoholism and alcohol challenge did not rise by thousands of percent over

a decade. Opiate prescription drugs and volume of that did rise.

Alcohol did not contribute to killing
West Virginians in this way. Opioid drugs did. So
it would not be fair to blame alcohol for the sins
of the volumes that have called West Virginians.

- Q. And just to be clear, Doctor, I'm not trying to do that. I'm just trying to understand the prevalence of alcohol use disorder in West Virginia. Would you agree --
- A. But you -- sorry. If you are wanting to do that, then we would be sharing data from CDC, from behavior risk to factors surveyed on the prevalence of binge drinking. We would be in a way different area right now than what we are doing picking and choosing pieces to cobble together.

This is not the type or the veracity of data, I'm -- you know, you can look up and you can see the West Virginia alcohol use data. I have the surveys of those, and I can tell you this is not where you go to look for that data.

Q. So to be clear, you are not sure about the accuracy of the data that is represented in this publication that was published by the West Virginia

Department of Health and Human Resources while you were Commissioner for the Bureau for Public Health?

A. That is absolute misconstruing of my statement.

- Q. Okay. How am I misconstruing your statement, Doctor?
- A. Because I am trying to provide you context and you are misconstruing that to the letters and the statements are false, which is just anything but the truth.
- Q. Okay. So if the statements regarding the increase in alcohol use disorder in West Virginia is accurate, then is it fair to say that your testimony that alcohol use has been a long-standing challenge in West Virginia is accurate as well?

 MR. COLANTONIO: Object to the form of the question.
- A. In the last nine hours or so, you have not provided me an iota of evidence that suggests the claims you are making now.
- Q. To be clear, Doctor, I'm not making these claims. I'm just reading to you what is from the document, asking whether this is in agreement with your testimony in front of Congress.

MR. COLANTONIO: That is -- wait a minute. That's not a question. You want to ask him a question?

MS. JINDAL: I guess what I'm trying --

Q. My question is: Did I read -- do you -- do you have any concern with how -- my accuracy of reading these statements into the record?

MR. COLANTONIO: Object to the form of the question.

- A. I do have concerns that you have construed the -- as an example, the last line, that "This is in addition to longstanding challenge of misuse and addiction" and you just made a statement about "the rising evidence of alcohol use in West Virginia" without providing me any evidence of such, and I do have objections to the characterization of the use of alcohol without any evidence -- and we're making West Virginians seem like they're been doing nothing but sitting on their toes and feet and just drinking alcohol, and I think that's a very unfair characterization of people of West Virginia.
- Q. And I want to be very clear that that is not what I am trying to say. I think you're being

Page 328 a little bit unfair right now. But I think we 1 2 should just take a break for about five minutes. 3 Let's cool off. And then we can reconvene. MR. COLANTONIO: Cool off? All right, 4 we're going off for five. 5 VIDEO OPERATOR: Going off the record. 6 7 The time is 5:56 p.m. (A recess was taken after which the 8 9 proceedings continued as follows:) 10 VIDEO OPERATOR: Now begins Media Unit 9 in the deposition of Rahul Gupta, M.D. We are 11 back on the record. The time is 6:01 p.m. 12 13 MS. JINDAL: Doctor Gupta, I have no more questions for you today, so I am going to pass 14 15 you as the witness. Thank you. 16 EXAMINATION BY MR. GOOLD: 17 18 Doctor Gupta, my name is Jim Goold. Good afternoon. I'll try to be as short as possible. 19 It really won't be very long, I promise. Just some 20 21 follow up on a couple of things. First, as Commissioner of Public Health 22 in West Virginia, you did understand that diversion 23 24 involved illegal acts. Is that right?

A. Yes.

- Q. Okay. And we talked earlier, there was discussion about a report -- I believe it was called the social autopsy report, and you mentioned that you commissioned it. Do you recall that just generally?
 - A. Yes.
- Q. I take it that you had the authority to commission a report on any aspect of the opioid crisis that you considered as something that was important to study.
- A. I would have the authority within the confines of the public health aspect of it to -- and at the same time, would be commissioning opioids and this crisis wasn't the only thing that was happening in West Virginia, so there was as I mentioned earlier 130 different program lines we were managing, so when I commission a report, I have to balance of the use of taxpayer dollars and resources with the necessity and importance and the ability for us to make an impact and change. I would have to measure that.
- Q. Understood. Thank you. And looking at the opioid crisis from a public health point of view --

Page 330 which was your perspective, right? 1 2 Α. Yes. 3 Q. -- that would include understanding -trying to understand the causes of the crisis, correct? 5 Α. Correct. 6 Okay. Did West Virginia ever do a study of 7 what substances people who had opioid overdoses had 8 9 consumed before they began using and misusing opioids? 10 11 Α. I am not aware of such. 12 Ο. Just to be a little more specific, in case 13 it helps, for example, did West Virginia ever look at the extent to which people who later had 14 problems with prescription opioids had first smoked 15 marijuana? 16 17 I am not aware of that, but I will also 18 caveat this with a -- the issue that I saw and experienced was that not everyone who received a 19 prescription necessarily was the only one that was 20 21 abusing the prescription. The core behind diversion was: There's 22

a lot of unsuspecting victims of this crisis that were obtaining the pills, not necessarily through

23

24

the doctor's office.

In fact, some of the data that I highlighted today from SAMSHA demonstrates that.

Q. Okay, thank you. I understand that not every person who later had a prescription opioid problem first smoked marijuana, but you never looked at or the state never looked at whether it was 40 percent or 50 percent or 70 percent or 80 percent or whatever number it was?

Am I right about that?

- A. I think the closest understanding of what happens to the opioid overdose deaths, you can find in the social autopsy work, that's as close as we've gotten to understanding the year before the death of individuals who have died from overdose.
- Q. Thank you. Just to make sure I've got it right then, that's what you would point to as the best source of data on the substance abuse history of people who died of opioid overdoses. Is that right?
- A. For one year. And I'm not aware -- to directly answer your question, I'm personally not aware of the data. It may exist. I'm not aware of that.

- Q. Okay. And have you ever looked at the literature for studies addressing that done by doctors or scientists in the United States?
- A. I cannot recall now. I'm sure I have in the past, but I don't recall it now.
- Q. Do you recall any data on the extent to I with amphetamine use precedes opioid -- prescription opioid misuse? Any studies on that question?
- 10 A. I do not recall.
- 11 Q. Okay. Same thing about benzodiazepines.
- 12 A. Correct.

1

2

3

4

5

6

7

8

9

17

18

19

20

21

- Q. Alcohol? Same question.
- 14 A. Correct.
- Q. And tobacco, same question.
- 16 A. Correct.
 - Q. Okay. You also talked about Dopamine in your examination by Mr. Colantonio. Do you recall that? I'm just taking you back to that subject generally. Okay?
 - A. Yes.
- Q. Am I right that the point that you were
 making was that elevated levels of Dopamine in the
 brain can be addictive?

2.4

Page 333

A. No, and please let me clarify the point I was making. I'm sure I said very similar earlier as well, which is: Any substance, we can use opioids, but you can also attach a number of other substances. It's also true for some foods; it's also true for smoking and other things.

A pathway -- the reward pathway is the same, which is when you take the drug, it stimulates the release of Dopamine or the continued action of Dopamine that then tells the -- signals the front part of your brain that you're happy, you're satisfied, and that's the reward mechanism that is fed by opioids and a lot of other substances, as you just have mentioned.

But as I stated to you, I'm not aware of someone who's doing heroin or amphetamine now wants to go back and use a prescription drug to reap the same rewards. In fact, we've seen exactly the opposite.

- Q. Do you know what level of Dopamine is required to trigger addiction?
- A. I am not aware of exact micro -microlevels in the blood or in the brain at this
 time.

Q. And you don't know how long or how much exposure over time there needs to be to an elevated level of Dopamine in order to trigger addiction.

Is that right?

A. The time factor can vary within individuals and human beings, and at some point, the -- there's a need for higher escalation of dose, and then for variable period of time - that varies within the population and individuals - then there occurs more escalation for the dose, because we build something called tolerance.

And as tolerance gets built - which is different from different -- for different people - it requires a higher dose or strength of the substance.

- Q. Do you know whether smoking tobacco leads to an increased level of Dopamine in the brain?
- A. Tobacco's effects are more -- have to do with nicotine, and it is -- so there's multiple substances in tobacco. There are many cancerous substances, but most of the impacts of tobacco comes from a substance known as nicotine which breaks down into cordamine that actually stimulates the heart, stimulates the -- your heart rate and

breathing and others and also goes through your brain as well, and similar type of pathways.

- Q. Okay. Do you have any understanding as to whether smoking tobacco leads directly or indirectly to an increased level of Dopamine in the brain?
 - A. It could lead to increased levels.
- Q. Okay. Do you know -- have a -- know any data that emperically compares the level of Dopamine from smoking tobacco to any particular dose of an opioid?
- A. I'm not aware of such that I can recall that data.
- Q. How about alcohol? Do you have any understanding as to whether drinking alcohol directly or indirectly leads to an increase of Dopamine in the brain?
- A. So alcohol can serve through various pathways and different mechanisms, and for those who become chronic alcoholics, that could be a potential path with them.
- Q. And do you have any understanding as to comparisons of Dopamine levels for alcohol or alcoholism and opioids?

- A. I'm not -- I cannot recall any data that may compare that.
- Q. Okay. Let me ask the same questions about cocaine. Do you have an understanding as to what level of increased Dopamine cocaine leads to and as compared to opioids?
- A. I'm not able to recall any emperical data comparing cocaine and opioids.
- Q. A couple more. Benzodiazepines? Same question.
 - A. Same answer.

- Q. Okay. How about behaviors, human behaviors or activities? Do you understand that there are human behaviors or activities that cause increased levels of Dopamine?
- A. So I want to just add that the suppressants like benzodiazepine, alcohol, you know, one of the things in the reward system that may or may not function through the reward system Dopamine.

 Behaviors certainly can.

So you could have addiction to food; you could have addiction to other things, which the pathways may be similar, although the receptors where these things act are different.

2.3

Page 337

Q. And are you able to empirically compare the effects of Dopamine from these activities to effects of Dopamine from opioids?

A. I think to the extent that we have learned that there are different receptors on which each of these and variety of these compounds and components can act to activate Dopamine. That's a differentiating point.

For example, opioids act on neuroreceptors to activate the system, and there are various different receptors of different types.

To that extent, we do have the knowledge of.

- Q. Are you an expert -- you consider yourself an expert on this area of neurobiology?
- A. I'm not necessarily an expert in neurobiology. I am a internal medicine physician with a long-term experience in both public health, prevention and especially in opioids.
- Q. But you're not able to empirically compare the effects of increased Dopamine from these other activities to opioids. Is that right?
- A. I am not a neurobiologist, and I cannot recall the data at this point.

```
Page 338
                  MR. GOOLD: Thank you. I'm finished
1
 2
     as well.
 3
                  MR. COLANTONIO: Read and sign?
                  MR. RUBY: So Adam --
 4
 5
                  MR. GOOLD: Thank you, Doctor.
                  MR. RUBY: Adam, if I'm right, we are
 6
 7
     at about, I'd say, six hours and ten minutes on the
     record if we exclude Colantonio's examination of
8
9
     what has now been represented as a -- or what has
10
     now been represented as a nonparty, I suppose,
11
     deposition.
                  VIDEO OPERATOR: Yes, that is very
12
13
     close.
                  MR. RUBY: Okay. So we -- we do, I
14
     think, have a few more minutes. Jyoti, do you have
15
16
     anything else you want to cover? You're muted.
17
                  MS. JINDAL:
                               I had to think. Doctor,
18
     if you're patience for a few more questions, I do
     have them. But I appreciate it's been a long day.
19
     So if you'll -- if you'll just bear with me, I
20
21
     promise it will be fast.
22
                  THE DEPONENT: Okay.
23
                        EXAMINATION
24
     BY MS. JINDAL:
```

Page 339 Could you please turn to Exhibit 20? 1 0. 2 MR. COLANTONIO: I'm sorry, 20? 3 MS. JINDAL: 20, 2-0. 4 MR. COLANTONIO: Okay. 5 GUPTA DEPOSITION EXHIBIT NO. 20 (E-mail chain between Gupta and others 6 7 Re: MEDIA REQUEST = Fatal overdose victims by county and where they were 8 9 from dated 9-27-17 to 9-29-17 was 10 marked for identification purposes as 11 Gupta Deposition Exhibit No. 20.) 12 Α. I have it. 13 Doctor Gupta, are you familiar with this Q. 14 document? 15 I am not. I am -- sounds like -- trying to 16 familiarize myself. 17 Ο. Just let me know when you're ready, Doctor. 18 Α. Okay. I'm ready. 19 Is this an e-mail chain -- and I'll just look at the top-most e-mail there. Is that an 20 21 e-mail from Doctor Allen Mock? Yes, I see Doctor Allen Mock and a number 22 23 of people, including myself, who have been -- this 24 e-mail has been sent to and copied to several

Page 340 others. 1 2 Ο. Okay. And this e-mail is dated September 3 29, 2017? Α. Correct. 4 And does this e-mail chain reflect a 5 discussion of the number of non-Cabell County 6 7 residents who have a fatally overdosed in Cabell County? 8 9 Α. It reflects a request from a reporter about fatal overdose victims who have died in Cabell 10 11 County up to this point in that year. 12 And you're looking at the bottom of the 13 e-mail, and I'm just going to read it out loud. Ιt says, "I'd like to request the county of residence 14 15 for each fatal overdose victim who died in Cabell 16 County up to this point in the year. " Correct? 17 Α. Yes. 18 And that reporter's e-mail is dated 19 September 27th, 2017, correct? 20 Α. Correct. 21 Ο. So the middle e-mail here from Gary Thompson -- do you see that? 22 23 Α. Yes. Who is Gary Thompson? 24 Q.

- A. Gary Thompson, at the time, was the State registrar.
- Q. And the e-mail directly below

 Mr. Thompson's e-mail from Toby Wagoner, does he -does Mr. Wagoner ask Gary or another individual

 named Dan, Daniel Christy, to look into whether the

 DHHR has this information?
 - A. That's what it seems so -- to be.
- Q. And so does Mr. Gary Thompson's e-mail respond to that with the information requested by the reporter?
 - A. It would seem so.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

2.3

24

- Q. And does Mr. Thompson -- would you have any reason to doubt the accuracy of the numbers that he reports here?
- A. Yes, because these would be preliminary numbers. These would not be final numbers. And final numbers can often change.
- Q. Are those preliminary numbers the number of overdoses?
- A. That's what it says in the -- that's what it says here.
- Q. Okay. But it's not preliminary in terms of the identity of the county of residence or the

individual who overdosed, correct?

A. Not necessarily. I mean, it could happen that new information could come out and that individual may actually be a resident of a different county or a different county resident could be a resident of Cabell County, so this is -- that's the reason when we produce data prematurely, we say it's preliminary data, and until the data is final, the data is not final.

And this does not seem to be anywhere stated here that this is a final data.

Q. Has DHHR ever published statistics like these?

MR. COLANTONIO: Object to form.

- A. We published -- I think all throughout the day, we talked about overdose deaths. We do publish overdose deaths. We publish overdose deaths by the county of residence each year.
- Q. So this data breaking down the number of deaths -- overdose deaths that were reported by county of residence is available in a final form elsewhere?
- A. I believe if you look at my report, you might find it there, but the final report for

Page 343 overdose deaths by county of residence should be 1 2 available year after year in the standard format. 3 MS. JINDAL: Okay, Doctor. I think those were all the questions I have. Thank you. 4 5 THE DEPONENT: Thank you. 6 MR. FITZSIMMONS: Read and sign. 7 MR. COLANTONIO: Anybody else? All right. He'll read and sign. 8 9 VIDEO OPERATOR: We are off the record 10 at 6:23 p.m., and this concludes today's testimony 11 given by Rahul Gupta, M.D. The total number of Media Units used was nine and will be retained by 12 Veritext. 13 14 (Having indicated he would like to 15 read his deposition before filing, 16 further this deponent saith not). 17 18 19 --000--20 21 22 2.3 24

Page 344 STATE OF WEST VIRGINIA, 1 2 COUNTY OF JACKSON, to wit; 3 I, Teresa S. Evans, a Notary Public within 4 and for the County and State aforesaid, duly commissioned and qualified, do hereby certify that 5 the foregoing deposition of RAHUL GUPTA, M.D. was 6 duly taken by me and before me at the time and place and for the purpose specified in the caption hereof, the said witness having been by me first 7 duly sworn. 8 I do further certify that the said deposition was correctly taken by me in shorthand 9 notes, and that the same were accurately written out in full and reduced to typewriting and that the 10 witness did request to read his transcript. 11 I further certify that I am neither attorney or counsel for, nor related to or employed 12 by, any of the parties to the action in which this deposition is taken, and further that I am not a 13 relative or employee of any attorney or counsel employed by the parties or financially interested 14 in the action and that the attached transcript 15 meets the requirements set forth within article twenty-seven, chapter forty-seven of the West 16 Virginia Code. 17 My commission expires October 25, 2020. Given under my hand this 15th day of September, Gı∧≒ıı dıla<u>e</u>ı Mıh Har 18 19 20 Teresa S. Evans RMR, CRR, RPR, WV-CCR 21 22

Veritext Legal Solutions

2324

Page 345 1 STATE OF WEST VIRGINIA 2 COUNTY OF KANAWHA, to wit; 3 I, Teresa Evans, owner of Realtime Reporters, 4 LLC, do hereby certify that the attached deposition 5 transcript of RAHUL GUPTA, M.D. meets the 6 requirements set forth within article twenty-seven, 7 chapter forty-seven of the West Virginia Code to 8 the best of my ability. 9 10 Given under my hand this 15th day of September, 11 2020. 12 13 14 15 16 17 Registered Professional Reporter/Certified Realtime Reporter 18 19 20 21 22 23 24

```
Page 346
                              Veritext Legal Solutions
1
                                 1100 Superior Ave
                                    Suite 1820
2
                               Cleveland, Ohio 44114
                                Phone: 216-523-1313
3
      September 16, 2020
5
      To: Mark Colantonio, Esquire
6
      Case Name: City of Huntington v. Amerisourcebergen Drug Corporation
7
      Veritext Reference Number: 4242146
8
      Witness: Rahul Gupta, M.D. Deposition Date: 9/11/2020
9
10
      Dear Sir/Madam:
11
      Enclosed please find a deposition transcript. Please have the witness
12
      review the transcript and note any changes or corrections on the
13
      included errata sheet, indicating the page, line number, change, and
14
      the reason for the change. Have the witness' signature notarized and
15
      forward the completed page(s) back to us at the Production address
      shown
16
17
      above, or email to production-midwest@veritext.com.
18
      If the errata is not returned within thirty days of your receipt of
19
      this letter, the reading and signing will be deemed waived.
20
21
      Sincerely,
      Production Department
22
23
      NO NOTARY REQUIRED IN CA
24
```

| | Page 347 |
|-----|---|
| 1 | DEPOSITION REVIEW |
| | CERTIFICATION OF WITNESS |
| 2 | |
| | ASSIGNMENT REFERENCE NO: 4242146 |
| 3 | CASE NAME: City of Huntington v. Amerisourcebergen Drug |
| | Corporation, et al. |
| | DATE OF DEPOSITION: 9/11/2020 |
| 4 | WITNESS' NAME: Rahul Gupta, M.D. |
| 5 | In accordance with the Rules of Civil |
| 6 | Procedure, I have read the entire transcript of |
| 7 | my testimony or it has been read to me. I have made no changes to the testimony |
| , | as transcribed by the court reporter. |
| 8 | |
| | |
| 9 | Date Rahul Gupta, M.D. |
| 10 | Sworn to and subscribed before me, a |
| | Notary Public in and for the State and County, |
| 11 | the referenced witness did personally appear |
| | and acknowledge that: |
| 12 | |
| | They have read the transcript; |
| 13 | They signed the foregoing Sworn |
| 1 4 | Statement; and |
| 14 | Their execution of this Statement is of their free act and deed. |
| 15 | their free act and deed. |
| ± J | I have affixed my name and official seal |
| 16 | - 1.0.1.6 0.121.100 m/2 1.0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0.110 0 |
| | this, day of, 20 |
| 17 | |
| | |
| 18 | Notary Public |
| 19 | |
| | Commission Expiration Date |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |

| | Page 348 |
|----------|---|
| 1 | DEPOSITION REVIEW |
| _ | CERTIFICATION OF WITNESS |
| 2 | |
| | ASSIGNMENT REFERENCE NO: 4242146 |
| 3 | CASE NAME: City of Huntington v. Amerisourcebergen Drug |
| | Corporation, et al. |
| | DATE OF DEPOSITION: 9/11/2020 |
| 4 | WITNESS' NAME: Rahul Gupta, M.D. |
| 5 | In accordance with the Rules of Civil |
| | Procedure, I have read the entire transcript of |
| 6 | my testimony or it has been read to me. |
| 7 | I have listed my changes on the attached |
| | Errata Sheet, listing page and line numbers as |
| 8 | well as the reason(s) for the change(s). |
| 9 | I request that these changes be entered |
| | as part of the record of my testimony. |
| 10 | |
| | I have executed the Errata Sheet, as well |
| 11 | as this Certificate, and request and authorize |
| | that both be appended to the transcript of my |
| 12 | testimony and be incorporated therein. |
| 13 | |
| | Date Rahul Gupta, M.D. |
| 14 | |
| 1 - | Sworn to and subscribed before me, a |
| 15 | Notary Public in and for the State and County, |
| 1.0 | the referenced witness did personally appear |
| 16 17 | and acknowledge that: They have read the transcript; |
| Ι/ | They have listed all of their corrections |
| 18 | in the appended Errata Sheet; |
| 10 | They signed the foregoing Sworn |
| 19 | Statement; and |
| | Their execution of this Statement is of |
| 20 | their free act and deed. |
| 21 | I have affixed my name and official seal |
| 22 | this day of, 20 |
| 23 | |
| | Notary Public |
| 24 | - |
| | |
| 25 | Commission Expiration Date |
| | |

| | | | Page 34 |
|-----------|------------|---------------|------------|
| | E | RRATA SHEET | |
| 7 | VERITEXT L | EGAL SOLUTION | IS MIDWEST |
| | ASSIGN | MENT NO: 4242 | 146 |
| PAGE/LINE | (S) / | CHANGE | /REASON |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Date | | Rahul Gup | ota, M.D. |
| SUBSCRIBE | D AND SWOR | N TO BEFORE M | E THIS |
| | | | |
| | | | |
| | Notary | | |
| | 2 | | |
| | | | |
| | | | |

[& - 2.32.] Page 1

| | 10 124.11 124.2 | 12 07.12 246.2 | 10(0 202.16 |
|---|---------------------------|---------------------------|--|
| & | 10 124:11 134:2 | 13 97:12 246:2 | 1860 202:16 |
| & 2:11,14,19 8:12 | 148:23 222:16 | 300:3,5 320:9 | 188 4:4 |
| 8:16,17 242:17 | 281:22 | 130 56:1 147:20 | 1890s 202:16 |
| 0 | 10,000 269:19 | 264:20 329:17 | 19 192:19 |
| 00039036-091 | 10-26-18 6:20 | 1332 187:19 | 1980 191:2,5,8 |
| 6:18 60:23 | 99:11 | 14 5:13 121:6 | 1987 60:9 |
| 0. 18 00.25 0038760 5:15 | 100 134:2 147:21 | 127:20,21 246:2 | 1988 60:9 |
| 308:11 | 164:15 166:16 | 304:6 308:2,3,4,6 | 1990 191:11,23 |
| | 196:19 198:4 | 308:17 309:7,8 | 192:11,12,19 |
| 0038761 5:18 | 203:16 215:15 | 141 5:5 12:8 | 193:6,8,10 200:23 |
| 308:15 | 244:22,23,24 | 15 5:16 16:23 75:5 | 203:13 |
| 0047102 5:21 | 245:3,4,5,22 | 97:12,12 124:11 | 1990s 140:8,17 |
| 303:19 | 264:21 | 162:6,16 281:22 | 143:5 144:1 146:8 |
| 0317258-322 6:8 | 10538 344:19 | 296:16 304:4,7 | 146:17 148:8,12 |
| 246:24 | 345:16 | 308:2,4,6,17 309:7 | 192:13,24 194:12 |
| 0391628-651 6:13 | 106.7 319:20 | 312:5 | 202:8,10,15,17 |
| 254:20 | 10:11 54:22 | 15.6 111:24 | 203:5 204:1,9,20 |
| 0391630 255:8 | 10:26 55:3 | 150 305:18 | 205:8 211:20 |
| 07 147:6 171:4 | 11.63 320:13 | 15th 344:17 | 213:17 214:3,21 |
| 09 127:18 175:12 | 1100 346:1 | 345:10 | 215:11 221:9 |
| 0920 101:20 | 1148108-126 6:16 | 16 5:19 146:17 | 222:5 |
| 0925 206:9 | 313:3 | 303:15,24 304:2,4 | 1993 120:1 |
| 0926 213:24 | 1148109 314:1 | 304:11,12,16,18 | 1994 192:1 |
| 0936 244:13 | 115 4:3 | 304:22 305:1 | 1995 89:13 |
| 0949 104:3 | 11:53 114:23 | 346:4 | 1996 195:24 |
| 0951 111:2 | 11th 1:21 7:4 | 16.9 245:13,23 | 1997 148:14 222:7 |
| 0953 112:9 | 129:12,13 | 1609 3:5 | 224:2 |
| 0954 104:13 112:9 | 12 5:3,5 12:8 43:9 | 1630 255:2,4,14 | 1999 40:3 192:19 |
| 096 211:3 | 45:22 103:7 | 1632 256:2 | 19th 27:7 |
| 1 | 106:24 209:7 | 1634 321:9 | 1:48 180:14,15,22 |
| 1 5:3 7:13 12:2,3 | 12-13-16 5:7 | 17 5:22 146:17 | 1st 316:7 |
| 12:10 13:11 182:9 | 299:13 | 182:8,13 244:12 | 2 |
| 182:11,16 218:7 | 123 122:18 | 246:8,8 255:19 | 2 55:2 107:8 |
| 246:5,9 297:21 | 126 302:6 | 260:22 303:13,15 | 147:14 183:22 |
| 311:11 320:7 | 128 5:7,8 299:12 | 304:1,11,13,16,19 | 184:2,4,13,19 |
| 1,000 134:2 167:18 | 299:13,22 | 17th 321:6 | 234:5 311:21 |
| 174:16 178:15 | 12:00 99:17,20 | 18 175:12 209:7 | 2-0 339:3 |
| 215:16 | 12:30 114:16 | 317:24 | 2.3 320:14 |
| 1.1 280:10 | 12:34 115:5 | 181 4:4 | 2.32 245:21 |
| 1.8 147:15 198:13 | 12th 129:14 | 1820 346:2 | 2.32 245.21 2.32. 245:19 |
| 266:17 | | | 2.32. 273.17 |
| | | | |

[2.79. - 303] Page 2

| 2.70 245.20 | 2000 70.7 94.16 20 | 2016/2017 146.0 | 25714 1100 2.0 |
|--------------------------|---------------------------|---------------------------|---------------------------|
| 2.79. 245:20 | 2009 70:7 84:16,20 | 2016/2017 146:8 | 25714-1180 2:8 |
| 20 6:2 24:12 75:5 | 91:1 92:11 102:9 | 2017 5:16 61:10 | 26 101:9 206:4 |
| 107:16 124:11 | 120:21 121:2 | 111:9 112:3,11 | 230:23 234:5 |
| 162:16 201:11 | 2010 121:6,11 | 124:13 167:17 | 244:10 310:16,22 |
| 281:22 296:8,16 | 145:19 156:18 | 182:8,14 188:17 | 26.3 320:8 |
| 296:24 317:23 | 191:15 | 188:20 207:10 | 26003 3:5 |
| 339:1,2,3,5,11 | 2011 79:21 121:15 | 209:10 245:13,17 | 27 310:17 |
| 347:16 348:22 | 2012 89:16 147:6 | 245:19 280:9 | 272 125:19 |
| 349:22 | 246:2 264:22 | 308:11 309:16 | 273 125:18 142:5 |
| 20,000 174:15 | 265:3,5,10,12 | 340:3,19 | 225:6 |
| 196:1 319:22 | 2012-2013 161:21 | 2018 80:1 101:9 | 27th 340:19 |
| 200 203:16 284:21 | 2013 245:10 | 102:7 125:19 | 28 2:5 |
| 285:10 305:18 | 2014 11:7 84:20 | 127:23,24 142:5 | 29 340:3 |
| 2000 73:18 96:10 | 91:2 165:24 | 165:24 167:14 | 29464 2:5 |
| 146:17 156:10 | 305:17,21 307:17 | 206:5 244:10 | 295 5:9 |
| 157:3 158:1 | 307:19 318:12 | 255:19 313:21 | 299 5:6 |
| 182:20 191:13 | 2015 55:10 89:17 | 315:5 316:4 321:5 | 2:00 181:4 |
| 192:14 193:3 | 91:3 96:10 102:7 | 321:6 | 2:55 226:22 |
| 196:21 198:8,20 | 111:21 121:11,19 | 2018.07.05 6:15 | 2nd 315:5 316:3,7 |
| 2000-2015 144:24 | 127:24 131:4 | 313:1 | 3 |
| 20001 2:21 | 161:18 162:5,16 | 2019 122:11 | 3 64:19 115:4 |
| 20005 2:12 | 171:3 182:18 | 203:13 255:9 | 256:1 302:16 |
| 2000s 78:8 79:12 | 204:22 251:7 | 2020 1:22 7:4 23:3 | 311:12 312:1 |
| 204:12 283:12 | 305:18,21 | 27:8 73:17 122:12 | 3-26&27-18 6:7 |
| 2001 129:13,14 | 2015-16 134:13 | 191:17 344:17,18 | 246:21 |
| 182:18 204:8,8,21 | 2016 5:11 6:7 | 345:11 346:4 | 3-29-17 5:15 |
| 245:9,12,17,18 | 11:24 12:13 111:7 | 20th 255:9 | 308:10 |
| 264:19 265:3 | 111:13,15,16,17 | 216-523-1313 | 30 103:9 104:2 |
| 305:9,14 307:13 | 111:21 112:11 | 346:3 | 105:15 107:2 |
| 307:15 | 124:12,21 126:3 | 22 24:16 | 103.13 107.2 |
| 2001-2015 183:5 | 162:6,16 183:23 | 23 6:22 | 127:6 149:15,16 |
| 2003 156:10 | 184:7,15 188:21 | 23rd 61:9 | 156:3 178:8,11 |
| 2004 167:14 | 206:24 215:8 | 24 89:24 | 180:3 207:6 223:6 |
| 318:19 | 224:18 243:3,17 | 246 6:5 | 223:7 247:14 |
| 2006 147:6,19 | 246:10,22 295:7 | 25 178:8,11 201:11 | 260:20 284:12,15 |
| 171:4 196:1 | 296:9,16 297:11 | 284:12,15 344:17 | 30-40 180:10 |
| 264:20 265:5,9,12 | 299:4 300:2,3,5 | 250 178:13 | 300 178:13 284:21 |
| 2007 120:21 121:2 | 303:5 305:9,14,19 | 250,000 178:17 | 285:10 |
| 269:20 | 306:12 318:8,10 | 25323 2:16 | |
| 2008 156:18 | 318:19 | 254 6:9 | 300,000 178:17 |
| | | | 303 5:19,22 |
| | | | |

[308 - able] Page 3

| 308 5:13,16 | 400 133:19 | 6-3-20 6:23 23:16 | 0 |
|--|---|--|--|
| 31 110:17,18 | 422 2:7 | 60 6:17 94:18 | 9 |
| 313 6:14 | 4242146 346:7 | 320:9 | 9 4:3 328:11 |
| 32 110:18 111:2 | 347:2 348:2 349:2 | 624 303:5 | 9-0 193:9 |
| 328 4:5 | 44114 346:2 | 65 319:19 | 9-27-17 6:4 339:9 |
| 33 158:22 167:20 | 45 6:14 310:10 | 65.9 319:22 | 9-29-17 6:4 339:9 |
| 338 4:5 | 312:22,23 313:5 | 6:01 328:12 | 9/11/2020 346:8 |
| 339 6:2 | 45-64 319:19 | 6:23 343:10 | 347:3 348:3 |
| 34 112:8 306:14 | 47700 302:14 | | 90 166:19 204:11 |
| 35 104:13 112:8 | 4:45 291:11 | 7 | 216:1,7 217:11,16 |
| | 4:45 291:11 4th 5:14 308:10 | 7 211:2 240:22 | 219:22 220:19 |
| 305:5,7,10 | | 7-5-18 6:16 313:2 | 901 2:15 |
| 35,000 195:24 | 5 | 70 248:16,16,20 | 9039 64:19 |
| 196:1 | 5 5:9 97:16 172:12 | 331:8 | 9040 79:16 |
| 350 305:18 | 174:14,16 181:2 | 700 147:12 | 9042 62:3,4 |
| 37 6:5 246:17,18 | 295:2,3,10 321:7 | 707 2:15 | 90s 147:24 195:20 |
| 247:2 | 5,000 270:1 | 72 276:9 | 196:6,8 |
| 38 6:9 254:12,13 | 5-1 61:3 | 725 2:12 | 92.8 319:18 |
| 254:22 321:1 | 5-17-18 6:13 | 780 114:3 147:5 | 99 6:19 216:8 |
| 3:00 296:21 | 254:20 | 198:12 | 244:24 |
| 3:10 227:3,23 | 5-27-17 5:10 295:5 | 8 | 9:04 7:3 |
| 3:17-01362 1:7 | 50 164:14 273:3 | 8 291:15 | a |
| 6:23 7:20 23:16 | 305:17 331:8 | | |
| | 303.17 331.0 | 0 16 16 5.2 12.5 | $a_{m} = 7.2 51.22$ |
| 3:17-01665 1:13 | 500 229:12 | 8-16-16 5:3 12:5 | a.m. 7:3 54:22 |
| 7:20 | 500 229:12 | 80 157:22 166:19 | 55:3 114:23 |
| 7:20 3:25 240:18 | 500 229:12 51 6:17 60:20,21 | 80 157:22 166:19 204:11,11 216:1,6 | 55:3 114:23 abate 48:18 52:17 |
| 7:20 3:25 240:18 3:29 240:23 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 |
| 7:20 3:25 240:18 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 |
| 7:20 3:25 240:18 3:29 240:23 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 4-4-17 5:14,18 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 5th 313:21 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 8533 296:15 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 345:8 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 4-4-17 5:14,18 308:8,14 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 5th 313:21 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 8533 296:15 8:00 129:15 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 345:8 abject 202:20 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 4-4-17 5:14,18 308:8,14 40 103:9 105:16 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 5th 313:21 6 6 62:6 206:8 227:2 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 8533 296:15 8:00 129:15 296:21 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 345:8 abject 202:20 able 13:9,23 15:17 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 4-4-17 5:14,18 308:8,14 40 103:9 105:16 107:3 108:14 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 5th 313:21 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 8533 296:15 8:00 129:15 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 345:8 abject 202:20 able 13:9,23 15:17 15:19,22 16:10 |
| 7:20 3:25 240:18 3:29 240:23 3rd 2:8 23:3 24:12 4 4 5:6 79:15 211:7 299:9,10,16 320:7 4,000 320:11 4-21-17 5:21 303:19 4-29-17 5:24 303:22 4-4-17 5:14,18 308:8,14 40 103:9 105:16 | 500 229:12 51 6:17 60:20,21 61:1,3 64:13 90:15 53 297:1 54 6:19 99:7,8,13 100:9 205:19 214:1 244:8 56 6:22 23:6,8,9,12 23:13,18 57.8 319:21 5:02 291:16 5:56 328:7 5th 313:21 6 6 62:6 206:8 227:2 | 80 157:22 166:19 204:11,11 216:1,6 217:11,16 219:22 220:19 264:13 265:8 273:6 331:8 81.5 319:19 8109 314:21 8119 317:5 8123 318:4 83 136:13 83.7 319:18 85 136:13 850 2:20 71:21 8533 296:15 8:00 129:15 296:21 | 55:3 114:23 abate 48:18 52:17 53:19 140:5 abated 158:14 abatement 288:7 288:11,21 289:2 289:14 290:7,8,14 abating 49:16 abdc 57:14 ability 13:21 20:23 21:3 50:2 51:20 57:11 84:11 141:5 173:14 329:21 345:8 abject 202:20 able 13:9,23 15:17 |

[able - addictive] Page 4

| 31:1,13 35:4,23,24 | academic 65:8 | 336:24 337:7,9 | adderall 172:3 |
|----------------------|-------------------|---------------------|-------------------|
| 36:1,24 38:18,24 | access 114:1 | 347:14 348:20 | addicted 132:21 |
| 45:1 52:4 72:22 | 134:19,24 135:1 | acting 160:9 | 149:22 150:6 |
| 74:14 89:17 93:17 | 250:6,10,13,17,22 | action 1:6,13,20 | 154:9 155:19 |
| 102:24 110:10 | 251:1,3,5,8,17,22 | 5:5,17 7:19 8:3 | 158:11 159:8,10 |
| 113:24 116:18,21 | 252:1,13 | 12:8 24:10 49:14 | 159:10,11 160:1 |
| 124:14 129:7 | accesses 294:5,5 | 266:23 267:10,18 | 163:7 164:19 |
| 134:15,16 135:6 | accidents 66:2 | 268:10 274:2 | 166:3 169:16 |
| 137:21 146:5,15 | account 195:12,14 | 308:14 309:18 | 172:6 178:2 |
| 154:9 156:20 | 196:2 | 333:10 344:12,14 | 179:14 221:13 |
| 159:15,19 161:12 | accountable 293:1 | actions 47:10,18 | 223:14,21 224:10 |
| 166:14,16 168:22 | accounted 174:6 | 47:23 91:17 93:12 | 224:15 281:2,10 |
| 171:10,11 172:18 | accounts 22:20 | 222:19 274:14 | 282:9,19 283:4 |
| 172:18 179:2 | accumulated | 293:1 | 284:22 285:11 |
| 189:19 200:7 | 200:6 | activate 337:7,10 | 311:21,22,24 |
| 230:11 235:24 | accumulating | active 63:18,21 | 312:2,4,5,8,10 |
| 242:5 246:14 | 131:5 | 177:2 | addiction 47:3,4 |
| 251:20,22 252:1 | accuracy 112:6 | actively 105:10 | 123:3 130:23 |
| 266:18 272:18 | 297:20 301:10 | activities 251:21 | 139:5,7 149:4,22 |
| 284:2 292:21 | 315:19 318:23 | 336:13,14 337:2 | 151:6,10,14,14,17 |
| 311:18 323:8 | 320:2,20 325:23 | 337:22 | 151:23,23 154:1 |
| 336:7 337:1,20 | 327:7 341:14 | activity 152:17 | 154:10,17 156:13 |
| abnormal 194:6 | accurate 13:5 | 153:21 | 158:3,12 160:22 |
| 202:21 | 98:22 195:2,13 | actors 40:23 | 163:18 165:7 |
| absolute 144:4,5 | 200:18 226:4 | 190:23 273:8 | 169:16,17 173:13 |
| 148:22 222:15 | 250:9 252:3 283:1 | acts 93:7,9,12 96:7 | 175:2 177:19 |
| 326:3 | 319:7 326:13,15 | 160:9 328:24 | 178:14,18,18 |
| absolutely 26:7 | accurately 13:24 | actual 97:24 114:2 | 179:18 221:14 |
| 64:14 177:20 | 62:11 344:9 | 114:6 211:20 | 222:21 223:14 |
| abstinence 97:17 | acetyl 302:14 | 280:18 298:2 | 225:21 274:20 |
| 136:20 168:13 | acknowledge | acute 141:10,15 | 275:11 277:5,16 |
| 170:17 | 36:24 347:11 | 196:23 | 278:4,7,11 279:11 |
| abuse 35:11 45:17 | 348:16 | acutely 78:14 | 279:17 281:16,24 |
| 48:14 52:1 85:4 | acryl 302:16 | adam 3:8 7:22 | 282:22 322:1 |
| 154:16 161:23 | act 48:4 49:24 | 228:18 286:10 | 327:14 333:21 |
| 165:22 311:5 | 50:9,22 51:1 | 338:4,6 | 334:3 336:21,22 |
| 321:23 331:18 | 90:20 92:20 94:6 | add 82:24 97:20 | addiction's 158:6 |
| abused 132:21 | 125:20 141:23 | 172:1 252:17 | addictive 166:6 |
| abusing 330:21 | 142:3,21 225:6 | 285:14 336:16 | 172:3 324:21 |
| aca 145:18 | 270:8 273:8 | added 245:2 | 332:24 |
| | 292:10,11 324:7 | | |
| | | | |

[addicts - amount] Page 5

| add: 4a 177.00 | advisavias 200.0 | 211.7 9 222.0 | alian 271.14 |
|-------------------|-------------------------|---------------------------|----------------------|
| addicts 177:22 | advisories 300:8 | 311:7,8 322:9 325:10 | align 271:14 |
| adding 200:20 | advisory 5:8 48:14 | | aligned 271:17 |
| addition 72:23 | 51:24 85:3 128:5 | agreed 142:18 | alimony 93:6 |
| 73:4 105:12 | 128:8 161:22 | 207:2 225:7,12 | alive 277:2 |
| 117:15 136:13,20 | 299:13,22 300:1,7 | 269:13 | allen 309:9 339:21 |
| 185:6 190:22 | 300:11 302:5,5 | agreeing 142:15 | 339:22 |
| 197:8 211:19 | affiliations 8:7 | agreement 159:1 | allow 134:24 |
| 229:5 234:6 | affirmatively | 233:18 326:23 | 135:1 152:5 161:9 |
| 285:14 302:16 | 284:23 | agreements 27:16 | 175:2 276:5 |
| 321:24 327:13 | affixed 347:15 | 242:12 | allowed 19:22 |
| additional 60:17 | 348:21 | ahead 12:11 13:10 | 128:10 |
| 145:17 211:3 | affordable 47:12 | 24:2,3,6 33:2 | allowing 324:11 |
| 322:14 | 90:20 278:16 | 49:20 51:13 54:17 | allows 161:8,10 |
| address 37:12,18 | aforesaid 344:4 | 60:1 114:15 | alluded 298:2 |
| 37:19 41:4 46:4 | afraid 277:3 | 115:11 141:9 | alterations 316:11 |
| 49:9 127:4 138:9 | african 69:1 | 199:7 238:4 267:7 | altered 158:7 |
| 142:22 256:14 | 319:18 | 283:7 292:5 | alternative 47:12 |
| 319:13 322:15 | afternoon 328:19 | 293:15 | 163:9 278:16 |
| 346:15 | ag 26:19 | ahold 278:12 | alternatives 197:7 |
| addressed 313:12 | age 205:2,5 206:20 | air 70:21,21 71:2 | amend 186:11 |
| addressing 40:15 | 213:6 319:19,19 | 131:3,8 | america 206:24 |
| 72:18 80:12 81:2 | agencies 58:3 | al 1:8,14 5:4 7:17 | american 10:16 |
| 332:2 | 128:11 130:6 | 12:6 347:3 348:3 | 69:1 78:12,20 |
| adequate 151:7 | 256:19 | alabama 63:5 | 101:23 259:3 |
| 245:7 264:8 323:7 | agency 59:7 | 64:23 65:5,6 | americans 103:6 |
| adequately 73:23 | 190:18 | 68:13 73:10 120:4 | 106:23 319:18 |
| 198:14 | agents 129:16 | 120:17 129:4 | amerisourceberg |
| adhering 272:10 | aggressive 179:16 | alarming 302:20 | 1:7,14 5:4 7:17 |
| adjunct 121:21 | aging 273:1 | alcohol 159:11 | 10:15 11:23 12:6 |
| adjust 172:18 | ago 9:10 19:21 | 311:21 319:15 | 12:14 21:23 57:6 |
| 196:10 | 36:15 54:15 97:23 | 322:1 324:15,17 | 57:9,14 59:3 |
| administer 8:2 | 106:19 290:4,6 | 324:23,23 325:3,5 | 346:6 347:3 348:3 |
| administration | agonist 160:7,10 | 325:9,19 326:12 | amount 31:13 |
| 60:18 63:7 120:8 | 160:14,15 | 326:14 327:15,18 | 83:3 113:18 126:4 |
| 190:16 | agree 7:11 14:16 | 327:21 332:13 | 126:12 145:22 |
| admitted 65:24 | 27:24 59:18 86:21 | 335:14,15,18,23 | 151:1,7 157:4,13 |
| advanced 60:14 | 86:24 87:2,6 | 336:17 | 167:1 169:4 |
| 62:13 | 92:19 193:24 | alcoholics 335:20 | 176:16 189:19,22 |
| adverse 154:16 | 198:11 256:23 | alcoholism 324:23 | 189:24 190:1,6 |
| 205:14 | 257:2 287:12,13 | 335:24 | 191:24 193:22 |
| | 287:15 291:2 | | 260:5 268:17 |
| | | | |

[amount - areas] Page 6

| 260 4 6 271 0 | 22.0.25.7.27.2 | 1 1 1 225 17 | 247 22 207 4 |
|---------------------------|-------------------|-------------------|-------------------|
| 269:4,6 271:8 | 33:8 35:7 37:2 | anybody's 235:17 | 247:22 286:4 |
| 275:5 | 41:3 49:20 50:7 | anyway 100:8 | 298:15 338:19 |
| amphetamine | 50:12 52:15 57:5 | apologies 241:10 | approach 67:23 |
| 318:16 332:7 | 73:7 84:12 88:8 | apologize 23:9 | 67:24 68:4,10 |
| 333:16 | 89:3 90:6 98:22 | 25:15 100:12 | 72:2,13 74:9 |
| anal 216:14 | 104:18 106:4,8 | 104:12 207:19 | 241:6,11 256:18 |
| analog 301:6 | 175:15 180:9 | 211:1 242:21 | 263:5 |
| 303:10 | 198:19 200:10 | 247:21 284:16 | approached 77:6 |
| analogs 302:13,20 | 211:16 215:24 | 299:18 300:4 | 77:11,15 241:15 |
| analyses 200:4 | 216:23 217:3 | 304:5,13 309:15 | 241:18 |
| 201:5,10,22,23 | 220:9,16 221:10 | 310:19 | approaches |
| 220:18 285:2 | 221:18,20 222:1 | appear 29:2 | 321:16 |
| analysis 6:8 146:5 | 224:3 227:20 | 184:20 347:11 | approaching 77:1 |
| 174:3 183:16,24 | 228:16 231:2 | 348:15 | 77:4 |
| 184:7,14,16 185:8 | 232:16 236:9 | appearance 8:10 | appropriate 37:3 |
| 198:2 199:2,10,12 | 238:2,13 249:18 | 29:9 239:14,15 | 61:15 66:17,18,20 |
| 199:21 200:1 | 250:1,20 252:10 | appearances 2:1 | 66:21,23 67:6 |
| 201:1,17 204:7,20 | 261:20 263:18 | 3:1 8:7,24 | 114:9 141:13,24 |
| 216:16,17 217:4 | 265:23,24 267:5 | appeared 117:20 | 150:23,24 156:23 |
| 217:11,16,19 | 269:9 278:22 | 122:21 185:19 | 159:14 175:8 |
| 218:1,11,17 243:4 | 281:10 282:24 | 186:2 239:4,9,20 | 203:20 214:15 |
| 246:23 299:6 | 331:22 336:11 | 240:2 | 237:1 282:4,5 |
| 305:10 306:19 | answered 25:3 | appearing 2:2,10 | 294:14 302:22 |
| analytically | 106:2,3 116:14 | 2:17 3:2 118:5,11 | 310:5,6 |
| 144:23 | 198:24 201:4 | 185:23 | appropriately |
| analyze 205:16 | answering 204:16 | appears 122:17 | 28:24 224:5 282:7 |
| anecdotal 200:10 | answers 26:13 | 297:13 | 283:3 |
| animal 152:19 | 98:19 148:2 | appended 348:11 | approval 259:14 |
| animals 152:8 | 236:15 | 348:18 | approved 159:4 |
| anita 314:3 | antagonist 160:14 | applicable 57:5 | 160:5 |
| ankle 260:23 | 160:18 | 187:16 194:1 | approximately |
| anne 2:3 8:19 | antibiotic 67:9 | 300:18 | 16:17,20 25:21 |
| 29:10 31:17 32:11 | antibiotics 66:18 | application 94:4 | 39:20 40:2 89:16 |
| 118:4 182:1 187:7 | 67:8,11,18 | applied 142:11 | 122:18 147:15 |
| 187:9,10,20 188:2 | anticipate 37:13 | applies 187:5 | 174:15 180:10 |
| 291:1 297:12 | antidote 44:15 | apply 262:13 | april 5:14 308:9 |
| annual 111:17 | antione 2:19 | appointment | aquiring 155:20 |
| anonymous | antonine 8:16 | 68:17 71:11 | area 22:19 42:3 |
| 314:13,18 | anybody 105:17 | appreciate 26:15 | 325:15 337:15 |
| answer 14:13,15 | 135:1 172:23,23 | 98:17 112:22 | areas 38:7 64:3 |
| 17:24 18:1 19:9 | 236:13 343:7 | 189:12 208:13 | 124:2 140:20 |
| | X7 '4 4 T | | |

[areas - authorize] Page 7

| | I | | |
|--------------------|-------------------------|--------------------|---------------------|
| 197:3,8,11 230:20 | asking 13:3 19:6 | associate 79:19 | attempts 44:24 |
| argue 231:4 | 29:1,6 41:6 48:2 | 121:13 | attendees 315:4 |
| arrangement | 50:20 52:12 | associated 31:22 | attending 8:6 42:4 |
| 287:20 290:19 | 105:21 130:3 | 175:19 243:11 | attention 79:15 |
| arrested 293:7,8 | 164:4 229:21,22 | 254:2 256:16 | 85:6,11,12 100:17 |
| 293:15,19 294:8 | 237:14 259:8 | association 300:21 | 171:11,12 211:19 |
| arresting 293:11 | 269:8 280:20 | 300:23 | attest 37:15 |
| arrive 198:6 218:3 | 281:9 326:23 | associations | attitudes 148:3 |
| 245:22 | asks 37:17 153:9 | 170:20 301:1 | attorney 8:10 9:12 |
| arthritic 140:21 | 216:20 217:2 | assume 53:5 | 10:14 17:22 18:18 |
| 196:3 | 236:20 | assuming 248:5 | 25:23 27:17 |
| arthritis 140:22 | aspect 35:6 43:1 | 282:5 | 344:12,13 |
| 143:11 145:14,17 | 49:5 54:7 71:5 | assumption 144:4 | attorneys 15:2,3 |
| 197:20 | 72:18 102:21 | 157:3 193:16 | 15:15,23 16:1,2,4 |
| article 344:15 | 107:14 132:5 | 194:19 195:1 | 16:8 20:10,19 |
| 345:6 | 225:1 329:9,13 | 199:16 200:19,24 | 27:4,5 28:8 |
| articles 122:19 | aspects 21:1 64:16 | 213:9 247:19 | attributed 136:16 |
| 123:19 | 65:17 70:19 71:3 | 248:2 | 303:10 |
| ascertain 13:1 | 71:7 72:20 73:5 | asterisk 209:12 | auburn 66:8 |
| ascertainable | 76:22 94:7 96:15 | attach 333:4 | audience 108:18 |
| 88:19 | 97:12 109:3 132:2 | attached 5:8,12 | 110:3,6,13 |
| ascertained 88:23 | 136:6 138:1 | 6:8 246:23 295:8 | audiences 103:8 |
| ashley 314:3 | 141:12 145:9 | 297:24 298:20 | 107:1 110:9,10 |
| 315:18,23 | 149:2 153:22 | 299:14 309:8,16 | audio 7:9,10 |
| aside 13:11 18:18 | 170:24 249:16 | 344:14 345:4 | 228:21 |
| 24:23 63:9,14 | 280:17 | 348:7 | auds 319:16 |
| 190:20 258:17 | asserted 203:18 | attaches 160:11 | august 5:11 182:8 |
| 268:21 293:18 | assertion 86:1 | attachment 61:7 | 182:13 295:7 |
| 299:3 | assessment 112:24 | 61:15 255:2,8 | 296:9,16,16 |
| asked 25:2 29:2,8 | 204:3 | 295:24 296:3 | authenticate 93:3 |
| 30:19 31:1 32:4 | assignment 347:2 | 299:21 314:6 | author 296:6 |
| 33:2 34:1,7,12,15 | 348:2 349:2 | 316:10,12 | 300:6 309:22 |
| 34:16 35:2 37:21 | assimilated 18:22 | attachments 314:9 | authored 309:20 |
| 49:6 53:17 76:17 | assistance 101:13 | attempt 28:11 | 319:4 |
| 95:6 106:1 124:13 | 126:23 | 55:23 56:6 128:12 | authority 49:8,23 |
| 124:15 133:20 | assistant 65:9 | attempted 188:21 | 50:1,21,24 51:20 |
| 134:4 198:23 | 120:16,20,24 | 232:6,8 | 52:13 91:16 |
| 213:23 220:11 | 121:9 | attempting 17:11 | 251:11 252:15 |
| 221:6 227:8 228:4 | assisted 314:8 | 42:19 45:13 47:8 | 329:8,12 |
| 229:19,19,20 | 316:22 317:9 | 50:4 | authorize 348:11 |
| 242:24 267:5 | | | |
| | | | |

[authorized - bates] Page 8

| | I | I | I |
|-------------------------|-----------------------|--------------------------|---------------------------|
| authorized 8:2 | 258:6,8,18,22 | 206:1 209:1 212:9 | 215:8 217:7,7,17 |
| 36:12 | 259:16,18 274:1,4 | 221:1 226:19 | 220:10,11 234:3 |
| authors 296:2 | 283:6,16,18 | 227:3,23 228:17 | 242:9 261:6 263:5 |
| automatically | 293:13 330:11,17 | 228:19 236:1 | 263:17 283:12 |
| 67:15 | 331:21,23,23 | 237:8 240:23 | 300:16 316:23 |
| autopsies 132:6 | 333:15,22 335:12 | 242:2 244:7 | 317:11 321:15 |
| autopsy 124:9,19 | awhile 320:3 | 246:10 253:19 | baseline 143:19,22 |
| 125:21 126:2 | awkward 115:22 | 278:1 282:23 | 143:24 144:8 |
| 135:10 138:12 | b | 289:6 291:16 | 157:2,8 167:3 |
| 178:10 243:1 | b 97:11 136:12 | 293:9 307:13 | 192:2,9,11,17,21 |
| 246:10 329:4 | 164:20 | 321:1 322:19 | 193:15 194:16,19 |
| 331:13 | babies 97:17 | 328:12 332:19 | 195:1 196:9 |
| availability 22:11 | 128:24 168:9 | 333:17 346:15 | 199:16 200:19,24 |
| 30:20 141:6 310:6 | 171:3,7,9 173:1,6 | background 60:2 | 202:1,10,11 203:6 |
| available 29:22 | 171.3,7,9 173.1,0 | 116:13 119:21 | 203:10,22 213:9 |
| 47:11 96:9 113:9 | baby 46:6 97:19 | 129:2 136:23 | 213:18 214:5,19 |
| 113:15 126:16 | 168:12,19 169:18 | 139:3 158:5 | 214:20 |
| 146:16 155:7 | 169:19 170:8,9,14 | 165:21 | basic 152:2 |
| 178:21 189:4 | 173:1 174:12,13 | backwards 213:3 | basically 94:23 |
| 242:9 257:16 | 173.1174.12,13 | 304:5 | 116:16 124:22 |
| 278:20 298:6 | baby's 169:20 | bad 44:20,21 | 128:24 129:23 |
| 342:21 343:2 | bachelor 60:4 | 46:14,21 72:3 | 130:1,3 134:16 |
| ave 346:1 | bachelor's 60:12 | 73:11 74:12,18,19 | 150:23 152:23 |
| avenue 3:5 | 210:13 211:9 | 74:19,20 76:7 | 153:8 154:5 |
| average 93:16 | back 10:19 17:7 | 131:1 163:6 | 155:10,17 156:1 |
| 97:13 192:16 | 25:20 39:23 45:23 | 179:11 262:24,24 | 158:16 160:19 |
| 193:1 194:8,11,15 | 46:7 47:17 55:3 | bag 197:24 198:1 | 164:22 172:4 |
| 195:20,20 205:5 | 59:4,14 71:10 | balance 329:19 | 174:5 176:24 |
| 214:24 244:19 | 73:15 75:5 77:23 | balancing 273:8 | 177:3 178:14,23 |
| 245:14,15,15 | 79:14 80:23 83:23 | ball 33:3 | 179:18 190:1 |
| 246:4,9 | 84:12 85:24 90:15 | bankrupt 45:9 | 214:13 242:11 |
| avoid 265:20 | 109:24 110:10 | bar 245:18 | basis 22:13 58:15 |
| aware 15:7 20:17 | 114:17 115:5,10 | base 83:9 | 66:9 77:20 98:12 |
| 23:1,4 24:18,24 | 124:20 125:21 | based 11:19 18:13 | 128:3 133:5 137:4 |
| 25:5,6,7,8,9,11,24 | 131:4 140:8 143:5 | 35:21 40:4 72:1 | 165:18 220:4,5 |
| 33:23 40:6,11,17 | 131:4 140:8 143:3 | 83:12 102:24 | 221:15 225:5 |
| 41:8 51:16,19 | 158:4 161:5,14 | 110:9 126:1 139:2 | 323:20 |
| 53:3 56:17 78:14 | 166:21,24 175:7 | 156:15 157:24 | bates 61:20 64:18 |
| 84:24 85:13,17 | 175:15 176:3 | 158:5 159:2 | 79:16 101:20 |
| 109:19 114:6,7,7 | 181:3 189:16 | 165:19 192:22 | 104:3,13 111:2 |
| 190:23 257:18 | 190:5 205:19 | 196:11,23 206:23 | 112:8 206:9 211:3 |
| | 170.3 403.17 | | |

[bates - board] Page 9

| 244:13 255:2,3,7 | behavioral 317:22 | 92:16 132:23 | birth 36:21 170:21 |
|--------------------------|---------------------------|--------------------------|----------------------------|
| 255:14 256:2 | behaviors 324:21 | 146:11 157:22,23 | 320:15 |
| 296:15 313:24 | 336:12,12,14,20 | 159:6 175:24 | births 174:15 |
| 314:21 317:5 | beings 74:20 | 176:6 200:23 | 320:10,11 |
| 318:3 321:9 | 152:19 334:6 | 202:8,11 203:5 | bit 9:10 23:10 60:2 |
| bathrooms 165:11 | believe 10:19 | 217:6 224:17 | 67:10,14 69:1 |
| bayer 10:19 11:1 | 11:14,19 12:1 | 263:20 331:18 | 86:21 88:10 |
| bear 338:20 | 13:7 37:24 52:21 | 345:8 | 100:13,19 106:19 |
| bears 208:22 | 62:6 79:23 83:6 | better 26:13 42:8 | 115:22 116:14 |
| becker 315:12 | 84:17 87:7 89:10 | 55:23 56:6 59:9 | 140:7 146:4,13 |
| becoming 43:3 | 90:2 93:4,24 | 72:7 83:17 132:10 | 151:13 160:12 |
| 92:12 127:17 | 96:13 118:10 | 135:8,11 179:12 | 163:4,15 176:18 |
| 149:22 162:7 | 119:9,10 129:14 | 187:12 243:11,14 | 178:4 179:20 |
| 196:1 221:13 | 136:22 138:24 | 250:6 279:18 | 189:16,16 197:11 |
| 223:14,20 224:10 | 139:4,6,16 140:12 | beyond 17:15,21 | 210:20 224:24 |
| 224:15 281:10 | 140:15 144:20 | 27:14 28:3 29:8 | 242:2,5 247:3 |
| began 77:18,19 | 148:5 158:6,11 | 40:22 83:11 | 262:16 277:1 |
| 150:10 163:23 | 175:17 182:4,20 | 173:20 213:6 | 280:21 304:13 |
| 164:16 197:6 | 184:3,6,8 196:22 | 242:6 289:2 | 323:10 328:1 |
| 276:15 330:9 | 206:10 216:1 | biased 173:19 | bits 116:15 |
| beginning 8:10 | 224:2 225:4 | big 103:10 106:12 | black 89:3 |
| 36:19 73:6 241:20 | 229:12 230:6,16 | 106:13,17 107:3,5 | blair 174:5 |
| 319:9 | 239:9 242:17,19 | 107:7,9,12,13,15 | blame 83:15 98:12 |
| begins 55:1 115:3 | 245:22 247:9 | 107:18,21,24 | 102:22 103:20 |
| 181:1 227:1,21 | 273:12 277:24 | 108:2 147:12 | 293:3 325:5 |
| 240:21 255:2,7 | 307:18 311:15 | bigger 164:9 | blank 104:7 |
| 256:5 291:14 | 315:8 318:2 320:4 | bill 74:23 76:2 | 131:12 |
| 328:10 | 329:3 342:23 | 125:18,19 142:5,7 | blood 197:23 |
| begun 156:2 | believed 86:11 | 225:6 283:11 | 333:23 |
| 275:14 | 306:2 | 313:13 315:2 | bloodstream |
| behalf 8:12 11:10 | believing 221:15 | 316:2 | 169:24 |
| 11:18,21 25:17 | benefit 73:16 | billion 97:19 | blue 24:11 245:11 |
| 28:15 117:23 | benzodiazepine | 174:17,18 | 245:18 |
| 118:3,5 186:15,21 | 132:18 336:17 | bills 125:22 | board 40:18,18 |
| 186:22 188:8 | benzodiazepines | binge 325:14 | 41:9,10,18,24 42:4 |
| 234:18 239:21 | 321:21 332:11 | biology 60:11,12 | 51:16,16,19,23 |
| 289:15 | 336:9 | biostatistics 194:5 | 52:5,9,12,16 53:3 |
| behave 169:11 | best 13:21 14:2,12 | bird's 35:17 | 53:12,13,17 54:3 |
| behavior 153:11 | 20:23 21:2 38:11 | birmingham 63:5 | 85:13,21 86:2,3,6 |
| 325:13 | 53:5 57:13 74:22 | 65:5 68:13 120:4 | 86:14 91:14,17,21 |
| | 88:8 90:6 92:14 | | 92:8,10,13 122:9 |
| | | | |

[board - cancerous] Page 10

| 122:11,12 124:18 | 170:1 177:15 | bullets 107:8 | 296:18 297:1,11 |
|---------------------------|---------------------------|--------------------------|-------------------------|
| 124:18 133:18 | 279:16 332:24 | bunch 168:1 | 299:4 340:6,7,10 |
| 134:11,15 135:7 | 333:11,23 334:17 | buprenorphine | 340:15 342:6 |
| 188:16 189:5,7 | 335:2,6,17 | 160:6,13 | cabinet 149:19 |
| 251:16,18,24 | break 51:7,9,11 | bureau 9:15 22:17 | 223:11 225:19,21 |
| 264:2 274:1 | 54:18 96:24 99:17 | 30:9 31:8 39:19 | 226:2,10,14 294:1 |
| boards 93:9 | 99:20 114:16 | 42:16 48:10,23 | 294:21 315:3 |
| 123:13 | 179:21 180:17 | 91:8 101:13 | 316:2 |
| bob 8:20 16:10 | 226:18 231:6 | 183:12,18 184:5 | cabinets 294:24 |
| 232:14 235:21 | 286:9,11 328:2 | 184:21 206:24 | calculated 174:11 |
| 239:7 240:6 | breaking 342:19 | 243:5 250:22,24 | call 5:17 24:24 |
| bodies 131:5,11,17 | breaks 138:5 | 251:19 296:23 | 50:5 52:4,8 81:11 |
| 131:18 165:15 | 177:1 334:23 | 301:4 315:11,12 | 82:13 117:3 |
| body 132:13 | breathing 335:1 | 317:20 326:2 | 156:22 178:9 |
| 139:10 151:19 | bridgeside 2:5 | burling 2:19 8:16 | 232:20 244:23 |
| 154:6,20 158:7 | brief 16:6,19 59:8 | 8:17 117:2 | 251:9 272:9 |
| 177:6,11 | briefly 30:11 | business 60:18 | 308:13 309:18 |
| boggs 5:14 308:9 | 120:16 181:6 | 63:6 120:8,9 | called 9:5 24:14 |
| bolus 277:3 | bring 138:11 | bust 163:6 | 30:2 44:15 71:16 |
| bombarded 74:6 | broad 35:17 65:21 | busts 179:14 | 82:10 89:10,12 |
| bones 66:2 | 159:1 | busy 122:14 | 123:3 125:19 |
| boone 5:4 12:7 | broadly 18:13 | butyrnl 302:15 | 152:12 164:13 |
| border 248:23 | 22:8 42:8 90:2 | buy 149:5 | 168:14 171:9 |
| born 97:17 168:19 | 151:17 | buying 280:16 | 172:3 270:7 325:6 |
| 171:4 172:5 | broke 46:7 | c | 329:4 334:11 |
| bottom 76:15 | broken 66:2 | c 5:5 7:1 12:8 97:7 | calling 293:2 |
| 79:18 96:19 | brought 28:15 | 106:6 136:12 | 312:19 |
| 100:20 111:10 | 85:5,11,12 125:8 | 234:5 | calls 16:19,21 |
| 160:19 204:17 | 129:23 233:2,5 | ca 346:24 | 133:7 296:19 |
| 215:21 263:15 | budget 45:7 | cabell 1:11 7:16 | camc 71:15 |
| 340:12 | budgets 136:15 | 17:2 21:18 22:9 | camera 115:20 |
| boulevard 2:5 | bug 81:13 | 27:4 28:16 32:7 | 116:6 |
| box 14:21 15:3,6 | build 218:2 334:10 | 97:3 115:8 117:17 | campus 72:16 |
| 38:1 245:12 | building 132:3 | 118:16,23 119:3 | 121:11 |
| 262:23 | built 334:12 | 137:10 138:16 | cancer 66:1 |
| bph 296:24 | bullet 80:10 90:18 | 140:1 148:7 | 140:19 144:11 |
| brain 152:3,4,5 | 91:11 101:22 | 172:14 182:2 | 145:5,23 196:12 |
| 153:1,8,9,16,19,20 | 104:1 131:24 | 187:6,17,20 | 197:18 222:8 |
| 154:5,6,11,19 | 252:5,7,18,23 | 234:24 239:22 | 281:4,6,8 |
| 155:8,9 158:4 | 253:2 315:2,9 | 240:3 275:20 | cancerous 334:20 |
| 160:4,8 169:20 | 316:1,21 | 293:14 295:21 | |
| | | | |

[cannabis - challenges]

| cannabis 320:12 | case 6:23 11:2,5,6 | categorization | 272:17 281:16 |
|---------------------------|--------------------|-------------------------|---------------------------|
| capacity 130:7 | 11:23 12:14 13:6 | 261:5 | 282:1,11,13 |
| 176:9 183:17 | 15:9 17:3 18:8 | categorize 261:13 | 306:17 |
| 184:4 187:8 217:1 | 21:16,24 22:4,5 | 262:21 | certainly 31:12 |
| 252:11 | 23:15 25:17 26:10 | category 263:4,6 | 64:12 67:20 73:21 |
| capita 111:17 | 26:11,16,18,19,21 | causal 312:13,17 | 137:16 161:21 |
| 112:10 | 27:7,19 28:15,20 | causative 168:9 | 167:1 186:7 |
| caption 344:6 | 30:13,15,17 31:10 | cause 85:23,24 | 197:19 274:17 |
| cardinal 2:10 8:12 | 33:13,14 34:22 | 130:12 148:5 | 275:15 336:20 |
| 8:14 9:12 21:22 | 35:4 53:6 54:8 | 175:9 221:7 | certainty 90:11 |
| 55:6,8,12 56:16 | 110:8 116:4 | 302:11 336:14 | 181:17,18,18,18 |
| 57:1 59:2 188:9 | 117:24 118:22 | caused 77:22 83:5 | 194:17 195:3 |
| care 45:4 64:4,22 | 173:23,23 185:20 | 150:5 166:1 168:5 | 199:20 200:8 |
| 65:10,12 68:4,23 | 185:21 187:18,20 | 274:6 | 251:6 298:7 |
| 71:21 72:8,24 | 231:7,9,16,19,20 | causes 96:3 98:23 | certificate 93:13 |
| 75:9 77:17 78:2 | 231:22,24 232:4 | 137:1 139:22 | 348:11 |
| 85:7 90:20 129:3 | 232:24 233:16,17 | 243:9 278:16 | certificates 62:23 |
| 136:14 144:7 | 233:19,21,22 | 321:22 330:4 | 93:14 |
| 148:2,11,11 | 234:8,10,11,14,17 | causing 59:10 | certification |
| 149:12 155:16 | 235:1,2,3 236:21 | 153:1 | 122:13,15 347:1 |
| 157:9 159:7,14 | 237:5,11,17,18 | caveat 33:22 | 348:1 |
| 171:19,20 193:15 | 239:5,6 240:4 | 108:23 330:18 | certified 122:9,11 |
| 196:14,20,23 | 257:3 258:6 | ccr 344:20 | 345:17 |
| 197:4,5,15 204:6 | 272:14 288:10,18 | cdc 58:3 94:23 | certify 344:5,8,11 |
| 222:4,4 223:3 | 289:1,10 290:16 | 123:20,22,24 | 345:4 |
| 258:24 259:1,10 | 290:16,22 330:12 | 127:1 134:12 | chain 6:2,5 40:23 |
| 260:19 261:14,19 | 346:6 347:3 348:3 | 142:19 188:21 | 105:2 109:19 |
| 262:12 263:5,9,23 | cases 10:12 11:9 | 225:3 271:14,15 | 246:19 266:9 |
| 271:13,21 272:5 | 11:13 59:16 81:12 | 272:7 325:12 | 339:6,19 340:5 |
| career 71:18 | 82:11 117:18 | cdc's 224:17,22 | chairman 97:23 |
| cares 281:11 | 136:14 151:3 | cdcs 215:7 | 142:15 174:5 |
| caretaking 84:6 | 171:17 197:18 | celebrex 75:14 | challenge 5:23 |
| 84:18 | 234:19 241:21 | cell 7:7 | 58:14 103:4 |
| carey 2:14 | 290:20 297:1,2 | cellular 7:6 | 106:21 303:21 |
| carfentanil 302:6 | cash 74:17 | census 206:24 | 321:24 324:16,18 |
| 302:17 | casualties 75:19 | center 2:20 24:11 | 324:24 326:15 |
| carnage 22:7 | cataloged 125:6 | 68:17 318:14 | 327:13 |
| 130:8 265:20 | categories 144:19 | certain 93:4 | challenges 35:3 |
| carnal 131:21 | 213:3,5 261:20 | 199:24 200:18,22 | 58:16 69:2 71:22 |
| carolyn 255:9 | 262:1 | 216:3 239:18 | 72:19 80:13 81:3 |
| | | 248:1 251:10 | 81:6,16 103:2 |
| | | | |

[challenges - clearly]

| 136:13 | characterization | children 45:4 | clandestine 164:14 |
|--------------------------|---------------------------|-------------------------|-------------------------|
| chan 121:18 | 291:2 327:17,22 | 137:6 150:3 155:3 | clarification 14:5 |
| chance 13:7 18:23 | characterize 73:11 | 293:16 | 208:24 |
| 142:24 143:2 | charge 11:16 | china 94:22 | clarified 237:9 |
| 144:17 218:19,21 | charitable 71:16 | chip 176:2 | 239:8 |
| change 77:18 78:9 | charity 73:3 276:8 | choice 141:19,20 | clarify 64:15,17 |
| 79:4 129:8 144:10 | charleston 2:16 | choosing 325:16 | 87:8 214:9 234:16 |
| 144:14 146:3 | 70:12 71:12 79:20 | christenson 2:4 | 333:1 |
| 148:2,10 153:11 | 80:9 90:17 91:1 | christina 255:10 | clarifying 35:9 |
| 155:17 157:8 | 121:6,11,14 | christy 5:19 | clarity 286:14 |
| 161:16 167:24 | 131:23 | 303:16 341:6 | clarity's 235:5 |
| 193:14 196:14 | chart 274:22 | chronic 87:1 | class 80:2,11 81:9 |
| 199:14 222:3 | 275:12 307:23 | 140:17,23 141:1 | 82:5 90:19,21 |
| 258:23 259:1,4,7 | charts 96:6 | 335:20 | 94:14,17,20 95:5,7 |
| 259:10,16,17 | chase 2:15 | circuit 5:4 12:6 | 95:23 96:2 |
| 260:18 263:9 | chats 16:6 | 315:4 316:3 | classes 95:2 |
| 329:21 341:18 | cheap 278:20 | circumstances | clean 70:21 298:20 |
| 346:13,14 348:8 | cheaper 47:11 | 31:14 116:4 | clear 11:16 14:3 |
| 349:3 | 278:16 | 141:24 | 18:21 25:15 26:9 |
| changed 140:16 | check 38:2 52:3 | cited 225:3 318:13 | 26:24 29:5 34:3 |
| 144:7 146:7 | 61:11 89:5 90:8 | cities 46:7 126:20 | 34:19,24 43:3 |
| 148:11,15,17 | 181:8 | 138:6 | 57:8 109:10 |
| 149:11,15 156:10 | chemical 152:12 | citizens 272:22 | 117:15 129:21 |
| 193:3 196:20 | 176:22 177:4 | city 1:4 2:20 7:15 | 185:18,19 186:10 |
| 197:5,15 222:4,8 | 284:4,7,9 | 17:3 21:18 22:9 | 197:24 199:11 |
| 222:10 223:3,6 | chemically 177:8 | 27:4 32:7 44:3 | 200:9,21 207:20 |
| 263:22 | 177:13 | 68:24 70:13 115:8 | 208:7 210:16 |
| changes 89:13 | chemicals 258:17 | 117:17 118:5 | 212:11,12 214:7 |
| 104:22 138:10 | chest 63:1,10 | 131:2 182:2 | 214:10 216:12 |
| 144:13,18 193:19 | chhd 296:19,24 | 186:23 187:6,16 | 218:5 219:17 |
| 194:20 205:1 | chicago 62:17 | 234:22,24 239:11 | 220:17,21 231:14 |
| 346:12 347:7 | chief 22:18 58:12 | 239:14 240:3 | 232:23 233:23,24 |
| 348:7,9 | 125:15 127:13,22 | 346:6 347:3 348:3 | 235:7 241:22 |
| changing 77:21 | 128:18,19 130:19 | civil 1:6,13,20 5:5 | 265:7 271:24 |
| 78:7 79:3,12 | 132:11 253:2 | 7:19 12:7 237:16 | 306:8 325:7,22 |
| 157:15,16 261:19 | 301:5 309:11,13 | 347:5 348:5 | 326:21 327:23 |
| chapter 344:15 | child 45:5 93:6 | civilization 167:7 | clearer 270:6 |
| 345:7 | 133:12 147:21 | civilizations 166:7 | clearly 43:2,15,24 |
| characteristics | 174:8 264:21 | claim 245:7 | 81:20 146:19 |
| 135:8 159:17 | childhood 205:15 | claims 326:20,22 | 147:15,22 157:24 |
| 243:14 | | | 187:23 260:21,24 |
| | | | |

[clearly - coming] Page 13

| | | I | T |
|----------------------------|-------------------------|--------------------|---------------------------|
| 263:1 264:19 | code 71:1 344:16 | 219:17 220:1 | 75:23,24 77:5,10 |
| 265:5,21 266:18 | 345:7 | 221:17,23 225:22 | 264:9 |
| 272:13 | codeine 258:14 | 226:5,20 227:19 | collect 246:14 |
| cleveland 346:2 | coff 226:16 | 228:15 229:2,17 | collected 20:17 |
| client 17:22 | coffee 226:17 | 230:3 231:11 | 101:3 |
| 238:20 240:8 | cognitive 320:15 | 232:7,22 233:20 | collecting 58:10 |
| client's 272:3 | colantonio 3:3 4:3 | 234:13 235:4,13 | college 68:16 69:7 |
| clients 234:18 | 8:20,20 12:11,16 | 235:16,20 236:7 | 121:1 |
| 289:16 | 14:23 15:2 16:9 | 236:22 237:10,17 | colloquial 119:15 |
| clinic 64:23 68:12 | 16:24 17:18,20 | 237:24 238:12 | combination |
| 71:16 73:3,10 | 18:21 23:7,11,19 | 239:9 241:6 | 279:13 321:21 |
| 74:2 276:8 277:10 | 23:24 24:6 25:2,7 | 248:10 249:22 | combinations |
| 277:10 | 26:6,8,20 27:1 | 250:18 252:9 | 279:4 |
| clinical 40:1 71:13 | 28:21 30:4,16,23 | 261:15,23 266:2 | combine 160:17 |
| 72:14,15 75:9 | 31:11 33:1,15,19 | 266:22 267:2,13 | combined 70:13 |
| 120:20 121:4,9 | 34:2,18 48:1 | 267:21 268:4,14 | 279:5 |
| 142:20 | 49:18 50:13 51:5 | 270:3 271:2,10 | come 22:14,23 |
| clinics 64:9 74:17 | 51:8,13 52:19 | 272:20 279:21 | 29:20 45:23 56:13 |
| 138:13 | 53:15 59:20 62:4 | 280:8 286:20 | 56:14 74:15 81:23 |
| clock 43:10 | 68:3 73:14 87:13 | 287:5,7,12,18,24 | 82:16 84:16 88:1 |
| close 114:7 331:13 | 88:6 99:14,23 | 288:3,9,15 289:3 | 94:4 109:17 |
| 338:13 | 100:2,5 104:16 | 289:21 290:2,13 | 114:17 142:12 |
| closely 42:12 | 106:1,15 108:9 | 290:24 291:4,8 | 148:23 150:14 |
| 123:22 290:22 | 114:20 115:12,13 | 294:22 299:1 | 161:5 185:7 |
| closer 187:13 | 115:18,21 116:2 | 304:8,15,20 308:3 | 193:16 200:2 |
| closest 113:23 | 117:11,19 118:1,9 | 310:11 312:18 | 201:2,20 222:15 |
| 193:2 214:20 | 118:13,19 119:5 | 322:7,24 323:13 | 224:12,13 226:19 |
| 331:11 | 119:18,19 179:24 | 326:16 327:1,9 | 232:11 238:19 |
| closet 149:18 | 180:3,7,12,16,20 | 328:4 332:18 | 249:2 260:19 |
| 223:10 | 181:11,13,21 | 338:3 339:2,4 | 298:21 342:3 |
| coach 50:11 | 185:13,16 186:12 | 342:14 343:7 | comes 32:2 85:17 |
| coached 50:8 | 186:16 187:8 | 346:5 | 88:15 92:1 107:5 |
| cobble 324:10 | 193:7,10 195:4,9 | colantonio's 229:1 | 147:4 201:15 |
| 325:16 | 198:23 199:5,18 | 229:5,16 230:2 | 215:13 272:8 |
| cocaine 307:7,11 | 200:13 202:13 | 236:6 237:4 | 334:22 |
| 307:12,14,20,23 | 203:14,24 205:20 | 238:10,17 239:11 | coming 43:16 |
| 307:24 312:4 | 205:23 206:6 | 241:4,11 310:13 | 45:10 58:2 74:7 |
| 318:17 321:20 | 207:16,24 210:15 | 338:8 | 76:13 86:8 131:19 |
| 324:4 336:4,5,8 | 210:19,23 214:6 | cold 67:17 | 136:21 138:15 |
| cocktail 165:24 | 216:18,22 217:21 | colleagues 72:2 | 150:22 198:12 |
| | 218:8,10,22 219:5 | 73:8,20 74:11 | 215:23 259:22 |
| | Vonitoyt I o | , | |

[coming - conducted]

| 2603: 285:21 comment 267:3 comment 267:3 comment 267:3 comment 267:3 comment 267:3 committee 6:10 commaission 305:13 336:8 compelling 147:2 compered 77:10 competed 77:10 compered 77:10 competed 77:10 compet | 260 2 205 21 | | . 157.10 | 1 77 10 |
|---|-------------------|-----------------------|-----------------------|-------------------|
| comments 123:24 187:15 297:23,24 298:18 committee 6:10 142:16 161:23 254:16 255:18 321:3,12,15 comparisons 335:23 concerning 70:3 116:19 143:1 7:16 78:18 183:20 240:3 259:3 309:24 310:4 329:9,18 344:17 2349:25 344:5 common 201:21 201:23 202:18 commonplace complete 97:9 complete 62:15,19 complete 62:15,19 complete 64:1,10 64:21 65:4 346:15 completely 276:19 conclusion 193:16 conclusion 193:16 conclusion 193:16 completely 276:19 201:22 24:2 329:5 344:5 communicated communicated communication completely 276:19 276:20 conclusions 116:18 146:6 318: 35:16 39:19 40:14 41:15 43:2 48:10,23 52:6 55:6 56:20 57:10 57:15,21 59:5 85:3 86:4 91:3,7 96:8 103:4 106:22 113:24 124:14 125:13 138:14 125:13 138:14 125:13 138:14 125:13 138:14 125:13 138:14 125:13 138:14 125:13 138:14 125:13 138:14 125:12 129:22 20:23 217:1 20:22 206:24 202:23 217:1 277:19 300:15 compare 137:24 147:10 202:16 330:2 337:1,20 commissioner's comprehensively concerns 20:31 64:21 65:4 346:15 completely 276:19 206:23 completics 103:1 completes 103:1 completes 103:1 completes 20:23 337:6 components 42:14 337:6 components 42:14 337:6 components 42:14 337:6 completely 276:19 206:23 207:3 220:19 conditions 66:9 69:18 141:2157:6 comprehensively 55:24 95:17 277:19 300:15 compurer 310:20 computer's 100:12 201:3 220:19 conditions 66:9 69:18 141:2157:6 comprehensively 212:1270:24 212:52 212:1270:24 212:1270:24 212:21 32:6 186:21 200:1,2 201:1,2 216:16 200:1,2 216:1 244:29 132:66; 238:3 commissioner's commissioners 17:1 3167:9 209:7 336:6 comperte 97:9 complaint 18:8,10 18:17,59:16 complete 62:15,19 completio 104:14 complete 104:10 complete 104:10 complete 62:15,19 comple | | | | |
| 187:15 297:23,24 254:16 161:23 254:16 255:18 254:16 254:14 254:16 256:18 254:16 255:18 254:16 254:14 254:16 254:14 254:16 256:18 254:16 254:14 254:16 254:14 254:16 254:14 254:16 256:18 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 254:14 254:16 25 | | | | · · |
| 298:18 254:16 255:18 321:3,12,15 compelling 147:2 304:23 concerns 323:18 commission 1:11 7:16 78:18 183:20 240:3 259:3 common 201:21 complaint 18:8,10 327:11 concludes 343:10 | | | _ | |
| commission 1:11 321:3,12,15 compete 97:9 concerns 323:18 240:3 259:3 309:24 310:4 201:23 202:18 common 201:23 202:18 complete 62:15,19 concludes 343:10 329:9,18 344:17 commonly 320:13 complete 64:21 65:4 346:15 conclusion 193:16 349:25 communicate 95:1 completely 276:20 20:3 220:19 conclusions 20:3 22:17 30:9 31:8 35:16 39:19 communication complex 103:5 106:23 complex 103:5 condition 143:12 196:4 197:22 condition 143:12 196:4 197:22 196:4 197:22 condition 131:3 condition 66:21 5:19 condition 60:18 14:12 196:4 197:22 condition 131:3 condition 60:18 14:12 196:4 197:22 condition 60:18 14:12 196:4 197:22 condition 60:18 14:12 < | | | | |
| 7:16 78:18 183:20 240:3 259:3 309:24 310:4 329:9,18 344:17 347:19 348:25 commissioned 144:22 224:2 329:5 344:5 communicate 9:15 18:15 19:17 20:3 22:17 30:9 31:8 35:16 39:19 40:14 41:15 43:2 48:10,23 52:6 55:6 56:20 57:10 57:15,21 59:5 85:3 86:4 91:3,7 91:12,23 92:24,9 96:8 103:4 106:22 113:24 125:13 138:14 12 | | | | |
| 240:3 259:3 common 201:21 18:17 59:16 concludes 343:10 309:24 310:4 201:23 202:18 complete 62:15,19 conclusion 193:16 329:9,18 344:17 347:19 348:25 commonplace 44:7 completed 64:1,10 194:2 198:6 200:2 239:5 344:5 communicated 53:24 completion 104:14 completion | | · | | |
| 309:24 310:4 201:23 202:18 complete 62:15,19 conclusion 193:16 329:9,18 344:17 347:19 348:25 advine place 44:7 64:21 65:4 346:15 201:3 220:19 201:3 220:19 conclusions 106:23 completion 104:14 completion 104:14 completion 104:14 completion 104:14 completion 104:14 conclusions 106:23 conclusions 116:18 146:6 185:3 concurrent 297:6 conditions 143:12 196:4 197:22 conditions 143:12 196:4 197:22 conditions 66:9 69:18 141:21 196:4 197:22 conditions 66:9 69:18 141:21 177:13 37:6 69:18 141:21 197:13,16 211:20 197:13,16 211:20 | | | _ | - ' |
| 329:9,18 344:17 commonly 320:13 completed 64:1,10 194:2 198:6 200:2 201:3 220:19 349:25 44:7 completely 276:20 201:3 220:19 conclusions commissioned 144:22 224:2 329:5 344:5 completion 104:14 completion 104 | | | | |
| 347:19 348:25 commonplace 44:7 64:21 65:4 346:15 201:3 220:19 conclusions commissioned 144:22 224:2 102:24 completely 276:20 116:18 146:6 185:3 commissioner 53:24 communicated complex 103:5 concurrent 297:6 9:15 18:15 19:17 20:3 22:17 30:9 28:5 314:23 complexities 103:1 condition 143:12 20:3 22:17 30:9 28:5 314:23 communications complexities 103:1 196:4 197:22 condition 131:3 48:10,23 52:6 315:23 communities 50:3 81:4 113:19 compound 177:12 conditions 66:9 69:18 141:2 157:6 69:18 141:2 157:6 69:18 141:2 157:6 69:18 141:2 157:6 157:14 196:3 201:3 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 220:19 201:13 22 | | | _ | |
| 349:25 44:7 communicate ommunicate 276:20 conclusions 144:22 224:2 329:5 344:5 communicated 106:23 concurrent 297:6 9:15 18:15 19:17 20:3 22:17 30:9 28:5 314:23 complexities 103:1 condition 143:12 20:3 22:17 30:9 28:5 314:23 communications complexities 103:1 196:4 197:22 condition 143:12 48:10,23 52:6 315:23 communities 50:3 components 42:14 conditioning 71:3 48:10,23 52:6 315:23 communities components 42:14 conditioning 71:3 48:10,23 52:6 315:23 community 47:1 compound 177:12 conditioning 71:3 57:15,21 59:5 81:4 113:19 compound 177:12 conditions 66:9 81:12,32 4 124:14 84:6,18 85:7,8 86:13 135:20 25:24 95:17 25:13 138:14 49:4,15 52:10 143:7 161:18 137:6,7,8 150:2 192:22 206:24 202:23 217:1 225:11 259:13 277:19 300:15 <td></td> <td>-</td> <td>_</td> <td></td> | | - | _ | |
| commissioned communicate 95:1 276:20 116:18 146:6 185:3 329:5 344:5 communicated 53:24 complex 103:5 condition 143:12 196:4 197:22 condition 143:12 197:13 condition 143:12 196:4 197:22 condition 143:12 197:13 197:13 197:13 197:13 197:13 <td></td> <td>_</td> <td></td> <td></td> | | _ | | |
| 144:22 224:2 102:24 communicated complex 103:5 concurrent 297:6 329:5 344:5 53:24 communication complex 103:5 condition 143:12 9:15 18:15 19:17 20:3 22:17 30:9 28:5 314:23 complexities 103:1 196:4 197:22 condition 143:12 31:8 35:16 39:19 40:14 41:15 43:2 48:10,23 52:6 315:23 complex 103:5 condition 143:12 48:10,23 52:6 315:23 communications 317:20 conditions 66:9 55:6 56:20 57:10 57:15,21 59:5 81:4 113:19 compound 177:12 conditions 66:9 85:3 86:4 91:3,7 80:12,16,18 81:1,6 177:1 337:6 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive 212:5,9 133:4 124:14 86:13 135:20 177:1 337:6 212:5,9 133:14 137:6,7,8 150:2 256:18 55:24 95:17 49:4,15 52:10 183:11,18 184:5 161:12 169:9 56:12 20:17 217:4 184:21 199:22 192:22 206:24 comprehensively 251:21 270:24 202:23 217:1 225:11 259:13 142: | | , | | |
| 329:5 344:5 communicated 53:24 complex 103:5 concurrent 297:6 9:15 18:15 19:17 20:3 22:17 30:9 28:5 314:23 complexities 103:1 196:4 197:22 condition 143:12 31:8 35:16 39:19 40:14 41:15 43:2 48:10,23 52:6 315:23 compliance 317:20 conditions 66:9 55:6 56:20 57:10 55:6 56:20 57:10 communities 50:3 81:4 113:19 components 42:14 337:6 components 42:14 conditions 66:9 85:3 86:4 91:3,7 community 47:1 compounds 65:22 177:1 337:6 157:14 196:3 197:13,16 211:20 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive conduct 47:24 49:4,15 52:10 133:11,18 184:5 161:12 169:9 56:12 56:12 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 56:12 201:7 217:4 202:23 217:1 225:11 259:13 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 147:10 202:16 336:2 337:1,20 299:18 201:1,2 216:16 20missioner's 147:13 167:9 concede 247:10 <td></td> <td></td> <td></td> <td></td> | | | | |
| commissioner 53:24 106:23 condition 143:12 9:15 18:15 19:17 20:3 22:17 30:9 28:5 314:23 complexities 103:1 196:4 197:22 condition 131:3 31:8 35:16 39:19 communications 29:12 94:15 317:20 conditions 131:9 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 communities 50:3 81:4 113:19 compound 177:12 conditions 66:9 85:3 86:4 91:3,7 community 47:1 compounds 65:22 197:13,16 211:20 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive 157:14 196:3 197:13,16 211:20 13:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 212:5,9 13:3:11,18 184:5 16:12 169:9 56:12 53:11,23 54:10 82:19 199:9 184:21 199:22 192:22 206:24 202:23 217:1 225:11 259:13 271:6 271:6 20:13 25:7 277:19 300:15 computer's 100:12 124:22 132:6 186:21 200:1,2 <td></td> <td></td> <td>_</td> <td></td> | | | _ | |
| 9:15 18:15 19:17 communication complexities 103:1 196:4 197:22 conditioned 131:3 31:8 35:16 39:19 40:14 41:15 43:2 29:12 94:15 317:20 conditions 131:9 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 57:15,21 59:5 81:4 113:19 components 42:14 69:18 141:2 157:6 85:3 86:4 91:3,7 66:8 103:4 106:22 81:14 82:23 83:7 88:14 82:23 83:7 177:1 337:6 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 86:13 135:20 256:18 212:5,9 131:9 compound 177:12 157:14 196:3 197:13,16 211:20 131:9 compound 177:12 157:14 196:3 197:13,16 211:20 20:11:2,23 92:2,4,9 80:12,16,18 81:1,6 177:1 337:6 212:5,9 40:14:4:14 86:13 135:20 55:24 95:17 49:4,15 52:10 143:7 161:18 137:6,7,8 150:2 256:18 201:17 217:4 256:12 184:21 199:22 192:22 206:24 202:23 217:1 225:11 259:13 229:18 | 329:5 344:5 | | _ | |
| 20:3 22:17 30:9 28:5 314:23 compliance conditioned 131:3 31:8 35:16 39:19 40:14 41:15 43:2 29:12 94:15 317:20 conditioned 131:9 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 communities 50:3 81:4 113:19 compound 177:12 conditions 66:9 85:3 86:4 91:3,7 go:12,16,18 81:1,6 compound 177:12 157:14 196:3 197:13,16 211:20 96:8 103:4 106:22 81:14 82:23 83:7 compounds 65:22 177:1 337:6 212:5,9 113:24 124:14 86:13 135:20 177:1 337:6 212:5,9 conduct 47:24 143:7 161:18 137:6,7,8 150:2 256:18 53:11,23 54:10 53:11,23 54:10 184:21 199:22 192:22 206:24 comprehensively 82:19 199:9 251:21 270:24 202:23 217:1 250:11 259:13 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 336:2 337:1,20 concede 247:10 201:1,2 216:16 328:22 | | 53:24 | | condition 143:12 |
| 31:8 35:16 39:19 communications compliance 131:9 40:14 41:15 43:2 29:12 94:15 317:20 conditions 66:9 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 communities 50:3 81:4 113:19 compound 177:12 conditions 66:9 85:3 86:4 91:3,7 community 47:1 compounds 65:22 177:1 337:6 157:14 196:3 | 9:15 18:15 19:17 | communication | complexities 103:1 | 196:4 197:22 |
| 40:14 41:15 43:2 29:12 94:15 317:20 conditioning 71:3 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 81:4 113:19 69:18 141:2 157:6 85:3 86:4 91:3,7 community 47:1 157:14 196:3 96:8 103:4 106:22 81:14 82:23 83:7 compounds 65:22 197:13,16 211:20 113:24 124:14 84:6,18 85:7,8 55:24 95:17 conduct 47:24 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 250:22 32:2 336:2 337:1,20 compared 110:19 10:12 299:18 143:6 147:13 167:9 concede 247:10 201:1,2 216:16 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 20:3 22:17 30:9 | 28:5 314:23 | compli 286:21 | conditioned 131:3 |
| 48:10,23 52:6 315:23 components 42:14 conditions 66:9 55:6 56:20 57:10 57:15,21 59:5 81:4 113:19 69:18 141:2 157:6 69:18 141:2 157:6 85:3 86:4 91:3,7 community 47:1 compound 177:12 157:14 196:3 197:13,16 211:20 96:8 103:4 106:22 81:14 82:23 83:7 compounds 65:22 177:1 337:6 212:5,9 13:24 124:14 84:6,18 85:7,8 55:24 95:17 212:5,9 conduct 47:24 13:21 138:14 86:13 135:20 256:18 53:11,23 54:10 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 56:12 184:21 199:22 192:22 206:24 comprehensively 251:21 270:24 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer's 100:12 124:22 132:6 310:3 326:2 337:1,20 concede 247:10 201:1,2 216:16 20missioner's 147:13 167:9 concepts 69:23 217:20 218:1 143:6 | 31:8 35:16 39:19 | communications | compliance | 131:9 |
| 55:6 56:20 57:10 communities 50:3 337:6 69:18 141:2 157:6 57:15,21 59:5 81:4 113:19 compound 177:12 157:14 196:3 157:14 196:3 81:12,23 92:2,4,9 80:12,16,18 81:1,6 80:12,16,18 81:1,6 212:5,9 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 86:13 135:20 212:5,9 200 13:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 49:4,15 52:10 143:7 161:18 137:6,7,8 150:2 256:18 53:11,23 54:10 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 201:17 217:4 184:21 199:22 192:22 206:24 225:11 259:13 277:19 300:15 277:19 300:15 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 336:2 337:1,20 299:18 186:21 200:1,2 201:1,2 216:16 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 217:20 218:1 commissioner's 147:13 167:9 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 40:14 41:15 43:2 | 29:12 94:15 | 317:20 | conditioning 71:3 |
| 57:15,21 59:5 81:4 113:19 compound 177:12 157:14 196:3 85:3 86:4 91:3,7 80:12,16,18 81:1,6 177:1 337:6 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive conduct 47:24 113:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 205:11 259:13 250:21 251:7 277:19 300:15 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 48:10,23 52:6 | 315:23 | components 42:14 | conditions 66:9 |
| 85:3 86:4 91:3,7 community 47:1 compounds 65:22 197:13,16 211:20 91:12,23 92:2,4,9 80:12,16,18 81:1,6 177:1 337:6 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive conduct 47:24 113:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 277:19 300:15 computer's 100:12 124:22 132:6 310:3 326:2 336:2 337:1,20 299:18 186:21 200:1,2 238:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 55:6 56:20 57:10 | communities 50:3 | 337:6 | 69:18 141:2 157:6 |
| 91:12,23 92:2,4,9 80:12,16,18 81:1,6 177:1 337:6 212:5,9 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive conduct 47:24 113:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concepts 69:23 217:20 218:1 143:6 147:13 167:9 53:22 73:13 75:2 296:23 315:5 | 57:15,21 59:5 | 81:4 113:19 | compound 177:12 | 157:14 196:3 |
| 96:8 103:4 106:22 81:14 82:23 83:7 comprehensive conduct 47:24 113:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 85:3 86:4 91:3,7 | community 47:1 | compounds 65:22 | 197:13,16 211:20 |
| 113:24 124:14 84:6,18 85:7,8 55:24 95:17 49:4,15 52:10 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 299:18 186:21 200:1,2 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 compared 110:19 147:13 167:9 concerts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 91:12,23 92:2,4,9 | 80:12,16,18 81:1,6 | 177:1 337:6 | 212:5,9 |
| 125:13 138:14 86:13 135:20 256:18 53:11,23 54:10 143:7 161:18 137:6,7,8 150:2 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 20mpromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 147:10 202:16 299:18 186:21 200:1,2 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 compared 110:19 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 96:8 103:4 106:22 | 81:14 82:23 83:7 | comprehensive | conduct 47:24 |
| 143:7 161:18 137:6,7,8 150:2 comprehensively 82:19 199:9 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 299:18 186:21 200:1,2 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 113:24 124:14 | 84:6,18 85:7,8 | 55:24 95:17 | 49:4,15 52:10 |
| 183:11,18 184:5 161:12 169:9 56:12 201:17 217:4 184:21 199:22 192:22 206:24 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 299:18 186:21 200:1,2 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's compared 110:19 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 125:13 138:14 | 86:13 135:20 | 256:18 | 53:11,23 54:10 |
| 184:21 199:22 192:22 206:24 compromise 251:21 270:24 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 computer's 100:12 124:22 132:6 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 143:7 161:18 | 137:6,7,8 150:2 | comprehensively | 82:19 199:9 |
| 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 299:18 124:22 132:6 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 183:11,18 184:5 | 161:12 169:9 | 56:12 | 201:17 217:4 |
| 202:23 217:1 225:11 259:13 142:19 271:6 250:21 251:7 277:19 300:15 computer 310:20 conducted 7:21 300:9 309:23 compare 137:24 299:18 124:22 132:6 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 147:13 167:9 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 184:21 199:22 | 192:22 206:24 | compromise | 251:21 270:24 |
| 300:9 309:23 compare 137:24 computer's 100:12 124:22 132:6 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 143:6 147:13 167:9 concepts 69:23 217:20 218:1 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 202:23 217:1 | 225:11 259:13 | _ | 271:6 |
| 300:9 309:23 compare 137:24 computer's 100:12 124:22 132:6 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's 143:6 147:13 167:9 concepts 69:23 217:20 218:1 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 250:21 251:7 | 277:19 300:15 | computer 310:20 | conducted 7:21 |
| 310:3 326:2 147:10 202:16 299:18 186:21 200:1,2 328:22 336:2 337:1,20 concede 247:10 201:1,2 216:16 commissioner's compared 110:19 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 300:9 309:23 | compare 137:24 | | 124:22 132:6 |
| commissioner's compared 110:19 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | 310:3 326:2 | 147:10 202:16 | _ | 186:21 200:1,2 |
| commissioner's compared 110:19 concepts 69:23 217:20 218:1 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | | 336:2 337:1,20 | concede 247:10 | / |
| 143:6 147:13 167:9 concern 53:10,13 243:5 266:3 285:3 commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | commissioner's | / | concepts 69:23 | · · |
| commissioners 209:7 336:6 53:22 73:13 75:2 296:23 315:5 | | _ | _ | |
| | | | <u> </u> | |
| | | | | |
| | | 1 | | |
| | | | | |

[conducting - cord] Page 15

| | I | I | I |
|---------------------------|---------------------------|---------------------------|------------------------|
| conducting 19:10 | consider 30:19 | contain 142:7 | 49:23 125:11 |
| 83:17 84:7 199:20 | 66:21 141:16 | contained 185:9 | 137:19 154:19 |
| conference 5:21 | 143:23 208:8 | contains 15:7 | 171:10,13 195:1 |
| 303:18 305:4 | 209:19 210:4 | 219:21 | 254:19 255:23 |
| conferencing 7:22 | 211:12 212:16,17 | contaminated | 281:7,19 294:20 |
| confidence 159:21 | 213:24 214:2 | 179:3 | 294:24 296:17 |
| confidential 85:15 | 268:9 269:22 | contamination | 300:16 |
| confines 135:4 | 337:14 | 277:4 | controlled 36:13 |
| 329:13 | consideration | contd 3:1 6:1 | 37:22 38:17 39:1 |
| confirm 231:6 | 196:11 212:20 | contemporary | 39:13 40:10,19 |
| confirmation | considered 234:3 | 5:22 81:3 142:23 | 42:1,14 48:4 |
| 72:13 | 236:16 329:10 | 303:20 | 49:24 50:9,22 |
| conflate 28:10 | considering | content 322:14 | 51:1 89:11 94:2 |
| conform 250:1,2 | 208:10 | context 33:13 | 127:9,10 189:21 |
| conforms 202:18 | considers 321:15 | 55:12,15 59:13 | 189:22 191:1 |
| confounded 170:5 | consistent 214:8 | 144:24 149:11 | 213:20 247:14 |
| confused 210:20 | 214:11,22 216:12 | 221:5,19 223:2 | 250:6 251:12 |
| 213:7 218:23 | 285:24 305:20 | 256:24 257:19 | 257:22 270:8,17 |
| 316:7 | 322:4,9 | 260:18 267:15 | controlling 45:7 |
| confusing 26:10 | consistently | 322:8,10,15 323:8 | 199:13 264:8 |
| 40:9 304:14 | 167:19 | 324:1,6,8 326:7 | conversation |
| congress 255:18 | construed 144:8 | continue 7:10 80:8 | 25:10 54:14 72:6 |
| 326:24 | 327:11 | 99:19 141:5 | 161:3 289:5 |
| connection 21:12 | consult 69:2 72:12 | 153:23 169:17 | 304:23 |
| 118:24 123:21 | consultant 34:21 | 278:13 | conversations 7:6 |
| 176:21 283:20 | 227:6,17 228:2,13 | continued 17:15 | 17:1,15 27:15 |
| connolly 2:11 8:12 | 230:6,8,12,18 | 52:24 54:24 73:2 | 52:11 54:10,12 |
| consensus 259:14 | 231:1,16,21,24 | 115:1 136:11 | convert 179:17 |
| consequence 79:1 | 232:24 234:10 | 150:10,18,19 | convey 209:24 |
| 132:1,1 140:19 | 241:7,12,16,18,24 | 180:24 226:24 | 210:2 |
| 222:21 243:12 | consulting 229:15 | 240:20 275:16 | conway 124:7 |
| 285:19 | 230:1,1 236:6,15 | 291:13 328:9 | cool 328:3,4 |
| consequences | 238:9 241:4 288:4 | 333:9 | cop 253:9 |
| 22:12 40:16 56:4 | consumed 75:17 | continuing 230:13 | copied 339:24 |
| 67:22 72:20 75:21 | 330:9 | contradictory | copies 19:13 |
| 96:17 99:5 106:6 | contact 17:6,11 | 70:1 | copy 12:18 13:6 |
| 137:7 139:12,24 | 25:16,24 28:11 | contribute 325:3 | 24:1 218:20 |
| 149:4 154:17 | 29:17 40:17 86:1 | contributing | 298:20 |
| 172:17,22 | contacted 27:3,6 | 301:6 | copying 15:21 |
| conservative | 28:14 59:6 241:23 | control 6:12 44:19 | cord 170:7 |
| 174:22,23 | | 44:24,24 45:6 | |
| , | | | |
| Varitant Lagal Solutions | | | |

[cordamine - court] Page 16

| | | | I |
|------------------------|--------------------|-------------------------|---------------------------|
| cordamine 334:23 | 228:3,14 231:12 | correlates 103:23 | county 1:11 5:5 |
| core 330:22 | 231:22 234:12,23 | correlation 113:10 | 6:3 7:16 12:7 17:2 |
| corner 61:19 | 243:6,9 244:4 | 166:11 312:16 | 21:18 22:9 27:4 |
| 100:20 176:12 | 248:9 249:9 250:8 | cortex 153:10 | 28:16 30:7,8 31:6 |
| 276:13 310:22,23 | 250:11,14,15,23 | cost 45:2,5 172:24 | 32:8 44:3 70:13 |
| 317:17 | 251:3,17 252:5,6 | 174:11,19 | 70:18 71:7 97:3 |
| corp 8:17 | 253:15,22 257:10 | costs 97:18 174:6 | 115:8 117:17 |
| corporation 1:8 | 257:13 259:5,23 | 174:7,8,9,9 | 118:16,24 127:14 |
| 1:14 2:17 7:17 | 260:4 262:6 | council 48:13,14 | 127:17,18 133:18 |
| 56:19,23 57:6,14 | 269:16 270:18,21 | 51:24 85:4 128:8 | 137:10 138:16 |
| 59:3 346:6 347:3 | 271:1 272:19 | councils 128:6 | 140:1 148:7 |
| 348:3 | 274:3,7 275:18 | counsel 7:15 8:5 | 172:14 182:2 |
| correct 13:8,14 | 278:21 279:13 | 29:12,13,14,18 | 186:15,22 187:6 |
| 14:22 24:16,17 | 282:17 284:5,8,10 | 50:8,10 59:6 | 187:17 235:1 |
| 38:9,19 39:2,7 | 284:13,22 292:19 | 99:18,21 101:2,3 | 239:22 240:3 |
| 41:11,15,19,20 | 295:13 300:2 | 114:17 115:7,13 | 275:21 293:13,14 |
| 48:11,14,15,18,24 | 302:8,21 303:5 | 116:24 117:7,16 | 293:14 295:21 |
| 52:1,6 53:14,20,24 | 306:6,7,12,15,20 | 117:17,23 118:8 | 297:1,11 299:4 |
| 57:11 60:13 86:23 | 306:21,23 307:21 | 118:12 124:5 | 314:15 339:8 |
| 87:12 88:20 91:3 | 309:12,18 311:5 | 166:23 185:21,23 | 340:6,8,11,14,16 |
| 91:8 94:10,11 | 311:12,13,16,19 | 185:24 186:2 | 341:24 342:5,5,6 |
| 101:16 108:8,15 | 311:22 312:3,11 | 204:4,5 214:14 | 342:18,21 343:1 |
| 108:18,19 110:20 | 312:15 313:13 | 221:6 231:9 | 344:2,4 345:2 |
| 111:21,24 112:11 | 315:24 317:17,24 | 233:18 234:10,11 | 347:10 348:15 |
| 117:19 118:9,16 | 321:3 330:5,6 | 234:22,24 237:4 | couple 51:10 81:8 |
| 119:1,23 120:5,13 | 332:12,14,16 | 238:18 239:4,7 | 154:3 182:3 |
| 120:18 121:7,15 | 340:4,16,19,20 | 240:2 286:16 | 328:21 336:9 |
| 121:19,24 122:19 | 342:1 | 288:22 289:8 | course 49:14 |
| 123:14,17 127:15 | correction 112:18 | 290:19 297:12 | 93:11 102:8 |
| 129:5 140:11 | corrections 346:12 | 344:12,13 | 141:10 189:11,14 |
| 182:6,19 183:6,7 | 348:17 | counsel's 221:6 | 193:13 229:15 |
| 183:13,14,19 | correctly 80:14 | counseling 159:6 | 230:1 236:5 238:9 |
| 184:22 185:4,9 | 91:18 102:2 202:7 | counter 145:15 | 241:3 294:6 |
| 190:17,19 192:12 | 246:6,7 256:21 | 257:16,21 258:8 | courses 65:15,19 |
| 196:24 200:12,15 | 297:4 301:8,16 | country 50:2 | 69:11 70:2,5 |
| 202:12 203:7 | 306:3 315:7,13 | 80:24 97:8 104:23 | court 1:1 5:4 7:18 |
| 207:4 209:11 | 318:20 319:23 | 110:20 124:2 | 7:24 8:24 12:7 |
| 210:10 211:4,9,10 | 320:17 322:2 | 126:20 129:19 | 14:11 26:5 187:9 |
| 213:21 214:5 | 344:9 | 132:24 147:18 | 227:11 228:7,17 |
| 215:12 216:17 | correlate 114:1 | 205:12 256:11 | 228:23 230:4,5,15 |
| 223:24 227:7,18 | | 273:4 280:11 | 230:17 231:4 |
| | Varitant I ac | | |

[court - days] Page 17

| 236:2 253:20 | 98:1,7 99:5 | 62.10.21.04.9 | 225.0 12 226.1 7 |
|-----------------------|-------------------------|---------------------------------|--|
| 308:19,24 347:7 | 101:23 102:9,11 | 63:19,21 94:8 cursory 314:11 | 335:9,13 336:1,7 337:24 342:7,8,8,9 |
| courteous 17:14 | 101.23 102.9,11 | curve 196:7,10 | |
| | 128:13 133:22 | · | 342:11,19 database 90:9 |
| courtesy 27:12 | | cut 14:19 164:9,16 | |
| 28:4,18 | 136:8 139:17 | 170:7,8 179:3 | 249:20 250:20 |
| courtroom 13:17 | 142:23 144:23 | 228:21 254:5 | 251:12 |
| cover 64:5,16,16 | 145:1 156:16 | 283:8 292:6 | date 25:4,6 36:21 |
| 183:3 255:1,8 | 158:10 163:23,24 | ev 128:6 | 55:9 61:12,14 |
| 295:12 298:19 | 164:1,2,2 169:2 | cycling 173:17 | 102:6 207:9,10 |
| 299:20 304:6,12 | 242:1 254:18 | czar 125:14 | 209:10 317:21,23 |
| 304:18 309:7,8 | 255:22 256:6,8,12 | d | 346:8 347:3,9,19 |
| 338:16 | 275:14,14 279:1 | d 7:1 9:4 | 348:3,13,25 |
| coverage 74:5 | 321:16,19 324:2 | daily 58:15 65:22 | 349:20,25 |
| covid 116:4 | 329:10,15,24 | 66:8 69:15 73:21 | dated 5:3,7,10,13 |
| covington 2:19 | 330:4,23 | 98:12 128:3 133:5 | 5:15,18,21,23 6:4 |
| 8:15,16 117:1 | criteria 202:3 | 137:4 165:18 | 6:6,13,16,20 12:5 |
| craig 174:5 | crook 155:6 | 200:5 201:7 | 24:10,11 99:10 |
| create 42:21 | cross 124:15 | dam 46:7 137:24 | 101:9 182:13 |
| 101:14 124:19 | 248:23 | 138:1,5 | 206:4 246:21 |
| 125:10 128:13 | crouch 313:13 | dan 341:6 | 254:19 255:9 |
| 175:22 316:14,16 | 314:14 315:3 | daniel 341:6 | 295:5 299:12 |
| created 96:6 | 316:2 | dark 136:6 245:11 | 300:1,3 303:19,22 |
| 101:11,12 177:19 | crr 344:20 | dashboard 285:20 | 308:8,10,14 313:2 |
| 220:12 | cry 165:9 178:10 | data 5:20 58:10 | 316:6 321:5 339:9 |
| credible 46:22 | 218:2 | 68:5 74:9 75:3,7 | 340:2,18 |
| 214:16 | crying 168:22 | 79:8 83:11,22 | dates 17:7 62:11 |
| credibly 215:17 | csi 124:23 | 96:10 111:9,13,18 | david 2:14 8:13 |
| crescendo 246:3 | csmp 89:12 248:23 | 112:1,3,6 114:2 | day 1:21 51:4 58:8 |
| criminal 45:14 | 249:2 250:11,13 | 132:23 134:20,24 | 74:4 92:3,6,6 |
| 93:7 253:10 | 250:23 251:6,8,17 | 135:2 190:6 | 105:16 107:17 |
| 256:12 | 252:1,13,13,16 | 202:20 203:19,20 | 114:11 131:19 |
| crises 72:18 95:20 | ct 6:23 23:15 | 202:20 203:19,20 | 176:7 212:5 216:2 |
| crisis 6:11 11:8,15 | ct2 6:21 99:11 | | 263:15 265:16 |
| 11:20 32:6,20,21 | curb 47:18 86:8 | 220:6,14,15 248:23 249:1 | 267:9 273:17 |
| 32:22 34:14 35:12 | cure 163:21 | 250:7,11 251:17 | 275:8 276:21 |
| 40:16 42:20 45:9 | cured 158:13 | 250:7,11 251:17 | 296:22 338:19 |
| 45:24 49:10 52:14 | current 26:19 | | 342:16 344:17 |
| 52:23 55:16,17,24 | 37:21 56:7 164:2 | 296:7 303:17 306:13 318:10 | 345:10 347:16 |
| 56:8,12 59:9 81:3 | 209:16 311:17 | | 348:22 349:22 |
| 83:4 94:16 95:1 | currently 28:19 | 323:8 325:12,18 | days 126:5 127:7 |
| 95:13 96:2,10 | 29:7 30:12,14 | 325:19,21,23 | 149:15,16,21,23 |
| , | | 331:2,18,23 332:6 | |

[days - deponent] Page 18

| 156:3 159:24 | 138:6 158:18 | decision 59:18,24 | 107:22,23 |
|---------------------------|-------------------------|--------------------------|--------------------------|
| 160:24 168:20 | 161:5 166:21 | 242:9 271:7 | demanding 155:20 |
| 221:12 223:7,7,13 | 243:12,13 244:3 | decisions 28:7 | demographic |
| 223:15,20 224:9 | 246:20 302:12 | 75:8 | 193:19 199:14 |
| 224:15 225:8,10 | 331:15 | decline 264:23 | 205:1 207:21 |
| 225:12,14,18 | deaths 5:23 22:6 | declines 124:10 | 211:3,6 |
| 247:14 260:20 | 43:4 58:8 105:11 | 275:11 307:3 | demographics |
| 346:18 | 124:21 127:6 | decrease 111:20 | 195:15 206:13 |
| dc 2:12,21 | 130:22 131:1 | 111:23 275:10 | 213:24 |
| dea 35:22 36:1,5,8 | 156:9 162:8,9,12 | decreased 146:18 | demonstrate |
| 36:11,11,16,20,20 | 162:20,23 167:11 | deed 347:14 | 92:18,22 124:5 |
| 39:13,17 40:6,23 | 167:13,13 168:4 | 348:20 | demonstrated |
| 53:4,7 87:10 | 182:12,19 183:4 | deemed 346:19 | 280:1 |
| 93:13,21 112:14 | 218:14 243:9,15 | defects 170:21,21 | demonstrates |
| 112:16 189:16,18 | 243:16,17,24 | 170:22,23 | 274:22 283:17 |
| 190:8,15,20 191:1 | 256:10,16 274:16 | defend 179:11 | 331:3 |
| 249:9 270:20 | 301:7 302:7,18 | defendant 2:10,17 | demonstrating |
| 292:21 | 303:6,8,9,22 305:9 | 9:5 | 93:8 |
| dea's 191:10 | 306:2,6,9,10,16 | defendants 1:9,15 | dental 143:13 |
| dead 125:1 131:5 | 307:12,20,23 | 1:19 7:15 9:12 | dentist 260:20 |
| 131:11,15 135:9 | 318:12,18 331:12 | 11:11 21:20,21 | department 22:22 |
| 165:15 | 342:16,17,18,20 | 257:3 258:6,12 | 59:7 70:13,14,15 |
| deadly 67:4,21 | 342:20 343:1 | deficit 171:12 | 91:1 121:21 |
| 98:10 | decade 192:19 | define 151:14 | 124:15 296:18 |
| deal 58:14 128:2,7 | 193:14,17,20 | 312:13 | 297:3 301:1 314:2 |
| 133:4 134:8,9 | 200:23 201:24 | definitely 83:15 | 317:15 326:1 |
| 136:5 140:24 | 202:5,9,11 203:5 | definition 151:15 | 346:22 |
| 281:24 | 203:22 204:2 | degree 60:3,5,16 | departments 31:7 |
| dealer 276:19,20 | 213:17 214:21 | 63:5 90:11 119:22 | 175:20 302:19 |
| dealers 165:8 | 319:17 325:1 | 139:5,7,17 181:17 | depend 272:11 |
| dealing 58:8 103:2 | decades 205:6 | 194:17 195:2 | depending 28:22 |
| 130:10 136:19 | decedents 132:8 | 210:13 211:9,24 | depends 88:22 |
| 164:1,7 167:10 | 132:14 248:14,19 | degrees 60:15 | 89:2,3 |
| dealings 11:20 | december 127:20 | 62:13 201:13 | depo 180:5 187:19 |
| dealt 97:6 130:4 | 127:21 255:9 | delhi 60:7 119:23 | deponent 3:2 |
| 135:13 | 300:3,5 303:5 | delivered 15:4 | 23:21 29:22 54:20 |
| dear 346:10 | decently 72:13 | 130:13 148:6 | 62:5 114:21 |
| death 6:6 58:15 | decided 76:3 | 168:7 170:8 | 115:19 185:12 |
| 103:23 113:11 | 84:13 | demand 101:24 | 210:18 279:22 |
| 124:11 125:3,4 | deciding 90:9 | 102:4 103:12 | 323:4,16 338:22 |
| 126:6,11 127:7 | | 105:2 107:13,19 | 343:5,16 |
| | | | |

[deposed - differentiate]

| deposed 10:18 | derivatives 301:13 | detectors 81:18 | 301:4 303:19 |
|---------------------|--------------------------|-------------------|---------------------------|
| 21:12 22:21 31:20 | describe 36:10 | determinant | 308:11,15 313:3 |
| 59:12 229:20 | 37:21 41:21 73:12 | 212:19 | 313:13 314:1 |
| deposited 168:6 | 86:10 129:8 297:7 | determinants | 315:3,11,12 341:7 |
| deposition 1:19 | 302:4,4 | 211:22 | 342:12 |
| 5:3 7:9,14,21 8:22 | described 120:15 | determination | diabetes 197:23 |
| 10:5,14 12:3,4,10 | 134:7,9 139:3 | 216:5 | diagnose 171:23 |
| 12:18,23,24 14:22 | 140:9 143:1 | determine 13:3 | diarrhea 81:12 |
| 15:8,14,16 18:20 | 160:22 | 190:9 192:21,21 | 82:11 168:24 |
| 19:8 20:7,11 | describes 90:18 | 199:15 202:11 | die 133:13,14 |
| 23:13,18 26:14 | 91:6 297:9 315:1 | 203:5,22 205:17 | 138:22 151:5 |
| 55:2 60:21 61:1 | 315:2,23 | 206:14 207:12 | 164:24 165:7,8 |
| 99:8,13 115:4 | describing 279:14 | 208:1,4 209:3 | 169:2 179:2 217:4 |
| 181:2 182:10 | description 96:5 | 215:2 285:3,9 | 276:24 |
| 185:20 219:12 | 105:20 | determined 30:24 | died 110:7,7 126:8 |
| 227:2,9,16,22 | designated 119:3 | 35:22 190:4 | 126:8,10 163:1 |
| 228:5,12 229:23 | 119:6 231:1,6 | 203:21 | 178:16 247:12,15 |
| 230:14,22 237:5 | 238:22 288:14,16 | determining | 248:17,21 331:15 |
| 238:18 239:16,17 | designation | 109:11 192:10,17 | 331:19 340:10,15 |
| 240:22 246:18 | 240:10 | 193:13 199:12,16 | dies 167:4 178:7 |
| 247:2 254:13,22 | designations 181:9 | 200:19,23 209:19 | difference 157:18 |
| 286:24 288:18 | desire 277:23 | 210:5 211:12 | 178:24 245:13 |
| 289:5,9,12 290:17 | desires 151:20 | 213:17 214:2,4 | 279:3 |
| 291:15 295:3,9 | destroyed 132:4 | devastating 56:7 | different 30:22 |
| 299:10,16 303:15 | 277:20 | devastation 59:10 | 56:2 67:10 69:2,6 |
| 303:24 308:6,17 | destruction 58:15 | develop 169:16 | 122:22 123:13 |
| 308:19 312:23 | 103:23 113:11 | 250:4 | 160:9 169:10 |
| 313:5 328:11 | 138:7 | developed 42:8 | 175:13 179:20 |
| 338:11 339:5,11 | detail 41:21 58:24 | 131:11 258:1,3,4 | 234:10,14 239:2 |
| 343:15 344:5,9,13 | 75:22 322:18 | 285:20 | 239:24 244:20 |
| 345:4 346:8,11 | detailed 148:20 | developing 169:22 | 278:17 280:21 |
| 347:1,3 348:1,3 | 200:3 201:5,9 | 170:2,5 258:7 | 285:15 298:12 |
| depositions 10:9 | detailing 95:13 | 281:23 | 314:15,18 324:18 |
| 18:14 185:22 | 96:2 | development | 325:14 329:17 |
| 186:3,3 239:10,19 | details 37:18 | 67:11 103:15 | 334:13,13,13 |
| 239:21 | 39:10 57:1 222:13 | 174:9 310:4 | 335:19 336:24 |
| depressants | 224:2 | develops 170:4 | 337:5,11,11 342:5 |
| 105:12 279:6 | detected 301:5,14 | dhhr 5:15,18,21 | 342:5 |
| depth 175:14 | 302:17 | 6:8,13,16 136:16 | differentiate 35:4 |
| 258:11 | detectives 81:18 | 175:19 246:24 | 168:16 |
| | | 254:20 255:8 | |
| | | | |

[differentiating - docs]

| differentiating | disabled 207:14 | disorder 5:17 | 51:17,21 52:10 |
|---------------------|-----------------------|--------------------------|----------------------------|
| 337:8 | 207:23 273:3 | 171:13 278:9 | 53:1,11,23 54:11 |
| differently 169:12 | disabling 140:17 | 308:12 309:17 | 58:22 77:3 190:10 |
| 263:17 | 140:21 | 324:15,17 325:9 | 246:12 247:7 |
| difficult 10:20 | discern 146:15 | 326:12 | 250:10 257:17 |
| 42:6 55:14 66:14 | disciplinary 91:17 | disorders 319:14 | 258:13,19 259:19 |
| 135:22 140:23 | disclosed 23:2 | 319:14,16 320:12 | 265:14 266:5,7,8 |
| 176:14 198:11 | 233:13,15 234:5 | dispense 39:5,13 | 266:11 268:20 |
| 224:24 298:8 | 239:6 289:17 | dispensed 43:18 | 270:9 274:3 |
| difficulty 45:6 | disclosure 233:24 | 88:5 89:24 90:1 | 292:22 294:20,23 |
| digits 64:18 | disconnected | dispensing 39:16 | district 1:1,1 7:18 |
| diligence 82:19 | 227:12 228:8 | 42:11 82:22 105:6 | 7:19 |
| 83:18 84:7 130:2 | discriminate | dispute 301:10,18 | diversion 44:9,11 |
| 265:16 266:4 | 177:16 | 301:23,24 302:2 | 46:2 149:6,24 |
| 273:22 | discuss 77:19 78:6 | 302:23 303:1 | 150:1,7 151:2 |
| dimes 128:14,20 | 98:23 99:3 102:10 | 318:22 | 154:16 156:5,6 |
| 128:22 173:3 | 107:12 113:6 | disrespecting | 157:18 163:14 |
| diminish 319:13 | 238:20 324:18 | 131:15 | 193:22 223:16 |
| diploma 63:2 | discussed 62:13 | dist 6:23 23:15 | 225:15 226:3,11 |
| direct 29:16 | 66:9 77:20 90:24 | distill 103:5 | 260:11 261:22 |
| 100:17 113:10 | 103:18 199:14 | 106:22 | 262:5,14,18 |
| 117:6 166:10 | 206:20 288:10 | distinction 232:6 | 280:15 291:18,20 |
| 296:14 | discusses 101:22 | 279:2 | 291:21 294:2,7 |
| directed 49:3 | discussing 66:11 | distribute 257:4,6 | 328:23 330:22 |
| 93:21 300:20 | 216:15 246:11 | 257:9,12 | diversions 163:21 |
| 315:3 | discussion 90:21 | distributed 266:16 | divert 154:23 |
| directing 231:2 | 96:5 99:3 103:13 | 300:15,21 | diverted 114:13 |
| direction 101:16 | 104:5,14,20 | distributing | 150:20 155:13,24 |
| 185:1 | 105:22 109:4,6,10 | 257:17 258:19 | 156:5,6 157:23 |
| directions 195:13 | 109:12,14 110:11 | distribution 35:14 | 163:16 166:11 |
| directly 136:7 | 110:16 225:9 | 35:19 39:16 40:10 | 169:4,7,15 178:20 |
| 137:19 169:3 | 227:10 228:6 | 40:12 41:7,14 | 178:24 204:12,14 |
| 268:24 331:22 | 235:19 242:7 | 42:1,10 48:21 | 216:7,7,8 249:1 |
| 335:4,16 341:3 | 329:3 340:6 | 105:5 137:22 | 260:10 262:4,19 |
| director 70:17 | discussions 53:24 | 193:21 292:17 | 278:10 280:12 |
| 123:23 127:1 | 95:3 289:10,11,19 | distributor 76:24 | divide 245:21 |
| 317:19 | disease 63:10 | 77:7,12 268:7,12 | divided 245:3 |
| directors 300:17 | 140:22 154:1,4 | 269:15 | doc 81:12 |
| disability 197:21 | 278:4,8,10,15 | distributors 35:24 | docs 44:20,21 76:7 |
| 208:4 209:2,6 | diseases 63:2 | 41:8 43:17 47:24 | 163:6 179:11 |
| 213:6 | 127:3 | 48:5 49:4,15 | 262:24 |
| | | | |

[doctor - drug] Page 21

| doctor 8:21 9:9 12:12,16 15:4,13 | 309:6,13,15 310:16 312:21 | 314:23 | 179:13,16 265:20 |
|---|------------------------------|-------------------------|--------------------------|
| 17.17 16 15./112 | 310·16 310·01 | 1 1 0 7 1 1 60 1 7 | · · |
| , , , | | doing 25:14 69:15 | 265:21 |
| 15:24 21:11 23:5 | 315:12 322:10,17 | 70:10 83:2 96:19 | downtown 68:21 |
| 23:23 24:9 25:15 | 323:1,11 325:7 | 103:24 115:22 | dr 5:3 12:4 187:15 |
| 27:3,22 29:11,13 | 326:6,21 328:13 | 130:1 131:13 | 227:15,20 228:11 |
| 29:20,24 30:2 | 328:18 338:5,17 | 133:1 138:11 | 228:16 315:10 |
| 31:3,18 32:18,23 | 339:13,17,21,22 | 175:10 183:17 | draft 34:12 61:16 |
| 33:3,11,17 34:11 | 343:3 | 198:4 263:2,7 | 142:6 297:13,16 |
| 34:19 35:7,13 | doctor's 119:22 | 269:5 272:12 | drafted 142:9 |
| 36:10 38:23 46:1 | 171:22 323:18 | 273:6,9 274:3 | dramatic 148:6 |
| 47:15 48:9 49:13 | 331:1 | 294:8 325:15 | 221:7 |
| 49:20 51:15 54:19 | doctors 46:14,21 | 327:19 333:16 | dramatically |
| 55:5 60:16,19 | 72:3 73:11 74:12 | dollars 97:19,19 | 318:12 319:16 |
| 61:5,13,18 62:20 | 74:19 112:15 | 138:17 174:12,17 | draw 79:15 |
| 73:7 79:14 94:8 | 196:15 198:4,7,20 | 174:18 329:19 | drink 152:13 |
| 98:17 100:1,14 | 332:3 | donate 73:3 | drinking 152:14 |
| 106:21 114:14 | document 24:23 | door 88:15 133:6 | 325:14 327:21 |
| 115:13,14,23 | 25:12 61:6,19 | dopamine 152:12 | 335:15 |
| 116:3,11 117:4,5 | 62:1 100:15 182:8 | 152:14,21 153:2,5 | drive 75:8,8 |
| 117:16,22 118:22 | 183:3 188:24 | 332:17,23 333:9 | 150:18 |
| 119:20 150:13 | 255:7,13 279:23 | 333:10,20 334:3 | driven 45:10 68:5 |
| 155:1 180:5 | 295:18 297:9,15 | 334:17 335:5,10 | 74:9 75:3 103:1 |
| 181:14 182:1,17 | 305:8 315:16 | 335:17,23 336:5 | driver 72:21 104:6 |
| 183:11 184:3 | 316:6,13,15,16 | 336:15,19 337:2,3 | 256:10 |
| 185:11,23 186:21 | 317:23 318:3 | 337:7,21 | drivers 104:8,11 |
| 187:4 188:1,7 | 322:12,13,16,16 | dora 6:14 312:24 | 104:15 105:23 |
| 191:23 198:17 | 322:20 326:23 | 313:8,10,17,18 | 106:14 107:6 |
| 199:7 203:4 | 339:14 | dose 153:8 276:23 | 108:6,12 109:12 |
| 205:18 210:9 | documentary | 277:1 334:7,10,14 | drives 159:21 |
| 211:1 213:8,16 | 123:2,6 | 335:11 | 278:15 |
| · · | documentations | double 320:9 | driving 71:20 |
| 219:8,20 221:1 | 15:18 | doubt 13:5 73:17 | 273:6 |
| · · · · · · · · · · · · · · · · · · · | documents 15:7 | 112:5 166:10 | dropped 74:8 |
| 242:24 244:7 | 15:10 18:6,19,23 | 168:8 313:15,19 | drops 277:9 |
| 247:5 248:24 | 19:7,10,11,15,19 | 315:21 320:1,19 | drove 150:17 |
| 254:12,24 255:11 | 19:20 20:1,1,6,13 | 341:14 | drowning 44:2 |
| 275:2 280:20 | 20:18,21 21:4,5 | douglas 2:14 | drug 1:7,14 5:23 |
| 286:8,14,17 | 62:1 93:2 100:24 | downstream 44:1 | 6:12 7:17 57:6,14 |
| 289:20 295:2,13 | 101:1,5 182:5 | 44:23 83:3 137:13 | 97:11 125:11,14 |
| 295:14,14 298:15 | 184:9 188:11 | 138:4,7,19,20 | 132:2 134:14 |
| 298:22 304:3,22 | 189:9 306:22,23 | 173:7 175:10 | 136:8 153:12 |
| | | | |

[drug - enforcement]

| 163:5 165:8 167:5 | duly 9:6 344:4,6,7 | easy 77:24 102:19 | elicited 199:10 |
|-------------------|-----------------------------------|---------------------|---------------------|
| 172:3 173:6 | duty 78:3 265:15 | 102:20 104:17 | 202:4 |
| 179:14 182:12,18 | dvts 75:21 | 134:21 | eligible 38:4 |
| 183:4 190:15 | dwarfed 150:24 | eat 152:9,10 | else's 293:17 |
| 247:13 253:13,20 | dying 46:9 98:2 | eating 56:8 | email 346:17 |
| 253:23,24 254:19 | 125:5 126:4 | eco 94:22 | emanate 94:4 |
| 255:23 258:19 | 151:10,10 | ed 297:3 | embed 134:15 |
| 276:19,20 278:3,5 | dynamics 106:9 | edges 45:8 | 135:6 251:15 |
| 278:19,20 279:10 | 144:10 | editor 283:13 | embedded 81:1 |
| 296:17 302:11 | e | editorial 123:13 | 251:18 |
| 303:4,21 306:6 | e 5:6,9,13,14,19 | educating 46:2 | emergency 64:5 |
| 311:12 312:14,14 | 6:2,5,14 7:1,1 | 82:12 | 74:3 285:22 |
| 320:13 333:8,17 | 17:6,8,12 27:10,13 | education 62:9 | 296:20 297:2 |
| 346:6 347:3 348:3 | 28:1,17 61:7,12,14 | 63:16 66:6 94:20 | 302:18 |
| drugs 47:14 82:22 | 242:21 246:19 | 95:18 133:18 | emerging 256:15 |
| 105:10 132:8,13 | 255:1,9 295:4,12 | 203:1 319:20 | 321:22 |
| 132:17,18,20,22 | 295:22 298:20 | educational | emperical 336:7 |
| 153:23 154:16 | 299:11,20 303:16 | 119:21 | emperically 335:9 |
| 158:11 163:11,14 | 304:6,12,19 308:7 | effect 246:3 | emphatic 147:8 |
| 163:16,17 165:24 | 308:9 309:7,8 | effects 137:1 138:4 | empirically 337:1 |
| 166:12 169:4,7 | 312:24 313:7,9,12 | 138:7 158:7,10 | 337:20 |
| 172:8 178:21 | 312:24 313.7,9,12 | 170:19 172:24 | employed 344:12 |
| 189:20 244:16,19 | 339:6,19,20,21,24 | 334:18 337:2,3,21 | 344:14 |
| 245:15,15 252:21 | | effort 98:11 | employee 56:16 |
| 252:21 253:14,22 | 340:2,5,13,18,21 | 142:22 148:10,18 | 57:3 135:7 251:18 |
| 254:2,7 256:15 | 341:3,4,9 earlier 39:4 77:2 | 222:3,11 | 252:1 344:13 |
| 258:2 274:12 | 85:19 86:1 128:9 | efforts 44:1 | employees 101:13 |
| 276:21 279:10 | 184:15 185:17 | 175:13 | ems 124:17 296:21 |
| 280:2,22 293:17 | 239:9 251:15 | eight 25:21 27:11 | enclosed 314:22 |
| 305:8,11,23 | 260:2 277:24 | 171:4 | 346:11 |
| 306:15,18,20 | 284:11 324:20 | either 17:2 135:1 | encounters 297:3 |
| 311:12 321:20 | 329:2,17 333:2 | 151:24 185:1 | ended 125:22 |
| 324:3 325:1,4 | 1 | 192:23 260:10 | 142:21 |
| dry 275:6 | early 169:1 283:12 earth 176:1 | 278:24 287:17 | ends 62:3 79:16 |
| drying 163:15,17 | earth 1/6:1 ease 323:18 | elected 293:15 | 101:20 104:13 |
| 179:16 | easier 62:7 100:19 | electronic 37:11 | 211:2 244:13 |
| due 82:19 83:17 | | 88:22 | 255:13 256:2 |
| 84:7 130:2 251:22 | 102:18 163:3,4 323:10 | electronically 21:2 | 282:9 317:4 |
| 265:16 266:3 | | elements 163:2 | enforcement |
| 273:22 277:23 | easily 100:8 east 2:15 | elevated 332:23 | 130:6 132:1 |
| | cast 2.13 | 334:2 | 134:19,23 163:5 |
| | | | , |

[enforcement - example]

| 165:3 190:15 |
|--|
| 294:19 68:24 214:3 224:16 324:4 evolve 163:23,23 engage 153:21 263:22 establishing 17:10 254:5 275:16 engaged 40:15 31:20 32:10 96:4 218:3 265:2 279:2 78:4 288:4 96:16 101:24 218:3 265:2 279:2 engagement 235:11 237:23 108:13,21 113:1 12:6 347:3 348:3 79:12 108:21 286:15 287:23,24 288:1 135:14 139:18 222:14 254:17 255:22 288:1 166:22 168:10 evans 1:21 7:24 256:6,9 275:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 ensuing 35:12 epidemics 96:16 event 148:9 222:2 exact 80:3 89:18 ensure 82:21 86:7 194:6 302:3 event 148:9 222:2 270:9 272:1 equally 57:5 262:13 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| engage 153:21 263:22 establishing 17:10 254:5 275:16 engaged 40:15 31:20 32:10 96:4 218:3 265:2 279:2 78:4 288:4 96:16 101:24 et 1:8,14 5:4 7:17 evolved 103:22 engagement 103:16 105:24 12:6 347:3 348:3 79:12 108:21 235:11 237:23 108:13,21 113:1 ethical 148:21 254:17 255:22 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 and 283:13 epidemics 96:16 epidemics 96:16 event 148:9 222:2 exact 80:3 89:18 ensuring 35:12 epidemiological event 205:15 333:22 exactly 17:7 40:2 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 eric 147:4 129:19 142:18 284:19 333:18 |
| 159:4 epidemic 5:17 estimate 217:7 evolved 103:22 78:4 288:4 96:16 101:24 et 1:8,14 5:4 7:17 evolving 6:11 engagement 103:16 105:24 12:6 347:3 348:3 79:12 108:21 25:11 208:21 235:11 237:23 108:13,21 113:1 ethical 148:21 254:17 255:22 256:6,9 275:13 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 345:3 event 148:9 222:2 282:12 285:7 ensuing 35:12 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 events 205:15 333:22 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| engaged 40:15 31:20 32:10 96:4 218:3 265:2 279:2 r8:4 288:4 96:16 101:24 et 1:8,14 5:4 7:17 evolving 6:11 engagement 103:16 105:24 12:6 347:3 348:3 79:12 108:21 235:11 237:23 108:13,21 113:1 ethical 148:21 254:17 255:22 286:15 287:23,24 135:14 139:18 222:14 256:6,9 275:13 england 283:13 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 enjoy 172:19 321:19 345:3 exact 80:3 89:18 enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 events 205:15 333:22 ensure 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 78:4 288:4 96:16 101:24 et 1:8,14 5:4 7:17 evolving 6:11 235:11 237:23 108:13,21 113:1 12:6 347:3 348:3 79:12 108:21 286:15 287:23,24 135:14 139:18 222:14 256:6,9 275:13 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 345:3 event 148:9 222:2 ensuing 35:12 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 eventually 156:4 292:17 262:13 279:19 288:17 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| engagement 103:16 105:24 12:6 347:3 348:3 79:12 108:21 235:11 237:23 108:13,21 113:1 ethical 148:21 254:17 255:22 286:15 287:23,24 135:14 139:18 222:14 256:6,9 275:13 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 event 148:9 222:2 exact 80:3 89:18 ensure 82:21 86:7 epidemiological events 205:15 333:22 ensure 82:21 86:7 194:6 302:3 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 50:4 51:2 64:15 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 235:11 237:23 108:13,21 113:1 ethical 148:21 254:17 255:22 286:15 287:23,24 135:14 139:18 222:14 256:6,9 275:13 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 enjoy 172:19 321:19 253:18 344:4,20 92:5 ensuing 35:12 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 events 205:15 333:22 eventually 156:4 292:17 262:13 279:19 288:17 50:4 51:2 64:15 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 286:15 287:23,24 135:14 139:18 222:14 256:6,9 275:13 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 345:3 exact 80:3 89:18 enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 288:1 166:22 168:10 evans 1:21 7:24 ex 5:4 12:5 91:13 england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 345:3 exact 80:3 89:18 enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| england 283:13 308:13 309:17 253:18 344:4,20 92:5 enjoy 172:19 321:19 345:3 exact 80:3 89:18 enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 eventually 156:4 50:4 51:2 64:15 292:17 262:13 eventually 156:4 50:4 51:2 64:15 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| enjoy 172:19 321:19 345:3 exact 80:3 89:18 enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| enormous 45:5 epidemics 96:16 event 148:9 222:2 282:12 285:7 ensuing 35:12 epidemiological events 205:15 333:22 ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| ensuing 35:12 epidemiological events 205:15 333:22 ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| ensure 82:21 86:7 194:6 302:3 exactly 17:7 40:2 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 270:9 272:1 equally 57:5 eventually 156:4 50:4 51:2 64:15 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 292:17 262:13 279:19 288:17 71:9 89:18 217:9 ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| ensuring 19:11 equivalent 170:10 everybody 115:15 231:13 282:15,24 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| 81:2 95:16 264:4 eric 147:4 129:19 142:18 284:19 333:18 |
| |
| 264:10 292:23 errata 12:19 175:18 176:5 exam 122:12 |
| |
| enter 36:20 89:23 346:13,18 348:7 264:11 265:17 examination 4:1 |
| 98:2 175:2 348:10,18 349:1 everybody's 9:7 116:1 117:6 |
| entered 348:9 erroneously 102:13 122:15 181:23 |
| entire 55:21 93:15 171:24 evidence 72:1 188:5 310:13 |
| 105:1 106:8 errors 13:8 74:10 75:3,8 328:16 332:18 |
| 108:14 154:20 escalation 153:7 102:24 126:1 338:8,23 |
| 172:13 175:23 334:7,10 159:2 186:20 examine 142:24 |
| 192:19 243:12 escape 102:9 193:23 199:1 143:2 |
| 262:21 277:19 especially 136:23 200:10 208:23 examiner 124:18 |
| 347:5 348:5 140:18 169:2 215:8 245:7 130:20 131:23 |
| entirety 106:8 337:19 259:18 263:5 132:11 301:5 |
| 109:7 esquire 2:3,4,6,11 274:9,10 316:23 309:12,13 |
| entities 27:6 2:13,14,18,19 3:3 317:11 321:15 examiner's 58:13 |
| 123:13,17 3:4,8,9 346:5 326:19 327:15,16 131:6 252:5,23 |
| entitle 231:23 essence 87:20 327:18 253:3 |
| entitled 1:20 6:10 142:19 168:17 evidentiary 180:5 example 41:7 |
| 117:5 230:6,16,24 essentially 103:14 evidently 231:8 67:13 75:12 76:1 |
| 254:16 316:22 125:23 128:3 evolution 109:1 81:19,21 82:15 |
| envelope 100:6 297:7 161:15,16,19 83:1 88:11 94:16 |
| 165:17 166:12 96:14 123:6 |

[example - fact] Page 24

| 124:16 144:11 | 308:2,2,6,17 309:6 | expert 11:13 33:12 | expressed 220:23 |
|--------------------------|--------------------------|---------------------------|--------------------------|
| 145:6 194:22 | 309:7,8 312:21,23 | 34:4,9,12 119:3,6 | 229:13,23 236:4 |
| 195:19,21,22,23 | 313:5 321:1 339:1 | 119:10,12 202:21 | 238:7 241:2 |
| 197:17 201:16 | 339:5,11 | 220:23 227:6,16 | expressing 75:2 |
| 243:20,22 258:14 | exhibits 219:11 | 228:2,12 229:15 | extensive 31:19 |
| 259:2 264:5 276:6 | 309:21 | 230:1,10,19,19 | 32:5 38:13 220:12 |
| 306:11 327:12 | exist 272:11 | 231:2,7,9,16,17,18 | extent 32:2 33:19 |
| 330:13 337:9 | 331:23 | 231:18,20 232:2,4 | 36:7 38:14 57:18 |
| examples 67:21 | existed 143:5 | 233:16,16 234:1,3 | 79:4 99:1 109:19 |
| 81:8 123:1 141:2 | 167:6 279:7 | 234:6 236:6,15 | 187:3 190:12 |
| exception 134:1 | existing 59:23 | 238:9,20,21,23 | 215:10 264:7 |
| exclude 338:8 | 270:13,14 | 239:6 241:4,7,12 | 296:5 330:14 |
| exclusive 54:6 | exists 138:17 | 241:15,18,24 | 332:6 337:4,12 |
| exclusively 33:7 | 152:8 218:12 | 286:18 288:4 | extraordinary |
| 38:22 109:2 197:3 | 220:13 307:5 | 289:17 290:20,21 | 116:3 148:17 |
| 249:4 305:22 | expand 173:5 | 337:14,15,16 | 169:11 222:10 |
| excuse 257:14 | 197:8 | expertise 30:5 | extravagant 76:19 |
| 259:12 | expanded 289:1 | 31:4,13,14 32:19 | extremely 103:5 |
| executed 348:10 | expanding 197:10 | 200:7 201:12 | 106:22 151:1 |
| execution 347:14 | 197:11 | 202:18,23 | eye 35:18 |
| 348:19 | expansion 90:19 | experts 94:21 | eyre's 147:4 |
| executive 94:20 | 145:18 | 125:9 230:9 | f |
| exhibit 5:1,3,6,9 | expect 13:13 30:3 | expiration 347:19 | faber 117:18 |
| 5:13,16,19,22 6:1 | 31:9 53:12 271:23 | 348:25 349:25 | fabricated 82:18 |
| 6:2,5,9,14,17,19 | expectations | expires 344:17 | face 72:19 88:21 |
| 6:22 12:2,3,10 | 176:14 | expiring 37:6 | 264:12 |
| 13:11 23:5,13,18 | experience 18:14 | explain 26:13 | faces 79:1 264:10 |
| 60:20,21 61:1,2 | 30:5 31:4 34:13 | 102:15 108:12 | facets 96:15 |
| 64:13 90:15 99:7 | 36:11,16 41:4 | 109:16,17,18 | 105:13 |
| 99:8,13 100:9 | 116:13 129:3,4,8 | 115:6 196:4 | facilities 47:4 |
| 182:11,15 183:22 | 134:6 136:1,23 | 208:14 211:16 | 126:15 151:8 |
| 184:2,13 205:18 | 139:2,4 158:6 | 213:13 290:3 | 317:22 |
| 205:19 214:1 | 165:22 200:3 | explained 131:13 | facility 88:13 |
| 218:7 219:4 244:8 | 201:5,9,12 202:24 | 163:18 | facing 34:17 35:10 |
| 246:17,18 247:2 | 203:1 217:7,18 | explaining 103:11 | 142:23 |
| 254:12,13,22 | 285:24 337:18 | 324:12 | facp 6:18,20 60:23 |
| 295:2,3,9 299:9,10 | experienced | explanation | 99:10 |
| 299:16 303:13,15 | 143:24 330:19 | 103:14 | fact 17:5 31:24 |
| 303:24 304:2,4,6,7 | experiences | exposed 205:15 | 59:1 87:17 129:11 |
| 304:11,11,12,13 | 132:20 234:4 | exposure 334:2 | 131:16 158:21 |
| 304:19,22 305:1 | | | 201:24 205:10 |
| | | | |

[fact - fill] Page 25

| 207 (222 24 | 0.141 0.60 0.1 0.4 | 0 4 11 2 40 7 | 0.1 07.16 | |
|---------------------------|----------------------------|----------------------------|---------------------------|--|
| 207:6 222:24 | faith 263:21,24 | fatally 340:7 | felony 37:16 | |
| 232:7,8 244:15 | 273:9 | favor 194:10 | felt 72:24 74:24 | |
| 246:1 250:21 | fake 129:24 | fbi 129:16 | 261:18,18 263:6 | |
| 262:23 271:5 | 154:24 | fda 94:23 159:3,3 | 263:10 | |
| 279:9 324:9 331:2 | fall 274:16,17 | 160:5 | fentanyl 105:7 | |
| 333:18 | fallen 176:13 | fearful 129:19 | 155:7 164:13,14 | |
| factor 205:14 | 274:13 | 153:18 | 165:23 166:13 | |
| 207:15,21,21 | false 198:6 326:9 | feature 123:7 | 179:17 254:5 | |
| 209:1 211:11 | familiar 12:22,23 | featured 123:4,5 | 256:9,15 257:7 | |
| 216:10 259:15 | 33:12 36:6,9 39:9 | fed 164:12 168:22 | 277:4,4 301:14 | |
| 334:5 | 61:5,6 100:14,16 | 169:21 333:13 | 302:14,15,15,16 | |
| factories 258:2 | 101:4 142:1 185:2 | federal 1:20 49:24 | 302:16,20 303:10 | |
| factors 98:24 99:4 | 255:14 295:18 | 58:3 138:3 148:16 | 303:10 305:12,15 | |
| 103:15,18 104:21 | 299:20 339:13 | 173:21,21 190:18 | 305:16 306:2,10 | |
| 104:24 110:12,13 | familiarize 339:16 | 222:9 230:15,23 | 318:11 | |
| 112:24 113:8 | families 58:6 | 231:3,4,18,20 | fentanyls 301:6 | |
| 195:11 196:11 | 133:5,8,16 150:5 | 232:4 234:7 | fewer 149:23 | |
| 199:13 200:4 | family 64:4 136:17 | 236:14 237:15 | field 181:19 | |
| 201:6 209:18 | 161:2,4,12 173:14 | 270:13,14,16 | 200:11 201:12 | |
| 210:10 211:4,6 | 173:18 174:1 | 271:5 272:2 | 203:1 | |
| 212:2,19 215:2,3,3 | 280:15 294:1 | 292:16 | fifteen 308:22 | |
| 216:4 220:24 | far 57:20 74:15 | fedwv 5:15,18,21 | fifth 78:13 79:3 | |
| 243:11 325:13 | 88:16 106:13 | 6:8,13,16,18 60:23 | 305:11 | |
| facts 34:9 | 117:4 159:16 | 246:24 254:20 | fight 175:21 267:9 | |
| factual 34:5 234:1 | 186:4 193:18 | 255:8 303:19 | fighting 98:1 | |
| faculty 68:15 | 236:1 248:5 259:9 | 308:11,15 313:3 | figure 33:3 44:18 | |
| 71:11,13 79:23 | 278:19 288:5 | 314:1 | 81:16 98:6 131:9 | |
| 94:15,24 121:4 | 307:12 | feed 153:22 155:9 | 150:9 173:11 | |
| fail 172:11 | farrell 2:6,7 8:18 | 169:17 177:11,15 | 201:19 202:1 | |
| failed 83:7 85:7 | 8:18 28:14 29:19 | feeding 169:23 | 212:2 214:15 | |
| failing 84:6 | 29:20 187:7 | 177:15 | figuring 44:8,14 | |
| fair 20:1 32:11,13 | fast 211:2 338:21 | feel 95:16 152:8,10 | 102:12 | |
| 68:2 87:3 88:2 | faster 98:20 | 152:11,21 153:5 | file 59:19 | |
| 99:22 112:23 | fatal 6:3 178:12 | 160:24 161:4,4 | filed 6:23 7:17 | |
| 144:3 146:2 154:7 | 244:19 245:16 | 323:5,7 | 23:3,16 24:9 59:2 | |
| 192:3 197:22 | 279:20 284:12,14 | feeling 160:16 | 240:2 | |
| 198:9 217:20 | 284:20 285:3,9 | feelings 161:4 | files 20:24 21:1,3 | |
| 324:11,23 325:5 | 339:7 340:10,15 | fees 37:3 | 298:22 | |
| 326:13 | fatality 6:7 183:23 | feet 327:20 | filing 24:9 343:15 | |
| fairly 144:8 | 184:7,16 243:3 | fell 76:6,8 | fill 36:3 89:6 90:9 | |
| | 246:22 | | 154:10,12 265:13 | |
| | <u>-</u> | | | |
| | Veritext Legal Solutions | | | |

[fill - follows] Page 26

| 266.1 12 272.10 | finishing 20.24 | fitzsimmon 51:6 | flowed 193:23 |
|---|--|---------------------------|--|
| 266:1,13 272:18 filled 40:5 88:5 | finishing 39:24 fired 165:14 | | |
| 112:10 126:5 | | fitzsimmons 3:4,4 | flowing 113:18 fluoro 302:15 |
| | firm 3:4 7:23 8:1 | 8:21 16:10 17:1 | |
| 247:13 266:10,12 | 229:1,5,16 230:2 | 17:18 118:21 | focus 60:10 61:24 |
| 273:7 | 236:6,21,22 237:4 | 219:3 232:10,17 | 65:19,21,22 67:10 |
| filling 266:4 | 238:10,17 239:2,5 | 233:9,14 235:23 | 75:23 79:18 80:8 |
| final 6:15 297:15 | 239:10,11 241:4 | 236:10 238:1,11 | 91:11 95:23 96:1 |
| 298:1,11 313:1 | 241:11 242:15,17 | 239:5 240:5,12,16 | 96:21 98:11,13,15 |
| 316:21 341:17,18 | 286:15,18 288:2 | 287:3 288:13 | 98:18 108:17 |
| 342:9,9,11,21,24 | firms 236:12 | 290:11 298:23 | 196:21 211:19 |
| finally 124:12 | first 9:6 24:22 | 343:6 | 223:18 255:1 |
| 167:17 | 55:8,13 66:24 | five 16:17,22 42:7 | 319:9,12 321:17 |
| finance 97:23 | 68:6 78:2 80:10 | 132:15 149:21 | focused 46:2 60:11 |
| 120:9 174:4 | 91:5 96:7 97:9 | 159:24 171:18 | 84:14 95:12 109:2 |
| financially 8:4 | 100:18 101:18 | 210:20 221:12 | 110:22 173:4 |
| 344:14 | 116:12 122:7,12 | 223:13,20 224:9 | 212:4 |
| financing 78:15 | 133:16 138:14,15 | 224:15 225:10 | focusing 85:9 |
| find 15:20 23:11 | 138:16 141:19,19 | 305:11 328:2,5 | 90:16 108:5 |
| 42:20 46:24 47:3 | 144:24 148:4,9 | fix 14:19 96:21,24 | 111:11 113:8 |
| 85:24 122:6 135:5 | 151:17 154:3 | 116:21 134:22 | 197:11 210:8,9 |
| 137:9 150:8 163:8 | 164:2 182:8 200:9 | 138:22 140:4 | 227:15 228:11 |
| 163:9 165:15 | 206:19 210:13 | 159:16 160:4 | 245:9,11 280:21 |
| 176:1,9,12 204:20 | 212:4,15 215:9 | 161:10 163:18 | 314:20 |
| 205:23 214:19 | 222:2 223:18 | 273:11 | fold 146:19 |
| 217:24 218:15 | 236:11 241:23 | fixed 158:13 | folks 102:22 215:3 |
| 230:11 278:12 | 257:1 260:12 | flags 135:23 | follow 27:22 76:3 |
| 279:10 288:19 | 276:23 281:10 | flat 194:12 | 76:4,5 162:8 |
| 317:4 331:12 | 282:11 295:12,22 | flip 210:18 | 182:3 188:10 |
| 342:24 346:11 | 296:13,15 301:3 | flood 46:10 | 189:13 282:3 |
| finding 29:12 | 313:7 314:20 | flooded 46:8 | 307:14 328:21 |
| 132:12 138:12 | 315:1,2 316:1 | flooding 138:6 | followed 63:6 |
| findings 126:1,1 | 328:22 330:15 | floor 2:8 69:21 | 188:22 |
| fine 35:8 99:23,24 | 331:6 344:7 | 235:8 | following 24:13 |
| 115:17 180:19 | firsthand 129:7 | florala 64:23 | 123:10 200:5 |
| 235:20 240:11 | 130:5 135:13 | 68:11 71:22 73:8 | 201:6 271:15 |
| 279:6 287:10 | 136:24 137:4 | 73:10,19 79:13 | 314:23 |
| finish 14:13,14 | 277:14 | 81:10,11 84:9 | follows 9:6 54:24 |
| 116:17 216:23 | fish 252:15 | 129:13 | 115:2 180:24 |
| finished 40:2 | fishing 251:9,11 | flow 114:12 | 226:24 240:20 |
| 338:1 | fit 50:16 | 178:23 | 291:13 328:9 |
| | | | |
| | | | |

[food - generate] Page 27

| food 70:24 159:11 336:21 | format 343:2 formed 204:10 | frank 262:24 frankly 98:4,13 | funerals 133:8 furanyl 302:15 |
|---------------------------------|-------------------------------|--------------------------------------|----------------------------------|
| foods 333:5 | former 9:14 | 164:7 | further 8:24 |
| football 260:22 | 125:15 202:23 | fraudulent 248:2 | 154:16 166:15 |
| force 49:7 71:20 | formerly 234:20 | 248:7 | 172:9 181:21 |
| 125:8,16 143:7 | forming 188:12 | free 134:24 135:1 | 207:12 215:19 |
| forces 155:10 | 189:11 | 159:3 173:6 | 276:14 343:16 |
| foregoing 344:5 | forms 166:6 | 178:23 277:10 | 344:8,11,13 |
| 347:13 348:18 | formula 214:21 | 347:14 348:20 | future 172:7 |
| foremost 212:4 | forth 344:15 345:6 | friday 187:24 | 174:19 |
| forget 290:5 | forty 344:15 345:7 | friends 150:4 | g |
| form 30:4 31:11 | forward 194:18 | 280:14 | g 7:1 9:4 |
| 36:22 37:9 46:9 | 196:10 202:5 | front 13:17 23:22 | gain 251:16 |
| 48:2 49:19 50:19 | 217:8 346:15 | 74:1 150:24 | game 23:20 32:13 |
| 52:19 53:15 59:20 | foster 45:4 136:14 | 246:13 298:4 | 98:12 103:20 |
| 68:3 73:14 87:13 | 171:19 | 314:12 321:3 | gary 340:21,24 |
| 88:6 104:16 | found 45:15 114:3 | 326:24 333:11 | 341:1,5,9 |
| 106:16 108:9 | 126:3,6,9,11 | fuel 278:13 279:10 | gas 165:10 |
| 122:3,3 125:7,8 | 132:13,15 145:4,6 | fueled 278:4,5,7 | gas 103.10 gastric 170:21 |
| 143:22 146:6 | 147:1 164:8 | fulfill 83:7 84:6 | gather 226:19 |
| 154:22 156:16 | 165:12 248:14 | 85:7 | 296:7 |
| 167:5 177:3 199:5 | 280:11 307:10 | fulfilling 84:18 | gay 136:2 |
| 199:18 200:13 | foundational | 86:12 | geared 49:16 |
| 202:13 203:14,24 | 152:3 | full 60:5 74:2 | gears 60:1 |
| 207:17 214:6 | founding 95:15 | 105:20 264:3 | gender 173:19 |
| 216:18 217:21 | four 9:24 10:6 | 277:3 319:1 | general 10:14 |
| 218:8,10,15 220:1 | 41:4 42:7 64:18 | 321:11 344:10 | 35:13 59:6 67:24 |
| 225:22 226:6,11 | 65:1 79:5,9 123:3 | fully 13:24 18:12 | 68:21 103:6 |
| 248:10 249:22 | 123:4 126:9 | 218:19 247:10 | 106:24 167:3 |
| 250:18 252:9 | 159:15,24 169:14 | function 161:13 | 245:10 259:14 |
| 254:10 258:20 | 171:18 210:19 | 272:12 336:19 | 307:1,3,16 |
| 261:15,23 266:2 | 225:8,12 248:15 | functional 281:23 | generally 22:7 |
| 267:13,21 268:4 | 248:21 255:3 | functioning | 40:11 75:6,7 |
| 268:14 269:9 | 321:8 | 320:16 | 76:11 88:11 92:17 |
| 270:3 271:2,10 | fourth 206:23 | fund 138:15 | 95:12 112:21 |
| 272:20 280:8 | 211:6 318:3 | fundamental | 138:2 167:3 |
| 294:22 312:19 | fractures 141:11 | 152:4 | 212:19 310:4 |
| 322:7 326:16 | frame 12:23 27:10 | funded 134:12 | 329:6 332:20 |
| 327:9 342:14,21 | 140:9 166:1 | 148:14 222:7 | generate 82:13 |
| formally 25:5 | 190:13 | funding 122:6 173:20,21,21 | 258:10 |
| | 1 | L | |

[generated - grandchildren]

| generated 83:5 | 114:15 115:11 | 50:10 51:3,3 | 142:20 149:5 |
|---------------------------|-----------------------|---------------------------|-------------------------|
| generation 102:11 | 116:12,14,16 | 54:21 55:22 58:14 | 152:10,11,21 |
| georgetown 80:7 | 117:9 120:15 | 60:1 61:11,24 | 153:5 160:16 |
| getting 40:1 73:20 | 133:8,9,23 134:1,4 | 64:7 73:15,16 | 218:2 222:22 |
| 135:11 149:13 | 140:8 141:9 | 79:14 80:10 81:6 | 225:9 242:7 |
| 150:16 153:14,15 | 149:18 153:20 | 81:13 90:6 96:24 | 263:21,24 273:9 |
| 169:18,22 171:5 | 154:11 155:1,3,6 | 98:17,21 100:17 | 309:5 328:18 |
| 214:8 222:13 | 157:1 161:2 163:5 | 104:12 107:19 | goods 74:23 76:2 |
| 223:4 264:1 | 163:9 165:10,10 | 114:22 115:7,14 | 283:11 |
| 271:20 323:7 | 165:11 166:20,23 | 119:20 133:18 | goold 2:18 4:5 |
| give 13:17 17:23 | 173:22 178:3,21 | 137:5,6 141:10 | 8:15,15 116:24 |
| 50:8 81:8 116:20 | 179:10 183:8 | 143:11 145:5,12 | 117:1 118:10,17 |
| 123:1 146:24 | 184:18 189:15 | 145:24 149:10 | 119:2,13,17 |
| 147:11 159:23 | 199:7 205:19 | 151:2 153:16 | 180:13 181:5,6 |
| 164:11,11 175:8 | 212:4 217:2 221:1 | 157:12 164:24 | 186:24 242:19 |
| 176:2 204:8 | 223:10 231:3 | 170:18 178:5 | 308:18,21 309:5 |
| 219:12 255:20 | 232:12 235:24 | 179:17,19 180:21 | 310:12 328:17,18 |
| 263:10 276:13 | 238:3,4 240:14 | 188:4,9 189:15 | 338:1,5 |
| 309:3,3 | 251:11 267:7 | 197:24 198:16 | gotten 278:11 |
| given 93:17 | 277:8,10 283:7 | 209:1,17 212:12 | 331:14 |
| 126:13 187:5 | 287:7 291:9 292:5 | 213:3 219:7 | governed 138:3 |
| 230:14 281:6 | 293:9,11 296:11 | 221:17 223:2,17 | government 6:10 |
| 343:11 344:17 | 298:10 300:9 | 226:21 240:17 | 37:4 148:17 |
| 345:10 | 322:17,24 323:2 | 246:10 256:4 | 222:10 254:15 |
| gives 218:1 | 325:21 333:17 | 266:12,19 278:15 | 255:18 |
| giving 170:13 | goal 109:18 | 281:4 287:10,10 | governor 96:13 |
| 215:24 236:14 | goes 17:21 51:4 | 291:2,10 297:16 | 125:24 145:19 |
| glean 179:6 | 84:12 160:11 | 300:5 307:12 | 161:21 216:20,24 |
| go 7:11 12:11,15 | 170:9 190:5 | 308:21,22 314:17 | 217:3 |
| 13:10 19:21 24:2 | 277:17 282:23 | 318:6 319:8 | governor's 48:13 |
| 24:3,6 25:20 33:2 | 297:6 302:4 | 321:11 323:14 | 51:24 85:3 128:8 |
| 33:4 36:19 38:18 | 318:15 320:7 | 328:5,6,14 340:13 | 161:22 |
| 38:24 39:6 44:20 | 335:1 | gonna 107:18 | graceful 131:14 |
| 46:14 47:7,17 | going 7:3 9:10 | 114:13 133:14 | gracefulness |
| 49:20 51:13 54:17 | 12:17 14:2 15:7 | 178:20 220:7 | 131:10 |
| 55:20 60:1 64:9 | 17:24 23:10 24:19 | 224:24 262:19 | gradual 265:4 |
| 71:10 73:6,15 | 30:13 32:1,4 33:4 | 277:11 290:10 | graduates 95:17 |
| 75:5 76:17 77:23 | 34:20 36:18 37:13 | good 7:2 9:9 17:24 | grand 95:11 |
| 79:4 83:15 84:13 | 38:3 39:24 42:13 | 25:14 67:19,20 | grandchildren |
| 99:16 106:14 | 42:13 43:20,21,22 | 69:24 72:14,22 | 150:3 |
| 109:22 110:17 | 45:4,8 47:16 50:5 | 93:8 117:4 139:6 | |
| | | | |

[grandma's - health]

| 1 1 202 14 | 22.5.12.15.22 | | 2040222 |
|---------------------------|-----------------------|--------------------------|--------------------------|
| grandma's 292:14 | 23:5,13,17,23 | haddy 5:6,6 | 204:9 222:23 |
| grandmother | 25:15 27:3 29:11 | 299:11,11 | 302:3 329:16 |
| 276:9 | 29:13,20 31:3,18 | hager 3:8 7:23 | happens 139:8 |
| grandparents | 32:18 33:17 34:11 | half 132:5 257:1 | 140:19 149:20 |
| 171:20,20 | 36:10 51:15 55:2 | 280:14 | 150:12 155:17 |
| grant 134:13,14 | 55:5 60:19,21,22 | halfway 317:7 | 172:1 223:12 |
| graph 274:22 | 61:1,5 99:8,10,13 | halls 133:9,10 | 273:15 294:17 |
| 305:7 319:6 | 100:1,14 115:4,13 | hampshire 167:22 | 331:12 |
| graphs 306:5 | 115:14,24 117:16 | han 5:7 299:12 | happy 19:21 27:20 |
| great 14:4 58:24 | 117:22 118:22 | hand 61:19 131:20 | 33:5 49:11 78:24 |
| 171:20 188:7 | 180:6 181:2 182:1 | 133:21,23 134:4 | 218:15 264:10,11 |
| 207:3 | 182:17 183:11 | 310:21,23 317:17 | 269:9 285:12 |
| greater 320:14 | 184:3 185:11,23 | 344:17 345:10 | 286:2 308:23 |
| 322:10,18 | 186:21 187:4 | handful 126:23 | 333:11 |
| greatest 111:23 | 188:1,7 191:23 | hands 43:19 44:15 | hard 75:5 77:8 |
| grips 278:8 | 219:20 227:2,5,15 | 45:1 303:12 | 90:4 100:18 145:8 |
| ground 58:7 98:1 | 227:20,22 228:1 | happen 68:7 127:2 | 173:2 216:12 |
| grounded 73:1 | 228:11,16 240:22 | 135:5 138:7 | 260:16 261:17 |
| group 132:18 | 241:1 246:18,19 | 141:11,12 150:1 | 307:6 |
| 277:18 281:19 | 247:1 254:13,14 | 164:6,6 168:18 | harm 68:7 82:23 |
| 305:14 306:18 | 254:22 289:20 | 174:10 193:19 | 138:12,16 155:3 |
| groups 66:19 | 291:15 295:2,3,9 | 282:2 285:18 | harvard 80:5 94:9 |
| grown 205:6,8 | 299:10,15 303:15 | 305:22 342:2 | 94:13 121:18 |
| 307:20 | 303:17,22,24 | happened 51:2 | hasten 46:6 |
| guess 34:1 82:3 | 304:22 308:6,7,14 | 75:23 97:3 104:22 | hazards 31:22 |
| 88:9 172:1 182:9 | 308:16 312:23,24 | 105:9 125:5 | he'll 28:23,23 |
| 199:23 203:20 | 313:4 315:10 | 142:13 146:9 | 30:16 33:1 35:2 |
| 280:20 293:22 | 328:11,13,18 | 150:7 163:22 | 343:8 |
| 315:22 327:4 | 339:5,6,11,13 | 165:4 173:10 | head 66:2 161:1 |
| guidance 188:17 | 343:11 344:5 | 277:22 286:22 | 193:11 282:15 |
| guided 110:13 | 345:5 346:8 347:4 | 290:4 324:12 | heading 62:9 |
| guidelines 142:19 | 347:9 348:4,13 | happening 44:23 | 91:12 318:7 |
| 224:18,19,23 | 349:20 | 46:11 49:10 96:18 | heads 128:11 |
| 271:16 272:7 | gupta's 187:15 | 113:11 123:8,11 | health 2:10 5:8,10 |
| guiding 190:7,8,11 | 286:15,17 298:22 | 124:6 130:8 | 5:23 6:19 8:12,14 |
| gun 165:13 | guys 180:4,4 | 131:20 135:12 | 9:12,15,16 11:4,15 |
| gupta 1:19 5:3,13 | 232:24 | 136:8,15 137:4 | 21:22 22:18,18,22 |
| 5:18,20,23 6:2,6,9 | h | 143:14 144:6 | 30:7,8,9,10 31:5,6 |
| 6:14,17,20 7:14 | h 9:4 | 149:7 151:12 | 31:7,9,22 32:6,10 |
| 8:21 9:9 12:3,4,9 | habit 153:23 172:9 | 158:21 161:7,24 | 32:21 35:12,16,17 |
| 12:12 15:13 21:11 | 278:13,14 | 163:3,13 171:7 | 39:20 40:14,14,16 |

[health - holds] Page 30

| 42:17 48:3,9,10,24 | 337:18 | helping 69:9 | 221:13 223:13,15 |
|--------------------|---------------------------|------------------------|------------------------|
| 49:22 50:1 55:6,8 | healthy 128:23 | 263:24 | 223:20 224:10 |
| 55:13 56:4,8,16 | hear 30:11 55:8,12 | helps 330:13 | 225:15 226:3,11 |
| 57:1 59:2,7 60:17 | 106:16 131:1 | hep 97:11 106:6 | 258:21 319:20 |
| 63:4 65:16,18 | 133:11 187:10 | hepatitis 97:5,7 | higher 167:20 |
| 67:20 70:12,12,13 | 188:1 191:19,20 | 136:6,12 164:21 | 172:14 210:14 |
| 70:14,16,23 71:5,7 | heard 55:5,10 | hereof 344:7 | 211:9 224:14 |
| 71:16,17,19,23 | 56:18 57:9 77:5 | heroin 47:13 | 273:3 277:1 334:7 |
| 72:8,8,10,13 73:5 | 86:10 98:22 124:8 | 105:7 155:7,7 | 334:14 |
| 80:12 81:3,5 | 124:9 133:15 | 161:17 163:12 | highest 97:7,10 |
| 84:13,19 86:3,4,5 | 143:18 228:21 | 164:1,7,10,16 | 136:12 167:19 |
| 91:1,7,8,12 92:2,4 | hearing 170:23 | 165:23 166:13 | 201:13 205:11 |
| 94:10 95:11,12,15 | 187:10 255:21 | 176:19,21,23,24 | 206:23 271:20 |
| 95:19,19 99:9 | heart 170:21 | 177:1,3,17,18,22 | 272:6 |
| 101:7,23 107:12 | 175:17 334:24,24 | 178:1,22 179:1,3,3 | highlighted 111:1 |
| 113:24 120:4 | heartbreaking | 179:8,17 243:22 | 204:5 331:3 |
| 121:18,22,23 | 133:15 | 254:3,4 257:4 | hijack 152:24 |
| 122:7 123:18 | hearts 175:17 | 274:5,23 276:4,15 | hijacked 154:20 |
| 125:12 127:14,14 | held 120:12 121:4 | 277:5 278:20,24 | 279:17 |
| 127:16,17 128:19 | 149:1 222:17 | 279:8,12 280:2 | hijacking 152:24 |
| 129:1 142:16 | 272:6 | 284:5 302:19 | hijacks 154:5 |
| 143:12,13,24 | hello 191:19 286:5 | 306:23 307:2,4,5 | hindsight 46:17 |
| 181:18 183:12,12 | help 44:4,12 46:3 | 307:19 311:1,4,11 | 47:6 77:24 |
| 183:18 184:5,21 | 46:15 52:14,17 | 311:22 312:2,6,10 | hint 204:8 |
| 188:9 199:21 | 53:19 54:4 74:22 | 318:11 324:3 | hired 125:14 |
| 206:4 212:5,9 | 74:24 78:3 83:2,4 | 333:16 | historic 97:10 |
| 215:3 217:1,2,6 | 87:9 98:20 125:1 | hey 29:20 81:12 | historical 96:6,8 |
| 243:5 244:10 | 126:10,13 128:13 | 129:16 145:4 | 96:14 144:23 |
| 250:22,24 251:19 | 159:15 165:9 | 153:20 179:22 | 182:13,18 183:4 |
| 251:21 256:19 | 176:2,7 178:11 | 185:13 231:11 | 218:9 |
| 272:5 277:10 | 179:6 192:7 220:8 | 240:5 276:17 | history 31:19 |
| 295:5 296:18,22 | 263:7,14 276:17 | 286:10 | 55:21 97:4 101:24 |
| 296:24 297:9 | 276:18 296:14 | hhs 124:4 | 140:8 331:18 |
| 299:13,21,22 | helped 45:19 | high 11:3 57:22 | hiv 97:2,4 106:6 |
| 300:7,8,9,11,15 | 46:17 47:18 95:14 | 91:6 94:20 97:10 | 135:17,19 164:21 |
| 301:1,4 302:5,5 | 122:3,3,5 125:7,7 | 139:4,16 149:21 | hold 23:12,24 |
| 303:21 314:2 | 125:10 138:15 | 149:23 151:1 | 93:24 133:10 |
| 315:10,11 317:15 | 142:6 | 153:14 159:21 | 216:22 267:2 |
| 317:22,22 318:13 | helpful 216:13 | 164:11 168:1 | 323:13 |
| 319:14 326:1,2 | 263:12 | 172:5 197:23 | holds 54:2 |
| 328:22 329:13,24 | | 199:19 200:8 | |
| | | | |

[holes - inappropriate]

| halas 121.24.252.5 | househ-14 010 15 | h | 206.2 |
|-------------------------|--------------------------|------------------------|------------------------|
| holes 131:24 252:5 | household 212:15 | hypothetical | 306:2 |
| 252:8,18,23 253:2 | huge 172:11,13 | 156:17 | illicitly 257:6 |
| home 20:24,24 | huh 10:6 11:22 | i | illinois 62:17 |
| honest 75:11 | 213:11 253:17 | icu 174:7 | imagine 129:18 |
| 136:3 176:15 | 260:2 288:8 | idea 122:7 135:11 | 169:20 |
| 262:24 | human 22:22 59:7 | 146:24 147:11 | immediate 170:19 |
| honestly 98:13,15 | 74:20 152:19 | 194:16 | immediately 21:6 |
| honor 314:13 | 314:3 317:15 | ideas 116:20 | 193:14 |
| honorable 314:3 | 326:1 334:6 | identification 12:9 | immigration |
| hook 155:5 | 336:12,14 | 23:17 60:24 99:12 | 194:23 |
| hope 162:1 249:7 | hundreds 74:16 | 182:14 184:1 | immune 160:7 |
| 249:10 289:24 | 167:7 266:15 | 247:1 254:21 | impact 72:17 83:4 |
| hopeful 162:7,19 | hungry 152:9 | 295:8 299:15 | 110:2 173:8 |
| hopefully 116:20 | hunter 3:8 230:21 | 303:23 308:16 | 175:10 265:22,23 |
| 140:3 | 231:22 236:8 | 313:4 339:10 | 268:24 269:4 |
| hopkins 80:6 | 238:12,13 239:2 | identified 24:13 | 271:7 329:21 |
| 125:9 | 240:10 242:2,13 | 151:8 207:22 | impactful 72:23 |
| hospital 62:16 | 242:14,14,15,16 | 209:2 230:9,18 | 102:11 |
| 65:22 68:21 69:3 | 242:17 | 232:1 246:5 262:1 | impacts 110:4,6 |
| 71:14 74:3 78:22 | hunter's 237:13 | 296:24 | 334:21 |
| 300:16 | huntington 1:4 2:8 | identify 205:24 | implications 186:7 |
| hospitalist 65:8,11 | 7:16 17:3 21:18 | 206:22 211:3 | importance |
| 66:6 68:22 78:23 | 22:10 27:5 32:7 | 243:9 249:12,21 | 329:20 |
| 264:6 | 115:8 117:18 | 262:2 | important 14:10 |
| hospitals 64:9 | 118:5,23 119:4 | identifying 134:8 | 43:10 69:22 73:1 |
| 69:5,16 136:1 | 125:15 135:18 | identity 253:8 | 102:22,23 109:8,9 |
| 264:5 | 172:15 182:2 | 341:24 | 126:17 138:18 |
| host 44:22 | 187:6,17,20 | ignore 215:7 246:1 | 140:4 141:5 143:9 |
| hosted 124:3 | 234:22,24 239:12 | ii 36:12 37:14 | 152:18 273:21 |
| hotels 71:4 | 239:14 240:4 | iii 37:14 | 281:13 329:11 |
| hour 54:5 116:12 | 261:4 275:21 | illegal 87:5 105:10 | impossible 262:20 |
| 229:9,11 286:12 | 296:9,17,18 346:6 | 132:14 292:10,11 | improper 50:7 |
| 297:1 | 347:3 348:3 | , | improved 42:9 |
| hours 16:17 43:9 | huntsville 65:6 | 328:24 | impulse 171:11,13 |
| 45:22 89:24 103:7 | 69:15 | illegitimate 87:4 | inappropriate |
| 106:24 168:19 | hurt 46:18 273:19 | 87:11,16 105:10 | 114:10 150:10,22 |
| 310:10 326:18 | hurting 273:17 | 219:23,24 | 151:1 155:11,12 |
| 338:7 | hydrocodone | illicit 256:9,14,15 | 155:22 156:1,22 |
| house 6:9 142:16 | 307:4 | 256:18 257:12,14 | 236:22 259:22 |
| 142:16 254:14 | hypothesize 259:8 | 257:23 258:1,3,5 | 260:4,7,8,9 262:3 |
| 255:17 321:3 | · • | 277:4 280:2 | 264:15 265:10 |
| | | 302:11 305:12 | |

[inappropriate - instruct]

| 280:12 | incomes 319:21 | indirectly 335:5 | 303:12 314:7 |
|---------------------------|--------------------|----------------------|----------------------|
| inappropriately | incorporated | 335:16 | 341:7,10 342:3 |
| 204:13 224:5 | 348:12 | indisputable | ingrained 136:10 |
| incarcerated | increase 147:1 | 274:24 | inhale 165:4 |
| 45:17,19 126:7 | 148:6 156:9,11 | individual 72:24 | inherent 91:22 |
| incarceration | 168:4 169:5,5 | 133:8 135:6 200:4 | inherently 272:21 |
| 69:20 | 221:7 246:4 | 201:6 205:15 | initial 36:14 38:12 |
| incentives 74:14 | 305:16 307:2,4,16 | 215:3 225:17 | 44:22 75:18 |
| incessant 168:21 | 319:18,19,20,21 | 252:22 253:1,4,6,9 | 134:18 225:7 |
| incidence 307:19 | 319:22 326:12 | 341:5 342:1,4 | 233:12 268:17 |
| inciting 148:9 | 335:16 | individual's | 298:12 |
| 222:2 | increased 144:20 | 294:21 | initially 148:14 |
| incline 132:12 | 146:19 155:23 | individually 58:7 | 153:3 222:7 |
| include 21:22 | 318:12,18 319:16 | individuals 24:13 | 278:23 288:7 |
| 38:21 96:3 103:13 | 334:17 335:5,7 | 176:9 252:20 | initiated 161:22 |
| 106:9 107:24 | 336:5,14 337:21 | 254:1 258:9 | inject 164:20 |
| 109:11,16 110:12 | increases 197:20 | 319:21 331:15 | 165:12 254:1 |
| 127:10 132:17,17 | 197:21 | 334:5,9 | 277:2 |
| 137:10 168:21 | increasing 155:18 | indoor 70:21 | injecting 254:9 |
| 202:2 215:3,4,6 | 157:13 274:22 | induce 225:21 | injection 47:14 |
| 243:24 244:16 | 302:12 | industry 145:8 | injuries 141:12 |
| 247:7 248:7 | increasingly | 195:21 | 143:14 145:11,24 |
| 256:19 330:3 | 256:16 | inefficient 176:15 | 197:19 |
| included 10:14 | incremental 46:5 | infant 128:24 | injury 196:23 |
| 19:12 24:19 66:17 | 46:16 47:19 83:4 | 264:21 | inner 68:24 152:4 |
| 70:20 109:13 | 173:8 274:14 | infection 300:16 | 153:1,8,16,19 |
| 132:16 252:21 | 275:7 | inflammation | 154:5,19 |
| 297:2 346:13 | incrementally | 67:15 | innocent 43:19 |
| includes 32:7 93:1 | 47:9 138:9 | influence 84:11 | input 59:23 |
| 106:5,8 243:19,22 | incurring 174:19 | 252:20,24 253:6 | inquire 31:21 |
| 272:7 275:17 | index 4:1 5:1 6:1 | 253:10,12 | 230:17,20 |
| including 15:20,21 | indicated 291:23 | inform 125:1 | inquiries 28:1 |
| 19:10 22:16 38:6 | 310:22 318:11 | 127:4 | inside 131:23 |
| 65:23 66:10 69:19 | 343:14 | information 17:23 | 154:21 169:22 |
| 87:1 93:12 140:1 | indicates 210:21 | 27:18 31:15 34:5 | 251:11 |
| 196:12 257:1 | indicating 256:17 | 35:1 36:23 37:9,9 | instance 118:21 |
| 268:17 293:16 | 346:13 | 38:6 63:8 88:3,18 | instances 86:17 |
| 314:18 339:23 | indication 67:6 | 88:18 89:23 96:11 | 87:7 185:20 |
| inclusive 54:7 | indications 259:17 | 113:2 179:7 | instill 122:6 |
| income 211:24 | 261:10 | 219:10 230:7,24 | instruct 18:1 |
| 212:15 | | 234:2 246:15 | |
| | | | |

[instructed - judgment]

| instructed 232:16 investigation 5:10 171:13 1 instructing 236:8 85:22 86:15 96:3 234:7 238:13 124:23 130:2 iuds 173 insurance 208:18 295:6 296:22 iv 37:14 | 221:20,24 226:15 |
|--|-------------------------------------|
| 238:13 124:23 130:2 iuds 173 | |
| | 22/:4,24 238:5,6 |
| Insurance 208:18 295:6 296:22 IV 3/:14 | 07.11 |
| 10000 | |
| intend 28:19 30:14 297:9 136:8 16 | |
| 122:14 investigations 6:6 253:13,2 | |
| intended 24:24 85:14 246:21 254:2 | 286:6 291:17 |
| 50:14,15 249:15 investments 76:19 | j 304:10,18 308:5 |
| intends 32:13 invite 50:23 j 315:23 | 323:17 327:4 |
| intent 87:18 involve 69:11 iackson | 328:13 338:17,24 |
| intention 30:15 90:21 95:2,13 iail 69:2 | 1 133·12 339:3 343:3 |
| intentions 176:6 144:10 292:12 | Job 25:14 83:17 |
| 263:18 involved 22:21 iailed 29 | 91:23 98:5,6 |
| Interaction 86:11 39:15 43:8 69:9 iails 173 | :16 |
| 172:19 69:15 141:22 james 2: | 1/1/1:13 1/15:0 |
| interactions 52:20 183:15 190:21 315:12 | 161:11 171:15 |
| 56:16 57:3 245:16 306:10 jane 283 | 198:5 200:5 201:7 |
| interactive 95:5 328:24 january | 1 7779.2.2.2 |
| intorost /X6·1/ involvement /6·11) | 2:7 127:24 jobs 144:12 145:6 |
| interested 8:4 92:8 185:2 jaywalkin | 1/15.8 105.21 21 |
| 344:14 involves 33:20 jcaho 78 | |
| interfere 7:8 36:18 244:3,19 148:15 2 | 1 7/12-72 7/1/1-2 |
| interference 7:6 involving 306:6 jim 117: | iohng |
| interim 128:19 307:12 308:21 3 | Liohnson 1/18:13 |
| $\begin{bmatrix} intownal & 62.21 & iota & 226.10 & \end{bmatrix}$ | 220:10 222:6 224:1 |
| $\begin{vmatrix} 62 \cdot 1 & 64 \cdot 1 & 2 \end{vmatrix}$ invitable $\begin{vmatrix} 62 \cdot 1 & 64 \cdot 1 & 2 \end{vmatrix}$ | 11 4:3,4,5 joined 92:4 |
| 65:11,16,17 69:8 iso 302:15 8:11,11 15:5 18: | 9:8,11 ioining 55:11 |
| 122.0 227.17 issue 24.22 42.4 13.3 10. | ioint 79.19.250.2 |
| internose 117.3 46.4 15.67.12 21:10.23 | 0.9 24.4,0 iosanh 62.16 |
| interrogete 252:13 75:11 102:1 5 13 | journal 283.14 |
| 252.16 107.13.20.118.6 29:0.30: | iournals 123.18 |
| interrogetion 151.0 168.0 173.5 32:1/4] | 1:22.42:2 ir $2:6.8:18.28:14$ |
| 174.2 3 232.23 47:21 48 | 5:8 51:10 indga 13:18 |
| interrupt 26:9 233:8 256:12 51:14 53 | 117.18 232.21 |
| 34.3 220.8 277.13 330.18 35:4 61: | 314.4 8 12 15 |
| introduce 0:10 issued 182:6 185:3 87:24 99 | 315.18 18 22 |
| introduced 118:11 180:5 222:24 100:18 1 | indges 6:15 313:2 |
| introducing 90:16 233:6 11 302:5 | 315.4316.3 |
| investigate 85:23 issues 34:6735:1 | 193:9 |
| investigated 125.3 05.12.07.24.103.5 193.0.13 | 98:18 indoment 88:4 |
| 270.11 106.23 128.2 | 253.11 |
| 210:22,2 | 24 217:15 |

[july - landscape] Page 34

| | , | | |
|---|---------------------|--------------------|---------------------------------------|
| july 269:20 313:21 | kessler 2:14 | 100:2 103:9 106:4 | 282:23,24 283:12 |
| jumping 23:10 | kid 260:22 | 107:2 108:24 | 285:2,6 289:5,16 |
| 67:16,18 | kids 171:9,17 | 109:21 110:6 | 291:4 292:12 |
| june 23:3 24:12 | 172:2,5,10,16 | 114:2 115:21 | 298:3,5 301:12 |
| jurisdiction 70:18 | 175:4 | 116:8 117:4 124:5 | 313:17,18 316:13 |
| 84:22 86:7 | kilkenney 5:9 | 126:23 130:6,20 | 319:2 322:20 |
| jus 75:15 | 295:4 | 131:2,11,22 | 325:18 333:20 |
| justice 45:14,14 | kilkenny 295:13 | 133:13 138:10 | 334:1,16 335:8,8 |
| 96:13 256:12 | 295:14 | 142:6,11 143:14 | 336:17 339:17 |
| justify 196:5 | killed 136:3 | 144:11 145:4,8,11 | knowing 33:9 |
| jyoti 2:11 8:11 | killer 49:10 | 145:12,13,13,16 | 253:5 |
| 9:11 26:17 188:8 | killing 43:8 54:5 | 147:2,3,17 148:19 | knowledge 11:20 |
| 238:2,4 338:15 | 103:6 106:23 | 148:24 149:10,15 | 14:1 30:6 31:4 |
| k | 324:2 325:3 | 149:18 150:16,23 | 32:5 34:13,16 |
| | kind 23:19 37:9 | 152:5 155:16 | 39:3 52:20 53:6 |
| kanawha 30:7 | 83:1 84:10 88:18 | 156:18 159:9,17 | 57:4 83:11 85:17 |
| 31:6 70:12,18 | 110:15 116:12 | 159:20,23 160:2 | 116:15 145:7 |
| 91:1 127:14,16,18 293:13 345:2 | 126:16 145:1,7 | 164:4,4,19,24 | 167:12 190:22 |
| kearse 2:3 4:4 | 160:13 314:13 | 166:6 170:3,10,17 | 200:6 217:8 |
| | kinds 82:7 | 171:9 172:4,16,20 | 220:12 234:7 |
| 8:19 29:10,10,24 31:17,17 61:2 | knew 108:13 | 172:21,24 173:16 | 250:12 257:5 |
| * | 135:24 138:18 | 174:9 175:6,24 | 258:11 337:13 |
| 118:4,4 181:24 | 260:17 261:2 | 176:2 177:8 178:4 | known 57:24 |
| 182:1,7 183:1,8 184:12,18 185:11 | 262:10,11 263:1 | 179:10,15 187:11 | 334:22 |
| 187:3,7,14,24 | know 13:16,21,22 | 190:24 191:3,4,10 | knows 31:21 32:9 |
| 188:3 233:23 | 14:7,19 17:7 | 193:4,11 194:5,5 | 32:10 |
| | 18:10 19:4 27:16 | 195:24 209:21,23 | l |
| 234:16 237:9 239:8,18 254:10 | 27:21,21 28:8,10 | 211:1,23 215:6,16 | 1 9:4 |
| 289:15 291:1 | 28:12,24 29:11 | 215:24 216:3 | lab 164:14 |
| | 31:24 33:6 35:5 | 217:13 218:12 | labor 145:8 |
| 297:12,13 298:21 kearse's 188:10 | 37:2,5 40:20 42:2 | 219:13,14,20 | laboratories |
| | 44:19 46:17 54:1 | 223:1,6,10 225:23 | 132:10 |
| keep 14:11 33:6 131:6,10 171:11 | 55:17,18 56:2,10 | 226:16 234:17 | |
| 188:4 204:16 | 58:18 66:2 67:13 | 242:3,8,12 251:4 | labs 94:22,22 |
| 281:23 287:10 | 71:2 72:3,12 | 252:22 253:1,4,5,8 | 132:10 |
| keeps 160:12 | 73:15 74:12,19,21 | 254:24 258:11 | laced 155:7 302:20 |
| 285:21 | 74:21 76:7,17 | 259:9 260:14,18 | lack 75:3 |
| kellyanne 124:7 | 78:18 80:4 82:10 | 261:2,13 262:8,18 | lacking 133:1 |
| kentucky 97:9 | 83:16,21 86:1,17 | 264:7,22 266:12 | laid 174:6,8 |
| kentucky 97.9 kept 127:22 | 93:5 96:20,22 | 278:23 280:5,16 | · · · · · · · · · · · · · · · · · · · |
| Kept 121.22 | 97:16 98:4 99:16 | 281:3 282:1,8,12 | landscape 311:1 |
| | | | |

[lapse - limited] Page 35

| lange 122.12 | 224.16 225.4 16 | 133:10 173:24 | lgbt 135:20 |
|--------------------|---------------------------|---------------------|---------------------------|
| lapse 122:13 | 334:16 335:4,16 336:5 | 175:20 225:11 | 0 |
| large 126:20 136:9 | | | liability 97:20 |
| 168:5 | learn 39:21 41:23 | legitimate 46:22 | liable 149:1 |
| larger 72:17,22 | 55:13 56:22 59:14 | 140:10,14,15 | 222:18 |
| 311:5 | 109:23 124:24 | 143:1,4 146:7,11 | liberal 72:3 |
| largest 70:14 | 127:3 130:12 | 192:10,18 195:18 | 149:16 223:7 |
| 71:14 97:4 136:15 | 132:19 | 199:15,17 202:2 | liberator 158:19 |
| late 148:7,12 | learned 39:18 | 203:6,12,23 | license 38:6 40:4,5 |
| 204:9 221:8 222:5 | 40:24 41:13 42:22 | 206:14,14 207:12 | 52:24 63:22 93:10 |
| lauren 3:9 | 47:5 48:20 57:13 | 208:10 209:3,19 | 93:18 |
| lavish 76:18 | 84:4 179:9 337:4 | 210:5 211:12,13 | licensed 36:4 |
| law 2:7 3:4 49:3 | learning 41:17 | 211:18 212:7 | 87:10 112:15,16 |
| 49:24 89:9 130:6 | 42:5,18 56:11 | 214:16 282:4 | 248:9 249:6,14,21 |
| 132:1,7 134:19,22 | 57:16,20 | 294:14 | 252:12 292:21 |
| 134:23 135:5 | leave 225:18 267:8 | legitimately | licensee 92:10,13 |
| 138:3 163:5 165:3 | led 98:24 99:4 | 281:18 | licenses 51:17 53:1 |
| 251:20 256:13,19 | 103:15 112:24 | lesion 67:14 | 53:4 63:18,21 |
| 270:13,14,17,23 | 125:5,16 148:14 | letter 283:13 | licensing 51:21 |
| 271:6,9,12,22 | 150:8 220:18 | 314:1,12,14,15,20 | 71:1,4 91:16 |
| 272:2 293:19 | 222:7 260:11 | 315:2,9,16,17,22 | 92:17,24 94:7 |
| 294:19 | 261:21 262:5,14 | 316:1,6,6,8 346:19 | licensure 249:16 |
| laws 161:20 | 262:17 | letterhead 317:16 | 249:19 |
| 272:10 292:16,16 | left 68:11,12 80:1 | letters 61:21 | licit 258:2,4,7 |
| lawsuit 9:13 58:21 | 92:6 100:20,20 | 323:23 326:8 | lie 155:2 |
| lawyer 15:1,9 29:1 | 167:14 176:11 | level 11:3 44:4 | life 66:1 140:18 |
| 293:17,23 294:11 | 317:17 | 57:22 58:1 72:23 | 161:11 164:23 |
| lawyers 13:22 | leg 323:24 | 72:24 75:22 91:6 | 169:22 172:11,19 |
| 14:9 17:2 | legal 26:3 33:13,20 | 94:21 109:24 | 175:4,5 196:12,22 |
| lay 110:5 173:23 | 33:23 132:14 | 148:22 159:21 | 276:6 281:5,12,13 |
| 290:21 | 241:19 312:20 | 199:19 200:6,8 | 285:23 |
| laying 293:2 | 346:1 349:1 | 201:7 222:15 | lifelong 159:7,12 |
| lead 52:20 82:13 | legalities 35:5 | 265:23 274:15 | 159:14,20 |
| 99:4 144:20 | legally 294:18 | 324:20 333:20 | light 162:3 |
| 155:23 258:9,11 | legislation 5:16 | 334:3,17 335:5,9 | limit 190:1 |
| 268:18 335:7 | 44:6 48:11 125:18 | 336:5 | limitation 190:3 |
| leaders 54:3 | 138:10 142:9 | levels 97:7,10,10 | limitations 44:19 |
| 142:17 | 268:9,16 271:8 | 136:12 201:13 | 137:15 |
| leadership 121:22 | 285:19 308:12 | 332:23 335:7,23 | limited 31:13 33:7 |
| leading 132:2 | 309:16 | 336:15 | 46:14 176:6 |
| leads 154:15 156:4 | legislature 58:17 | levy 46:9 | 185:22 196:22 |
| 156:5 320:14 | 58:18 122:6 | v | 272:15 277:18 |
| | | | |

[limiting - lunch] Page 36

| limiting 98:19 | 238:23,24 241:7 | 119:14 141:17 | looking 44:14 |
|----------------------------|--------------------|---------------------|------------------------|
| 225:7 | 241:12,16,24 | 172:17,22 174:10 | 59:13 112:23 |
| line 66:24 74:1,16 | 288:5 | 221:21 242:4 | 149:9 194:11 |
| 76:15 96:19 | little 9:10 35:9 | 276:10 281:7,18 | 211:17 222:24 |
| 160:19 168:2 | 67:10,14 69:1,5 | 282:7 321:24 | 227:8 228:4 |
| 169:23 215:9,21 | 86:21 88:10 | 324:15,16 326:14 | 244:18 245:24 |
| 279:6 305:16 | 100:12 115:22 | 328:20 334:1 | 264:9 293:4,11 |
| 307:7,14,16 | 116:13 140:7 | 337:18 338:19 | 295:23 296:13 |
| 327:12 346:13 | 145:14 146:4,12 | longstanding | 304:10,16 305:10 |
| 348:7 349:3 | 151:13 160:12 | 327:13 | 310:20 329:23 |
| lines 56:2 131:12 | 163:4,15 174:12 | look 20:5 52:9 | 340:12 |
| 236:17 329:17 | 176:18 178:4 | 71:10 77:24 82:18 | looks 101:4 306:14 |
| link 280:1 | 179:20 189:16 | 100:16 108:19 | 314:11 316:1 |
| linked 169:3 | 192:5 210:20 | 109:22 116:5 | lortabs 260:23 |
| 302:18 | 211:2 213:7 | 131:14 144:17,22 | lose 100:7 |
| list 6:22 23:2,15 | 218:23 224:24 | 145:3 147:9 | losing 45:21,22 |
| 24:20 26:1 107:10 | 240:9 247:3 | 156:19 162:4 | loss 145:9 146:9 |
| 233:12 | 262:16 264:11 | 166:21 178:14 | 146:20 195:17 |
| listed 63:1,7 64:13 | 277:1 280:14,21 | 179:5 193:1 194:3 | lost 150:15 |
| 128:6 210:12 | 304:13 307:6 | 195:22 197:16 | lot 37:24 47:15 |
| 213:24 300:6 | 323:10 328:1 | 201:24 202:4 | 58:23 68:24 71:22 |
| 322:19 348:7,17 | 330:12 | 203:19 204:3,17 | 74:5,16 75:14 |
| listen 103:21 | live 44:17 281:8 | 204:19 208:3 | 81:22 98:11,20 |
| 108:22 162:2 | lived 137:5 140:2 | 213:5,6,16 215:14 | 105:13 108:24 |
| 276:18 | lives 277:9 | 215:15 216:20 | 133:2,15 138:20 |
| listened 242:8 | living 102:8 125:1 | 217:23 245:17 | 140:16 151:21 |
| listening 105:17 | 211:23 | 249:16 263:16 | 160:2,16 165:6 |
| listing 348:7 | llc 345:4 | 264:18,24 284:1 | 170:3,18 173:4 |
| lists 25:12 | load 300:5 | 285:17 290:18 | 195:11 197:22 |
| literally 46:11 | local 11:15 30:7 | 297:21 304:2 | 219:8,9 265:20 |
| 58:8 78:7 129:22 | 31:5,5 58:5 70:14 | 306:16 309:6 | 276:5 282:21 |
| 134:3 151:3 | 70:16 71:16 74:3 | 325:18,21 330:13 | 292:12 330:23 |
| 165:18 170:9 | 84:19 127:16 | 339:20 341:6 | 333:13 |
| literature 170:22 | 130:7 136:1 301:1 | 342:23 | lots 168:1 279:19 |
| 224:16,20 284:18 | located 1:21 | looked 43:20 | loud 340:13 |
| 285:1,2,7 286:1 | location 37:12 | 122:17 125:3 | love 28:11 |
| 332:2 | logorhythmically | 205:18 279:24 | lower 61:19 |
| litigation 21:13 | 155:18 | 280:5 283:19 | 147:24 282:3 |
| 30:12 118:24 | london 120:8 | 284:3 319:6 331:7 | 310:21,23 |
| 227:6,17 228:2,13 | long 16:14,20 | 331:7 332:1 | lunch 99:20 |
| 230:17 235:12 | 79:21 91:20 93:18 | | 114:15,24 |
| | | | |

[m - meaning] Page 37

| | 282:17 283:2 | manuscripts | 286:17 287:22 |
|-----------------------|------------------------------------|--------------------------|--------------------------------|
| m | 305:23 306:1,1 | 295:20 298:10 | 288:5 |
| m 9:4 | making 19:13 | march 61:9 | matters 155:9 |
| m.b.a. 63:7 | 25:14 32:12 59:24 | 128:14,20,21 | mayor's 296:16 |
| m.d. 1:19 7:14 | | 173:3 207:10 | |
| 55:2 115:4 181:2 | 70:21,23 71:1,4 75:9 76:20 78:5 | 209:10 | mba 6:18,20 60:22 99:10 |
| 227:2,22 240:22 | 194:19 195:24 | marijuana 312:1 | mcginness 2:3 |
| 291:15 328:11 | 264:1,6 271:19 | 330:16 331:6 | mckesson 2:17 |
| 343:11 344:5 | | | |
| 345:5 346:8 347:4 | 323:20 326:20,21 327:18 332:23 | mark 3:3 8:20 | 8:17 21:22 56:18 |
| 347:9 348:4,13 | | 16:9,19 26:18 | 56:19,22 57:3 |
| 349:20 | 333:2 | 115:12 117:13 | 59:3 117:2 181:6 |
| m.p.h. 63:4 | male 191:18 286:5 | 118:7 179:22 | mcms 5:14 308:10 |
| madam 346:10 | malls 165:11 | 182:9 185:15 | md 6:17,20 60:22 |
| magic 33:3 | man 264:21 | 186:10 187:8 | 99:10 |
| mahaney 3:9 | manage 69:18 | 218:20 238:11 | mdl 239:19 |
| mail 5:6,9,13,14 | 135:22 179:13 | 239:6 286:13 | mean 26:8,19 |
| 5:19 6:2,5,14 | managed 129:24 | 308:20 346:5 | 28:23 32:19 34:3 |
| 27:13 28:1,17 | management 63:8 | mark's 187:23 | 35:11 42:17,23 |
| 61:7,12,14 246:19 | 66:9,10,11 69:12 | 239:3 | 43:1 52:2 57:8 |
| 255:1,9 295:4,12 | 69:24,24 70:3 | marked 12:8 | 80:16 88:7 102:4 |
| 295:22 298:20 | 121:22 264:3 | 23:16 60:24 99:12 | 107:20 113:15 |
| 299:11,20 303:16 | managing 74:2 | 182:14 183:24 | 114:9 129:18 |
| 304:6,12,19 308:7 | 329:18 | 246:24 254:21 | 133:17 134:23 |
| 308:9 309:7,8 | mandate 56:3,3 | 295:8 299:14 | 137:14 145:7 |
| 312:24 313:7,9,16 | manner 103:1 | 303:23 308:15 | 152:7 155:13 |
| 313:20 316:11 | manufacture | 313:3 339:10 | 167:16,17 170:15 |
| 339:6,19,20,21,24 | 137:21 | market 302:11 | 201:10,11 219:13 |
| 340:2,5,13,18,21 | manufactured | marshall 125:9 | 220:8 233:1,4 |
| 341:3,4,9 | 257:7 | massey 5:9 295:4 | 239:14 241:19 |
| mail's 313:12 | manufacturer | 295:14 | 279:11 283:8 |
| mailed 6:15 313:1 | 78:16 189:19,23 | master's 60:17,18 | 287:1 288:6 |
| mailing 37:12,19 | manufacturers | 72:9 120:3,7 | 290:10,18 293:9 |
| mails 17:6,8,12 | 35:22 43:16 76:10 | mat 6:15 313:2 | 300:24 301:22 |
| 27:10 242:21 | 76:14 77:16 | 318:7 | 310:22 313:17 |
| maintaining 272:8 | 190:10 | maternal 128:24 | 342:2 |
| maintenance | manufacturing | math 174:18 178:4 | meaning 33:23 |
| 34:22 | 39:15 105:3 | 178:6 216:3 | 44:12 112:13 |
| major 67:12 | 137:21 | matter 7:15 32:24 | 150:2 160:10 |
| 256:10 306:15,20 | manuscript 298:4 | 103:9 105:15 | 162:8 170:7 |
| majority 166:4,9 | 298:9 | 107:2 131:16 | 211:23 |
| 166:14,18 274:5 | | 155:8 262:22,23 | |
| 100.17,10 2/7.3 | | | |

[means - midwest] Page 38

| 10.11.05.01 | 101 10 10 7 10 | 1.0. | |
|--------------------|-------------------|--------------------------|-------------------|
| means 13:14 25:24 | 181:18 197:13 | medicines 160:5 | 329:4,17 333:14 |
| 44:7 137:19 152:7 | 202:19 212:9 | meet 16:14,18 | merit 1:21 |
| 157:12 215:7 | 252:4,23 253:3 | 28:5 | mess 100:7 |
| 244:21 248:18,22 | 259:13 296:20 | meeting 17:17 | message 76:6,9 |
| meant 26:21,23 | 297:22 301:5 | 18:5 42:3 134:1 | 86:5 149:8 210:1 |
| 35:8 43:6 124:20 | 309:11,13 315:13 | 196:15 | messages 74:7 |
| 179:11,12 209:24 | medically 280:23 | meetings 20:9 | 153:19 |
| measure 147:12 | 281:1 | 42:4 | messaging 76:9 |
| 209:3 329:22 | medication 145:21 | meets 344:15 | met 9:9 15:24 |
| measures 15:22 | 149:5 159:3 163:7 | 345:5 | 16:13,16 142:15 |
| mechanism 53:9 | 222:22 294:5 | meharry 68:15 | meth 105:11 |
| 55:18 169:21 | 314:8 316:22 | 69:7 121:1 | 166:13 279:7 |
| 170:13 177:15 | 317:9 | melton 6:5 246:19 | methadone 160:6 |
| 333:12 | medications 46:23 | member 91:14 | 160:7,10 |
| mechanisms | 66:19 67:3,3,4,6 | 92:5 | methamphetamine |
| 170:11,12 275:7 | 75:16 150:6 | member's 294:1 | 256:17 257:9,13 |
| 335:19 | 151:16 152:22 | members 51:23 | 257:14,23,24 |
| media 6:3 7:13 | 155:5 160:3 161:9 | 82:23 133:10 | 258:4,7,10,10,18 |
| 55:1 58:4 115:3 | 163:8 169:15,18 | 300:21,23 | 258:19 275:18 |
| 181:1 227:1,21 | 197:2 212:21 | memory 295:23 | 276:3 279:12 |
| 240:21 291:14 | 278:11 283:4 | 296:4 | 284:8 318:17 |
| 328:10 339:7 | 291:21 292:1,3 | men 147:21 | 321:20 |
| 343:12 | medicine 40:18 | 173:17 | methamphetami |
| median 206:20 | 60:16 62:21 63:1 | mental 277:10 | 165:23 244:1 |
| 212:15 | 63:11 64:1,4,4 | 319:14 | 276:1 |
| mediation 289:22 | 65:10,11,16,17,18 | mention 93:12 | method 133:6 |
| medicaid 124:17 | 67:19 68:1 69:8 | 127:5 129:11,11 | methodology |
| 207:3,8 208:6,9,16 | 72:14 86:3 91:14 | 148:1 | 285:8 |
| 208:17,18,19 | 91:21 92:9,10,13 | mentioned 10:7,24 | methyl 302:16 |
| 209:14 215:4 | 92:19 93:10 | 11:6 22:16 25:4 | meticulous 132:24 |
| 320:10 | 120:17,21 121:1,6 | 27:9,10 28:3 36:5 | mexico 258:2 |
| medical 38:6 | 121:10 122:10 | 45:21 103:19 | micro 333:22 |
| 58:12 63:12 64:23 | 124:19 149:19 | 105:14 109:15 | microlevels |
| 65:13 68:8,11,16 | 159:5,6 188:16 | 128:9 129:2 | 333:23 |
| 68:17 69:6,7,18,24 | 189:6,7 217:5 | 137:12 146:11,22 | microphones 7:4,8 |
| 73:8,10 76:4 | 223:11 225:19,20 | 155:11 190:23 | mid 94:20 148:8 |
| 87:10 91:16 92:20 | 226:2,10,13 264:2 | 194:20 204:1 | 221:9 |
| 93:1 94:6 121:1 | 272:6 283:14 | 205:1 215:5 | middle 129:22 |
| 123:18 124:18 | 294:1,21,24 | 253:13,21 259:2 | 340:21 |
| 128:19 130:20 | 337:17 | 273:1,2 275:13 | midwest 346:17 |
| 131:6,23 132:11 | 331.11 | 276:7 278:17 | 349:1 |
| 131.0,23 132.11 | | 2/0./2/0.1/ | JT7.1 |
| | | - | |

[migration - nashville]

| migration 194:22 | misstate 298:13 | 134:14 143:8 | mt 2:5 |
|----------------------------|-------------------------------|--|--------------------------------|
| miles 74:16 273:6 | mistake 14:18 | 250:7 251:13 | muffled 192:5 |
| million 97:18 | 224:1 | | mullen 255:10 |
| 114:4 147:5,12,14 | mistaken 90:7 | monogamous 110:15 | mullins 255:10,12 |
| 147:15 174:12 | misuse 321:23 | monster 154:21 | multi 136:10 |
| | 322:1 327:13 | 161:1 277:24 | |
| 198:12,13 266:17 280:10 | 332:8 | | multiple 73:21 192:16 197:1 |
| millions 266:16 | | month 37:6,23 80:3 269:19 270:2 | |
| | misusing 330:9 mixed 198:1 | | 244:4,16 301:13 |
| mind 43:24 81:7 | | months 25:21 | 319:17 334:19 |
| 83:20 84:1 166:10 | ml 239:19 | 27:11 93:17 | multiply 174:18 |
| 202:10,14 203:10 | mlp 26:21 30:13 | 138:15 260:23 | 245:21 |
| 214:9 240:6,7 | 34:22 227:19 | 281:8 | mute 191:21 |
| mine 264:9 | 228:15,24 231:16 | moons 36:14 | muted 185:14 |
| minimum 92:24 | 231:22 232:24 | morgantown | 338:16 |
| 146:2 | 234:17,21 236:21 | 315:5 316:4 | n |
| mining 144:12 | 237:3,24 239:19 | morning 7:2 9:9 | n 7:1 |
| 145:6,11,12,23 | 287:1 288:5 | 129:15 | n.w. 2:12 |
| 195:20,23 197:19 | 289:10,16 290:6 | morphine 153:3 | naive 163:20 |
| miniscule 145:22 | mmwr 5:10 295:5 | 164:15 170:13,14 | naloxone 44:15 |
| minuscule 26:4 | 298:1 | 177:2,4 | 126:12 160:6,17 |
| 52:21 167:9 | mobile 131:12 | mother 169:24 | name 7:22 23:1 |
| minute 83:3 | mock 5:13 308:7 | mothers 133:11 | 24:16,19 73:9 |
| 108:14 179:21 | 309:9,11,13,15 | 320:10,11,14 | 166:13 183:10 |
| 180:17 226:18 | 339:21,22 | motion 231:3 | 188:13 189:12 |
| 267:2 286:8 327:2 | mom 80:23 | motley 2:4 234:18 | 253:5 285:7 |
| minutes 16:23 | moment 240:6 | 236:13 | 313:10,11 328:18 |
| 51:9 54:18 103:9 | 309:3 321:19 | move 32:8 50:16 | 346:6 347:3,4,15 |
| 103:9 105:16 | moms 128:23 | 115:19 198:18 | 348:3,4,21 |
| 107:3,3 180:1,10 | 173:6 | 212:12 217:8 | named 341:6 |
| 308:22 310:10 | money 174:24 | 232:11,11,18 | names 28:12 |
| 328:2 338:7,15 | 175:8 176:16 | 266:19 286:19 | 131:12 |
| miscommunicati | monique 2:4 182:7 | moved 70:7,9,11 | napoli 229:2,4 |
| 219:7 | 183:1,8 184:18 | 171:17 | 242:19,20 |
| misconstruing | monitor 56:3 | movement 195:17 | napolini 242:17,18 |
| 326:3,5,8 | 143:10,16 | moving 177:24 | narrow 321:17 |
| missed 228:18 | monitored 70:24 | 194:18 196:9 | narrowly 22:9 |
| 259:24 267:17 | 270:10 | 211:1 323:6 | nas 168:9,12,13 |
| 303:6 | monitoring 40:19 | mph 6:17,20 60:22 | 172:5,22 173:1,1 |
| missing 209:23 | 42:15 58:11 70:20 | 99:10 | 174:13,14 |
| mission 128:21 | 88:24 89:5,11 | mr.colantonio | nashville 68:16,21 |
| | 130:21 132:7 | 187:1 | 68:21 69:4 121:1 |
| | | | 00.21 07.T 121.1 |

[nation - number] Page 40

| | I | | I |
|----------------------|--------------------|---------------------------|---------------------------|
| nation 113:7 | 179:12 192:2,10 | neurosurgery | noon 114:14 |
| 206:23 | 192:18,21,22 | 66:3 | norm 150:2 |
| nation's 97:4 | 195:18 196:16 | never 45:23 | normally 300:8 |
| national 6:12 | 199:15,17 200:24 | 228:20 257:8 | northwestern |
| 31:12,15,16 32:18 | 201:16,20 202:5 | 283:3 290:10 | 62:16,17 |
| 58:4 97:13 122:22 | 203:6,12,19,23 | 331:6,7 | nos 7:19 112:9 |
| 179:5 254:19 | 204:17 205:2,16 | new 99:14 127:3 | 303:15,24 308:6 |
| 255:23 275:22 | 206:13,14 208:1,4 | 131:2 167:21 | 308:17 |
| 320:9 | 208:11 209:3,19 | 169:22 283:13 | notarized 346:14 |
| nationally 57:24 | 210:5 211:12,13 | 302:20 342:3 | notary 344:4 |
| 105:21 122:21 | 212:20,21 213:9 | news 131:2 | 346:24 347:10,18 |
| 220:13 319:14 | 213:18 215:11 | nice 264:11 | 348:15,23 349:23 |
| native 304:14 | 226:17 273:8 | nicole 2:19 8:16 | note 7:4 12:17 |
| natural 177:10 | 278:12 281:22 | nicotine 334:19,22 | 50:6 54:14 298:19 |
| nature 10:11,23 | 319:13 322:10 | nine 171:4 326:18 | 346:12 |
| 11:1 37:20 71:23 | 334:7 | 343:12 | noted 8:24 119:17 |
| 85:15 151:18 | needed 27:22 | ninth 2:7 | notes 226:19 344:9 |
| 234:2 278:5 | 46:23 145:20 | nodded 284:23 | notice 1:20 6:22 |
| 286:14 310:19 | 163:18 198:12 | non 340:6 | 23:14 239:15 |
| nearly 311:10 | 212:17 256:20 | nonfatal 178:9 | noticed 180:6 |
| necessarily 103:17 | 279:10 286:2,3 | 274:18 284:15 | 239:13 |
| 103:20 157:15 | needs 5:20 88:3 | 285:4 | noticing 8:10 |
| 208:6,12,14 | 143:4 146:7 155:9 | noninvolved 167:2 | notified 296:18 |
| 209:22 211:15,22 | 164:11 177:11 | nonmedical 275:4 | noting 298:22 |
| 212:3 244:5 | 191:21 199:2 | nonopioid 213:2 | nova 123:2 |
| 254:11 282:20 | 200:1 201:2 | 215:20 275:17 | novel 5:7,8 299:12 |
| 330:20,24 337:16 | 211:18 303:17 | nonparty 338:10 | 299:14 300:11 |
| 342:2 | 334:2 | nonpharmaceuti | 302:11 |
| necessary 280:23 | negotiation 142:14 | 212:22 213:1 | november 127:24 |
| 281:1 | neither 11:11 | 215:18 | nows 168:14 |
| necessity 329:20 | 165:7 294:10 | nonprescription | nuclear 94:21 |
| need 14:5 27:21 | 344:11 | 253:14,22 | number 21:4 22:6 |
| 38:17,18,24 39:6 | neonatal 97:17 | nonprescriptions | 36:20,21 57:24 |
| 39:12 46:23 | 136:20 168:13,14 | 305:13 | 61:22 62:2 66:19 |
| 109:24 116:8 | 170:17 | nonresponsive | 100:22 101:20 |
| 142:11 143:3 | neurobiologist | 198:19 266:20 | 104:3,13 108:1 |
| 144:1,14,20,21 | 337:23 | nonretained 119:6 | 110:12 111:3,16 |
| 146:3,11 153:20 | neurobiology | 119:10,11 231:19 | 112:9,13 113:20 |
| 154:12 156:13 | 337:15,17 | 233:16 | 113:21 123:9 |
| 159:12,18,20 | neuroreceptors | nonthreatening | 130:13,17,22 |
| 164:11 177:11,19 | 337:10 | 173:13 | 131:18 132:8,12 |
| | | rol Colutions | |

[number - okay] Page 41

| 140:22 141:1 | oath 8:3 9:19 | obligation 148:21 | 124:17 125:11,12 |
|-------------------|--------------------------|---------------------------|--------------------------|
| 144:19 146:23,24 | 13:13,16 68:6 | 222:14 | 129:15,20 131:7 |
| 155:18 157:20 | oaths 80:18 | obligations 42:15 | 132:11 133:7 |
| 158:10 167:12,18 | obesity 72:19 | obtain 93:18 | 143:9 165:17 |
| 169:6 172:13 | 143:10 145:15 | 119:22 230:7 | 171:22 239:22 |
| 177:21,24 192:12 | 197:23 | 292:19 | 240:1 252:5,23 |
| 193:4 194:7,10 | object 17:20 30:4 | obtained 71:9 | 253:2,3 254:18 |
| 203:9,10,11 | 31:11 48:1 50:16 | 120:3,7 248:24 | 255:22 296:16 |
| 205:14 214:4 | 52:19 53:15 59:20 | obtaining 258:21 | 301:4 317:19 |
| 215:2 224:12 | 68:3 73:14 87:13 | 330:24 | 331:1 |
| 244:19 245:14,15 | 88:6 104:16 106:1 | obtains 269:15 | officer 9:15 11:16 |
| 245:21,22 266:24 | 106:15 108:9 | 292:8 | 22:19 30:7,10 |
| 267:11,19 268:10 | 117:8 199:5,18 | obviously 31:18 | 31:6,8 35:17 |
| 268:24 272:15 | 200:13 202:13 | 37:16 96:15 127:1 | 40:15 48:3,9 |
| 274:18 281:16 | 203:14,24 207:16 | 127:13 178:16 | 49:22 70:12,16 |
| 284:17,24 299:22 | 214:6 216:18 | 183:10 289:17 | 84:20 86:5 91:8 |
| 303:4,9 306:5 | 217:21 218:8,10 | occasion 17:13 | 91:12,24 92:2,4 |
| 310:21,21,23 | 225:22 226:5 | 134:8 | 127:14,15,16,17 |
| 331:9 333:4 | 248:10 249:22 | occasions 64:5 | 127:22 128:19,20 |
| 339:22 340:6 | 250:18 252:9 | occupied 160:12 | 183:13 217:2 |
| 341:19 342:19 | 254:10 261:15,23 | occupy 160:15,20 | 300:9 315:10 |
| 343:11 346:7,13 | 266:2 267:13,21 | occupying 160:20 | offices 76:13 |
| numbered 211:7 | 268:4,14 270:3 | occur 36:17 | 131:23 |
| numbers 61:20 | 271:2,10 272:20 | occurred 22:8 | official 347:15 |
| 97:20 114:6 144:4 | 280:8 294:22 | 39:23 297:10 | 348:21 |
| 145:3 147:22,23 | 312:18 322:7 | occurring 28:6 | officially 25:12 |
| 149:14 158:1 | 326:16 327:9 | 43:11 130:23 | officials 165:3 |
| 166:21 178:15 | 342:14 | 161:19 | 171:2 |
| 194:12,14 196:8 | objecting 230:23 | occurs 44:9 334:9 | officio 91:13 92:5 |
| 215:14 223:5 | objection 25:2 | ocme 301:5 | oftentimes 42:19 |
| 245:18 255:3 | 49:18 50:8,14,15 | october 27:7 101:9 | 81:10 97:9 103:17 |
| 285:4 321:8 | 50:15,20 117:3,10 | 122:16 206:4 | 103:18 133:17 |
| 341:14,17,17,18 | 117:12 119:13 | 244:10 300:1 | 141:11 171:2,23 |
| 341:19 348:7 | 181:7 186:8 | 344:17 | 252:19,21 272:24 |
| nursing 68:9 | 198:23 200:14 | offense 324:9 | 282:21 |
| nw 2:20 | 220:1 230:4,13 | offenses 37:17 | oh 51:8 238:19 |
| 0 | objections 8:8 | offer 48:17 173:12 | ohio 167:22 346:2 |
| o 7:1 | 32:15 50:11,19 | 173:17 277:7 | okay 10:11 11:5,9 |
| o'clock 99:20 | 219:6 327:17 | offered 12:20 | 12:2,11 13:10 |
| 129:15 181:4 | objectives 107:11 | office 6:12 43:23 | 14:7 15:5 17:17 |
| 127.10 101.1 | 107:16,17 108:3 | 58:13 102:7 | 19:24 23:1,12,23 |
| | | | |

[okay - opioids] Page 42

| 24:2,8,23 26:22 | 310:11,18 314:20 | operator 7:2 8:23 | 55:16 57:16,21 |
|-------------------|------------------------|---------------------------|-------------------|
| 27:21 49:13 51:8 | 315:1 316:9,20 | 9:3 54:21 55:1 | 59:9 72:4 95:13 |
| 51:12 52:4,8 62:9 | 317:3,7 321:10 | 114:22 115:3 | 96:1,2,3,9 98:24 |
| 64:12 81:22 85:2 | 322:24 326:5,11 | 180:21 181:1,12 | 99:1,5 101:24 |
| 86:18,20 87:22 | 329:2 330:7 331:4 | 226:21 227:1,21 | 103:16 105:20,24 |
| 89:4 91:10 100:1 | 332:1,11,17,20 | 228:20 240:17,21 | 108:13,20 110:22 |
| 100:3,4,10,11 | 335:3,8 336:3,12 | 291:9,14 309:2 | 111:20 112:10 |
| 101:6,15 106:11 | 338:14,22 339:4 | 310:8,14 328:6,10 | 125:8,20 128:2 |
| 111:1,6,11,19 | 339:18 340:2 | 338:12 343:9 | 130:11 133:22 |
| 112:2 114:14,19 | 341:23 343:3 | opiate 256:8 | 136:7 137:1 |
| 114:20 115:12,15 | old 26:19 171:5 | 296:24 325:1 | 139:17 142:2 |
| 115:18 116:9,10 | 216:17 260:22 | opiates 5:7,8 | 144:23 146:17 |
| 116:22 117:12 | 276:9 296:10 | 140:16 141:19 | 148:6 149:16 |
| 118:18 119:13 | oldest 205:12 | 192:3 208:11 | 153:4 157:7 160:8 |
| 162:18 176:18 | once 28:9 29:17 | 299:12,14 300:12 | 161:15 162:17 |
| 180:1,7,18 182:22 | 84:4 151:6 159:8 | opinion 13:9 34:15 | 163:16,23 166:2 |
| 184:11 186:5,18 | 163:7 176:13 | 59:22 83:13,14 | 168:6,10,15 171:9 |
| 187:14,24 188:2,7 | 214:7,10 246:8 | 113:22 148:4 | 177:19,22 178:2 |
| 191:10 192:9,17 | 267:23 | 154:14,15 156:21 | 196:5 202:5 |
| 193:10,13 195:19 | ones 10:13,24 21:9 | 165:19 168:3 | 211:18 213:2 |
| 200:16 202:7 | 74:21 85:6 113:1 | 177:17 181:7 | 221:7 223:8 |
| 203:9,21 204:23 | 128:10 189:1 | 199:20,24 200:7 | 224:18,18,22,22 |
| 206:19 207:3 | 210:5 229:24 | 200:18,22 201:14 | 225:6 227:6,17 |
| 208:13,24 209:17 | 260:12 262:13 | 202:8,21 204:10 | 228:2,13 235:11 |
| 211:11 212:11 | 305:12 319:5 | 219:21 220:9,10 | 241:7,12,16,24 |
| 213:7,23 214:11 | ongoing 21:12 | 220:23 | 242:1 243:15 |
| 215:15,21,22 | 63:16 81:4 95:20 | opinions 34:6,10 | 254:17 255:22 |
| 217:11 219:16 | 97:20 | 35:1 83:9 116:20 | 256:5,11 260:21 |
| 224:7 226:1,13,20 | online 21:7 96:9 | 119:11 156:16 | 274:7 286:18 |
| 228:23 231:13,16 | 189:4 | 181:15 185:3 | 293:24 295:6 |
| 232:17 235:20 | onwards 204:8,12 | 188:12 189:11 | 296:8,19 297:10 |
| 240:16 244:12,15 | 000 343:19 | 229:13,14,22 | 302:13 305:22,23 |
| 249:11 255:6 | open 12:2 23:5 | 230:7 235:9,10 | 312:9 321:16,18 |
| 256:3,8 257:19 | 60:19 100:6 133:6 | 236:3,5,16 237:11 | 324:1,3,7 325:4 |
| 258:17 265:12 | 250:19 | 237:22 238:7,8 | 329:9,24 330:8 |
| 269:22 279:21,22 | opens 36:22 | 241:1,3 | 331:5,12,19 332:7 |
| 287:18 288:3 | operations 46:21 | opioid 5:11 6:11 | 332:8 335:11 |
| 290:18 291:7,8,10 | operative 141:12 | 30:12 31:20 32:20 | opioids 22:11 |
| 293:18 295:17 | 196:23 | 32:21 34:14 35:11 | 31:22 33:8 35:15 |
| 303:14 304:15,20 | operatively | 40:16 43:13 48:18 | 39:6 42:1 47:19 |
| 305:15 309:5 | 141:15 | 49:16 52:17 53:19 | 66:13,18,24 67:16 |
| · · · | - | | , -, |
| | | | |

[opioids - overwhelming]

www.veritext.com

| | | | 9 |
|--------------------|--------------------------|---------------------------|-------------------|
| 67:23 69:13 75:13 | 269:14,19 270:1 | 272:16 334:3 | 184:7,16 220:15 |
| 76:10 77:1,13 | 272:16 274:23 | ordered 96:7 | 243:4,9,17,24 |
| 78:11 81:23 82:4 | 275:2,15,24 276:2 | 183:20 | 244:3,20 245:16 |
| 82:14 86:22 87:4 | 276:10,14 277:15 | ordering 267:14 | 246:20,22 250:5 |
| 87:9 88:2,14 89:7 | 278:10 279:1 | orders 188:17 | 256:10,16 274:16 |
| 90:10,22 95:3,8,21 | 280:1,6,12 281:6 | 270:10 272:9,10 | 275:11 284:12,14 |
| 104:21,22 113:3 | 281:19,22 282:7 | original 166:1 | 284:21 285:10 |
| 122:23 123:21 | 282:10,18 284:5,8 | originally 168:6 | 295:6 296:20,24 |
| 127:11 128:7 | 291:19 292:9,18 | osteopathic 121:5 | 297:10 301:6 |
| 129:9 130:3 | 293:6,20 302:11 | outbreak 5:11 | 302:7,12,18 303:4 |
| 132:16 136:17 | 305:14 319:9,12 | 97:4,5 135:17,19 | 303:8,21 305:8 |
| 140:10,14 141:3 | 321:18,21 329:15 | 136:4,7,10 295:7 | 306:16 307:20 |
| 141:13,24 142:8 | 330:10,15 333:4 | 295:21 297:11 | 318:12 331:12,15 |
| 143:2,16 144:1,12 | 333:13 335:24 | 299:4,7 | 339:7 340:10,15 |
| 144:14,21 146:7 | 336:6,8 337:3,9,19 | outbreaks 97:2 | 342:16,17,17,20 |
| 148:3 152:1,2 | 337:22 | 135:22 | 343:1 |
| 154:21 159:24 | opportunities | outcome 8:4 | overdosed 126:8 |
| 161:17 168:16 | 138:23 | outed 136:2 | 165:5 340:7 342:1 |
| 169:23 170:4,6 | opportunity 18:16 | outer 153:9,20 | overdoses 113:12 |
| 176:19,22,23 | 44:17 59:15 100:9 | outline 42:7 | 130:17 178:5 |
| 177:9,10 179:1,8 | 115:9 322:15 | outlining 216:15 | 244:16 247:13 |
| 188:19 191:4 | 323:7 324:11 | outpatient 65:12 | 274:19 284:15 |
| 192:1,11,18,22 | opposed 26:4 | 68:23 | 285:3,4,21 296:8 |
| 193:6 197:2,7,9,12 | 80:20 104:23 | outset 186:13 | 318:15 330:8 |
| 197:14 201:1 | 145:23 176:23 | outside 20:9 25:10 | 331:19 341:20 |
| 203:7,12 206:15 | 224:14 279:7 | 131:17 | overdosing 284:13 |
| 208:2,5,20 209:4 | opposing 99:18,21 | overall 76:11 | overlaid 218:13 |
| 209:20 211:14,21 | 114:17 | 113:12 143:11,14 | overlap 306:8 |
| 212:6,8,24 213:10 | opposite 87:17 | 146:10 147:17 | overlay 230:14 |
| 213:18,19 214:17 | 333:19 | 179:23 212:21 | oversaw 130:20 |
| 215:9,22 218:13 | options 212:22 | overdoes 183:4 | 135:17 |
| 219:22,23 220:14 | 213:1,2,2 215:18 | 302:19 318:18 | oversight 6:10 |
| 220:20 221:12 | 215:20 | overdose 5:11,23 | 254:15 255:17 |
| 223:23 224:6,8 | order 127:4 138:3 | 6:3,6,7 22:6 | oversupply 22:10 |
| 225:17,20 243:19 | 153:11,22 155:2 | 124:22 151:10 | overview 182:13 |
| 252:8,21,24 253:6 | 176:12 179:13 | 162:23 163:1 | 182:18 183:4 |
| 256:10 258:24 | 188:15 189:5 | 165:1 166:21 | 218:9 |
| 259:11,12 260:6 | 202:1 214:15 | 167:11,13,13 | overwhelmed |
| 263:21 266:13,24 | 217:8 266:13 | 168:4 178:7,9,10 | 131:18 |
| 267:11,19 268:3 | 267:1,12,20 269:1 | 178:12,16 182:12 | overwhelming |
| 268:11,19 269:2 | 269:2,14,18 270:1 | 182:19 183:23 | 43:6 45:2 142:10 |
| | | | |

[owned - pdf] Page 44

| owned 81:11 | 78.12 12 15 20 20 | narrating 50.7 | ness 115.7 10 |
|--------------------------------------|------------------------------------|--|-----------------------------|
| owned 81:11 owner 345:3 | 78:12,13,15,20,20 78:24 79:3,12 | parroting 50:7 part 38:8 41:17 | pass 115:7,10 328:14 |
| | · | _ A | |
| oxycodone 191:7 191:11 306:11 | 86:23 87:1 103:18 | 42:18 50:1 72:6 | passed 43:24 44:5 |
| | 140:17,19 141:10 | 76:21 81:21 93:21 | 122:12 142:10 |
| 307:4 | 141:16 144:7 | 94:24 95:4 110:11 | 167:17 270:23 |
| oxycontin 259:14 | 148:10,11,12,15 | 113:7 122:12 | 271:12 |
| p | 148:22 149:12 | 136:9 137:7 143:6 | passing 92:23 |
| p 7:1 9:4 | 157:9 196:17,21 | 145:9 169:1,8,9 | 125:23 142:21 |
| p.m. 115:5 180:22 | 196:23,24 197:2,4 | 174:23 184:9 | passionate 102:14 |
| 181:4 226:22 | 197:5 198:5,8,14 | 200:9 201:23 | 102:20 |
| 227:3,23 240:18 | 198:21 199:15,17 | 220:4 221:10 | path 335:21 |
| 240:23 291:11,16 | 202:3 207:12 | 237:22 255:20 | pathway 163:19 |
| 296:21,21 328:7 | 211:13 212:21 | 259:21 260:3 | 316:23 317:12 |
| 328:12 343:10 | 222:3,4,5,15 223:3 | 265:21 266:9 | 333:7,7 |
| pace 247:6 | 259:2,3,11 260:19 | 273:9 275:20 | pathways 335:2 |
| packet 6:15 313:1 | 261:19 263:23 | 294:6 303:6 311:4 | 335:19 336:23 |
| 314:7,10,17,18 | 264:3,8,10 279:19 | 314:16,22 316:10 | patience 338:18 |
| 315:20 316:8 | 281:7,19 282:4,8 | 333:11 348:9 | patient 68:5 77:17 |
| page 24:15 62:2,6 | 292:14 294:14 | participants 94:19 | 86:10 88:1,15 |
| 64:18,19 79:15 | painkillers 312:9 | 95:6 | 90:20 112:17 |
| 90:16 91:5,10 | pandemic 96:16 | participate 63:15 | 130:5 252:14 |
| 100:18,19 107:8 | 131:3 | particular 18:17 | 276:17 292:2 |
| 183:3,9 184:19 | panned 283:15 | 27:17 53:10,22 | patients 44:13 |
| 207:24 208:1 | paper 97:22 174:4 | 83:19,24 85:5 | 46:22 65:12,24 |
| 207:24 208:1 | 316:21 322:5,18 | 93:17 94:14 | 66:3,5 67:5 74:15 |
| 255:2 256:1,5 | para 302:15 | 108:23 118:20 | 75:1,20 78:3 |
| 295:12,16,22 | parachute 201:18 | 189:20 191:5 | 148:22 222:14 |
| 295.12,10,22 | 201:19,20 | 192:14,23 194:13 | 252:17 263:8,20 |
| 299:21 313:7,23 | paragraph 256:5 | 206:17 214:23 | 276:8 277:14 |
| 317:4 318:3 321:7 | 296:15 297:7 | 217:18 219:21 | 294:12 |
| | 302:10 318:6 | 261:10 284:1,19 | pattern 266:18 |
| 346:13,15 348:7 | 319:8 321:12 | 285:8 294:4,4 | 274:11 |
| 349:3 | 322:11,12 323:11 | 306:6 335:10 | paul 2:6 8:18 |
| pages 257:1 | 323:19,22,23 | parties 1:21 7:11 | 28:14 29:19 187:6 |
| paid 229:7 231:8 | parallel 144:14 | 125:23 344:12,14 | paused 228:22 |
| 231:16,18 233:17 | 290:20,22 | partners 300:18 | pay 37:2 134:16 |
| 233:20,21 234:9 | parent 59:7 | parts 109:9 256:11 | paying 290:20 |
| 286:17 | parents 171:2,16 | party 8:3 11:11 | payors 124:19 |
| pain 46:23 65:20 | 171:16 | 117:5 119:8 | pbs 123:2 |
| 65:23 66:10,11 | parking 74:16 | 239:20 290:19 | pdf 310:20 |
| 69:12,19,24 70:3 | F | | 1 |
| 73:24 77:19 78:10 | | | |
| | | | |

[pdmp - phone] Page 45

| | I | | |
|--------------------------|------------------------|--------------------------|-----------------------|
| pdmp 89:12 | 208:19 211:21 | period 146:14 | 248:15,16,21 |
| pdo 134:13 | 212:6 215:16 | 243:13 245:9,16 | 265:12,14,21,24 |
| peak 156:11 | 217:4 243:11 | 264:16,17,24 | 266:3 267:14 |
| peaked 246:1 | 247:12 263:14 | 265:1 297:1 | 268:19 269:23,24 |
| peaking 264:22 | 264:7,21 271:18 | 306:17 316:16 | 271:6,9 |
| pediatrician | 271:19 273:17 | 334:8 | pharmacist 80:12 |
| 171:22,23 | 274:18 277:19 | permissible 17:22 | 80:21,22 82:10,20 |
| peek 204:2 | 278:23 279:7 | permitted 40:4 | 83:7 86:11,13,14 |
| peer 122:18 | 280:10,14,22 | person 34:9 81:10 | 87:22 88:1,3,11 |
| 123:16 | 281:2,9,16,18,20 | 119:11 133:16 | 90:3 |
| peia 175:19 | 281:21 282:13,18 | 134:15 136:2 | pharmacists 80:17 |
| pending 232:15 | 283:2 284:12,21 | 143:24 147:19 | 80:18,24 83:6 |
| 235:8,21 298:24 | 285:10 292:11,12 | 153:18 154:18 | 85:8 89:4,22 90:8 |
| pennsylvania | 292:17 293:8,12 | 159:5,8 178:5,7 | 270:9 |
| 167:23 | 293:15 311:11,20 | 241:20 244:22 | pharmacology |
| penultimate 256:4 | 311:24 312:4,8 | 245:2,6 278:8 | 65:21 66:16 |
| people 28:10 43:7 | 314:19 327:22 | 281:11 331:5 | pharmacy 39:11 |
| 44:4,12 45:16 | 330:8,14 331:19 | personal 10:23 | 40:18 41:9,11,18 |
| 46:9 47:2,5 70:22 | 334:13 339:23 | 20:24 73:3 117:6 | 41:24 51:16,17,20 |
| 74:18 90:14 98:2 | people's 294:24 | 118:11 185:24 | 51:23 52:5,9,12,16 |
| 98:2 103:8,12 | percent 97:16 | 186:2 252:16 | 53:3,12,14,18 54:3 |
| 105:14 107:1 | 111:24 124:11 | personally 97:6 | 66:8,8 68:9 79:21 |
| 123:4,9 126:4,6,10 | 136:14 157:22 | 127:2 160:22 | 80:9,20,21 81:11 |
| 126:13 132:21 | 158:22 162:6,16 | 187:2 220:22 | 84:9 85:13,21 |
| 134:2,2,2,4,23 | 166:16,19 167:20 | 251:7 309:22 | 86:2,6,14,14 90:5 |
| 137:23 138:22 | 172:12 174:14,16 | 331:22 347:11 | 90:18,19 112:16 |
| 144:19 145:17,20 | 196:19 204:11 | 348:15 | 121:14 124:18 |
| 145:23 147:14,15 | 207:7,13,22 209:7 | perspective 39:11 | 134:12,16 135:7 |
| 147:21 150:3,5,8 | 209:7 216:1,6,7,8 | 42:5 96:6,8 262:8 | 251:16,18,24 |
| 150:12 154:2,8 | 217:12,16 219:22 | 330:1 | 266:14,24 267:11 |
| 155:18 158:11 | 220:19 245:23 | pertained 19:11 | 267:20 268:2,2,6 |
| 159:15,18,22,24 | 246:5,9,9 264:13 | pets 155:4 | 268:11 269:1,2,13 |
| 160:1,21 163:1,6 | 265:8 273:3 | pharmaceutical | 269:18 272:16 |
| 163:17 164:7,12 | 324:24 331:8,8,8,9 | 73:22 170:12 | 273:7 274:2 |
| 164:18 165:6 | percentage 150:21 | 213:1 215:20 | 292:22 |
| 166:3,5 167:1,2,4 | 172:14 208:9,17 | 257:15 258:9 | phenomena |
| 175:24 176:1,23 | 211:8 245:13 | pharmacies 36:2 | 275:19 |
| 177:24 178:1,2,8 | 272:17 281:1,9 | 39:5,12 43:18 | phenomenon |
| 178:10,11,13,15 | 282:2,3,8,12,13,16 | 83:16,19 84:1,5,14 | 164:6 |
| 178:17 179:13,16 | perfectly 32:13 | 84:17 85:5,10,21 | phone 16:19,20 |
| 201:17,18 208:9 | 35:7 | 85:24 90:3 105:5 | 27:15 119:16 |
| | | | |

[phone - policy] Page 46

| 187:13 228:21 | pills 35:23 36:1 | 23:2,14 24:10,12 | 303:13 308:1,5 |
|--------------------|---------------------|------------------------|-------------------------|
| 346:3 | 43:13 47:8 103:19 | 24:24 25:16 27:3 | 312:21 317:3 |
| phones 7:7 | 113:18,21 114:4,9 | 28:1 29:2 33:14 | 318:2 321:7 |
| phrase 277:23 | 114:12 130:13 | 117:23 118:8 | 323:18 333:1 |
| physical 151:18,22 | 146:17,24 147:5 | 214:14 231:9 | 339:1 346:11,11 |
| 294:24 | 147:13 148:6 | 233:12,18 234:11 | plenty 83:14 |
| physically 132:3 | 149:17,18 154:24 | 234:23 237:5 | plus 198:4 201:11 |
| physician 25:23 | 156:7,19 157:12 | 239:4,7 240:3 | 245:13 319:19 |
| 63:16 64:22,23 | 166:11 168:6 | plan 29:7 37:13 | pogue 2:14 8:14 |
| 65:5,9 68:23 | 177:14 178:20 | plane 201:17 | point 11:17 20:5 |
| 70:17 71:21 74:1 | 193:23 198:12 | planning 173:14 | 34:22 38:15 55:15 |
| 82:13 84:8 123:23 | 223:9,10 226:1,9 | 173:18 174:1 | 55:15 59:4 71:19 |
| 129:3 143:23 | 226:10,13 266:16 | 317:19 | 78:24 80:11 84:3 |
| 225:10 247:18 | 275:5 330:24 | plans 37:22 | 94:3 106:17 |
| 252:12 276:13 | pink 302:14 | plausible 248:12 | 107:21 118:14 |
| 280:13 293:23 | pinky 302:14 | play 155:10 | 127:1 145:2,16 |
| 337:17 | place 7:7,11 38:5 | 230:15 260:19 | 150:11,20,24 |
| physicians 38:16 | 82:17 138:1,2 | played 79:2 | 154:18,20 161:16 |
| 38:21,22 44:8 | 142:17 161:21 | 165:13 259:19 | 169:14 171:5 |
| 46:2,24 76:17 | 220:21 230:3 | playing 98:12 | 181:10 185:22 |
| 78:2 110:4 188:17 | 269:13 275:8 | 164:22 | 200:10 215:10 |
| 249:12,20 261:8 | 344:6 | pleadings 119:7 | 221:21 230:11,12 |
| 261:11 264:14 | placed 68:22 | pleasant 2:5 | 230:18 232:1 |
| 265:9,15 300:16 | 148:18 222:11 | pleasantly 175:7 | 236:8 240:8 247:9 |
| physiological | 266:13 | please 7:4,6 8:9 | 247:10 255:6 |
| 151:18 | placenta 169:19 | 9:1,3 12:2 14:13 | 282:14 296:4 |
| pick 7:5 | 170:8 | 20:15 22:2 23:5 | 297:19 299:5 |
| picking 187:11 | places 68:19 | 24:1,7 32:15 | 306:13 329:24 |
| 325:15 | 141:13 152:4 | 36:10 41:12 43:24 | 331:17 332:22 |
| piece 72:5 161:8 | 165:16 269:18 | 54:14 62:2 64:8 | 333:1 334:6 337:8 |
| 190:14 228:18 | 314:18 | 64:15 92:16 93:23 | 337:24 340:11,16 |
| 324:13 | plainly 43:8 | 99:7 108:10,10 | pointed 233:13 |
| pieces 44:6 96:11 | plaintiff 1:5,12 | 113:4 181:12 | points 103:10 |
| 109:8 116:15 | 21:16 25:13 | 183:2 192:6 | 106:12,13 107:3,5 |
| 125:18 138:19,21 | plaintiff's 182:9 | 205:22 206:8 | 107:7,9,12,13,18 |
| 323:6 324:9 | 182:11,15 183:22 | 211:16 214:12 | 107:24 108:1,2 |
| 325:16 | 184:1,4,13 204:5 | 216:23 226:8 | police 125:15 |
| piecing 322:13 | 218:6 221:5,6 | 227:14 228:10 | policies 43:24 |
| pill 221:8 292:14 | plaintiffs 2:2 6:22 | 244:12 253:16 | policy 6:12 44:6 |
| pillars 216:4 | 8:19 10:16 11:10 | 259:24 268:1 | 72:8 73:4 75:9 |
| | 11:12,18 21:17 | 285:5 299:9 | 78:5 92:21 121:22 |
| | | | |

[policy - prescription]

www.veritext.com

| 125:11 138:10 | positions 48:16 | practiced 63:24 | prescribed 129:9 |
|--------------------------|----------------------|-------------------------|--------------------|
| 254:19 255:23 | 120:11 128:1 | 64:3 | 172:2 224:5 |
| 273:16 276:12 | positive 152:15 | practicing 68:18 | 225:17 280:13 |
| 296:17 317:19 | poss 198:8 | 68:20 79:13 | 282:7 283:3 |
| political 208:21 | possess 139:4,6,16 | 188:19 261:9 | 291:22 292:3,9,18 |
| politico 123:7 | 293:20 | practitioner 137:5 | 293:6,21 294:3 |
| polysubstance | possession 189:3 | precedes 332:7 | prescriber 82:17 |
| 318:7 | 293:5 | precise 281:17 | 88:13 252:12 |
| poor 143:12 | possible 49:7 | precursor 258:17 | prescriber's 275:3 |
| 197:22 211:24 | 176:11 196:15 | predictions 194:17 | prescribers 38:20 |
| 320:15 | 198:7,10,20 | predilection 172:6 | 38:21,24 46:24 |
| pops 80:23 | 248:12 264:7 | predominant | 74:20 76:2 78:2 |
| population 69:1,5 | 272:7 282:13 | 321:22 | 112:18 113:2 |
| 72:18 143:4 146:9 | 328:19 | prefrontal 153:10 | 247:20,24 248:6,8 |
| 147:14 149:10 | post 141:12,15 | pregnancy 320:9 | 249:5,13,17 |
| 156:12 157:6,15 | 196:23 | pregnant 169:6,8 | 260:13,17 261:3 |
| 166:19 167:4,6 | posted 69:16 | 169:14 175:3 | 261:12 262:9,16 |
| 169:9 172:13 | potent 164:15 | 320:13,14 | 262:21 263:1,17 |
| 193:18 194:20 | 165:2 | preliminary 6:22 | 263:19 265:15 |
| 195:17 198:13 | potential 139:14 | 9:18 23:2,14 | 268:22 270:16 |
| 199:14 201:14 | 172:3 335:21 | 298:4 303:3 | prescribing 37:13 |
| 205:3,6 207:14,23 | potentially 52:23 | 306:12 318:10 | 37:22 42:11 66:12 |
| 208:7,16,17 209:7 | 67:4 82:23 83:2 | 341:16,19,23 | 66:17,18,20,22,23 |
| 209:8 211:8 223:1 | 116:21 140:4 | 342:8 | 67:23 68:1 72:4 |
| 266:17 273:2,3 | 194:11 195:14 | prematurely | 75:4 94:2 110:5 |
| 280:21 282:6,9 | 279:20 | 342:7 | 114:10,10 141:23 |
| 324:21 334:9 | power 45:1 53:19 | preparation 18:4 | 149:16 150:10 |
| populations | 54:4 86:7 138:11 | 19:7 | 157:7 162:22 |
| 205:12 319:17 | 176:8 | prepare 15:13 | 188:18 214:22 |
| 321:23 | powerpoint | 17:19 | 223:7 224:18 |
| porter 283:14 | 309:15 | prepared 34:6,10 | 259:11 263:21,23 |
| portfolio 33:6 | powerpointing | 185:7 | 268:18 270:17 |
| portion 166:5 | 305:2 | preparing 18:20 | 282:4,5 294:14 |
| position 48:11,16 | powerpoints | prescribe 36:8,12 | prescription 22:11 |
| 48:23 55:11,20 | 304:14 | 36:24 37:14,22 | 35:15 39:6 43:13 |
| 65:9 91:22 92:1,6 | practice 37:12 | 38:3,4,17 39:1 | 47:19 66:13 67:3 |
| 92:7 117:21 118:2 | 40:1 55:19 63:22 | 44:10 46:3 67:16 | 68:1 69:13 76:10 |
| 121:5 128:10,17 | 64:22 65:7 86:19 | 67:18 73:23 | 77:1,13 78:11 |
| 186:11 187:23 | 92:19,20 94:6 | 140:10,14 141:20 | 82:4,14,17 86:22 |
| 234:12 237:21 | 142:20 157:9 | 248:7 268:23 | 87:3,9,15,16,18,19 |
| 283:10 290:21 | | 292:2,21 | 87:21,23 88:2,4,14 |
| | | | |

[prescription - privileged]

| 88:19,21,22,24 | 331:5 332:8 | present 3:7 8:5 | previous 10:3,5 |
|--------------------|--------------------|--------------------------|-------------------------|
| 89:5,6 90:10,22 | 333:17 | 201:22 305:3 | 54:1 93:7,9 106:4 |
| 95:3 105:9 111:20 | prescriptions 36:3 | presentable 14:3 | 181:8 190:7 278:5 |
| 113:17 126:5 | 39:16 68:4 74:14 | presentation 5:13 | 282:24 283:10 |
| 127:7,8,9 129:24 | 81:23 82:16 88:13 | 6:19 99:9 101:6 | 306:14 309:21 |
| 134:14 147:18 | 89:24 94:1 110:19 | 101:19 106:19 | 322:16 323:4,16 |
| 154:24 155:1,2 | 110:23,23 111:4 | 107:9 108:4,14 | 323:23 |
| 156:2,3,5 163:8,14 | 111:17 112:10,13 | 113:8 147:16 | previously 16:14 |
| 163:17,20 166:11 | 113:3,6,16,20 | 162:5 206:4,9 | 40:21 196:16 |
| 177:14 178:20 | 114:8,12 130:13 | 209:15 244:9 | 205:18 |
| 179:1 191:4 192:1 | 144:6 145:24 | 304:24 305:3 | price 124:4 |
| 192:2,10,18 193:5 | 146:22,24 147:20 | 308:8 309:20,24 | primarily 45:9,18 |
| 195:19 197:12,14 | 149:11,13 150:9 | 310:3,5,7,17,24 | 68:5,20 71:23 |
| 200:24 203:6,12 | 150:15 155:11,14 | 317:8 319:6 | 94:15 254:2 278:7 |
| 206:15 208:4,11 | 155:20,21,23 | presentations | primary 64:4,22 |
| 209:4,20 211:13 | 156:6,14,19 157:4 | 309:22 | 65:8,10 68:15,23 |
| 211:18 213:9,18 | 157:12,19,23 | presented 112:15 | 71:20,21 72:21 |
| 213:19 218:13,13 | 162:15,17 191:24 | 266:7 316:2 | 78:2 129:3 292:23 |
| 219:22,23 220:14 | 192:12 193:5,22 | presenting 109:5 | principally 63:24 |
| 221:11 223:23 | 196:5 202:2,6 | 316:18 | principle 190:8 |
| 224:6,8,8 225:8,20 | 203:11,16,16 | preserve 186:8 | principles 190:8 |
| 226:9,10,13 | 204:14,15 212:7,8 | president 91:15 | 190:11 |
| 243:19 248:20 | 214:16,17 215:16 | 124:5 128:18 | prior 9:23 14:21 |
| 253:24 254:7 | 217:12,17 220:19 | pressure 197:23 | 16:18 18:13 62:24 |
| 259:11 260:21 | 221:8 223:2,4 | presumption | 92:6 124:12 125:4 |
| 261:1 266:13,24 | 247:13,17,20,23 | 283:11 | 127:17 135:19 |
| 267:11,19 268:3 | 248:3,6,7 249:1,4 | pretty 72:13 94:5 | 157:8 166:22 |
| 268:11 269:2,14 | 249:13,14 260:6 | 139:6 160:11 | 192:14 193:2,14 |
| 269:19 270:1 | 260:14 261:10,12 | prevalence 319:15 | 193:17 194:3 |
| 272:16 274:6,12 | 262:2,10,11,14,17 | 325:9,13 | 243:13 259:15 |
| 275:1,3,15,24 | 262:18 263:11,12 | prevent 44:11 | 276:7 302:4 |
| 276:1 277:15 | 264:14,20 265:9 | 97:16 138:3 | prioritize 197:6 |
| 278:10 279:9 | 265:13 266:1,4,7 | 173:11,12 265:19 | 212:20 |
| 280:1,6,7,22,23 | 266:10,12 267:15 | 270:13 | prison 45:20 |
| 281:1 282:9,18 | 268:17 269:1,5,6 | prevented 176:17 | 173:15 |
| 284:5 291:19 | 272:17 274:13 | prevention 70:23 | prisons 173:22 |
| 292:8,18 293:5,17 | 276:10,14 294:13 | 337:19 | private 7:5 69:4 |
| 293:20,24 294:4 | 305:23 324:7 | preventionists | privilege 240:9 |
| 305:11 312:9 | presence 170:4 | 300:17 | privileged 17:23 |
| 324:3 325:1 | 302:10 305:8 | preventive 65:18 | 238:17,21 |
| 330:15,20,21 | | | |
| | | | |

[proactive - providing]

| proactive 138:24 | process 15:19 | programs 59:11 | prospective 261:7 | | |
|-------------------|-----------------------|--------------------------|-------------------|--|--|
| probably 36:15 | 34:20 36:6,18 | 70:22 122:22,23 | prostitution | | |
| 113:23 209:15 | 38:8,12,14,16,23 | 159:2 175:3 | 153:22 | | |
| 224:17 298:2 | 39:5,10,18,21,22 | progress 207:1 | protection 90:20 | | |
| problem 34:17 | 40:5,7,21 41:1 | progressive | protocol 15:8 | | |
| 35:10,11 46:6 | 42:3,10 56:10 | 140:23 156:9 | provide 13:9 | | |
| 48:18 49:16 52:17 | 59:24 87:21 92:12 | prominent 128:9 | 15:18,20,22 21:8 | | |
| 53:19 57:16,21 | 93:15,19,22 94:5 | promise 328:20 | 27:17 30:5 31:1 | | |
| 84:22 98:10,16,24 | 95:14 141:21 | 338:21 | 31:15 34:15 36:1 | | |
| 99:1 105:20 | 142:14 151:17 | promoted 78:13 | 36:23 37:8,10,11 | | |
| 116:15,22 128:3 | 251:22 | 259:4 | 38:6 44:15,19 | | |
| 130:11,11 134:9 | processes 140:22 | prompted 71:18 | 51:21 59:21 130:1 | | |
| 134:22 137:1 | produce 35:23 | 72:6 259:7,9,17 | 141:6 143:16 | | |
| 138:5 158:15 | 124:14 189:20 | prompting 259:16 | 148:22 159:3 | | |
| 161:15 163:19,21 | 342:7 | promulgate | 176:15 184:10 | | |
| 164:18 171:14 | produced 20:2 | 268:16 | 194:9 200:7 | | |
| 172:11 175:14,21 | 97:22 101:2 | proper 50:15 71:2 | 202:21 216:19 | | |
| 232:14 236:18,20 | 164:14 257:15 | properly 69:18 | 217:5,6,9 218:16 | | |
| 250:5 253:13,21 | 298:17,18 304:4 | 70:24 71:5 291:22 | 222:14 237:11 | | |
| 253:23,24 286:18 | 316:10,17 | 291:23 | 268:7 276:6 | | |
| 311:5 331:6 | product 76:14 | properties 160:14 | 285:13 286:2 | | |
| problematic 73:5 | 164:5 | 160:15 | 310:3 323:8 326:7 | | |
| 85:6 86:12 | production 105:3 | proponent 145:19 | provided 17:13 | | |
| problems 45:17 | 346:15,17,22 | proportion 45:16 | 27:12 28:18,18 | | |
| 97:15 127:4 | products 220:12 | 167:6 | 31:12 57:1 66:6 | | |
| 134:18 135:15 | 257:16 258:8,9,13 | proportional | 67:5 101:5 174:4 | | |
| 138:9,22 277:6 | professional 56:15 | 275:11 | 199:19 218:4 | | |
| 278:18 330:15 | 57:2 87:11 345:17 | proportionate | 229:15,19,24 | | |
| procedurally | professor 65:9 | 274:16 | 235:10 236:5 | | |
| 230:16 | 79:20 80:5 120:17 | propose 48:11 | 237:21 238:9 | | |
| procedure 1:20 | 120:20,24 121:10 | 49:2,14,23 266:23 | 241:3 244:21 | | |
| 237:16 347:5 | 121:13,17,21 | 267:10,18 268:23 | 247:20 260:6 | | |
| 348:5 | proficiency 92:18 | 271:7 | 326:19 | | |
| procedures 92:21 | profit 164:5,9 | propulsion 94:22 | provider 82:1 | | |
| proceeding 8:9 | program 40:19 | prosecutor 293:15 | providers 36:4 | | |
| proceedings 26:4 | 42:15 56:2 65:13 | 293:23 294:10 | 81:15,17 300:15 | | |
| 54:24 115:1 | 69:8,9 89:1,6,11 | prosecutor's | provides 245:6 | | |
| 180:24 226:24 | 122:4 124:17,17 | 239:22 240:1 | providing 15:20 | | |
| 240:20 291:13 | 138:16,17 173:6 | prosecutors | 19:14 42:4 58:11 | | |
| 328:9 | 250:7,7 251:13 | 294:19 | 93:2 126:22 159:6 | | |
| | 329:17 | | 172:8 192:2 | | |
| | | | | | |

[providing - questions]

| 202:22 217:10 | publication 298:1 | pushed 78:20 | 198:16 199:6,23 |
|-----------------------|--------------------------|--------------------------|-------------------|
| 220:10 229:18 | 325:24 | pushing 150:13,14 | 200:17 201:8 |
| 305:2 322:14 | publish 342:17,17 | put 34:20 46:8 | 203:15 204:16 |
| 327:16 | published 85:18 | 48:16 49:6 51:3 | 207:17,20 217:3 |
| prudent 263:5 | 114:2 122:19 | 82:9 108:4,11 | 217:22 220:2,9,11 |
| psychological | 125:6 317:14 | 113:5 206:1 | 224:11 225:24 |
| 151:23 | 325:24 342:12,15 | 228:18 232:10 | 226:6,7,8 227:13 |
| public 5:10,23 | pull 182:7 205:20 | 252:22 253:2 | 228:9 232:14,15 |
| 9:16 11:4 18:15 | pulled 149:14 | 275:8 281:5 | 234:15 235:7,8,21 |
| 22:18,20 30:9 | 156:4 223:5 | 287:19 297:14 | 235:23 236:20,23 |
| 31:8,22 32:6,21 | pulling 286:13 | putnam 30:8 31:6 | 236:24 237:2,3,8 |
| 35:12,17 39:20 | pulmonary 63:1 | putting 131:17 | 237:10,13 238:2 |
| 40:16 42:16 43:19 | pump 178:19 | q | 238:16 248:11 |
| 44:16 48:10,23 | punish 153:16 | qualifications | 250:2 252:11 |
| 56:3,7 60:17 63:4 | punishment | 92:23 | 253:16 261:16,24 |
| 65:16,18 67:20 | 153:19 | qualified 344:5 | 267:4,5,16,18,22 |
| 69:3 71:7,19,23 | punitive 149:2 | qualify 17:5 | 267:23 268:5,15 |
| 72:9 73:5 80:12 | 222:19 | 280:24,24 291:19 | 269:7 270:4,5 |
| 81:3,5 83:10 | pure 80:18 | quality 281:12 | 271:3,11 278:22 |
| 84:13 86:4,4 91:8 | purpose 87:20 | quantify 166:15 | 298:23 299:2 |
| 91:24 94:10 95:11 | 161:11 243:8,10 | 166:17 172:24 | 312:19 326:17 |
| 95:12,15,18,19 | 249:23,24 292:15 | 177:23 303:9 | 327:2,3,6,10 |
| 96:12 101:23 | 292:16,20,23 | quantities 294:16 | 331:22 332:9,13 |
| 103:20 109:5 | 344:6 | quantity 268:11 | 332:15 336:10 |
| 113:24 120:3 | purposes 8:21 | quarantined | questioning |
| 121:18,23,23 | 12:9 23:17 60:24 | 270:11 | 114:18 117:22 |
| 122:7 123:18 | 99:12 182:10,15 | queries 251:23 | 118:2,8 137:13 |
| 131:13 143:24 | 184:1 186:3 247:1 | question 14:6,13 | 146:23 186:14,14 |
| 145:7 181:17 | 251:8 254:21 | 14:15 18:3,11 | 186:18 188:10 |
| 183:12,18 184:5 | 258:21 295:9 | 25:15 26:12 32:1 | questionnaires |
| 184:21 217:6 | 299:15 303:23 | 32:3,11 33:24 | 93:5,7 |
| 243:5 250:19,22 | 308:16 313:4 | 35:9 40:8 41:3,5 | questions 9:18 |
| 250:24 251:19,21 | 339:10 | 47:22 48:2,7 | 13:20 14:3 16:6 |
| 293:3 295:5 | pursuant 1:20 | 49:13 50:20 53:16 | 32:9 33:2,5,10 |
| 296:22,23 297:9 | 15:8 63:18 224:8 | 64:17 81:24 87:8 | 35:2,6 37:1 49:6 |
| 299:22 301:4 | 275:2 280:7,22 | 87:14 88:8 98:21 | 51:11 93:11,20 |
| 303:20 315:11 | pursue 71:18 | 113:4 116:8 117:8 | 94:1,4 98:18 |
| 326:2 328:22 | purview 56:1 | 118:20 133:20 | 99:19,21 115:9,14 |
| 329:13,24 337:18 | 58:13 | 140:4 144:16 | 116:6,14 148:1 |
| 344:4 347:10,18 | push 160:16 | 175:16 180:10 | 176:20 181:16,22 |
| 348:15,23 349:23 | | 188:10 192:6 | 185:17 221:6 |
| | | 100.10 172.0 | |

[questions - receives]

www.veritext.com

| 328:14 336:3 | 143:12,13,13 | 281:5 285:23 | 142:22 181:17 |
|---------------------|-------------------------------|--------------------------|-----------------------|
| 338:18 343:4 | 166:21 320:9 | 286:10 | 194:2,16 195:2 |
| quick 188:9 | 334:24 | reality 277:13 | 263:4 |
| 286:10 | rates 111:20 | realized 29:17 | reasonably 251:10 |
| quickly 110:18 | 130:23 143:10,11 | 164:8 | reasons 140:10,14 |
| 119:20 179:2 | 143:16 144:11,18 | really 28:8 33:23 | 140:15 143:15 |
| quintilesims 111:8 | 145:5 167:19 | 46:22 77:21 80:23 | 148:20 173:3 |
| 112:3 | 208:3 285:17 | 81:9,23 98:6,10,11 | 198:3 202:17 |
| quit 290:11 | rationale 77:16 | 98:15 104:17 | 222:12 |
| quite 242:5 320:3 | reach 116:18 | 110:18 114:6 | reassert 293:10 |
| quota 35:21 | reaching 43:7 | 123:24 136:10 | rebecca 317:18 |
| 189:17,18 190:3,5 | reactive 138:21 | 138:23 140:16 | rebuild 161:11,12 |
| 190:9,24 191:10 | read 12:24 18:8,17 | 142:11 148:13 | recall 10:11,13 |
| 273:6 | 22:19 59:15 80:14 | 149:4,7 150:11 | 11:2 17:8 19:24 |
| quotas 105:4 | 83:10 91:18 92:21 | 166:18 190:5,5 | 38:11,13,15 39:20 |
| 109:17 137:20 | 102:2 147:3 | 216:13 222:6,21 | 52:2 54:13 55:9 |
| 190:21 | 221:18,24 237:8 | 222:23 242:3,4 | 55:14 57:11,13,18 |
| quote 148:19 | 242:22 253:19 | 244:18 273:8 | 58:20,21,23 59:1 |
| 222:12 | 256:4,21 297:4 | 278:14 296:10 | 59:17 66:14 73:8 |
| quotes 311:1 | 298:7 300:5 301:8 | 324:8 328:20 | 75:2 76:24 77:3,9 |
| 321:18 | 301:16 306:3 | realtime 66:7 78:7 | 77:10,14,14 78:8,9 |
| r | 315:7,13 318:6,20 | 345:3,17 | 78:12,17 80:2 |
| r 2:13,14 7:1 9:4 | 319:23 320:17 | reap 333:18 | 84:2,4,21 86:16 |
| rahul 1:19 6:17,20 | 321:11 322:2,11 | reason 13:5,23 | 92:12,16 93:23 |
| 7:14 55:2 60:22 | 323:6,11,14,15,19 | 17:24 45:18 72:9 | 94:3 95:4,9 128:7 |
| 99:10 115:4 181:2 | 323:22 327:6 | 73:2 76:12 85:16 | 167:16,17 189:9 |
| 227:2,22 240:22 | 338:3 340:13 | 110:8 112:5 152:9 | 225:4 285:6,8,12 |
| 291:15 315:10 | 343:6,8,15 344:10 | 152:11 156:8 | 299:3,6 319:3 |
| 328:11 343:11 | 347:5,6,12 348:5,6 | 163:12 202:15,16 | 329:5 332:4,5,6,10 |
| 344:5 345:5 346:8 | 348:17 | 215:5 248:13 | 332:18 335:12 |
| 347:4,9 348:4,13 | readily 47:11 | 273:20 281:17 | 336:1,7 337:24 |
| 349:20 | 278:20 | 298:5 301:10,18 | recalling 225:1 |
| raise 82:1 133:21 | reading 84:9 | 301:23,24 302:2 | receipt 346:18 |
| 135:23 | 223:17 246:5,7 | 302:23 303:1 | receive 39:13 |
| raised 270:10 | 323:9 326:22 | 311:15 313:15,19 | received 14:21 |
| range 16:23 65:24 | 327:8 346:19 | 318:22 320:1,19 | 15:3,3 27:12 |
| 66:4 216:1 217:14 | reads 296:15 | 341:14 342:7 | 62:12 74:23 229:8 |
| ranked 111:16 | ready 24:5 181:11 | 346:14 348:8 | 257:8 296:20 |
| ranks 111:3 | 339:17,18 real 97:24 214:4 | 349:3 reasonable 52:7 | 330:19 receives 87:22 |
| rate 45:6 110:18 | 267:24 276:6 | 90:11 108:16 | 10001100 01.22 |
| 111:3 131:5 | 201.24 210.0 | 90.11 100.10 | |

[receiving - reinforcement]

| receiving 17:6 | 182:23 183:9 | referenced 111:9 | regain 122:14 |
|----------------------------|--------------------------|--------------------------|-------------------|
| 126:19 281:18 | 184:12 187:11,23 | 347:11 348:15 | regard 14:18 |
| receptor 160:11 | 188:8 189:13 | references 93:3 | 32:24 |
| receptors 160:8,20 | 226:21 227:3,10 | 285:13 | regarding 11:1 |
| 160:21 177:6 | 227:23 228:6,18 | referred 86:13 | 54:10 227:11 |
| 336:23 337:5,11 | 228:19,21 232:11 | referring 76:9 | 228:7 242:1 |
| recess 54:23 | 235:13,14 240:15 | 89:22 142:2 | 296:19 314:8 |
| 114:24 180:23 | 240:17,23 267:9 | 171:15 183:5 | 326:11 |
| 226:23 240:19 | 286:11 287:4,5,8 | 184:14 210:17 | regards 32:20 |
| 291:12 328:8 | 287:11,17,19 | 218:6,11,24 | 185:8 234:7 |
| recognize 10:20 | 291:10,10,16 | 219:14 221:11 | registered 1:21 |
| 84:23 99:15,18 | 297:14,18 298:16 | 223:22 224:4 | 39:12,22 87:10 |
| 108:6 163:4 | 310:9 327:8 328:6 | 242:15 251:14 | 112:14,16 249:9 |
| 266:18 313:11 | 328:12 338:8 | 257:20,21,23,24 | 252:12 345:17 |
| recognized 72:12 | 343:9 348:9 | 258:14 | registering 36:11 |
| 74:13 137:16 | recorded 7:14 | refers 243:3 275:5 | registrant 36:12 |
| recollect 9:22 17:5 | recording 7:10 | reflect 62:11 104:5 | 53:7 |
| 21:3,5 27:15 | 123:9 | 104:14 105:20,22 | registrants 35:24 |
| 36:15 54:13 114:5 | records 22:20 | 106:12 107:4 | 36:2,5,8 39:17 |
| 145:2 246:15 | recovery 316:23 | 112:9 206:12 | 40:23 292:22,23 |
| 297:20 303:11 | 317:12 | 207:6 244:15 | registrar 341:2 |
| 310:1 | reduce 47:9 52:14 | 245:14 255:6 | registration 36:6 |
| recollection 10:1 | 266:23 267:10,19 | 304:23 306:5 | 36:14,16 37:4,6 |
| 19:16 20:3 38:1 | 268:10 269:6 | 314:1,5,6,7 319:5 | 38:12 40:7 53:8 |
| 90:23 297:8 | reduced 215:17,19 | 340:5 | 93:21 |
| 315:15,17 | 344:10 | reflected 63:4 | regular 73:20 |
| recommend 212:3 | reduces 268:16 | reflects 111:19 | regulate 47:23 |
| recommendation | reducing 163:20 | 305:1 313:7 315:9 | 48:3 271:9 |
| 197:1 | reduction 125:20 | 340:9 | regulated 41:10 |
| recommendations | 138:13,16 142:3 | refocus 198:16 | 250:14 264:2 |
| 78:19 125:17 | 162:9,10,10,12,14 | reform 6:10 45:14 | 270:16,20,23 |
| 188:22 215:8 | 162:15,17,20,22 | 45:14 254:15 | regulates 51:17 |
| 271:15,15 | 162:23,24 197:18 | 255:18 | 271:6 |
| reconvene 286:9 | 197:19 225:6 | refrain 50:10 | regulating 269:23 |
| 328:3 | 268:18 | 321:17 | 292:16 |
| record 7:3,12 8:7 | reductions 162:4 | refresh 19:15 | regulation 49:3 |
| 12:18 29:14 34:21 | refer 85:20 89:21 | 295:23 297:8 | regulations 70:22 |
| 50:6 52:3 54:21 | 108:2 275:2,4 | 315:15 | 90:5 268:23 |
| 55:3 97:8 114:22 | reference 64:13 | refreshed 20:2 | regulatory 58:1 |
| 115:5 117:9,15 | 224:17 346:7 | refused 265:13 | reinforcement |
| 180:21 181:3,7,10 | 347:2 348:2 | 266:1 276:13 | 152:16 |
| | | | |

[reininvestments - reserve]

| | T | ı | |
|--------------------------|-------------------|--------------------|-------------------|
| reininvestments | remains 102:23 | 218:6,18,19,21 | represented 21:21 |
| 45:15 | remember 10:20 | 219:21 220:6 | 29:11,13,17 |
| reiterating 33:7 | 17:15 19:22 21:3 | 246:10,11,13,16 | 325:23 338:9,10 |
| rel 5:4 12:5 | 71:9 75:10,16 | 247:11 274:12 | representing 8:21 |
| relate 69:12 75:13 | 82:24 84:24 | 296:7 297:17,20 | 186:17 187:2 |
| 107:14 109:24 | 133:17 134:14 | 298:3 299:3 319:1 | 239:16 240:1 |
| 110:10 186:8 | 147:23 161:3,6 | 319:2 323:1,2,3,14 | republican 173:24 |
| related 8:3 10:19 | 188:14 290:5 | 329:3,4,9,18 | request 6:3 15:17 |
| 10:22,23 11:7 | 319:3 | 342:23,24 | 19:12 268:7,12 |
| 22:6 95:8 113:12 | remotely 1:21 | reported 183:16 | 269:14 304:24 |
| 117:14 122:23 | 7:22 8:6 299:5 | 303:4 320:8 | 310:2 339:7 340:9 |
| 128:2 136:7 177:5 | render 34:6,10 | 342:20 | 340:14 344:10 |
| 188:18 189:20 | 119:11 | reporter 1:21 7:24 | 348:9,11 |
| 197:22 212:8 | rendered 181:15 | 9:1 14:11 187:9 | requested 15:18 |
| 253:14,21 271:21 | 181:16 | 227:11 228:7,17 | 54:2 184:9 310:2 |
| 271:22 290:22 | renew 52:24 53:8 | 228:23 236:2 | 341:10 |
| 318:11,11,17,17 | renewal 38:8,14 | 253:20 308:19 | requesting 268:19 |
| 344:12 | 53:4 | 309:1 340:9 | requests 126:19 |
| relates 80:23 | renewing 36:16 | 341:11 345:17,17 | require 89:20 |
| 137:18 | rep 106:11 | 347:7 | 92:18 145:8 153:7 |
| relating 34:13 | repeat 20:15 22:2 | reporter's 340:18 | 211:21 |
| relation 255:12 | 41:12 53:16 88:7 | reporters 345:3 | required 53:8 |
| relationship | 98:21 108:10 | reports 18:15 | 88:23 89:5,23 |
| 113:10 234:19 | 126:21 158:8 | 22:20 34:12 58:2 | 90:8,12 144:12 |
| 239:1,3 272:11 | 192:6 196:18 | 58:4,9,11 83:9,12 | 333:21 346:24 |
| 312:14 | 226:8 227:13 | 85:18 114:2 | requirement |
| relative 344:13 | 228:9 248:18 | 124:14 143:8 | 89:21,22 |
| relatively 157:5,6 | 253:16 259:24 | 182:5 184:24 | requirements |
| release 152:12,21 | rephrase 14:6 | 185:1,4,9 204:3 | 40:22 92:17,24 |
| 153:1,4 177:4 | 18:2 47:22 48:8 | 219:9,9 257:8 | 202:3 344:15 |
| 333:9 | 102:19 116:8 | 341:15 | 345:6 |
| released 126:7 | 236:24 262:15 | represent 76:13 | requires 53:4 |
| 152:15 | 267:24 274:10 | 100:24 117:1,2 | 270:8 334:14 |
| relevant 43:3 | 278:2 | 118:14,15,15,21 | research 79:8 |
| relied 57:24 | replicated 124:1 | 118:23 203:11 | 189:10 279:24 |
| 188:12 189:10,10 | report 85:24 96:8 | 239:11 247:6 | 280:4,5 283:16,19 |
| relieve 294:16 | 96:12,12 112:3 | 289:19 298:16 | 283:22 284:1,3 |
| rely 57:23 | 125:6,7 144:22 | 304:3 316:9 | 286:1 317:19 |
| remainder 225:19 | 145:1 183:5,10,21 | representatives | 320:22 |
| remained 130:19 | 184:13 204:6,17 | 73:22 76:12 | reserve 181:6 |
| | 204:19 217:24 | | |
| | | | |

[residence - right] Page 54

| residence 340:14 | 30:18 33:22 | resume 6:17 60:22 | reviewed 19:6,9 |
|-----------------------|-------------------|--------------------------|-------------------------|
| 341:24 342:18,21 | 135:14 174:24 | 61:8,9,16 62:6 | 19:20 83:22 119:7 |
| 343:1 | 181:15 221:5 | 64:19 71:10 79:14 | 122:18 224:20 |
| residency 39:24 | 273:24 276:18 | 79:16,19 91:5 | 225:2 280:5 |
| 40:3 62:15,19,24 | 296:22 | 122:17 | 283:23,24 285:7 |
| 64:2,11,21 65:13 | responses 13:1,4 | retail 80:21 | 322:6 |
| 69:9 93:1 | 28:4 | retain 119:21 | reviewers 297:22 |
| resident 342:4,5,6 | responsibility | retained 33:12,16 | reviewing 244:17 |
| residents 68:8 | 70:17,19 82:20 | 34:4,8,21 119:10 | 246:16 279:23 |
| 69:8,23 110:4 | 124:13 265:17,19 | 227:5,16 228:1,12 | revisions 297:22 |
| 207:7 271:20 | 265:22 271:24 | 231:1,8,15,17,18 | revitalizing 6:12 |
| 340:7 | 272:1 293:3 | 231:21 232:3,4,23 | 254:18 255:22 |
| resides 218:12 | responsible 71:6 | 234:20 235:1,10 | reward 152:20 |
| resignation 92:7 | 91:15 292:24 | 236:12,15 237:12 | 333:7,12 336:18 |
| resistance 67:11 | 294:18 302:6 | 237:22 287:1 | 336:19 |
| resolve 240:12 | responsibly 44:10 | 288:7,22 289:8 | rewarded 152:20 |
| resort 141:3,4 | 46:3 | 290:4,16 343:12 | rewards 333:18 |
| 211:22 | responsive 135:15 | retainer 233:17 | rgupta000919-966 |
| resorts 170:15 | responsiveness | retaining 287:20 | 6:21 99:11 |
| resources 22:22 | 19:4 | 289:20 | rice 2:4 234:18 |
| 58:16 133:2 | rest 110:20 113:7 | retention 288:17 | 236:13 |
| 175:21 176:7 | 154:5,6 273:4 | 288:20 289:11 | richman 5:14 |
| 314:3 317:15 | 280:15 319:2 | 290:9 | 308:9 |
| 326:1 329:20 | restate 113:4 | retrospective | right 9:11 10:13 |
| respect 30:6 41:6 | 261:24 269:8 | 149:9 222:24 | 13:2,10 19:2,24 |
| 41:24 49:15 66:12 | 285:5 | 261:6,7 | 20:19 21:13 30:2 |
| 67:8 77:12 78:10 | restaurants 70:24 | returned 346:18 | 38:23 39:9 46:16 |
| 268:22 270:17 | 165:10 | reverse 178:6 | 61:19 68:14 71:16 |
| 271:12 289:9 | result 22:10 49:5 | review 13:8 15:8,9 | 71:17 76:3 104:12 |
| 297:10 305:15 | 76:7 151:4,22 | 15:20 18:5,19,23 | 112:17 116:11 |
| respective 272:13 | 152:14 165:16 | 19:3,13 20:7 62:1 | 117:20 118:14 |
| respectives 273:22 | 243:12 252:18,19 | 75:17 123:16 | 119:8,20 123:12 |
| respond 17:12 | 276:14 277:20 | 147:3 203:22 | 130:9 136:22 |
| 28:3,24 33:1,5,17 | 295:21 | 204:6 207:13 | 140:7 141:7,15 |
| 35:2 37:23 52:23 | resulted 125:17 | 218:19 247:4,5,11 | 142:7 143:18 |
| 87:14 341:10 | 166:2 | 249:18,19 261:6 | 147:23 149:24 |
| responded 233:5 | resulting 22:12 | 296:11,14 314:9 | 151:13 154:7 |
| 267:4,5 | 32:21 | 314:10,11 318:24 | 156:15 158:3 |
| response 17:14 | results 67:19 | 346:12 347:1 | 161:14 170:2 |
| 19:5 20:2,13 21:8 | 161:24 185:8 | 348:1 | 175:11 177:17,21 |
| 27:12,24 28:18 | 301:14 302:18 | | 179:19 180:16,20 |
| | | | |

[right - school] Page 55

| 181:14 186:23 | road 235:3 | 236:18 237:2,19 | 156:9 162:5,13 |
|-----------------------|--------------------------|---------------------|-------------------|
| 188:13 189:1,15 | robert 3:4 148:13 | 238:4,19 239:1,13 | 164:6 165:6,24 |
| 189:23 193:12 | 222:6 224:1 | 239:23 240:11,14 | 166:2 168:4 169:3 |
| 194:21 197:10 | robust 81:17 | 286:10 287:6,9,16 | 169:4,5 178:9 |
| 206:20 207:10,23 | role 35:16 80:11 | 287:22 288:1,8,24 | 276:8 278:23 |
| 216:9,19 219:20 | 81:1 82:3 83:7 | 289:24 290:18 | 322:5 330:18 |
| 221:3 223:16,19 | 84:7,10,18 85:7 | 291:7 338:4,6,14 | saying 187:14 |
| 225:1,4,15 226:3 | 86:12,22 90:19 | ruby's 187:15 | 192:20 196:7 |
| 233:1,9 243:1 | 127:21,22 133:3 | ruggedness 196:3 | 198:2 199:11 |
| 244:6 246:15,15 | 183:17 185:21 | rule 133:24 234:5 | 214:1 220:4,5 |
| 250:17 254:3,9 | 186:1,4,17 188:15 | rules 1:20 94:6 | 237:13 266:11,15 |
| 255:13 266:6 | 190:14 256:13 | 138:2 230:23 | 269:24 283:10 |
| 274:4 277:21 | 259:19 269:4 | 236:14 237:16 | 315:21,22 |
| 281:19 282:14 | roles 9:18 130:9 | 272:10 347:5 | says 33:24 79:19 |
| 284:3,19 292:15 | 133:3 134:7 | 348:5 | 100:8 104:10 |
| 295:15 299:18 | 185:18 | run 117:6 | 111:12 204:21 |
| 304:17 306:22 | room 8:5 64:5 | rural 129:22 | 210:19 245:19,19 |
| 310:21,23 313:8 | 74:3 129:17 | 272:23 | 248:19 277:8 |
| 313:11 317:16 | 285:22 | russian 164:22 | 286:21 298:20 |
| 325:15 328:1,4,24 | rooted 192:18 | 165:13 | 301:3 302:10 |
| 330:1 331:10,17 | rotation 74:4,4 | S | 303:3 312:7,12 |
| 331:20 332:22 | roth 317:18 | s 1:21 7:1 192:13 | 314:22 318:8,10 |
| 334:4 337:22 | roulette 164:23 | 344:4,20 346:15 | 321:12 340:14 |
| 338:6 343:8 | 165:13 | 348:8,8 349:3 | 341:21,22 |
| rigorous 217:19 | rounds 65:23 | safe 70:20 149:5 | sc 2:5 |
| 217:24 | 69:15 95:11 | 222:22 263:12 | scale 78:24 |
| ringing 119:16 | routes 258:5 | safety 132:4 | scales 264:10 |
| rise 145:14,14,17 | routine 133:24 | saith 343:16 | scanned 20:18 |
| 264:19 265:5 | 194:4 | sake 235:5 | scanning 15:21 |
| 318:16 324:24 | rpr 344:20 | sales 190:6,6 | 19:13 |
| 325:2 | ruby 2:13,14 8:13 | samhsa 280:10 | scenario 263:10 |
| rising 45:5 327:15 | 8:13 26:17,22 | samples 74:8 | schedule 36:12 |
| risk 94:15 95:1 | 32:11 50:5,18 | samples 74.0 | 37:14 |
| 149:21,23 221:13 | 117:13,21 118:7 | sandbags 46:8 | scheduled 36:8 |
| 223:13,15,20 | 179:22 180:2,4,19 | satisfied 142:18 | school 65:10,14 |
| 224:10,14,14 | 185:14 186:5,13 | 333:12 | 66:7,8 76:4 79:20 |
| 225:15 226:3,3,11 | 186:18 187:19 | satisfy 19:4 177:18 | 80:9 90:17 93:1 |
| 320:15 325:13 | 231:5 232:5,13,19 | save 64:7 | 95:11,15,18 120:8 |
| risking 164:21 | 233:10,15 234:9 | saw 65:12,24 | 121:5,10,14,18,23 |
| rmr 344:20 | 234:15 235:6,15 | 129:10 135:17,18 | 122:3,7,8 133:19 |
| | 235:17,22,24 | 135:19 136:6 | 137:6 171:18 |
| | | 155.17 150.0 | |

[school - shirt] Page 56

| 319:20 | 188:16 189:6 | 286:1 | 340:2,19 344:17 | |
|------------------------------------|--------------------------------|------------------------------|---------------------------------------|--|
| school's 95:17 | 313:13 314:14 | seek 15:19 47:7 | 345:10 346:4 | |
| schools 94:10,12 | 315:3 314:14 | 72:7 126:10 | serial 61:21 | |
| 171:1 | security 36:21 | 153:11 154:21 | 100:22 | |
| science 60:4,12 | see 10:24 24:11,16 | 163:9 166:6 | serious 67:3 | |
| 68:6 76:5 80:19 | 40:8 46:13 50:16 | seeking 161:10 | seriously 68:7 | |
| 103:1 128:20 | 61:14,18 62:8,9 | seen 135:24 140:2 | serve 91:13,20 | |
| 144:5 159:20 | 66:5 81:22 84:10 | 155:4,5 170:20 | 241:7,11,15,18 | |
| 160:2 | 100:18,19,19 | 200:11 254:5 | 335:18 | |
| scientific 77:20 | 100:18,19,19 | 277:14 285:15 | served 123:12,16 | |
| 217:24 | 102.6 107.8,10 | 309:21 333:18 | 127:13 128:5 | |
| | 129:7 130:7 134:3 | seizures 168:23 | 130:10 133:3 | |
| scientifically 217:19 | 137:3 157:11 | select 305:14 | 207:7 | |
| scientists 332:3 | 161:16,20 162:2 | | service 91:22 | |
| scientists 332:3 scope 17:21 | 161:16,20 162:2 | selected 306:15,18 306:20 | service 91:22 services 59:8 | |
| _ | 178:24 190:3 | sell 76:14 | 315:13 | |
| 288:16,20,24 seal 347:15 348:21 | 192:7 204:7 208:8 | sen /0.14 semi 177:10 | | |
| | 210:22 214:18 | | serving 241:23 set 13:10 27:7 69:2 | |
| sealed 14:21 15:3 | | senate 97:23 | | |
| search 19:10 21:7 | 242:21 245:18,19 | 125:18,19,22,22 | 149:10 168:18 | |
| 162:21 | 249:5 255:11 | 142:5 174:4 225:6 | 191:1 192:11 | |
| searched 20:23 | 256:6,7 274:11,12 | senator 174:23 | 223:1 260:12 | |
| searching 20:13 | 274:15,17,21 | send 132:9 | 265:18 278:17 | |
| 20:21 | 275:10 279:4 | sends 153:19 | 290:20 344:15 | |
| seat 136:24 | 296:5,5 297:24 298:1 299:22 | senior 128:18 | 345:6 | |
| second 24:1,15 | | sense 79:10 162:3 | setting 24:23 | |
| 26:18 81:21 90:18 | 300:13 302:9 | 174:1 193:21 | 172:10 190:21 | |
| 91:10 97:4,9 | 305:16,22 307:6,7 | 201:22,23 292:11 | 258:17 293:18 | |
| 100:19 101:22 | 311:2 313:9,10 | 306:9 322:22 | 299:3 | |
| 122:15 131:22 | 314:14,22,24 | sensitive 7:5 135:2 | seven 302:13 | |
| 158:24 163:24 | 315:19 316:5,5,20 | 135:21 | 344:15,15 345:6,7 | |
| 164:20 167:20,21 | 317:1,8,13,18 | sent 18:24 20:18 | sewage 71:1,2 | |
| 183:1,9 240:13 | 318:8,9 319:10 | 61:7 149:8 313:20 | sexual 152:17 | |
| 281:14 299:19,21 | 321:13,14 323:17 | 314:7 315:23 | shape 154:22 | |
| 313:23 314:10 | 325:19 339:22 | 339:24 | shared 53:13 | |
| 315:9,16,16 | 340:22 | sentence 223:18 | sharing 248:23 | |
| 321:11 | seeing 24:22 71:22 | 283:13 301:3 | 325:12 | |
| secondary 68:17 | 71:24 75:20 82:16 | sentinel 81:15,17 | sheet 12:19 346:13 | |
| seconds 16:23 | 88:12 124:10 | 82:1,4 | 348:7,10,18 349:1 | |
| secretary 86:2 | 137:7 162:4,22,23 | separate 268:21 | shingles 276:10 | |
| 91:13,20 92:5 | 162:24 165:18 | september 1:21 | shirt 176:2,4 | |
| 124:4 129:16 | 275:22 285:23 | 7:3 129:12,13,14 | | |
| | | | | |

[shkolnik - sorry] Page 57

| shkolnik 3:8 229:3 | signature 344:19 | sins 325:5 | 335:4,10 |
|---------------------------|------------------------|---------------------------|---------------------------|
| 229:4 230:21,22 | 345:16 346:14 | sir 11:24 35:20 | social 5:20 36:21 |
| 232:15 236:11,19 | signatures 130:1 | 229:22 346:10 | 124:8,19 125:21 |
| 237:7,15 238:15 | signed 12:19,21 | sit 128:10 203:19 | 126:2 135:10 |
| 238:22 242:15,16 | 125:24 189:6 | sitting 115:23 | 138:12 172:19 |
| 242:18 | 347:13 348:18 | 216:10 225:20 | 178:10 214:3,3 |
| shopping 150:13 | significance | 327:20 | 242:24 303:18 |
| 248:24 | 186:20 187:21 | situations 140:24 | 329:4 331:13 |
| short 16:13 99:20 | significant 45:16 | six 16:17 210:20 | socially 212:18 |
| 141:17,18 172:22 | 58:23 108:18 | 281:8 338:7 | society 78:12,21 |
| 176:13 328:19 | 126:4,6 147:16 | size 199:14 | 148:16 172:18 |
| shorthand 344:9 | 150:21 162:24 | skeptical 75:19 | 222:9 259:3 |
| shot 175:4,4 253:9 | 259:21 260:3,5 | skin 67:14 | sold 74:23 76:2 |
| show 23:20 75:18 | significantly | slide 101:19 104:2 | 191:24 283:11 |
| 110:18 297:16 | 147:24 282:2 | 104:7,11,13 | solution 6:11 49:3 |
| 307:11,16 | 318:18 | 106:10 107:14 | 254:17 255:21 |
| showcase 124:6 | signing 346:19 | 108:20,23 110:17 | solutions 42:20 |
| showed 143:3 | signs 79:5,9 | 110:18 111:2,19 | 128:13 135:5 |
| 162:5 | similar 30:18 | 112:8 206:8 210:8 | 137:9 176:10,12 |
| shown 346:16 | 56:24 67:24 69:14 | 210:9,12,17 211:2 | 217:9 273:12 |
| shows 170:23 | 69:22 100:21 | 211:7 244:12,15 | 346:1 349:1 |
| 280:19 | 169:5 333:2 335:2 | 244:18 245:6,12 | solve 34:17 35:10 |
| shut 46:21 | 336:23 | 305:5,7,10 306:1 | 55:17 96:19 97:15 |
| sick 145:20 | similarity 284:4,7 | 306:14,14 310:16 | 98:6,10,16 163:19 |
| side 11:21 102:21 | 284:9 | 310:17,22,24 | solved 158:15,16 |
| 102:21 104:6,8,10 | similarly 68:22 | slides 100:16 | 158:18 |
| 104:15 105:23 | 152:23 249:10 | 106:10 107:21 | somebody 137:5 |
| 106:4,7,9,14 107:6 | simple 67:14 | 108:12 109:7 | 251:16 253:10 |
| 107:20,22,24 | 103:2 275:12 | 112:23 209:24,24 | 281:4 293:16 |
| 108:6,12 109:12 | simplified 105:15 | 305:2,3 | somewhat 188:18 |
| 109:19 112:24 | simplistic 124:22 | slight 162:4,13 | 278:12 |
| 113:8 116:7 | simplistically | 197:20,21 | son 110:7 277:9 |
| 131:22 155:15 | 245:24 | slip 195:8 | soon 168:19 |
| 170:19 | sincerely 346:21 | sliver 162:1 | sophisticated |
| sides 142:11 | singapore 94:23 | slowly 264:19 | 132:10 |
| sign 78:13,20 79:3 | single 58:8 97:21 | small 52:21 166:5 | sorry 14:3 16:1 |
| 79:8 338:3 343:6 | 125:3 131:19 | 167:1 276:23 | 19:2 20:15 22:2 |
| 343:8 | 133:23 173:1 | smoked 330:15 | 23:7 24:2,4 26:20 |
| signals 333:10 | 293:14 313:10 | 331:6 | 33:16 34:2 41:2 |
| signatory 91:16 | singular 86:5 | smoking 320:8 | 41:12 48:1 61:2 |
| | | 333:6 334:16 | 68:12 87:24 100:5 |
| | | | |

[sorry - state] Page 58

| 106:15,16,18 | 133:18 220:7 | spoken 15:15 | stands 119:14 |
|---------------------------|----------------------------|---------------------------|---------------------------|
| 111:14 115:16 | speaking 32:14 | spouse 10:23 | 168:13 |
| 141:9 158:8 | 34:23 42:8 50:7 | sprain 260:23 | start 14:4,12,22 |
| 162:10,13 185:14 | 50:10,14 110:3,5 | spring 315:4 316:3 | 61:20 82:15 94:13 |
| 193:7 195:4,7 | 110:14 131:14 | st 62:16 | 95:24 116:17,24 |
| 196:18 205:11,24 | 133:20 152:1 | stable 157:5,6 | 138:12 153:7 |
| 210:8,15 217:13 | 171:1 177:8,13 | staff 52:21 300:21 | 156:11 157:10 |
| 218:22 220:3 | 203:3 219:6 | 300:23 301:2 | 161:4 162:20 |
| 225:23 226:5 | special 62:22 63:3 | 304:23 305:1 | 204:3 263:16 |
| 228:23 235:16 | specialization 63:6 | 309:23 310:6 | 264:18 293:11 |
| 241:19 242:18,20 | specialized 63:12 | stamp 61:20 79:16 | 308:23 |
| 244:6 245:11 | 70:2,5 | 101:20 104:3,13 | started 40:9 |
| 248:16 249:13 | specific 10:1 33:13 | 255:7,14 256:2 | 126:19,22 129:20 |
| 255:3 265:7 | 35:5 36:23 37:8 | 296:15 314:21 | 135:8 136:9 150:1 |
| 267:14,17 279:23 | 41:3 54:9,12,14 | 317:5,16 321:9 | 162:15,21 163:11 |
| 283:8 285:5 286:6 | 55:9 84:5 86:17 | stamped 64:18 | 163:24 165:9,15 |
| 292:6 295:15 | 93:20 152:1 | 206:9 313:24 | 178:1 250:4 251:2 |
| 297:6 301:22 | 166:17 185:20 | 318:4 | 258:24 |
| 303:8 304:4,11 | 199:9 202:9,14,17 | stand 324:1 | starting 47:10 |
| 307:20 308:3 | 203:9 239:15 | standard 79:3,11 | 79:21 81:22 91:3 |
| 310:17 317:4 | 259:17 330:12 | 148:2,11,15 | 161:20 162:2 |
| 325:11 339:2 | specifically 18:17 | 149:12 157:8,9 | 264:23 305:21 |
| sort 55:19,22 56:2 | 19:7 32:1 41:6 | 193:15 196:14,20 | starts 88:12 |
| 57:22 77:19 79:2 | 54:2 66:15 95:9 | 197:4,5,15 222:4,8 | 264:19 275:9,10 |
| 93:1 100:21 | 95:20 98:19 | 223:3 258:24 | state 5:3 6:19 8:6 |
| 118:17 123:10 | 110:23 111:20 | 259:1,10 261:14 | 8:9 9:14 12:5 22:8 |
| 131:9 133:6 | 128:7 236:20 | 261:19 262:12 | 26:10,18 30:10,13 |
| 143:22 190:7 | 283:22 284:3 | 263:9 271:21 | 31:7,19,23 32:6 |
| sound 99:22 | 321:16 | 300:10 343:2 | 35:16 38:7 40:14 |
| sounds 99:23 | specifics 36:20 | standards 77:18 | 43:17 44:3 45:7,9 |
| 339:15 | 81:7 | 77:21 78:6,10 | 48:3,9 49:8,22 |
| source 43:14,15 | specified 344:6 | 144:7 148:10 | 50:1 51:18 56:4,8 |
| 111:8 331:18 | specify 61:6 | 155:16 188:19 | 58:1,5,9 63:22 |
| sources 57:22 58:1 | speech 32:12 | 193:3 222:3 | 70:14 71:14 86:3 |
| 58:1,1,19 322:19 | spell 279:19 | 260:19 263:23 | 86:4,9 87:10 91:7 |
| southern 1:1 7:18 | spend 105:16 | 271:13 272:5,6 | 91:12,23 92:2,4,20 |
| 135:20 | 108:13 176:16 | standing 93:8 | 93:13,17 95:19,21 |
| span 147:5 | spending 286:12 | 117:3,12 321:24 | 97:18,21 99:9 |
| speak 14:10 16:3 | sphere 202:19 | 324:16 326:14 | 101:7 102:12 |
| 16:10 69:17 90:4 | spoke 16:2,4 242:2 | standpoint 80:20 | 107:12 112:14,16 |
| 108:22 122:5 | | 130:5 163:14 | 113:12 122:8 |
| | | | |

[state - subpoenaed]

| 125:12 127:14,17 | statements 285:14 | 187:3 231:11 | 226:15 266:20 |
|---------------------------|---------------------------|-----------------------|---------------------------|
| 127:22 128:12 | 298:13 318:23 | 238:2 240:5 | 270:15 |
| 130:14 136:1,10 | 323:21 326:9,11 | 287:14 289:15 | strong 128:23 |
| 138:17 139:24 | 327:8 | steven 2:13 | 312:16 |
| 158:22 167:20,21 | states 1:1 7:18 | stick 84:15 | strongly 321:17 |
| 168:2 174:20 | 24:12 39:2 50:3 | sticker 264:11 | structures 124:16 |
| 176:8 183:12 | 91:13 92:18,23 | stigma 277:16 | struggling 42:19 |
| 184:5 188:23 | 93:4 126:19,23 | stigmatizing 212:2 | 44:2 176:7 |
| 192:22 194:23 | 137:15 168:1 | stimulant 318:15 | students 68:9,9,10 |
| 195:9 198:11 | 208:15,16 248:23 | stimulants 105:12 | 69:7,17,22 82:12 |
| 199:21 205:12 | 261:3 262:22 | 257:22 279:1,5 | 82:21 96:23 |
| 206:3,17 216:20 | 273:16 301:15 | stimulates 160:12 | studied 205:2 |
| 216:24 217:1,1 | 320:24 321:19 | 333:9 334:23,24 | 211:4 |
| 230:4,5,17 231:22 | 324:19 332:3 | stimulus 152:5 | studies 75:18 |
| 231:24 243:18 | stating 271:13 | stipulate 286:16 | 332:2,8 |
| 244:10 248:9 | stations 165:11 | 287:17 | study 127:6 |
| 249:6 260:16 | statistic 111:6 | stipulation 287:13 | 202:11 206:13 |
| 266:17 270:24 | 146:15 | 287:14 | 225:3 243:8 |
| 272:23 274:15 | statistically | stood 79:6 | 249:15,16,23,24 |
| 292:16 300:9 | 192:24 | stop 54:4 98:1 | 284:19 285:8 |
| 315:10 331:7 | statistics 142:24 | 223:17 | 296:8 329:11 |
| 341:1 344:1,4 | 143:3,22 146:21 | store 294:15 | 330:7 |
| 345:1 347:10 | 179:6 311:17 | stored 21:2 | stuff 165:2 |
| 348:15 | 318:13,14 319:5 | stories 133:16 | subgroups 319:17 |
| state's 22:18 30:8 | 320:2,4,5,20 322:5 | 134:5 | subject 30:19,21 |
| stated 85:19 148:9 | 342:12 | street 2:7,12,15,20 | 31:14 32:23 78:24 |
| 175:22 222:2 | status 208:18 | 37:18 47:8,10,12 | 286:17 287:22 |
| 245:8 250:3 311:9 | 215:4 | 132:17 133:14 | 288:5 332:19 |
| 314:5 333:15 | statute 91:24 94:5 | 155:6 163:7,10 | subjective 79:7 |
| 342:11 | statutory 56:3 | 164:17 166:12 | submit 246:14 |
| statement 54:1 | stay 235:18 | 177:1 178:21 | submitted 184:8 |
| 186:13 208:21 | staying 90:15 | 278:16 279:5 | 188:14 189:2 |
| 244:21 251:10 | stays 133:12 | 305:23 | 204:18 295:20 |
| 256:23 257:2 | steal 150:17 | streets 43:5 | 317:18 |
| 301:11,19 302:22 | stealing 150:16 | strength 157:14 | subpoena 15:19 |
| 302:24 303:3 | 153:21 280:16 | 334:14 | 19:5 20:2,14,17 |
| 311:7,8 319:1 | step 240:7 | strengthen 256:13 | 28:23 229:20 |
| 326:4,6 327:14 | steps 46:6 275:7 | strike 21:10 41:22 | 233:1,1,3,5,7,11 |
| 347:13,14 348:19 | steve 8:13 32:16 | 47:21 53:2 82:8 | 288:12,21 |
| 348:19 | 50:14 51:6 117:13 | 87:24 198:18 | subpoenaed 28:22 |
| | 180:10 185:13 | 205:17 217:15 | |
| | | | |

[subpoenas - symptom]

| subpoenas 288:13 | successfully | support 93:6 | 248:13 251:4 |
|--------------------|---------------------------|-------------------|-----------------------|
| subscribed 347:10 | 142:10 | 142:10 159:12 | 257:11 262:1 |
| 348:14 349:21 | sudafed 258:15 | 256:13 | 264:1,6 269:11,12 |
| subsequent 78:23 | sued 263:13 264:1 | supported 78:15 | 271:17,19 272:5 |
| 126:18 | suffer 138:23 | supporter 102:21 | 273:16 276:23 |
| subsequently | suffered 160:21 | supportive 159:7 | 281:17 285:6 |
| 59:12 125:17 | 166:20 | suppose 251:14 | 286:14 288:6 |
| 135:18 251:1 | suffering 22:7 | 338:10 | 290:23 292:12 |
| subspecialty 63:9 | 43:5 130:5 133:17 | supposed 170:2 | 293:8 294:13 |
| substance 5:16 | 162:9 178:13,18 | 212:7 | 296:13 299:19 |
| 20:11 45:17 48:14 | 277:16 279:17 | suppressants | 313:19 314:16 |
| 49:24 51:24 85:4 | sufferings 43:11 | 278:24 336:16 | 322:21 325:22 |
| 89:11 127:9 | sufficient 126:12 | sure 11:17 12:19 | 331:16 332:4 |
| 151:20 161:23 | 294:15 | 13:3 18:11 19:1 | 333:2 |
| 164:10,17 278:9 | sufficiently 198:14 | 20:16 22:3 26:2,7 | surprised 175:7 |
| 308:12 309:17 | suggest 32:8 99:17 | 26:23 28:14 29:4 | surrogate 113:17 |
| 311:5 319:13 | 116:5 198:3 199:1 | 34:1 41:3,13 48:6 | 113:21 |
| 320:12 321:22 | suggestions 48:17 | 48:8 52:12 53:8 | surrounded 69:4 |
| 331:18 333:3 | suggests 326:19 | 53:17 54:20 64:17 | surveillance |
| 334:15,22 | suit 59:2,19 | 67:2,13 68:8 | 251:21 |
| substances 36:9 | suite 346:2 | 70:21,23 71:1,4 | survey 280:9 |
| 36:13 37:14,23 | summary 192:3 | 81:13 82:19 84:2 | surveyed 280:10 |
| 38:3,4,18 39:1,13 | sun 49:8 108:7 | 84:8,14 87:6 88:9 | 325:13 |
| 40:10,19 42:14 | superior 346:1 | 90:7 105:19 | surveys 325:20 |
| 48:4 50:9,22 51:1 | supervision | 108:11 115:16 | survival 152:19 |
| 94:2 127:10 | 125:12 | 117:14 142:17 | survive 44:4 |
| 132:15 162:24 | supp 160:16 | 158:9 175:1 182:5 | 126:14 152:6 |
| 166:7 168:16 | supplied 306:19 | 182:23 185:18 | surviving 153:14 |
| 189:21,22 191:1 | supplies 268:8,19 | 187:22 188:21 | suspect 302:19 |
| 213:21 218:14 | supply 40:23 47:9 | 189:1 190:13 | suspicious 270:10 |
| 244:4,23 245:1,2,5 | 86:8 101:24 102:4 | 192:7 195:1 | 272:9,9 |
| 247:14 250:6 | 103:12 104:6,7,10 | 196:19,20 203:3 | sustainable 6:11 |
| 251:13 254:6 | 104:15 105:2,23 | 204:19 207:20 | 254:16 255:21 |
| 256:18 257:22 | 106:4,7,9,13 107:5 | 210:3,16 211:17 | sustained 172:19 |
| 270:8,18 307:22 | 107:13,20 108:6 | 212:24 218:23 | swear 9:1 |
| 330:8 333:5,14 | 108:12 109:12,19 | 221:2,24 226:6,9 | switch 60:1 |
| 334:20,21 | 112:24 113:8 | 230:14 231:12 | sworn 9:2,6 344:7 |
| subtitle 317:11 | 141:14 153:12 | 232:22 236:2 | 347:10,13 348:14 |
| subtract 245:20 | 155:15 163:13 | 237:20 238:5 | 348:18 349:21 |
| successful 69:10 | 256:14 266:9 | 240:11 241:17 | symptom 79:7 |
| | 292:17 | 246:17 247:12 | |
| | | | |

[symptoms - tenure]

| symptoms 153:15 | 286:8 308:20 | 342:16 | teeth 286:13 |
|---------------------------|---------------------|--------------------|---------------------|
| 168:18,21 171:24 | 310:12 313:22 | talking 28:9,12 | television 122:22 |
| syndrome 97:18 | 316:19 320:23 | 40:9 46:4 58:6 | 161:5 |
| 136:20 168:14,15 | 323:1 324:6,9,22 | 105:16 129:21 | tell 28:4 40:1 |
| 168:18 170:17 | 328:2 329:8 333:8 | 133:11 166:18 | 76:20 82:12 89:18 |
| synthetic 177:9,10 | taken 1:19 7:14 | 172:12 197:6 | 92:14 101:19 |
| 256:9 274:23 | 54:23 94:21 | 212:24 213:8,19 | 107:23 116:9 |
| syringes 276:22 | 114:24 144:8 | 213:20 226:1 | 129:12 131:4 |
| system 26:5 35:14 | 180:23 187:18 | 231:23 240:8 | 134:5 135:21 |
| 35:18 40:9,11 | 226:23 235:18 | 290:11 | 146:22 154:8 |
| 41:7,14,24 48:21 | 237:6 240:19 | talks 141:23 | 171:3,8 174:21 |
| 81:17 152:20,24 | 274:15 280:6 | 242:12 297:21 | 175:23 177:6 |
| 156:10 171:18 | 291:12 328:8 | tap 178:19 275:10 | 191:3 216:9,10 |
| 172:7 265:18 | 344:6,9,13 | task 49:6 125:8,16 | 219:8,13 231:13 |
| 272:12 296:21 | takes 93:16 293:24 | tatterson 315:18 | 248:3 251:6 |
| 318:14 336:18,19 | talk 20:10 30:11 | taught 65:16 | 282:15 284:2,18 |
| 337:10 | 49:11 60:2 73:16 | 66:15,22 67:7 | 287:20 289:3 |
| systems 72:7,8 | 74:11 77:17 80:10 | 68:10,13 76:4 | 294:9,12,15 |
| 138:2 179:12 | 81:5 82:3 96:14 | 80:2,4 81:21 | 316:14 325:20 |
| t | 96:15,17,18,20 | taxpayer 329:19 | telling 73:22 77:15 |
| t 2:6 9:4 | 97:14,14,15,24 | taylor 5:13 308:7 | 154:21 269:22 |
| tab 285:21 | 98:14 102:12,15 | tea 226:17 | tells 152:15 154:11 |
| table 273:14 | 102:18 104:20 | teach 65:15 66:12 | 157:17 333:10 |
| take 7:11 20:5 | 105:1,2,3,4,4,5,6,6 | 70:2,4 79:21 80:5 | temporary 126:22 |
| 34:17 47:16,23 | 105:8,11 106:5 | 80:11 94:12,15 | ten 54:18 78:24 |
| 51:9,11 54:18 | 107:19,19 108:3,7 | 95:11 98:5 171:15 | 107:11 159:23 |
| 68:6,7 76:18 | 140:7 147:17 | teachers 133:19 | 171:5 194:12 |
| 96:11 99:17,20 | 151:13 158:4,9 | 171:2,8,15 | 226:18 286:8 |
| 108:18 109:1,6 | | teaches 94:24 | 308:22 338:7 |
| 114:15,17 118:1 | 204:24 212:23 | teaching 65:13 | tend 94:5 167:3,4 |
| 152:2 156:17 | 235:4 240:7 287:8 | 66:16 68:18 69:6 | tended 95:21 |
| 166:16 176:23,24 | 288:7,21 290:6 | 69:14,17 71:8,13 | tendered 92:6 |
| 179:20 180:8,17 | 291:3 298:8 | 72:15 94:9 95:4,7 | tends 194:8 258:1 |
| 192:14,24 193:17 | talked 86:20 88:10 | 120:11 121:4 | tennessee 70:6 |
| 193:20 194:13,15 | 106:7 175:12,13 | team 176:6 243:4 | 129:4 |
| 214:22 215:1 | 189:16 191:23 | tear 218:2 | tenth 2:20 |
| 216:5,11 226:18 | 192:9 221:1 242:3 | technological | tenuous 93:18 |
| 240:6 247:3 | 276:16 286:22,23 | 15:21 | tenure 33:8 89:19 |
| 273:22 276:15,22 | 290:7,14,15 | technology 63:8 | 92:3 97:6 124:12 |
| 276:22 277:1,2 | 291:18 324:19 | teens 148:8 221:9 | 143:9 199:21 |
| 278:24 282:18 | 329:2 332:17 | | |

[teresa - third] Page 62

| teresa 1:20 7:24 | 37:17 50:23 185:7 | 338:1,5 343:4,5 | 119:5 144:3,5 |
|--------------------------|---------------------------|--------------------|--------------------|
| 235:24 344:4,20 | 250:13 | thanks 24:2 | 147:2 148:13 |
| 345:3 | testifying 11:10,18 | 180:20 | 157:21,22 158:24 |
| term 33:13 40:13 | 25:16 27:6 28:15 | theoretical 277:13 | 161:19,19 162:2 |
| 41:14 106:12 | 229:21 230:19 | theory 322:13 | 163:20 168:8 |
| 124:8,9 137:12 | 232:1 | thing 55:22 76:3 | 169:11 174:1 |
| 141:17,17,18 | testimony 6:9 11:2 | 77:23 107:23 | 175:15 178:3 |
| 143:18 155:12 | 11:19 12:13,22 | 169:11 174:22 | 179:9 185:17 |
| 172:17,22 174:10 | 13:6 24:18,21 | 202:19,22 212:15 | 186:6,19 187:21 |
| 281:7,18 282:7 | 30:21 32:24 50:9 | 273:5 329:15 | 191:22 195:4 |
| 324:15 337:18 | 181:7 184:15 | 332:11 | 196:18 198:5 |
| terminal 281:8 | 185:6 187:4,5,15 | things 18:23 37:19 | 202:10 203:18 |
| terms 20:21 36:2 | 221:2 229:14,24 | 42:7,22 45:12 | 207:2 208:22 |
| 44:23 59:10 82:11 | 234:1,3 236:4 | 47:3 62:7 71:3 | 210:1 212:1,12 |
| 116:4 129:3 | 238:8 241:2 | 76:16 83:2 96:18 | 216:19 217:23 |
| 146:23 147:6 | 251:15 252:7 | 97:14 100:7 | 219:6,7 220:3,6 |
| 158:3,9 160:4 | 254:14 255:17,20 | 107:11 108:24 | 222:6 231:22 |
| 166:12,15 167:11 | 256:1,24 257:20 | 109:13,23 110:1 | 232:19 234:23 |
| 168:10 176:21 | 264:13 265:6,8,11 | 122:14 126:16 | 235:6,7,17 236:7 |
| 177:21,23 178:21 | 266:6,8 275:23 | 133:1 135:5,15 | 238:17 239:2,8 |
| 179:7 196:16 | 305:20 321:2,5,8 | 137:18 138:8 | 242:2,11 245:6 |
| 197:10 208:9 | 322:4,21 323:12 | 142:13 145:24 | 246:17 256:24 |
| 214:2 220:13 | 323:20 326:14,24 | 152:18 153:10 | 259:13 262:20,23 |
| 281:5 341:23 | 343:10 347:6,7 | 154:15 162:9 | 263:16 264:20 |
| terrible 49:9 | 348:6,9,12 | 173:7,10,22 | 265:4 282:2 283:1 |
| 187:10 | thank 15:24 23:21 | 175:10 182:3 | 286:21 287:13,15 |
| testified 9:6,19 | 24:7 26:15 27:22 | 194:24 213:4 | 289:4,7 292:20 |
| 10:3 11:22 13:12 | 29:24 32:16,23 | 220:24 242:10 | 293:2,10 297:15 |
| 18:22 20:16 48:20 | 33:21 35:8,13 | 276:5 285:18 | 307:10 319:24 |
| 77:2 106:18 120:5 | 40:8 54:20 64:15 | 293:4 328:21 | 322:8,11 324:13 |
| 182:4,17 184:6 | 86:18,20 112:22 | 333:6 336:18,22 | 327:21,24 328:1 |
| 192:4 235:9 | 114:20,21 117:10 | 336:24 | 331:11 337:4 |
| 249:24 250:4 | 182:21 185:11,12 | think 17:21 18:22 | 338:15,17 342:15 |
| 252:4 258:23 | 188:1 189:15 | 32:2 33:2 34:23 | 343:3 |
| 259:21 260:2,5 | 190:24 204:23 | 35:3 42:2 43:22 | thinking 59:4 |
| 274:5,8 284:4,11 | 208:24 209:17 | 51:11 52:3,16 | 261:18 |
| 284:14 322:22,23 | 216:13 258:23 | 54:17 55:15 59:21 | third 74:3,4 104:1 |
| testify 13:24 28:1 | 266:21 286:9 | 61:17 84:10 86:20 | 132:5 149:3 164:2 |
| 28:19,22 29:7,8,20 | 309:5 316:20 | 89:17 98:22 99:18 | 207:14,21,21 |
| 30:3,14,15,16 | 321:7 328:15 | 106:11 107:7 | 209:1 222:20 |
| 31:10 32:13 33:9 | 329:23 331:4,16 | 111:11 114:14 | 239:20 263:6 |
| Veritert Legal Solutions | | | |

[third - total] Page 63

| 280:12 318:6 | 57:12,19 58:20,24 | 288:17 289:13 | 138:17 167:10 |
|--------------------|--------------------|----------------------------|-----------------------|
| thirsty 152:13 | 59:5,23 64:7 | 291:10,16 296:6 | 173:3 181:16 |
| thirty 346:18 | 66:15 70:6 71:8 | 301:12,20 303:2 | 182:4,17 183:6 |
| thompson 340:22 | 71:24 72:11 73:3 | 303:11 305:21 | 184:15 185:6,23 |
| 340:24 341:1,13 | 73:18,18 74:2,6,13 | 306:17 308:18,19 | 186:1,17,20 |
| thompson's 341:4 | 75:12 77:8,23 | 308:24 309:1,4 | 199:10 214:17 |
| 341:9 | 78:1,14,17 79:5,24 | 310:1,15 311:13 | 220:23 229:14,20 |
| thoroughly 185:2 | 80:3 83:21,24 | 311:19 320:21,24 | 229:22,23 235:9 |
| thought 26:22 | 84:15,19 85:1,18 | 323:1 328:7,12 | 236:4 238:8 241:2 |
| 189:2 213:8 | 89:14 95:1 102:6 | 329:14 333:24 | 251:15 260:2 |
| 215:13 286:7 | 102:16,17,17 | 334:2,5,8 341:1 | 284:11 291:18 |
| 323:14 | 103:22 108:23 | 344:6 | 302:24 303:1 |
| thousand 124:21 | 110:16 114:5,8,23 | timeline 139:20 | 322:4 324:19 |
| 148:8 221:9 | 115:5 118:2,15 | 202:14 | 328:14 331:3 |
| thousands 167:8 | 123:8 125:13 | times 9:21,24,24 | today's 25:10 |
| 324:24 | 126:11,24 129:19 | 10:4,6 16:2,5,14 | 187:16 227:15 |
| three 9:23,24 42:7 | 130:8,14,18 140:9 | 84:21 97:12 | 228:11 343:10 |
| 107:7,11,18 123:4 | 143:8 144:9,15 | 138:20 154:3 | toes 327:20 |
| 126:9 132:15 | 145:5 146:4,10,14 | 164:15 171:18,21 | told 13:22 14:9 |
| 149:17,21 159:14 | 148:16 149:8,15 | 242:21 248:16,17 | 263:11 289:4,7 |
| 160:5 171:17 | 151:9,12 156:8,12 | 248:20 311:21 | tolerance 334:11 |
| 210:10,16,23 | 162:1 163:3,5 | 312:1,5,9 320:14 | 334:12 |
| 213:3 221:12 | 164:20,24 166:1,8 | timing 232:23 | toleranced 302:13 |
| 223:9,13,19 224:9 | 168:5 170:5 173:9 | tiny 167:6 | tom 124:4 |
| 224:15 225:10,18 | 174:5 175:23 | title 108:20 111:11 | tomblin 145:19 |
| 248:15 260:23 | 176:14 179:10,23 | 204:21 306:19 | 161:22 |
| 262:1 276:22 | 180:12,22 181:3 | titled 101:6 184:15 | tools 98:7,7 |
| 283:13 296:10 | 187:10 194:3 | 255:21 299:21 | tooth 149:14 156:4 |
| throw 201:18 | 197:17,19 209:15 | 300:11 302:6 | 223:5 |
| thursday 313:20 | 220:13 222:9,24 | 309:16 310:24 | top 24:11 61:24 |
| timber 195:21 | 223:6 224:24 | 317:8 | 62:1 69:21 108:20 |
| time 8:9 9:22 10:3 | 226:22 227:3,23 | tobacco 159:11 | 111:12 193:11 |
| 10:7 12:23 13:9 | 240:18,23 242:4,5 | 332:15 334:16,20 | 282:14 313:9 |
| 14:11 17:7 18:18 | 242:9 243:13 | 334:21 335:4,10 | 339:20 |
| 19:20 24:22 27:10 | 245:9,16 247:3 | tobacco's 334:18 | topic 99:16 102:13 |
| 28:5,6 40:7,20 | 251:2,20 252:24 | toby 341:4 | 179:20 |
| 42:5 43:2,23 44:8 | 253:7 257:2 | today 13:20,24 | total 113:9,14,15 |
| 45:3 46:20 47:13 | 262:19 264:16,17 | 15:4,8 19:8 21:22 | 147:17,18 156:19 |
| 47:16 50:6 52:2 | 265:1,1 268:13 | 23:10 25:11 27:22 | 156:21 166:16 |
| 52:11 53:5 54:13 | 269:3 274:21 | 29:9 31:21 73:17 | 169:4 177:24 |
| 54:22 55:3,9 56:6 | 276:11 284:1 | 117:16,22 129:12 | 244:24 309:4 |
| | | | |

[total - type] Page 64

| 310:10,15 314:7 | transitioned | true 13:5 87:17 | turn 7:7 24:15 |
|---------------------------|---------------------------|-------------------------|--------------------|
| 343:11 | 105:11 177:22 | 120:9,22 121:2,11 | 54:8 61:18 62:2 |
| totaled 303:5 | 277:15 324:2 | 122:10,23 128:15 | 99:7 101:18 104:2 |
| touch 165:4 | translate 197:13 | 135:13,16 137:10 | 178:19 206:8 |
| tough 174:2,2 | transmitted 97:11 | 141:22 166:7 | 244:7,12 254:12 |
| tower 2:15 | trauma 66:2 | 167:15 212:14 | 256:1 275:10 |
| town 71:21 73:19 | treat 73:24 170:11 | 234:13 283:15 | 295:2,16 299:9 |
| 129:22 132:3 | 170:13 198:14 | 333:5,6 | 303:13 305:5 |
| 133:9,10 | treated 67:2 | truly 154:4 | 308:1 310:16 |
| towns 113:19 | treating 196:17,21 | trust 276:19,20 | 312:21 313:23 |
| 138:6 | treatment 47:4 | trusted 137:9 | 317:3 318:2 319:8 |
| toxicology 301:14 | 65:19,23,23 69:12 | truth 288:23 | 321:1,7 339:1 |
| 302:17 | 70:3 78:10 86:23 | 326:10 | turned 79:7 |
| track 14:11 | 98:3 139:14 151:7 | try 47:7,16 64:7 | 276:12,12 |
| traditional 72:1 | 159:18 160:3,24 | 90:6 100:6 168:15 | turning 90:15 91:5 |
| trailers 131:3,8,17 | 175:3 215:10 | 180:11 241:22 | 91:10 161:14 |
| trained 44:9 62:24 | 259:1,10 277:7 | 307:14 323:18 | twelfth 2:12 |
| training 62:16 | 314:8 316:22 | 328:19 | twelve 25:21 27:11 |
| 63:3,9,10,12 74:22 | 317:9 | trying 42:19 44:2 | 93:16 |
| 116:13 139:3 | trend 31:15 | 44:11,18 45:13 | twenty 344:15 |
| 158:5 165:21 | 211:20 220:14 | 46:8 74:21,24 | 345:6 |
| 203:1 217:8 315:4 | 245:10,14 275:22 | 84:20 88:8,9,17 | twisted 214:8 |
| 316:3 | 279:14,15 302:20 | 98:1,2 100:6 | two 9:24,24 10:6 |
| trainings 62:22 | 305:10,13 306:19 | 135:4 138:9,21 | 10:21 27:5 36:17 |
| 63:15 | 307:1,3 | 157:21 160:4 | 42:7 61:20 63:2 |
| transcribed 347:7 | trending 136:23 | 167:16 203:17 | 81:12 82:11 93:16 |
| transcript 5:3 | trends 194:9 200:5 | 208:19 210:1 | 118:14 125:18,22 |
| 12:4,12 344:10,14 | 201:6 307:5 | 213:15 219:8 | 129:16 141:2 |
| 345:5 346:11,12 | trial 10:4,8,10 | 220:8 232:20 | 148:8 149:17 |
| 347:5,12 348:5,11 | 24:14 25:1,17 | 263:14,19 277:21 | 157:18 158:16 |
| 348:17 | 27:7 28:2,20,22 | 286:7 290:3 | 177:1 179:21 |
| transcripts 20:7 | 29:7,9,21 30:3 | 316:14 322:21 | 180:17 205:6 |
| transgenerational | 32:2,2 185:8 | 324:10 325:8,8 | 209:24 221:9 |
| 45:24 | 230:9,10,19 232:1 | 326:7 327:5,24 | 223:9 225:18 |
| transition 47:11 | 276:23 | 330:4 339:15 | 245:1,5,20 255:12 |
| 105:7,9 176:19 | tried 46:14 126:10 | tsunami 136:21 | 257:1 279:13 |
| 179:7,19 275:24 | 172:23,24 173:7 | tuberculosis 63:2 | 280:9 283:12 |
| 276:3,4,4 277:22 | trigger 333:21 | 63:10 | type 46:9 66:3 |
| 278:1,3,19,23 | 334:3 | tune 114:3 | 76:18,19 124:23 |
| 305:22 | trips 76:17 | tunnel 162:3 | 126:6 132:20 |
| | | _ | 153:4 175:9 |
| | | | |
| Varitavt Lagal Calutions | | | |

[type - users] Page 65

| 325:17 335:2 | 161:6 190:12 | unfortunataly | unturned 176:12 |
|------------------------|--------------------|------------------------------|-----------------------|
| | | unfortunately 84:11 137:3 | |
| types 103:8 107:2 | 196:19,19 199:7 | | unusual 290:19 |
| 337:11 | 200:20 202:7 | 158:20 169:1 | 291:5 |
| typewriting | 203:4 210:3 | 277:12 279:16 | update 107:12 |
| 344:10 | 213:15 225:24 | unidentified | updated 5:20 |
| typically 66:5 69:9 | 231:19 232:5 | 191:18 286:5 | 303:17 |
| 153:15 | 237:20 239:21 | unintended | upper 317:17 |
| typos 316:12,14 | 243:10,14 267:15 | 291:24 | upside 293:4,10 |
| u | 267:23 268:21 | unit 7:13 55:2 | upstream 45:11 |
| u 9:4,4 302:14 | 269:7 272:23,24 | 115:3 181:2 227:1 | 72:22 137:13,18 |
| u.s. 6:22 23:15 | 277:21 290:1,1,3 | 227:21 240:21 | 139:1 176:17 |
| 206:24 209:8 | 296:11 325:8 | 291:14 328:10 | 265:19 |
| uab 65:14 72:12 | 328:23 330:4 | united 1:1 7:18 | upward 245:14 |
| uh 10:6 11:22 | 331:4 336:13 | 39:1 261:3 262:21 | urban 69:1 |
| 213:11 253:17 | understandable | 332:3 | urge 321:17 |
| 260:2 288:8 | 14:4 | units 131:12 | use 5:17 64:12 |
| ultimate 158:19 | understanding | 343:12 | 67:8,9 69:13 |
| ultimately 171:21 | 21:17 22:3,5,14,15 | universities 62:12 | 78:11 96:14 97:12 |
| 214:4 220:18 | 22:24 26:3 35:14 | university 60:7 | 136:8 157:7 |
| unable 33:8 | 35:18,20,21 39:8 | 62:17 63:5 65:5 | 158:12 163:11 |
| 297:19 | 39:14 42:9,9 44:9 | 68:12,14 71:12,12 | 167:5 196:8 197:2 |
| unanimously | 56:11 59:9 69:17 | 79:20 80:7,9 | 197:7 208:20 |
| 125:23 | 72:7 73:4 106:13 | 90:16,17 94:9 | 210:7 211:21 |
| uncle 110:7 | 107:4 110:1 139:5 | 95:10,16 119:23 | 215:9,22 221:11 |
| underdiagnosis | 139:7,17 144:9 | 120:4,17 121:14 | 223:14,19 224:9 |
| 282:21 | 152:3 189:18 | 121:18 125:9,10 | 225:14,17 253:13 |
| undergraduate | 190:14 224:13 | unnecessary | 253:14,20,22,23 |
| 60:3,5 | 239:24 250:5 | 155:13 156:3 | 254:2 274:6,7 |
| underlying 225:2 | 268:6 301:21 | 204:14 217:12,17 | 275:1,2,4,24 278:9 |
| understand 9:14 | 330:3 331:11,14 | 220:20 260:10,11 | 279:12 307:23 |
| 13:14 14:20 15:11 | 335:3,15,22 336:4 | 260:13,15,21,24 | 308:12 309:17 |
| 15:15 18:11,13 | understood 15:12 | 261:6,13,21 262:3 | 311:4,11,11,12 |
| 21:11,15,19,21 | 19:3 35:8 54:16 | 262:4,9,11,13,17 | 318:7 319:13,15 |
| 26:3 33:11 39:9 | 119:18 187:22 | unrecognized | 320:12 324:15 |
| 39:11 42:12 48:6 | 329:23 | 196:16 | 325:9,19 326:12 |
| 55:20 56:7,13,14 | undertreating | unrelenting | 326:14 327:15,17 |
| 69:23 72:14 92:20 | 198:5,8,21 | 140:18 | 329:19 332:7 |
| | undone 298:3 | unretained 233:24 | 333:3,17 |
| 96:23 103:8 | unfair 32:3 272:21 | 234:6 | user 291:24 |
| 105:15,19 107:1 | 323:5 324:8,14 | unsuspecting | users 254:1 275:23 |
| 116:7 117:11 | 327:21 328:1 | 330:23 | 280:6 302:13 |
| 122:2 125:4 135:8 | | | |

[uses - virginia] Page 66

| usion 104:21 143:1 292:8 verified 248:4 292:8 verify 250:12 320:5 75:71 140:13 143:1,212 155:14 143:1,142:146:8 137:2 159:18 329:24 146:10 147:22 148:7 156:20 utilization 274:23 utilized 66:24 utilizing 75:7 verify 250:12 315:19 329:24 146:10 147:22 178:19 143:21,22 155:14 143:1,142:148:7 156:20 178:21 161:15 143:21,22 155:14 146:11 147:22 178:12 165:21 167:13 179:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 | 104 21 142 1 | · (° 1 240 4 | . 25 10 55 24 | 127 2 120 10 |
|--|-------------------|------------------------|---|---------------------------------------|
| utilization 274:23 utilized verify 250:12 315:19 143:21,22 155:14 329:24 143:4 144:2 146:8 146:10 147:22 146:10 147:22 1478:178:20 148:17 142:8 165:21 167:13 148:17 156:20 148:17 142:8 165:21 167:13 148:17 156:20 148:17 142:8 165:21 167:13 148:17 142:8 165:21 167:13 148:17 142:8 165:21 167:13 166:47 172:12 173:24 174:15,20 173:24 173:24 174:15,20 173:24 174:24,20 173:24 174:15,20 173:24 174:15,20 173:24 174:15,20 173:24 1 | uses 104:21 143:1 | verified 248:4 | view 35:18 55:24 | 137:2 139:18 |
| utilized 66:24 utilizing 315:19 veritext 7:23 8:1 viewing 136:24 viewing 136:21 161:15 v 349:1 348:13 346:1,7 views 142:8 violence 165:21 167:13 viox 165:21 167:13 viox 173:24 174:15,20 v 5:4 12:5 346:6 347:3 348:3 va versed 80:19 viox viox 75:14 viox 173:24 174:15,20 vasidid 209:16 validity valida 209:16 298:11,12 versions 298:91 5:11 6:7 7:19 9:16 175:24 178:15 175:24 178:15 175:24 178:15 175:24 178:15 175:24 178:15 182:12 183:4,23 194:23 195:5,67 188:12 2183:4,23 194:23 195:5,67 188:12 183:4,23 194:23 195:5,67 199:16 175:24 178:15 177:24 178:15 177:24 178:15 177:24 178:15 177:24 178:15 177:24 178:15 177:24 178:15 177:24 178:15 179:12 179:16 179:14 239:19 43:8,17 46:12 205:10 20:24 184:6,15 188:23 199:17 199:16 179:17 199:17 | | | | |
| utilizing 75:7 veritext 7:23 8:1 viewing 136:24 views 116:17 158:21 161:15 v 343:13 346:1,7 349:1 viewing 136:24 views 116:17 158:21 161:15 v 5:4 12:5 346:6 347:3 348:3 veritext.com. violence 252:19,19 viox 75:14 168:47,172:12 173:24 174:15,20 verson 98:12 5:11 6:7 7:19 9:16 175:24 178:15 175:24 178:15 175:24 178:15 175:24 178:15 175:24 178:15 182:12 183:42:3 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:11,10,11 198:22 20:24 197:17 198:12,13 198:22 20:24 197:17 198:12,13 198:22 20:24 197:17 198:12,13 198:22 20:24 207:77 209:6 221:8 197:17 198:12,13 198:22 20:24 207:77 209:6 221:8 197:17 198:12,13 198:22 20:24< | | | 1 | |
| v 343:13 346:1,7 views 116:17 158:21 161:15 v 349:1 veritext.com. 142:8 165:21 167:13 v 5:4 12:5 346:6 347:3 348:3 veritext.com. 346:17 violence 252:19,19 168:4,7 172:12 va 148:16 222:9 version 89:12 varied 209:16 version 89:12 159:4 171:12 virginia 1:1 2:15 174:24 175:12,18 173:24 174:15,20 validate 249:3 validity 13:1,4 values 246:1 vanderbiit 68:14 68:17 120:21 version 298:9,11 version 298:10:10:10:10:10:10:10:10:10:10:10:10:10: | | | | |
| v 349:1 142:8 165:21 167:13 v 5:4 12:5 346:6 347:3 348:3 veritext.com. 346:17 violence 252:19,19 168:4,7 172:12 173:24 174:15,20 va 148:16 222:9 versed 80:19 version 89:12 viox 75:14 virginia 1:1 2:15 174:24 175:12,18 174:24 175:12,18 174:24 178:15,20 validate 249:3 version 89:12 159:4 17:12 10:15,16 11:7,15 182:12 183:4,23 182:12 183:4,23 183:42 183:23 194:23 195:5,6,7 validate 249:3 versions 298:9,11 versions 298:9,11 version 298:9,11 21:23 156:22 197:14 239:19 31:19 32:6 34:14 197:17 198:12,13 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 198:22 202:24 197:17 198:12,13 207:72 198:62,13 198:22 202:24 207:72 198:62,13 198:22 202:24 207:72 198:62,13 198:22 202:24 207:72 198:62,13 198:22 202:24 207:72 198:62,13 207:72 198:62,13 <td>C</td> <td></td> <td></td> <td></td> | C | | | |
| v 5:4 12:5 346:6 347:3 348:3 veritext.com. 346:17 violence 252:19,19 viox 75:14 168:4,7 172:12 173:24 174:15,20 173:24 174:15,21 173:24 174:15,20 173:24 174:15,21 173:24 174:15,21 173:24 174:15,21 173:24 174:15,21 173:24 174:15,20 173:24 174:15,21 173:24 174:15,21 173:24 174:15,21 173:24 174:15,21 173:24 174:15,20 173:24 174:15,21 173:24 174:15,20 173:24 174:15,21 173:24 174:15,21 173:24 174:15,21 | 78:19 | · | | |
| 347:3 348:3 va 148:16 222:9 vaguely 92:14 valid 209:16 validate 249:3 validity 13:1,4 values 246:1 vanderbilt 68:14 68:17 120:21 variable 195:18 334:8 variables 195:14 195:15,16 varied 167:21 varies 334:8 variety 192:23 337:6 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 122:22 166:6 170:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 vary 334:5 varsative 117:14 veracity 325:17 verification 330:22 346:17 versed 80:19 vicex 75:14 virginia 1:1 2:15 5:11 6:7 7:19 9:16 10:15,16 11:7,15 11:23 12:13 20:24 197:14 239:19 31:19 32:6 34:14 197:17 198:12,13 194:23 195:5,6,7 194:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 174:15,20 174:24 175:12,18 175:24 178:15 188:21 218:4,23 188:23 22:63:414 197:17 198:12,13 198:22 202:24 205:10 206:22 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:2 23:11 209:19 14:2,114:10,11 209:19 206:22 206:10 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 207:7 209:6 221:8 200:10 122:22 166:6 170:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 201:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 202:11 10:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 201:10 11:19 | v | | _ | |
| 347:3 348:3 va 148:16 222:9 vaguely 92:14 valid 209:16 validate 249:3 validity 13:1,4 values 246:1 vanderbilt 68:14 68:17 120:21 variable 195:18 334:8 variables 195:14 195:15,16 varied 167:21 varies 334:8 variety 192:23 337:6 various 64:9 65:17 66:4 69:18 70:29 70:22 102:10 1122:22 166:6 170:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 vary 334:5 vary 334:5 variation 330:23 vary 334:5 var | v 5:4 12:5 346:6 | | 1 | , |
| va 148:16 222:9 versed 80:19 virginia 1:1 2:15 174:24 175:12,18 vaguely 92:14 version 89:12 5:11 6:7 7:19 9:16 175:24 178:15 175:24 178:15 validate 249:3 versions 298:9,11 298:11,12 11:23 12:13 20:24 48:46,15 188:23 194:6,15 188:23 194:23 195:5,67 197:17 198:12,13 182:12 183:4,23 194:23 195:5,67 197:17 198:12,13 192:28,23 194:23 195:5,67 197:17 198:12,13 194:23 195:5,67 197:17 198:12,13 194:23 195:5,67 197:17 198:12,13 194:23 195:5,67 197:17 198:12,13 194:23 195:5,67 197:17 198:12,13 194:23 195:5,67 197:17 198:12,13 198:22 202:24 205:10 206:22 207:77 199:16 205:10 206:22 207:77 199:16 205:10 206:22 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 199:16 207:77 1 | | | , | , |
| vaguely 92:14 valid 209:16 version 89:12 159:4 171:12 5:11 6:77:19 9:16 175:24 178:15 175:24 178:15 175:24 178:15 182:12 183:4,23 184:6,15 188:23 182:12 183:4,23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 184:6,15 188:23 182:12 183:4,23 184:6,15 188:23 205:10 14 205:11 185:14 | | | | · · · · · · · · · · · · · · · · · · · |
| valid 209:16 validate 249:3 validate 249:3 validity 13:1,4 versions 298:11,12 11:23 12:13 20:24 182:12 183:4,23 184:6,15 188:23 | | version 89:12 | 5:11 6:7 7:19 9:16 | 175:24 178:15 |
| validate 249:3 validity 13:1,4 versions 298:9,11 11:23 12:13 20:24 184:6,15 188:23 184:6,15 188:23 194:23 195:5,6,7 values 246:1 versions 7:16 10:15 31:19 32:6 34:14 197:17 198:12,13 19 | | 159:4 171:12 | 10:15,16 11:7,15 | 182:12 183:4,23 |
| validity 13:1,4 versions 298:9,11 21:1 22:8,23 194:23 195:5,6,7 vanderbilt 68:14 68:17 120:21 versions 7:16 10:15 31:19 32:6 34:14 197:17 198:12,13 variable 195:18 334:8 vertical 100:21 48:18 49:9,17 207:7 209:6 221:8 variables 195:14 195:15,16 vested 95:16 56:5 57:17 58:18 230:5,5 235:11 227:7,17 228:3,13 varies 334:8 victim 76:6,8 70:11 71:11,14,17 241:8,13,16,19 242:1 243:5,18 variety 192:23 339:8 340:10 85:20 86:9 89:4 246:22 248:9 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 8:23 9:3 54:21 92:11 93:5 94:6,9 241:8,13,16,19 242:1 243:5,18 various 64:9 65:17 8:23 9:3 54:21 92:11 93:5 94:6,9 241:9,18,20 242:1 243:5,18 vice 70:11 197:16 241:20 252:20 226:21 227:1,21 226:21 227:1,21 228:20 240:17,21 228:20 240:17,21 227:22,23 273:18 vart 235:18 337:11 | | 298:11,12 | 11:23 12:13 20:24 | 184:6,15 188:23 |
| values 246:1 versus 7:16 10:15 31:19 32:6 34:14 197:17 198:12,13 vanderbilt 68:14 68:17 120:21 12:13 156:22 35:11 41:10,11 43:8,17 46:12 205:10 206:22 variable 195:18 310:21 48:18 49:9,17 207:7 209:6 221:8 variables 195:15,16 vested 95:16 56:5 57:17 58:18 230:5,5 235:11 varied 167:21 vice 128:18 59:2 63:23 70:7,9 241:8,13,16,19 variety 192:23 337:6 victim 76:6,8 340:15 80:1,6 83:8,16 246:22 248:9 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 8:23 9:3 54:21 89:10 91:14,21,24 269:23,24 270:24 70:21 10:11 197:16 22:22 166:6 170:11 197:16 226:21 227:1,21 94:16 95:10,16 272:22,23 273:18 241:20 252:20 296:7 305:8 335:18 337:11 338:12 343:9 111:13,16,21,23 291:9,14 309:2 111:13,16,21,23 292:13 295:7 vary 334:5 243 224:30:9:34:39 112:46,61 125:10 | | versions 298:9,11 | 21:1 22:8,23 | |
| vanderbilt 68:14 12:13 156:22 35:11 41:10,11 198:22 202:24 68:17 120:21 197:14 239:19 310:21 43:8,17 46:12 205:10 206:22 variable 195:18 334:8 vertical 100:21 51:18 52:18 53:20 207:7 209:6 221:8 variables 195:15,16 vested 95:16 56:5 57:17 58:18 227:7,17 228:3,13 varied 167:21 victim 76:6,8 70:11 71:11,14,17 242:1 243:5,18 variety 192:23 339:8 340:10 80:1,6 83:8,16 246:22 248:9 various 64:9 65:17 66:4 69:18 70:19 70:21 102:10 8:23 9:3 54:21 85:20 86:9 89:4 262:22 264:15 various 64:9 65:17 8:23 9:3 54:21 92:11 93:5 94:69 271:9,18,20 70:22 102:10 180:21 181:1,12 96:22 99:1,2,6 271:9,18,20 122:22 166:6 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 229:13 439:9 111:13,16,21,23 292:13 295:7 </td <td>,</td> <td>versus 7:16 10:15</td> <td>31:19 32:6 34:14</td> <td>197:17 198:12,13</td> | , | versus 7:16 10:15 | 31:19 32:6 34:14 | 197:17 198:12,13 |
| 68:17 120:21 197:14 239:19 43:8,17 46:12 205:10 206:22 variable 195:18 334:8 334:8 vertical 100:21 48:18 49:9,17 207:7 209:6 221:8 variables 195:14 195:15,16 vested 95:16 vice 128:18 56:5 57:17 58:18 227:7,17 228:3,13 varied 167:21 varies 334:8 variety 192:23 337:6 340:15 80:1,6 83:8,16 80:1,6 83:8,16 241:8,13,16,19 242:1 243:5,18 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 122:22 166:6 170:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 vary 334:5 82:33 9:3 54:21 193:5 94:6,9 94:16 95:10,16 228:20 240:17,21 291:9,14 309:2 305:24 306:1 94:16 95:10,16 272:22,23 273:18 274:6 275:21 277:20 278:21 102:8 104:22,23 277:20 278:21 228:20 240:17,21 291:9,14 309:2 310:8,14 328:6,10 338:12 343:9 videoconference 1:19 videographer 3:8 7:24 309:3 310:9 videotaped 1:19 vienna 97:5 105:21 110:19 121:5,23 30:14,7,15 302:7 30:14,7,15 302:7 30:14,18,23,24 30:15 324:12,16 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 122:22 166:6 170:11 197:16 241:20 15:3 180:21 181:1,12 22:22 166:6 120:20 22:11 93:5 94:6,9 27:19,18,20 270:22 22:22 | | 12:13 156:22 | 35:11 41:10,11 | 198:22 202:24 |
| variable 195:18 334:8 variables 195:14 195:15,16 vertical 100:21 vested 95:16 vice 128:18 51:18 52:18 53:20 56:5 57:17 58:18 59:2 63:23 70:7,9 70:11 71:11,14,17 70:11 71:11,14,17 70:11 71:11 | | 197:14 239:19 | 43:8,17 46:12 | 205:10 206:22 |
| 334:8 variables 195:14 195:15,16 vice 128:18 52:18 53:20 227:7,17 228:3,13 230:5,5 235:11 230:5,5 235:11 230:5,5 235:11 230:5,5 235:11 230:5,5 235:11 230:5,5 235:11 230:5,5 235:11 241:8,13,16,19 242:1 243:5,18 246:22 248:9 242:1 243:5,18 246:22 248:9 242:1 243:5,18 246:22 248:9 249:4,6 261:4,4 262:22 264:15 242:1 243:5,18 246:22 248:9 249:4,6 261:4,4 262:22 264:15 242:1 243:5,18 246:22 248:9 249:4,6 261:4,4 262:22 264:15 249:4,6 261:4,4 262:22 264:15 249:4,6 261:4,4 262:22 264:15 269:23,24 270:24 271:9,18,20 271:9,18,20 272:22,23 273:18 274:6 275:21 271:9,18,20 272:22,23 273:18 274:6 275:21 277:20 278:21 | | 310:21 | 48:18 49:9,17 | 207:7 209:6 221:8 |
| variables 195:15,16 vice 128:18 56:5 57:17 58:18 230:5,5 235:11 241:8,13,16,19 varied 167:21 victim 76:6,8 70:11 71:11,14,17 242:1 243:5,18 246:22 248:9 variety 192:23 337:6 victims 6:3 330:23 84:15,16,17 85:9 249:4,6 261:4,4 262:22 264:15 various 64:9 65:17 video 7:2,10,13 89:10 91:14,21,24 269:23,24 270:24 269:23,24 270:24 various 64:9 65:17 8:23 9:3 54:21 94:16 95:10,16 272:22,23 273:18 271:9,18,20 various 19:11 197:16 241:20 252:20 296:22 99:1,2,6 274:6 275:21 277:20 278:21 vary 334:5 335:18 337:11 338:12 343:9 111:1,3,16,21,23 292:13 295:7 vast 282:17 283:2 305:24 306:1 videographer 3:8 122:8 123:5,11 303:4 305:9 verification videotaped 1:19 videotaped 1:19 130:14,18,23,24 319:15 324:12,16 verification 320:22 133:4 134:3,6 319:15 324:12,16 | | vertical 100:21 | 51:18 52:18 53:20 | 227:7,17 228:3,13 |
| 195:15,16 varied 167:21 victim 76:6,8 340:15 70:11 71:11,14,17 242:1 243:5,18 variety 192:23 337:6 330:23 84:15,16,17 85:9 249:4,6 261:4,4 various 64:9 65:17 66:4 69:18 70:19 85:20 86:9 89:4 262:22 264:15 various 64:9 65:17 8:23 9:3 54:21 92:11 93:5 94:6,9 271:9,18,20 70:22 102:10 122:22 166:6 170:11 197:16 226:21 227:1,21 96:22 99:1,2,6 272:22,23 273:18 241:20 252:20 296:7 305:8 335:18 337:11 310:8,14 328:6,10 113:7,13,19 292:13 295:7 vary 334:5 vast 282:17 283:2 305:24 306:1 videoconference 1:19 124:6,16 125:10 306:17 307:21 verification videotaped 1:19 videotaped 1:19 133:4 134:3,6 319:15 324:12,16 | | vested 95:16 | 56:5 57:17 58:18 | 230:5,5 235:11 |
| varied 167:21 victim 76:6,8 70:11 71:11,14,17 242:1 243:5,18 varies 334:8 victims 6:3 330:23 80:1,6 83:8,16 246:22 248:9 variety 192:23 339:8 340:10 85:20 86:9 89:4 246:22 248:9 various 64:9 65:17 video 7:2,10,13 85:20 86:9 89:4 262:22 264:15 various 66:4 69:18 70:19 55:1 114:22 115:3 89:10 91:14,21,24 269:23,24 270:24 70:22 102:10 122:22 166:6 170:11 197:16 241:29 252:20 94:16 95:10,16 272:22,23 273:18 241:20 252:20 296:7 305:8 335:18 337:11 228:20 240:17,21 105:21 110:19 285:16,21 286:19 291:9,14 309:2 310:8,14 328:6,10 1338:12 343:9 116:19 121:5,23 296:17,23 297:2 vast 282:17 283:2 videoconference 1:19 124:6,16 125:10 306:17 307:21 vein 117:14 veracity 325:17 videotaped 1:19 124:6,16 125:10 306:17 307:21 verification 320:22 130:14,18,23,24 313:4 134:3,6 | | vice 128:18 | 59:2 63:23 70:7,9 | 241:8,13,16,19 |
| varies 334:8 340:15 80:1,6 83:8,16 246:22 248:9 variety 192:23 339:8 340:10 84:15,16,17 85:9 249:4,6 261:4,4 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 823 9:3 54:21 92:11 93:5 94:6,9 271:9,18,20 70:22 102:10 122:22 166:6 170:11 197:16 241:20 252:20 94:16 95:10,16 272:22,23 273:18 241:20 252:20 296:7 305:8 335:18 337:11 291:9,14 309:2 105:21 110:19 285:16,21 286:19 291:9,14 309:2 310:8,14 328:6,10 1338:12 343:9 116:19 121:5,23 296:17,23 297:2 vast 282:17 283:2 videographer 3:8 122:8 123:5,11 303:4 305:9 vein 117:14 veracity 325:17 videotaped 1:19 124:6,16 125:10 306:17 307:21 verification 320:22 vienna 97:5 133:4 134:3,6 313:4 34:3,6 319:15 324:12,16 | | victim 76:6,8 | 70:11 71:11,14,17 | 242:1 243:5,18 |
| variety 192:23 victims 6:3 330:23 84:15,16,17 85:9 249:4,6 261:4,4 337:6 various 64:9 65:17 video 7:2,10,13 85:20 86:9 89:4 262:22 264:15 66:4 69:18 70:19 8:23 9:3 54:21 92:11 93:5 94:6,9 271:9,18,20 70:22 102:10 122:22 166:6 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 228:20 240:17,21 105:21 110:19 285:16,21 286:19 241:20 252:20 296:7 305:8 335:18 337:11 310:8,14 328:6,10 113:7,13,19 296:17,23 297:2 vast 282:17 283:2 videoconference 1:19 124:6,16 125:10 306:17 307:21 verin 117:14 veracity 325:17 videotaped 1:19 128:1,12 130:10 315:6,11 316:4,24 verification videotaped 1:19 videotaped 1:19 133:4 134:3,6 319:15 324:12,16 | | 340:15 | 80:1,6 83:8,16 | 246:22 248:9 |
| 337:6 339:8 340:10 85:20 86:9 89:4 262:22 264:15 various 64:9 65:17 66:4 69:18 70:19 70:22 102:10 122:22 166:6 170:11 197:16 241:20 252:20 296:7 305:8 335:18 337:11 vary 334:5 180:21 181:1,12 226:21 227:1,21 291:9,14 309:2 310:8,14 328:6,10 338:12 343:9 96:22 99:1,2,6 102:8 104:22,23 105:21 110:19 285:16,21 286:19 291:9,14 309:2 310:8,14 328:6,10 338:12 343:9 105:21 110:19 121:5,23 292:13 295:7 296:17,23 297:2 301:4,7,15 302:7 305:24 306:1 296:7 305:8 335:18 337:11 22:8 123:5,11 124:6,16 125:10 306:17 307:21 303:4 305:9 305:24 306:1 119 videographer 3:8 7:24 309:3 310:9 videotaped 1:19 videotaped 1:19 videotaped 1:19 vienna 97:5 128:1,12 130:10 315:6,11 316:4,24 317:12,14 318:13 319:15 324:12,16 | | victims 6:3 330:23 | 84:15,16,17 85:9 | 249:4,6 261:4,4 |
| various 64:9 65:17 video 7:2,10,13 89:10 91:14,21,24 269:23,24 270:24 66:4 69:18 70:19 8:23 9:3 54:21 92:11 93:5 94:6,9 271:9,18,20 70:22 102:10 122:22 166:6 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 296:7 305:8 310:8,14 328:6,10 113:7,13,19 296:17,23 297:2 296:7 305:8 310:8,14 328:6,10 338:12 343:9 116:19 121:5,23 296:17,23 297:2 vary 334:5 videoconference 1:19 124:6,16 125:10 306:17 307:21 verin 117:14 veracity 325:17 videotaped 1:19 128:1,12 130:10 306:17 307:21 verification 320:22 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | 339:8 340:10 | 85:20 86:9 89:4 | 262:22 264:15 |
| various 64.9 63.17 8:23 9:3 54:21 92:11 93:5 94:6,9 271:9,18,20 70:22 102:10 55:1 114:22 115:3 94:16 95:10,16 272:22,23 273:18 122:22 166:6 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 291:9,14 309:2 105:21 110:19 285:16,21 286:19 296:7 305:8 310:8,14 328:6,10 113:7,13,19 296:17,23 297:2 335:18 337:11 338:12 343:9 116:19 121:5,23 301:4,7,15 302:7 vast 282:17 283:2 1:19 122:8 123:5,11 303:4 305:9 videoconference 1:19 124:6,16 125:10 306:17 307:21 veracity 325:17 videotaped 1:19 130:14,18,23,24 317:12,14 318:13 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | video 7:2,10,13 | 89:10 91:14,21,24 | 269:23,24 270:24 |
| 50:34 69:18 70:19 55:1114:22 115:3 94:16 95:10,16 272:22,23 273:18 70:22 102:10 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 296:7 305:8 335:18 337:11 291:9,14 309:2 111:1,3,16,21,23 292:13 295:7 335:18 337:11 338:12 343:9 116:19 121:5,23 296:17,23 297:2 305:24 306:1 338:12 343:9 116:19 121:5,23 301:4,7,15 302:7 305:24 306:1 122:8 123:5,11 306:17 307:21 306:17 307:21 306:17 307:21 309:12,14 314:2,4 315:6,11 316:4,24 310:8,14 328:6,10 310:8,14 328:6,10 305:24 306:1 338:12 343:9 128:13:12 130:10 306:17 307:21 306:17 307:21 309:12,14 314:2,4 315:6,11 316:4,24 315:6,11 316:4,24 317:12,14 318:13 320:22 313:4 134:3,6 319:15 324:12,16 | | | 92:11 93:5 94:6,9 | 271:9,18,20 |
| 122:22 166:6 180:21 181:1,12 96:22 99:1,2,6 274:6 275:21 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 296:7 305:8 105:21 110:19 285:16,21 286:19 296:7 305:8 310:8,14 328:6,10 113:7,13,19 296:17,23 297:2 335:18 337:11 338:12 343:9 116:19 121:5,23 301:4,7,15 302:7 vast 282:17 283:2 videoconference 1:19 124:6,16 125:10 306:17 307:21 verification videotaped 1:19 130:14,18,23,24 317:12,14 318:13 320:22 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | 55:1 114:22 115:3 | 94:16 95:10,16 | |
| 170:11 197:16 226:21 227:1,21 102:8 104:22,23 277:20 278:21 241:20 252:20 296:7 305:8 105:21 110:19 285:16,21 286:19 291:9,14 309:2 310:8,14 328:6,10 113:7,13,19 296:17,23 297:2 335:18 337:11 338:12 343:9 116:19 121:5,23 301:4,7,15 302:7 vary 334:5 videoconference 1:19 124:6,16 125:10 306:17 307:21 vein 117:14 videographer 3:8 7:24 309:3 310:9 128:1,12 130:10 309:12,14 314:2,4 veracity 325:17 videotaped 1:19 130:14,18,23,24 317:12,14 318:13 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | 180:21 181:1,12 | 96:22 99:1,2,6 | 274:6 275:21 |
| 241:20 252:20 296:7 305:8 335:18 337:11 vary 334:5 vast 282:17 283:2 305:24 306:1 vein 117:14 veracity 325:17 verification 320:22 228:20 240:17,21 291:9,14 309:2 310:8,14 328:6,10 338:12 343:9 videoconference 1:19 videographer 3:8 7:24 309:3 310:9 videotaped 1:19 vienna 97:5 105:21 110:19 111:1,3,16,21,23 113:7,13,19 116:19 121:5,23 301:4,7,15 302:7 303:4 305:9 306:17 307:21 309:12,14 314:2,4 317:12,14 318:13 319:15 324:12,16 | | 226:21 227:1,21 | 1 | 277:20 278:21 |
| 291:9,14 309:2 296:7 305:8 335:18 337:11 vary 334:5 vast 282:17 283:2 305:24 306:1 vein 117:14 veracity 325:17 verification 320:22 291:9,14 309:2 310:8,14 328:6,10 338:12 343:9 videoconference 1:19 videographer 3:8 7:24 309:3 310:9 videotaped 1:19 videotaped 1:19 vienna 97:5 111:1,3,16,21,23 113:7,13,19 296:17,23 297:2 301:4,7,15 302:7 303:4 305:9 306:17 307:21 309:12,14 314:2,4 315:6,11 316:4,24 317:12,14 318:13 319:15 324:12,16 | | 228:20 240:17,21 | 105:21 110:19 | 285:16,21 286:19 |
| 335:18 337:11 vary 334:5 vast 282:17 283:2 305:24 306:1 vein 117:14 veracity 325:17 verification 320:22 310:8,14 328:6,10 310:14,7,15 302:7 300:17,307:21 300:17,307:21 300:17,307:21 300:17,307:21 300:17,307:21 310:18,14 318:13 310:18,14 328:6,10 310:18,14 32 | | | 111:1,3,16,21,23 | · · |
| 333:18 337:11 338:12 343:9 116:19 121:5,23 301:4,7,15 302:7 vast 282:17 283:2 1:19 122:8 123:5,11 303:4 305:9 305:24 306:1 videographer 3:8 125:15 126:18 309:12,14 314:2,4 veracity 325:17 videotaped 1:19 130:14,18,23,24 317:12,14 318:13 verification 320:22 133:4 134:3,6 319:15 324:12,16 | | 310:8,14 328:6,10 | | 296:17,23 297:2 |
| vary 334:5 vast 282:17 283:2 305:24 306:1 videographer 3:8 vein 117:14 videographer 3:8 veracity 325:17 videotaped 1:19 verification vienna 97:5 320:22 videoconference 122:8 123:5,11 303:4 305:9 306:17 307:21 309:12,14 314:2,4 309:12,14 314:2,4 315:6,11 316:4,24 317:12,14 318:13 319:15 324:12,16 | | | 1 ' ' | · · · · · · · · · · · · · · · · · · · |
| vast 282:17 283:2 1:19 124:6,16 125:10 306:17 307:21 vein 117:14 videographer 3:8 125:15 126:18 309:12,14 314:2,4 veracity 325:17 videotaped 1:19 128:1,12 130:10 315:6,11 316:4,24 verification vienna 97:5 133:4 134:3,6 319:15 324:12,16 | • | | 1 | , , |
| 305:24 306:1 vein 117:14 videographer 3:8 125:15 126:18 309:12,14 314:2,4 veracity 325:17 7:24 309:3 310:9 128:1,12 130:10 315:6,11 316:4,24 verification 320:22 videotaped 1:19 130:14,18,23,24 317:12,14 318:13 133:4 134:3,6 319:15 324:12,16 | | | 1 | |
| vein 117:14 veracity 325:17 verification 7:24 309:3 310:9 128:1,12 130:10 315:6,11 316:4,24 videotaped 1:19 130:14,18,23,24 317:12,14 318:13 320:22 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | videographer 3:8 | · | |
| verification videotaped 1:19 130:14,18,23,24 317:12,14 318:13 320:22 vienna 97:5 133:4 134:3,6 319:15 324:12,16 | | | | , , |
| vienna 97:5 133:4 134:3,6 319:15 324:12,16 | • | | · · · · · · · · · · · · · · · · · · · | , , , , , , , , , , , , , , , , , , , |
| 5/0:// | | _ | | |
| 122.12 123.15,17,21 | 320:22 | | · | · · |
| | | | | · - · · · · · · · · · · · · · · · |

[virginia - weeks] Page 67

| 326:12,15 327:15 | 275:9,9 325:1 | 277:8 281:22 | 141:11 151:4,9,16 |
|--------------------------|--------------------|--------------------|-------------------|
| 327:22 328:23 | volumes 325:6 | 287:9,19,19 290:1 | 152:13,17,19 |
| 329:16 330:7,13 | voluminous | 298:13 304:16 | 153:10 158:17,21 |
| 344:1,16 345:1,7 | 150:11 | 316:20 318:24 | 158:24 160:9,21 |
| virginia's 5:17,22 | voluntarily 29:2 | 323:15 327:2,23 | 172:20 173:13,18 |
| 58:21 59:18 96:9 | volunteer 276:7 | 336:16 338:16 | 177:23 179:4,5 |
| 135:14 205:5 | volunteering | wanted 18:24 | 187:12 194:4 |
| 251:12 303:20 | 71:15 | 26:23 52:5 98:8 | 198:1 208:18 |
| 308:13 309:18 | vouch 90:14 | 108:11,17 124:24 | 212:3,10 214:8 |
| virginian 45:22 | vs 1:6,13 | 126:21 129:10 | 217:5 235:14 |
| virginians 43:9 | W | 173:20,23 182:23 | 248:4 250:20 |
| 54:5 103:7 106:24 | wagoner 5:19 | 187:22 210:15 | 253:11 258:12 |
| 198:15 324:3 | 303:16 341:4,5 | 252:10,17 271:17 | 260:8 282:11 |
| 325:4,6 327:19 | wait 14:14 183:1 | 286:13 290:23 | 287:14 293:4,10 |
| vision 170:23 | 236:19 327:1 | 297:14,17 323:13 | 319:12 322:23 |
| visit 123:24 | waiting 129:17,17 | wanting 164:5 | 325:4,14 |
| visitation 285:17 | 228:22 300:4 | 176:1 325:11 | ways 46:16 102:10 |
| visiting 94:14 | waived 37:3 | wants 51:7 100:2 | 125:2 135:3 |
| 121:17 123:9 | 346:19 | 127:2 151:20 | 138:12 150:8,15 |
| visits 73:20,21 | walk 94:17 | 333:17 | 153:11 158:16 |
| 302:19 | want 12:17 14:6 | ward 69:21 | 159:10 170:16 |
| vital 78:13,20 79:3 | 18:11 25:22 26:2 | wards 69:16 72:15 | 173:12 262:2 |
| 79:5,8,9 318:14 | 26:11,12 28:9 | warm 176:1 | we've 90:24 98:9 |
| vividly 133:17 | 29:4,14 35:9 | wars 132:2 | 123:8 124:3 |
| vocabulary 197:8 | 38:17 64:16,16 | warwood 3:5 | 228:22 230:9 |
| voice 192:5 | 67:12 73:6 79:14 | washington 2:12 | 286:14 288:10 |
| volume 34:4 35:23 | 79:18 82:24 91:11 | 2:21 | 291:18 310:9 |
| 36:1 42:10,23 | 96:22 99:18 100:7 | watch 161:5 | 324:4,19 331:14 |
| 43:1,4,7,12,13,14 | 109:1,10 115:19 | water 10:17 11:6,8 | 333:18 |
| 43:15 45:10 46:4 | 116:16 117:2,9 | 11:15 70:20 94:16 | weak 226:17 |
| 46:15 47:18 82:16 | 158:12 165:7,8 | 152:14 | wealth 34:5 |
| 103:18,21 113:6,9 | 175:14,15 182:3 | way 39:23 44:7 | wearing 176:3 |
| 113:14,15 134:10 | 185:16 186:5 | 46:5 47:9,19 66:1 | web 136:6 |
| 146:16,19 147:1,7 | 200:9,20 203:3 | 67:17 72:4 77:20 | website 36:19 |
| 147:17,18 150:17 | 204:24 205:20 | 81:15 82:9 87:14 | week 5:21 37:7 |
| 150:18,19,21,23 | 207:20 208:3,7 | 102:16 103:3,7,11 | 94:14 303:18 |
| 151:2 155:23,24 | 219:1,2,5,11 221:1 | 103:12 105:15 | weekend 74:4 |
| 156:19,21 157:13 | 221:2 223:18,24 | 106:24 113:5,23 | weekends 76:18 |
| 166:2 168:5 | 225:16 230:12 | 114:8 124:23 | weekly 73:21 |
| 204:11 259:22 | 234:16 252:11 | 127:3,3 131:14 | weeks 19:21 |
| 260:3 261:9 275:5 | 265:7 267:3 273:5 | 133:1 136:16 | 160:24 |
| | 203.7 207.3 273.3 | | |

[weightage - work] Page 68

| | | I | |
|--------------------|-------------------|--------------------|-----------------------|
| weightage 208:23 | 125:15 126:18 | 308:13 309:12,14 | 119:3 181:8,9 |
| welcome 247:5 | 128:1,12 130:10 | 309:17 314:2,4 | 234:6 323:6 |
| 322:18 | 130:14,17,23,24 | 315:5,11 316:4,23 | 328:15 344:7,10 |
| welfare 45:5 174:8 | 133:4 134:3,6 | 317:12,14 318:13 | 346:8,11 347:1,4 |
| went 46:20 124:20 | 135:14,20 136:2 | 319:15 324:2,12 | 347:11 348:1,4,15 |
| 142:14 143:8 | 136:23 137:2 | 324:16 325:4,6,9 | witnesses 24:14 |
| 145:6 146:3,12 | 139:18,24 141:23 | 325:19,24 326:12 | 233:12 289:17 |
| 162:6 174:21 | 143:3 144:1 146:8 | 326:15 327:15,19 | witness' 346:14 |
| 177:18 194:14 | 146:10 147:21 | 327:22 328:23 | woman 264:21 |
| 228:20 248:14 | 148:7 156:20 | 329:16 330:7,13 | 276:9 |
| 293:15 307:23 | 158:21 161:15 | 344:1,15 345:1,7 | womb 169:19,22 |
| 324:4 | 165:20 167:13 | whatsoever 322:8 | women 147:21 |
| west 1:1 5:11,17 | 168:4,7 172:11 | wheeling 3:5 | 169:6,8,14 173:13 |
| 5:22 6:7 7:19 9:16 | 173:24 174:15,20 | whispering 7:5 | 173:16,17 175:2 |
| 10:15,16 11:7,14 | 174:23 175:11,18 | white 89:3 97:22 | 319:18 320:8,13 |
| 11:23 12:13 21:1 | 175:23 178:15 | 174:4 316:21 | women's 173:15 |
| 22:8,23 31:19 | 182:12 183:3,23 | 322:5,18 | wonder 277:11 |
| 32:6 34:14 35:11 | 184:6,15 188:23 | wholesale 49:4,15 | wood 148:13 |
| 41:10,11 43:7,9,17 | 195:6 197:17 | 52:10 53:1,11,23 | 222:6 224:1 |
| 45:22 46:12 48:18 | 198:11,12,14,22 | 54:10 58:22 76:24 | woodwork 150:14 |
| 49:8,16 51:18 | 202:24 205:5,10 | 77:3,6,12 80:21 | word 158:13 244:6 |
| 52:18 53:19 54:5 | 206:22 207:7 | 246:12 247:7 | 247:7 260:1 |
| 56:5 57:16 58:17 | 209:6 221:8 227:6 | 250:10 258:18 | 267:17 316:19 |
| 58:21 59:1,18 | 227:17 228:2,13 | 268:12 269:15 | words 21:24 |
| 63:22 70:7,9,11 | 230:5,5 235:11 | 274:2 294:20,23 | 200:20 |
| 71:11,14,16 80:1,6 | 241:8,12,16,18 | wife 100:8 | work 9:17 19:16 |
| 83:8,16 84:15,16 | 242:1 243:4,18 | wilkes 232:21 | 20:3 22:17 31:5,7 |
| 84:17 85:9,20 | 246:22 249:4,6 | williams 2:11 8:12 | 34:13 37:3,19 |
| 86:9 89:4,10 | 251:12 261:4,4 | wish 180:6 | 39:19 41:9,18,23 |
| 91:14,21,24 92:11 | 262:22 264:15 | wit 344:2 345:2 | 42:18 44:23 48:21 |
| 93:4 94:6,9,16 | 269:23,24 270:24 | withdraw 207:19 | 51:15 59:8 79:9 |
| 95:10,15 96:9,22 | 271:9,18,20 | withdrawal | 89:19 90:17,24 |
| 98:24 99:2,5 | 272:22,23 273:18 | 153:15 168:15 | 91:6 98:9 123:5,7 |
| 102:8 103:6 | 274:6 275:21 | 170:10 | 123:10,20 124:1 |
| 104:22,23 105:21 | 277:20 278:21 | withdrawals | 124:15 128:14 |
| 106:24 110:19 | 285:15,21 286:19 | 170:9,11 | 130:7 133:9 135:4 |
| 111:1,2,16,21,23 | 292:13 295:7 | witness 6:22 9:1,2 | 136:5 145:13 |
| 113:6,12,19 | 296:17,23 297:2 | 9:5 23:2,15 25:1 | 146:16 147:3,4 |
| 116:19 121:5,23 | 301:3,7,15 302:6 | 25:13 50:7,11,21 | 148:14 152:22 |
| 122:8 123:5,11 | 303:4,20 305:9 | 51:6 115:7,10 | 153:6 156:17 |
| 124:6,16 125:10 | 306:16 307:21 | 118:12,15,22 | 160:4 165:20 |
| , | | , , | |

[work - zoom] Page 69

| 167:12 170:18 | 245:12 247:17,23 | 156:18 158:22,23 |
|-------------------------|-----------------------|-------------------------|
| 173:4,4,8 177:5 | 248:6 298:17 | 171:18 174:18,18 |
| 200:3,11 201:4,9 | 302:1,9 305:24 | 174:19 175:7,8 |
| 220:12 222:7,9 | 311:4,10,20 | 190:7,9 192:14,24 |
| 224:1 229:7 | 315:12 320:21 | 194:11,13 204:7,8 |
| 232:20 234:4 | 344:9 | 214:23 243:13 |
| 242:5,12 243:10 | wrong 154:8 | 246:4,9 260:22 |
| 249:15 251:4,5 | 194:10 261:14 | 270:2 276:9 |
| 273:10 286:18 | 262:12 277:11 | 331:14,21 340:11 |
| 289:1 331:13 | wrote 113:2 | 340:16 342:18 |
| worked 22:19 | 249:12,14 260:14 | 343:2,2 |
| 42:12 64:10 | 260:20 261:11,12 | years 9:23 36:17 |
| 123:22 134:11 | 262:9,13,16,19 | 40:4 41:4 54:15 |
| 175:11 | 264:14 265:9 | 64:10 65:2 75:5,5 |
| worker 5:20 | wv 2:8,16 3:5 5:3 | 78:23 93:2 95:7 |
| 303:18 | 5:5,7 12:5,7 | 95:22 97:23 |
| working 44:12 | 299:12 320:8,10 | 120:12 130:12 |
| 45:22 73:4 81:15 | 320:11 344:20 | 157:11 159:19 |
| 128:12 130:12 | wvsma 6:18 60:23 | 167:7,8 171:5 |
| 135:3 148:16 | 61:21 | 192:16 193:1 |
| 151:15 173:2 | wvu 121:10 | 194:7,12,15 198:4 |
| 183:15 201:13 | X | 201:11 214:18 |
| 216:11 273:9 | xponent 111:9 | 246:8 259:15 |
| 289:18 310:20 | 112:3 | 274:11,14 281:22 |
| workings 22:21 | | 296:10 |
| works 109:16 | y | yesterday 16:4,9 |
| 190:13 217:6 | yea 187:1 | 16:15,16 17:17 |
| world 90:5 94:19 | yeah 51:5 62:5 | 18:4,5,19 |
| 194:6 | 73:23 144:3,16 | york 131:2 |
| worry 161:9 | 179:9 180:3 | Z |
| worst 101:23 | 182:20,20 185:14 | zero 148:22,23 |
| write 34:12 177:14 | 207:18 212:18 | 222:15,16 |
| 212:6,7 220:22 | 221:20 238:15 | zimmerman 180:9 |
| 256:8 294:12 | 240:14 270:7 | 180:14 |
| writer 261:1 | 287:6 290:24 | zoom 7:22 115:23 |
| writing 39:16 | 291:4 297:19 | 200m /.22 113.23 |
| 74:14 87:21 261:9 | year 60:4 63:2 | |
| written 36:3 87:9 | 73:18 97:21 | |
| 87:18,20 105:23 | 122:16 124:11 | |
| 112:14 192:1 | 125:4 126:11 | |
| 193:5 220:17 | 127:19 143:17,17 | |
| | T7 * T | ral Solutions |

Federal Rules of Civil Procedure Rule 30

- (e) Review By the Witness; Changes.
- (1) Review; Statement of Changes. On request by the deponent or a party before the deposition is completed, the deponent must be allowed 30 days after being notified by the officer that the transcript or recording is available in which:
- (A) to review the transcript or recording; and
- (B) if there are changes in form or substance, to sign a statement listing the changes and the reasons for making them.
- (2) Changes Indicated in the Officer's Certificate. The officer must note in the certificate prescribed by Rule 30(f)(1) whether a review was requested and, if so, must attach any changes the deponent makes during the 30-day period.

DISCLAIMER: THE FOREGOING FEDERAL PROCEDURE RULES

ARE PROVIDED FOR INFORMATIONAL PURPOSES ONLY.

THE ABOVE RULES ARE CURRENT AS OF APRIL 1,

2019. PLEASE REFER TO THE APPLICABLE FEDERAL RULES

OF CIVIL PROCEDURE FOR UP-TO-DATE INFORMATION.

VERITEXT LEGAL SOLUTIONS COMPANY CERTIFICATE AND DISCLOSURE STATEMENT

Veritext Legal Solutions represents that the foregoing transcript is a true, correct and complete transcript of the colloquies, questions and answers as submitted by the court reporter. Veritext Legal Solutions further represents that the attached exhibits, if any, are true, correct and complete documents as submitted by the court reporter and/or attorneys in relation to this deposition and that the documents were processed in accordance with our litigation support and production standards.

Veritext Legal Solutions is committed to maintaining the confidentiality of client and witness information, in accordance with the regulations promulgated under the Health Insurance Portability and Accountability Act (HIPAA), as amended with respect to protected health information and the Gramm-Leach-Bliley Act, as amended, with respect to Personally Identifiable Information (PII). Physical transcripts and exhibits are managed under strict facility and personnel access controls. Electronic files of documents are stored in encrypted form and are transmitted in an encrypted fashion to authenticated parties who are permitted to access the material. Our data is hosted in a Tier 4 SSAE 16 certified facility.

Veritext Legal Solutions complies with all federal and State regulations with respect to the provision of court reporting services, and maintains its neutrality and independence regardless of relationship or the financial outcome of any litigation. Veritext requires adherence to the foregoing professional and ethical standards from all of its subcontractors in their independent contractor agreements.

Inquiries about Veritext Legal Solutions' confidentiality and security policies and practices should be directed to Veritext's Client Services Associates indicated on the cover of this document or at www.veritext.com.